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ABSTRACT 
 
 Haemangioma is a primary tumour of the microvasculature characterised by 
active angiogenesis and endothelial cell (EC) proliferation followed by slow regression 
or involution whereby the newly formed blood vessels are gradually replaced by fibro-
fatty tissue. These developmental changes have been arbitrarily divided into the 
proliferative, involuting and involuted phases. The cellular and molecular events that 
initiate and regulate the proliferation and spontaneous involution of haemangioma 
remain poorly understood.  
This study examined the expression of a number of genes known to be 
associated with angiogenesis. These include members of the signal transducers and 
activators of transcription (STAT) protein family of transcription factors, STAT-3 and 
STAT-1, and the endothelial receptor tyrosine kinases, VEGFR-1 and VEGFR-2. While 
STAT-3, STAT-1 and VEGFR-1 expression was detected in all phases of 
haemangioma, VEGFR-2 expression was found to be abundant only during the 
proliferative phase and decreased with ongoing involution.  
 In this study the cellular structures that form capillary-like outgrowths in an in 
vitro haemangioma explant model were characterised as haemangioma-derived 
mesenchymal stem cells (HaemDMSCs) while the cells obtained directly from 
dissociated proliferative haemangioma tissue were defined as haemangioma-derived 
endothelial progenitor cells (HaemDEPCs). This investigation showed that although the 
vascular endothelial growth factor (VEGF), a key growth factor for ECs, was able to 
maintain HaemDEPCs morphology and immunophenotype for a limited period, these 
cells eventually differentiated into HaemDMSCs, which subsequently differentiated into 
adipocytes. Furthermore, while VEGF induced significant capillary-like sprouting from 
tissue explants, both capillary-like sprouting and HaemDMSCs proliferation was 
inhibited by the addition of AG490, a Janus kinase (JAK) inhibitor which has also been 
shown to inhibit the STAT protein pathway. These findings indicate that the 
 III 
development and differentiation of a progenitor cell and a stem cell population underlies 
the aethiopathogenesis of haemangioma and that VEGF and STAT signalling is 
involved in the programmed life-cycle of haemangioma.   
 The in vitro explant model for haemangioma offers an opportunity to study and 
identify novel treatment options for haemangioma. Interferon-alpha (IFN) has been 
used to treat steroid-resistant haemangioma but is associated with serious side-affects. 
The tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been 
shown to specifically induce apoptosis of cancer cells while sparing normal cells. As 
IFN has previously been shown to sensitise cells to TRAIL-induced apoptosis, this 
study examined the efficacy of low dose IFN in combination with TRAIL in the in 
vitro explant model and also in the purified HaemDMSCs.  Results showed that 
combining IFN with TRAIL led to synergistic inhibition of capillary-like outgrowth. 
These results indicate that IFN in combination with TRAIL serves as a potential 
treatment option for haemangioma. In contrast, HaemDMSCs were protected from 
TRAIL-induced killing. These cells were found to express high levels of the decoy 
receptors, osteoprotegerin (OPG) and decoy receptor 2 (DcR2). Increased OPG 
expression was also detected in the extracellular matrix and in the conditioned medium 
of HaemDMSCs. From these findings, we postulate that the increased level of 
extracellular OPG by HaemDMSCs is a stress response induced by their in vitro 
expansion and that secreted OPG functions as a protective shield preventing TRAIL 
action.  
The empirical and unsatisfactory nature of the current therapies for 
haemangioma underscores the importance of a scientific approach to this common 
tumour. A better understanding of the molecular mechanisms that govern haemangioma 
is of both clinical and biological interest as it may provide vital information with 
therapeutic potential for haemangioma and also for other angiogenesis-dependent 
conditions. 
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 1 
CHAPTER 1: GENERAL INTRODUCTION 
 
1.1 HAEMANGIOMA 
In 1982, Mulliken and Glowacki proposed to classify vascular anomalies into 
haemangioma or vascular malformations based on their biology (Mulliken & Glowacki, 
1982). The International Society for the study of Vascular Anomalies adopted this 
classification for vascular anomalies in 1996 (Enjolras & Mulliken, 1997). 
 The term haemangioma refers to a rapidly growing vascular tumour of infancy 
(Mulliken & Glowacki, 1982) commonly known as strawberry naevus (Vikkula et al., 
1998). It is a benign tumour of the microvasculature in which there is initial excessive 
angiogenesis (new blood vessel growth) followed by slow spontaneous regression of the 
newly formed vessels within five to 12 years (Mulliken & Glowacki, 1982; Mulliken, 
1988). Haemangioma does not occur during adolescence or adulthood (Mulliken, 1988). 
 
1.1.1 THE INCIDENCE OF HAEMANGIOMA 
 Haemangioma is the most common tumour of infancy affecting up to 12% of 
Caucasians but is uncommon in other races (Mulliken, 1988; Hildano & Nakajima, 
1972).  An incidence of 0.8%, 1.4% and 3% has been reported in Japanese (Hildano & 
Nakajima, 1972), Black (Pratt, 1953), and Asian Indian (Tan, 2001), respectively. The 
incidence increases to 23% in premature infants with a birth weight less of than 1000 g 
(Amir et al., 1996).  Girls are three times more affected than boys (Hildano & 
Nakajima, 1972).   
 
1.1.2. CLINICAL FEATURES 
 Haemangioma is distinct from vascular malformations.  70-90% of haemangioma 
appear by the fourth week of life (Mulliken, 1988; Simpson, 1959) with 30-40% being 
noticed at birth, usually as a pink macule, blanched area or telangiectasia surrounded by 
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a pale halo (Hildano & Nakajima, 1972; Payne et al., 1966). The majority of lesions 
present as single localised cutaneous tumours in the head and neck region (60%) with 
the remainder being found in the trunk (25%) or the extremities (15%) (Finn et al., 
1983).   
 Haemangioma may grow to an extensive tumour in a local area or proliferate 
simultaneously at multiple sites in the body (Mulliken, 1988). They have been found in 
lymph nodes, thymus, spleen, liver, gastrointestinal tract, gallbladder, pancreas, adrenal 
glands, urinary bladder and lung (Edmondson, 1956; Cooper & Bolande, 1965; 
Burmanet et al., 1967; Holden & Alexander, 1970; Cohen & Myers, 1986). Cases of 
haemangioma have also been reported in the brain, meninges and spinal cord (Cooper & 
Bolande, 1965; Burman & Mnasell, 1967; Cohen & Myers, 1986).  
  
1.1.3 THE DIAGNOSIS 
 The diagnosis of haemangioma is well described (Mulliken, 1988; Pratt, 1953; 
Tan, 2001). This tumour usually first noticed as a pink macule (Figure 1.1-A), typically 
exhibits rapid growth during infancy, out of proportion to the child’s growth. This rapid 
proliferation for the first 8-12 months is the hallmark of haemangioma. During this 
proliferative phase, the tumour assumes a bright crimson colour (hence the term 
strawberry naevus), is tense on palpation and is often tender to touch (Figure 1.1-B and 
-C) (Tan, 2001). 
 Following the proliferative phase, the tumour enters the involuting phase in which 
tumour growth is proportional to that of the child. During this phase, the lesion shrinks 
and softens. The crimson colour begins to fade becoming dull purple; the surface 
exhibits a mottled, greyish mantle with tiny white flecks (Figure 1.1-D). These 
cutaneous signs of involution start centrally and spread to the periphery. This takes at 
least 1-5 years. Once the haemangioma enters the involuted phase, which may take up 
to 10-12 years, its full life-cycle is spent (Takahashi et al., 1994).  The involved skin by 
haemangioma exhibits mild atrophy, has a wrinkled quality with few telangiectic 
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vessels and is slightly paler than the surrounding skin. There is often fibro-fatty tissue 
residuum with resultant contour deformity (Figure 1.1-E) (Tan, 2001). However, each 
lesion exhibits a spectrum of developmental changes, clinically and histologically 
(Mulliken, 1998; Tan, 2001). 
 50% of haemangioma show complete regression by the time the child is five years 
of age, and over 70% by the age of seven (Pratt, 1953; Simpson, 1959). Normal skin is 
restored in 50% of patients when involution is complete. Studies have also shown that 
the gender, race of the patient, size and site of the lesion, duration of the proliferative 
phase and clinical appearance of the lesion do not influence the rate of regression 
(Simpson, 1959; Finn et al., 1983).  
 About 10-20% of lesions require treatment during the proliferative phase because 
they threaten life or function, or cause tissue distortion or destruction (Takahashi et al., 
1994; Mulliken et al., 1995). Although all haemangioma eventually involute without 
treatment, they are disfiguring and may cause psychological distress, so intervention is 
required in a large number of patients (Tan, 2001).  
 
1.1.4 DIFFERENTIAL DIAGNOSIS 
 ‘Not all haemangioma look like strawberries’ (Mulliken, 1998). In the literature, 
almost all cutaneous vascular anomalies, at some point, have been called haemangioma. 
Terminological and clinical confusion between haemangioma and vascular 
malformations has been responsible for improper diagnosis, illogical treatment and 
misdirected research efforts (Mulliken & Glowacki, 1982; Mulliken et al., 1995). An 
example of the similarity between a capillary-venous malformation that can look 
remarkably similar to a haemangioma that involves  the skin and subcutaneous tissue is 
shown in Figure 1.2. 
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Figure 1.1: Natural progression of haemangioma on the right cheek and upper lip of a 
female patient. In Panels A-C, the haemangioma is in the proliferative phase. The lesion 
initially a pink macule noticed soon after birth then grew rapidly out of proportion of 
the growth of the child to assume a bright crimson colour. Photographs were taken 2 
days after birth (A), at 1 month (B) and at 8 months (C). Panel D shows the lesion in the 
involuting phase at 18 months. During this phase, the lesion began to shrink and soften. 
The crimson colour changed to a dull purple and the surface exhibited a mottled, 
greyish mantle with tiny flecks. These cutaneous signs of involution began centrally and 
slowly spread to the periphery. Panel E shows the lesion at 6 years when it had fully 
involuted. The involved skin that remained had a wrinkled quality with mild atrophy 
and hypopigmentation and few telangiectic vessels. The fibro-fatty tissue residuum 
gave rise to distortion and contour deformity (E). Panel F shows the child 9 months 
after surgical excision of the residuum (F) (Courtesy of Dr Swee.T.Tan).    
A B
C D
E F
 5 
 
 
 
 
 
Figure 1.2: Not all strawberries are haemangioma. (A) A capillary-venous malformation 
behind the knee of a 1-year old child mimicking the appearance of a haemangioma. 
Unlike haemangioma, this lesion was present at birth and grew proportionately with the 
child. (B) A haemangioma in the right parotid region involving overlying skin and 
subcutaneous tissue in a 7-month old child. Spontaneous regression is expected in this 
lesion as in all haemangioma (Courtesy of Dr Swee.T.Tan).  
 
1.1.5 CONGENITAL HAEMANGIOMA  
 There have been rare instances in which a fully-grown haemangioma is present 
at birth. These are known as congenital haemangioma (Boon et al., 1996). Vikkula et al 
(1998) suggested that the trigger for these lesions occured in utero. A subset of these 
lesions undergo rapid involution, usually within the first 14 months of life, leaving 
either atrophic or excess skin (Tan, 2001) (Figure 1.3) and are called rapidly involuting 
congenital hemangioma (RICH). There is also another type of congenital haemangioma 
called non-involuting congenital haemangioma (NICH). These lesions are present at 
birth but do not undergo post-natal regression (Mulliken & Enjolras, 2004). Some of the 
lesions have required steroid therapy or surgery because of their threat to life or 
function (Boon et al., 1996).  
 
 
 
 
 
 
 
 
A
B
A B
Figure 1.3: A congenital haemangioma. 
Panel A shows the lesion on the left thigh 
of a 3-week old infant. Panel B shows the 
lesion at 14 months. By this time, 
spontaneous complete involution had 
occurred leaving behind slight 
hypopigmented skin. (Courtesy of Dr 
Swee.T.Tan). 
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1.1.6 COMPLICATIONS OF HAEMANGIOMA 
The rapidly proliferating haemangioma may cause ulceration, obstruction of 
vital organs, tissue distortion or destruction, cardiac failure and skeletal changes (Tan, 
2001).  
Ulceration occurs in 5% of cases (Margileth & Museles, 1965) and is usually 
observed at the height of the proliferative phase (Bowers et al., 1960). Ulcerated 
haemangioma are painful and is sometimes accompanied by secondary infection 
resulting in extensive necrosis and destruction of facial soft tissues (Tan, 2001). The 
incidence of ulceration is much higher in segmental hemangioma (Waner et al., 2003) 
A growing haemangioma can cause obstruction and tissue distortion as they 
encroach on a critical anatomical structure. For example, obstruction of the visual axis 
may cause deprivation amblyopia and the failure to develop binocular vision (Tan, 
2001). Obstruction of the external auditory meatus can occur with haemangioma 
involving the parotid region (Figure 1.4-A and Figure 1.5-A). Hearing loss results if the 
lesion continues to grow beyond one year, when auditory conduction is necessary for 
normal speech development (Tan, 2001). Cardiac failure and skeletal changes such as 
overgrowth of the facial skeleton have also been described (Tan, 2001).   
 
1.1.7 HEAD AND NECK HAEMANGIOMA  
 Haemangioma of the head and neck has been identified to favour certain sites on 
the face (Waner et al., 2003). The importance of anatomic location is now well 
recognised as a major factor in determining whether complications such as visual axis 
occlusion, airway involvement, ulceration or permanent disfigurement may occur 
(Metry et al., 2001; Garzon et al., 2000; Zide et al., 1997; Haik et al., 1994). Waner et 
al (2003) categorised haemangioma into segmental and focal lesions.   
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  Focal lesions are localised and tumour-like and most commonly involve the mid 
cheek, upper lip and upper eyelid (Waner et al., 2003). An example of a focal lesion is 
depicted in Figure 1.6. 
  Segmental lesions are more widespread and plaque-like. The segmental 
distribution of these lesions is described as frontonasal, maxillary or mandibular and 
corresponds to the embryological mesenchymal prominences of the head and face.  
Ulceration and airway obstruction are more common in segmental lesions (Waner et al., 
2003). The female to male ratio of patients with segmental lesions is 5.7:1, almost twice 
that of patients with focal lesions (Waner et al., 2003). Figures 1.1, 1.2-B, 1.4 and 1.5 
show segmental haemangioma lesions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: A bilateral cervico-facial haemangioma. Panel A shows the lesion on a 1-
year old girl with the ‘beard’ distribution, impinging on the upper airway. In Panel B, 
accelerated regression had occurred after a 9-month course of IFN-2a therapy. 
Photograph was taken at age 1 year and 10 months (B) (Courtesy of Dr Swee.T.Tan). 
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Figure 1.5: A proliferating haemangioma on the left parotid region. Panel A shows a 
proliferating haemangioma in a 2-month old female infant with ulceration and 
obstruction of the auditory meatus. In Panel B, the lesion showed accelerated regression 
following systemic steroid therapy. Photograph was taken at 4 years and 3 months. At 
this stage, involution was complete leaving behind thin, atrophic and hypopigmented 
skin with some degree of fatty residuum (Courtesy of Dr Swee.T.Tan). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Natural progression of haemangioma near the right eye. The lesion initially 
a pink macule noticed soon after birth (A) became more prominent at 2 weeks of age 
(B) then grew rapidly to assume a bright crimson colour (C). Photograph was taken at 2 
months (C). At 4 years, the lesion had fully involuted (D). The remaining fibro-fatty 
tissue residuum was then surgically removed (Courtesy of Dr Swee.T.Tan). 
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Segmental haemangioma have been associated with a clinically recognised set 
of structural malformations and anomalies designated as PHACE or PHACES 
syndrome (Frieden et al., 1996; Reese et al., 1993). This association is characterised by 
posterior fossa anomalies, haemangioma that are typically plaque-like and segmental in 
the cervicofacial area, arterial anomalies, cardiac and aortic arch defects, eye anomalies 
and sternal clefts or supraumblical raphes. Brain abnormalities such as Dandy-Walker 
syndrome and cerebrovascular arterial anomalies have also been described (Adams & 
Lucky, 2006).  A child with PHACES syndrome with segmental haemangioma 
associated with a sternal cleft is shown in Figure 1.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: A patient with PHACES syndrome with segmental haemangioma associated 
with a sternal cleft. (Courtesy of Dr Swee.T.Tan). 
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1.1.8 TREATMENT 
The majority of haemangioma are harmless cutaneous lesions that require no 
intervention and should be left to involute spontaneously (Margileth & Museles, 1965). 
However, treatment is necessary during the proliferative phase in 10-20% of cases 
because the tumour threatens life or function, causes tissue distortion and destruction 
(Takahashi et al., 1994; Mulliken et al., 1995). Various therapeutic modalities have 
been described, but pharmacological therapy with high dose systemic or intralesional 
corticosteroids is the first line of treatment (Mulliken et al., 1995). Corticosteroids 
arrest growth in 30-90% of cases, however, side effects such as delayed skeletal growth, 
depressed immune function and personality changes limit their usefulness, particularly 
when prolonged treatment is required (Boon et al., 1999).  
In life-threatening cases that do not responded to steroids, IFN treatment has 
been used (Figure 1.5) (Ezekowitz et al., 1992; Chang et al., 1997). Both IFN-2a and 
IFN-2b are given subcutaneously with an average duration of 2 to 6 months (Drolet et 
al., 1999; Garmendía et al., 2001). The reported efficacy varies according to its 
definition in various series and ranges between 30-70% (Garmendía et al., 2001). 
However, its use has been limited due to reports of severe neurotoxicity in the form of 
spastic diplegia in up to 20% of patients treated with IFN-2a and in about 5% with 
IFN-2b (Barlow et al., 1998; Worle et al., 1999; Dubois et al., 1999). Chemotherapy 
has also been used to treat life-threatening, steroid-resistant haemangioma. 
Cyclophosphamide was used successfully in three infants with life-threatening, steroid-
resistant haemangioma (Hurvitz et al., 1986). A few reports on the use of vincristine 
also exist (Fawcett et al., 2004). Other strategies that have been utilised, with varying 
degrees of success, include embolisation, surgery, laser therapy and sclerotherapy 
(Enjolras et al., 1990; Jackson et al., 1993; Tan, 2001). Surgery is considered an 
effective treatment for localised problematic proliferating haemangioma (Tan, 2001). 
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1.1.9 GENETICS IN HAEMANGIOMA 
Although a family history has been noted in 10% of affected individuals 
(Margileth & Museles, 1965; Cheung et al., 1997), it is generally regarded that 
haemangioma does not have a hereditary basis (Tan, 2001). However, being a 
Caucasian female with a positive family history apparently lowers the threshold for 
haemangiogenesis wherein extragenetic factors can trigger the appearance of 
haemangioma (Vikkula et al., 1998). 
 
1.1.10 HISTOPATHOLOGY  
 The pathogenesis of haemangioma is not well understood. The life cycle of 
haemangioma has been arbitrarily divided into three phases: (i) the proliferative phase, 
(ii) the involuting phase and (iii) the involuted phase (Enjolras & Mulliken, 1997; 
Takahashi et al., 1994, Tan, 2001).  These phases describe the gross morphological 
changes associated with tumour onset, growth, and subsidence.   
In the early proliferative phase, the lesions are highly cellular and consist of 
syncytial masses of plump ECs with tiny lumens (Tan, 2001). Occasional mitotic 
figures can be seen but the nuclei do not exhibit pleomorphism (Figure 1.8-A). Later in 
the proliferative phase, vascular channels are less compact and capillary-sized lumens 
can be seen lined with plump, mitotically active ECs and pericytes (Figure 1.8-B) 
(Vikkula et al., 1998; Glukhova et al., 1991). Multilamination of the basement 
membrane (BM) and accumulation of other cellular elements including mast cells 
(MCs), macrophages, fibroblasts, plasma cells, and interstitial cells are also seen 
(Vikkula et al., 1998; Gonzalez-Crussi et al., 1991; Glowacki et al., 1982; Pasyk et al., 
1984; Dethlefsen et al., 1986; Takahashi et al., 1994; Tan et al., 2004).  As the 
haemangioma progresses to the involuting phase, the vascular lumens dilate, ECs flatten 
and the cellular elements are gradually replaced by fibro-fatty tissue, giving the 
haemangioma a lobular architecture (Figure 1.8-C). Progressive fibrosis is seen in the 
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late involuting phase (Figure 1.8-D and -E). In the involuted phase, marked fibrosis and 
a few thick-walled channels lined with flat endothelium are seen (Figure 1.8-F). A fully 
involuted haemangioma contains few capillary-like feeding vessels, and possess 
draining veins with flattened endothelia that lie in a stroma of fatty tissue containing 
collagen and reticulin fibres. 
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Figure 1.8: Histopathological features of haemangioma at different phases of 
development. A haemotoxylin and eosin (H&E) stained haemangioma specimen from 
an 18-day old infant, showing proliferating endothelial masses with tiny lumens 
(arrows) (A). Occasional mitotic figures (insert: arrowhead) can be seen but nuclei do 
not exhibit pleomorphism (A insert). Later in the proliferative phase, vascular channels 
are less compact and capillary-sized lumens (arrows) can be seen lined with plump ECs 
in a specimen from a 5-month old child (B). In the early involuting phase, the vascular 
channels (arrows) are larger but there are still areas of endothelial proliferation (right 
upper corner) in this specimen from an 8-moth old child (C). With further involution, 
the cellular elements are gradually replaced by fibro-fatty tissue (arrowheads). 
Progressive fibrosis is seen in this specimen taken from a 2 years and 9 months old 
child (D). Increasing fibrosis (arrowheads) with reduced cellularity occurs in the late 
involuting phase at 3 years and 6 months (E). Fibrosis replaced the cellular elements 
and few thick walled channels remain, lined with flat endothelium (arrows) in a 
specimen from an 8 years and 6 months old child (F). Original magnifications: 214X 
(insert: 640X) (Courtesy of Dr Swee.T.Tan).
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 Studies have also shown that although all samples predominantly exhibit the 
histological features characteristic of either the proliferative, involuting or involuted 
phases, distinct areas displaying proliferation or varying degrees of involution are 
evident in each lesion. This indicates a continuous spectrum of structural changes 
during the natural progression of haemangioma (Tan, 2001) (Figure 1.9). 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: A haemangioma on the elbow of a 13-month old girl. The image in panel A, 
shows the ‘Proliferative’ (P), ‘involuting’ (Ig), and ‘involuted’ (Id) regions representing 
the different stages within a single lesion. Panel B shows an H&E stained tissue section 
of the biopsy taken from A clearly showing defined regions of proliferation (lower 
right) and involution (upper left). Original magnification: 214X (Courtesy of Dr 
Swee.T.Tan). 
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1.2. CURRENT THEORIES ON THE ORIGINS OF   
HAEMANGIOMA   
1.2.1. PLACENTAL ORIGIN 
North et al (2001) recently identified the expression of a distinct constellation of 
tissue-specific markers, co-expressed in both haemangioma and placental microvessels.  
They found that a set of placenta-associated vascular antigens including FcRII and 
Lewis Y antigen (LeY) and placenta marker proteins including merosin and the glucose 
transporter-1 (GLUT-1) were expressed in 66 haemangioma lesions isolated from 
patients aged between 22 days and seven years.  
It is now known that with the exception of GLUT-1 and merosin being present in 
brain microvessels, none of the other placenta-associated markers are expressed in the 
microvessels of normal skin. GLUT-1 is widely expressed early in development, but 
foetal endothelial GLUT-1 expression rapidly disappears except in microvessels of 
developing neuroepithelial tissues (Froehner et al., 1998; Harik et al., 1993; Mantych et 
al., 1993a; Mantych et al., 1993b). In the mature brain, a component of the blood brain 
barrier, necessitates high GLUT-1 expression for adequate blood:brain glucose transport 
(Pardridge et al.,1990). In the placenta, GLUT-1 expression is required throughout 
gestation for adequate maternal-foetal glucose transfer (Jansson et al., 1993), 
independent of developmental stage (Hahn et al., 1995). Thus, North et al (2001) 
proposed that high GLUT-1 expression by haemangioma may permit tumour growth by 
providing fuel for mitosis. 
Intense expression of merosin in a broad, continuous, band-like pattern 
encircling lesional capillaries in GLUT-1 positive haemangioma during all stages of 
proliferation and involution has been reported (Martin-Padura et al., 1995; North et al., 
2001). Merosin expression is normally restricted to the nervous system, eyes (Villanova 
et al., 1996) and placenta (Voit et al., 1994). The merosin 2 chain, one of ten distinct 
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laminin chains, is also present in certain nonvascular BM, including those of placental 
trophoblast, schwann cells, striated muscle and skin (Engvall et al., 1990; Leivo et al., 
1988; Sewry et al., 1996). The heterogeneity of laminin subtypes in the BM and the 
highly restricted expression of merosin suggests tissue-specific and developmental 
stage-specific functional diversity. Merosin is essential for stability and survival of 
fused myoblasts in vitro, by inhibiting apoptosis (Vachon et al., 1996). Therefore, a role 
for merosin in the growth of haemangioma by inhibiting apoptosis has been suggested 
(North et al., 2001). 
The persistent expression of LeY and FcRII in the endothelium of 
haemangioma and placental vessels is of unclear functional significance. LeY is a 
glycosylated oligosaccharide, expressed on the cell surface in a tissue-specific and 
stage-specific manner. It is important in cell-cell recognition and adhesion during 
development. Its expression has been associated with malignant transformation and 
progression (Lloyd et al., 1987; Zhu et al., 1995; Wakabayashi et al., 1995) and also 
apoptosis (Hiraishi et al., 1993; Minamide et al., 1995). FcRII is a low affinity Fc 
receptor normally expressed in macrophages, Langerhan cells, platelets and other 
leukocytes (Sedmak et al., 1991; Pulford et al., 1986). Its restricted expression to 
placental endothelium and its ability to bind only immunoglobulins suggest that it may 
be uniquely advantageous in placenta perhaps assisting clearance of immune complexes 
and/or maternal-foetal immunoglobulin transport (Sedmak et al., 1991; Lang et al., 
1993). 
North et al (2001) suggested that this unique phenotype shared between 
haemangioma and the placental foetal microvessels may be due to haemangioma ECs 
that originated from either invading angioblasts and aberrantly differentiated towards 
the placental microvascular phenotype. Alternatively, the ECs could have come from 
embolised placental cells or precursors that were dislodged into foetal circulation during 
gestation or at birth. Given the previously identified increased incidence of 
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haemangioma in infants exposed to chorionic villus sampling (CVS) (Burton et al., 
1995), North et al (2001) suggested that embolic placental ECs, already committed to 
the placental phenotype (GLUT-1/merosin/LeY/FcRII) could have reached foetal 
tissues from the chorionic villi through the right to left shunts of normal foetal 
circulation. In addition, Marchuk (2001) suggested that the local placental injury that 
usually occurs in CVS could result in increased intravascular shedding of placental cells 
from the chorionic villi into the foetal circulation. Furthermore, if the embolus 
contained a single EC or only a small number of ECs, this would be compatible with the 
clonality results of Boye et al (2001) (see section 1.2.2.1.2, page 19).  
In contrast, the findings of Bree et al (2001) did not support the hypothesis that 
the placental trophoblast was the cell of origin for haemangioma as they lacked a villous 
architecture and did not express known placental trophoblastic markers. These 
investigators found no immunoreactivity for the trophoblastic markers, including human 
placental lactogen, placental alkaline phosphatase, and cytokeratins 7, 8, and 17, in 12 
haemangioma tissue specimens from patients aged five days to two years.  
 
1.2.2. EXPANSION OF ENDOTHELIAL CELLS IN HAEMANGIOMA: 
AN INTRINSIC OR EXTRINSIC DEFECT? 
The process of foetal vascular development and angiogenesis is complex with 
several receptor tyrosine kinases (RTKs) and their ligands, namely angiopoietin-1 
(Ang-1), angiopoietin-2 (Ang-2) and VEGF as known modulators (Cohen, 2002). 
Alteration in this system, at either the molecular or chromosomal level, has been 
suggested to account for the unregulated growth of blood vessels seen in haemangioma. 
In this paradigm, the rapid growth of these tumours in the postnatal period may be 
explained by the loss of angiogenic inhibitors derived from the placenta or mother 
(North et al., 2002). This idea has lead to another hypothesis for the highly proliferating 
ECs seen in haemangioma as being derived from angioblasts, aberrantly switched to a 
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placental phenotype by somatic mutations and/or other abnormal inductive influences 
(an intrinsic defect). Furthermore, Bielenberg et al (1999) found that the epidermis 
overlying proliferating haemangioma showed altered expression of angiogenic factors. 
They suggested that the underlying defect may be extrinsic to the vascular ECs, which 
were responding to an aberrant exogenous growth signal (an extrinsic defect).  
 
1.2.2.1. AN INTRINSIC DEFECT?  
This theory suggests that the dramatic changes in endothelial behaviour in 
haemangioma may be caused by somatic mutations in a single EC which results in the 
disruption of normal controlled EC growth (Berg et al., 2001; Boye et al., 2001; Walter 
et al., 2002). 
 
1.2.2.1.1. Familial Studies 
Although current evidence points towards the sporadic nature of haemangioma, 
a small number of families have been identified, wherein haemangioma and other 
vascular lesions segregated as a highly penetrant, autosomal dominant trait. Familial 
studies have suggested that the genetic alteration may be a somatic mutation or a 
common predisposing allele with incomplete penetrance (Vikkula, 2000; Tan, 2001). 
Families with suggestive autosomal dominant inheritance with incomplete penetrance 
and variable phenotypic expression have been identified (Blei et al., 1998). These 
families represent, (i) subtypes of rare mutations causing autosominal dominantly 
inherited haemangioma; (ii) kindreds in which a common low penetrant mutation shows 
autosomal dominant pattern of inheritance; or (iii) families with random aggregation of 
a common genetic trait. In gene linkage studies involving three kindreds with familial 
haemangioma, Blei et al (1998) found linkage to the 5q chromosome. Walter et al 
(1999) further mapped this region to be 5q31-33. Candidate genes involved in blood 
vessel growth within this region include fibroblast growth factor-4 (FGF-4), platelet-
derived growth factor-β (PDGF-β) and fms-related tyrosine kinase-4 (FLT-4). In 
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addition, a subsequent study by Berg et al (2001) found evidence for loss of 
heterozygosity on chromosome 5q (p < 0.05) in three out of six haemangiomas. They 
suggested that the deletion of a gene or genes in this chromosomal region may be 
caused by an intrinsic endothelial alteration rather than an external stimulus and that 
this somatic mutation may be the cause of sporadic haemangioma.  
 
1.2.2.1.2. Haemangioma-derived Endothelial Cell Studies 
 Boye et al (2001) purified ECs from proliferating haemangioma (HaemECs) 
obtained from eight female patients and found that these HaemECs were clonal. These 
authors identified a non-random X chromosome inactivation pattern for the human 
androgen receptor gene locus and proposed a clonal origin for these cells. In contrast, 
the non-endothelial stromal cells isolated from the same lesions, were not clonal. These 
results demonstrated that clonality was restricted to the ECs within the lesion. They 
hypothesised that EC clonality may be due to somatic mutations in the genes of the ECs 
but not in other cell types constituting haemangioma. These investigators also suggested 
that although stromal cells and the overlying epidermis of haemangioma exhibited 
properties, including aberrant expression of angiogenic factors (Bielenberg et al., 1999; 
Berard et al., 1997), the ECs would not be expected to develop as clones of a single 
founder cell if they were merely responding to an externally derived angiogenic signal. 
  Boye et al (2001) found that HaemECs exhibited increased proliferation and 
migration in response to VEGF as compared to normal ECs. Furthermore, VEGF-
induced migration in HaemDECs was stimulated instead of being inhibited by the 
angiogenesis inhibitor, endostatin. They suggested that alterations in the signalling 
pathways downstream of the VEGF receptor in HaemDECs, may be the result of 
somatic mutations that converted the inhibitory effect of endostatin to one of 
stimulation.  
Walter et al (2002) also identified significant skewing toward one allele in 
haemangioma lesions. These authors performed clonality assays on DNA isolated from 
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haemangioma tissue subjected to gross dissection without the selective step of EC 
growth in culture and thereby avoided changes in cell composition that could occur with 
cell cultures.  
Therefore, these studies provide strong support for the hypothesis that the clonal 
expansion and the abnormal proliferation of haemangioma is the result of one or more 
somatic mutations in key factors involved in angiogenesis. Although formal proof of 
this hypothesis awaits validation, Walter et al (2002) identified missense mutations in 
two VEGF receptors (VEGFRs), VEGFR-2 and VEGFR-3, which were only found in 
the haemangioma tissue and not in the patient matched normal skin. Therefore, these 
authors suggested that EC proliferation was the result of deregulated VEGF signalling.   
There have also been reports on experimentally induced haemangioma lesions in 
mice. Williams et al (1989) showed that the injection of mouse ECs expressing the 
polyoma middle-T oncogene into adult mice resulted in the development of tumours 
that resembled haemangioma. These lesions were composed of host-derived ECs, 
apparently recruited by the injected oncogenic cells (Williams et al., 1989).  In contrast, 
Boye et al (2001) showed no evidence for additional EC recruitment by the original 
tumour ECs.  
Li et al (2003) recently identified CD146 to be a possible marker for 
haemangioma ECs due to its reduced expression in these cells compared to the 
surrounding pericyte-like cells, and also to normal ECs. Studies have also shown that 
the ECs in haemangioma showed altered expression of several other angiogenesis-
related molecules, such as E-selectin, TIE-2, VEGF, FGF-2 and insulin growth factor 
(IGF) (Kraling et al., 1996; Yu et al., 2001; Ritter et al., 2001). These findings together 
with the down-regulation of CD146 expression suggest that haemangioma may be a 
consequence of a genetic alteration in haemangioma ECs (Li et al., 2003). 
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1.2.2.2. AN EXTRINSIC DEFECT? 
The extrinsic hypothesis invokes a defect in the local environment, which 
produces a signal or stimulus that causes haemangioma.  For example, Berard et al 
(1997) found that stromal cells isolated from proliferating haemangioma and cultured in 
vitro released VEGF. Transcripts for the VEGFRs, VEGFR-1 and VEGFR-2 are 
abundantly expressed in proliferating haemangioma (Yu et al., 2001), suggesting the 
high expression of these receptors in these lesions. Therefore, increased VEGF 
produced by stromal cells could accelerate the growth of haemangioma.
Bielenberg et al (1999) found a dramatic alteration in expression of IFNs in the 
epidermis overlying haemangioma. Compared with the epidermis of normal skin, there 
was a dramatic down-regulation of IFN in the epidermis overlying proliferating phase 
haemangioma. However, gradual restoration of IFN was observed as the lesion 
progressed to the involuting and involuted phases, with near-normal levels detected by 
five to 11 years of age. This dramatic down-regulation of IFN expression coinciding 
with the proliferating phase of haemangioma provides another example of a possible 
extrinsic alteration in haemangioma. 
 
1.2.3. THE ANGIOGENESIS CONCEPT 
The concept that tumours are ‘angiogenic dependent’ was first proposed by 
Folkman and suggests new insights into the life cycle of haemangioma (Folkman, 1997; 
Folkman & Cotran, 1976). Angiogenic molecules are known to act on ECs and 
pericytes to initiate the formation of capillary networks (Risau et al., 1988; Folkman & 
Klagsburn, 1987; Zetter, 1988; Breier et al., 1992; Pepper et al., 1992; Montesano et al., 
1986; Mignatti et al., 1989). This process is tightly regulated by inhibitors of EC 
growth, which help to maintain the microvasculature in a quiescent state under 
physiological conditions (Mignatti et al., 1989; Risau, 1995; Risau, 1997; Montesano et 
al., 1986) 
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The angiogenesis concept proposes that capillaries are normally prevented from 
growing by physiological regulation of angiogenic factors. These factors are found in 
neoplastic tissue but are also present in normal tissue where neovascularisation does not 
occur (Folkman, 1996; Risau et al., 1988; Montesano et al., 1986). Release of stored 
angiogenic factors occurs in short bursts of capillary proliferation during wound 
healing, and in female, ovulation and menstruation (Augustin et al., 1995; Klauber et 
al., 1997). The rapidly growing haemangioma is reminiscent of capillary proliferation 
seen during wound healing and the neovascularisation associated with tumour growth. 
Amongst the plethora of angiogenic regulators, VEGF, VEGFRs, Ang-1, Ang-2 and 
their RTKs, TIE-1 and TIE-2, play crucial roles in maintaining the balance between 
vascular growth and regression (Ferrara et al., 1992; Fong et al., 1995; Shalaby et al., 
1995; Suri et al., 1996; Carmeliet et al., 1996a; Hanahan, 1997; Maisonpierre et al., 
1997). Other factors such as FGF-2, transforming growth factor-  (TGF-), PDGF and 
interleukin-6 (IL-6) are highly relevant as is the extracellular matrix (ECM) (Folkman 
& Klagsbrun, 1987; Tomanek and Schatteman, 2000; Haas et al., 1999). Some of these 
factors are now known to be involved in both the proliferation and involution of 
haemangioma (Takahashi et al., 1994; Jang et al., 1998; Chang et al., 1999; Bielenberg 
et al., 1999) and are discussed in section 1.4, page 30.  
 
1.3. CELLULAR COMPONENTS OF HAEMANGIOMA 
1.3.1 ENDOTHELIAL CELLS 
The hallmark of a growing haemangioma is the proliferating ECs forming 
syncytial masses with or without luminal formation (Tan et al., 2000a). Occasional 
mitotic figures are seen but the nuclei do not exhibit pleomorphism (Mulliken, 1988). 
As the lesion progresses, the later stages of the proliferating tumour consists of less 
compact vascular channels and capillary-sized lumens lined with highly cellular plump, 
proliferating ECs organised into lobules within a limiting membrane of reticulin fibres 
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(Mulliken, 1988). Confocal microscopy showed the three-dimensional images of these 
densely disorganised tortuous networks of vessels in proliferating haemangioma 
compared with normal tissues (Takahashi et al., 1994).  
The ECs within the growing lesion are proliferating as identified by tritiated 
thymidine autoradiography (Mulliken & Glowacki, 1982) and by immunohistochemical 
staining for proliferating cell nuclear antigen (PCNA) (Tan et al., 2000a;  Tan, 2001). 
Studies showed that the majority of ECs in the proliferative and early involuting phase 
expressed PCNA but this number decreased with the on-going involution of 
haemangioma. PCNA staining in pericytes and MCs during the proliferative have also 
been identified (Hasan et al., 2000a). 
Electron microscopic (EM) studies showed that the ECs in haemangioma 
exhibited characteristics of intracellular activity such as a convoluted nuclear 
membrane, swollen mitochondria, membranes of rough endoplasmic reticulum, and 
clusters of free ribosomes (Dethlefsen et al., 1986; Hopfel-Kreiner, 1980). The luminal 
surface of these ECs exhibited thin projections whereas the basal side had thicker, club 
like projections (Dethlefsen et al., 1986; Mulliken, 1988). In contrast, the lumen in 
involuting haemangioma contained EC remnants, often lined by only one or two ECs 
with signs of endothelial discontinuity and vessel degradation. EM of involuted 
haemangioma showed that the vessels had reverted to a more normal architecture and 
contained single layers of ECs surrounded by pericytes. From these findings Mulliken 
(1988) suggested that with development, haemangioma becomes more organised, as the 
lobular components were separated by fibrous septae that contained large calibre 
feeding and draining vessels. 
ECs express specific markers that are used in their identification in vivo and in 
culture. Some of these include von Willebrand Factor (vWF), CD31 (Belloni & 
Tressler, 1990; DeLisser et al., 1994), CD34 (Krause et al., 1996), VEGFR-1 and 
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VEGFR-2 (Rettig et al., 1992; Eichmann et al., 1993; Quinn et al., 1993; Peters et al., 
1993; Mustonen & Alitalo, 1995).  
Studies have shown that although the ECs in haemangioma expressed CD31, 
vWF and urokinase in all phases, the levels of expression varied between phases. 
Takahashi et al (1994) showed that CD31 expression was significantly higher in the 
involuting phase compared to the involuted phase and vWF expression was higher in 
the proliferative and involuting phases but not in the involuted phase. Furthermore, Tan 
et al (2001a) found that not every vessel in the involuted phase expressed these proteins. 
These findings are consistent with the current knowledge of these markers, i.e., they are 
not always expressed by ECs (Parums et al., 1990; Kuzu et al., 1992). Irregular vWF 
expression has also been identified in capillaries and tumour vessels (Garlanda & 
Dejona, 1997). 
The glycoprotein, E-selectin is an EC-specific leukocyte adhesion molecule, 
involved in angiogenesis and is important in capillary tube formation (Nguyen et al., 
1993). High expression of E-selectin and VE-cadherin has been identified in the 
proliferative phase of haemangioma (Kraling et al., 1996).  
Expression of other endothelial markers such as CD34, intercellular adhesion 
molecule 1 (ICAM-1) and the very late antigen (VLA) integrin have also been 
identified in haemangioma.  Martin-Padura et al (1995) showed that these markers were 
expressed in haemangioma to similar levels as in normal ECs. Therefore, they 
suggested that the abnormal EC proliferation in the proliferating lesion was more 
related to the release of local factors and fibrinolytic agents, rather than an altered 
endothelial phenotype.  
GLUT-1 has recently been described as a marker for haemangioma.  North et al 
(2000) showed that the ECs of haemangioma from all phases expressed GLUT-1 while 
GLUT-1 immunoreactivity was absent in other vascular lesions.  
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Li et al (2003) described the transmembrane glycoprotein, CD146 as another 
marker for haemangioma. This molecule is also considered a marker for ECs (Bardin et 
al., 1996). It is involved in cell adhesion (Bardin et al., 2001) and in the regulation, 
paracellular permeability and in signal transduction of ECs (Bardin et al., 2001; 
Anfosso et al., 1998; Anfosso et al., 2001). Li et al (2003) found significantly low 
CD146 expression by the ECs of haemangioma biopsies from all phases of 
development. In contrast, the pericyte-like cells surrounding the endothelium in 
haemangioma showed strong immunoreactivity. Therefore, they suggested that CD146 
expression may be useful in distinguishing HaemDECs from normal ECs (Li et al., 
2003). Their studies also showed that CD146 expression differed from previously 
described markers such as merosin, GLUT-1, FcRII and LeY (North et al., 2001; 
North et al., 2000), in that, the reduced CD146 expression in haemangioma tissue was 
maintained even after the HaemDECs were isolated and cultured in vitro (Li et al., 
2003). On the other hand, while GLUT-1 and FcRII were strongly expressed in fresh 
or formal in fixed haemangioma tissue, their levels of expression became 
indistinguishable from that of normal ECs in culture (Li et al., 2003). 
 
1.3.2. MAST CELLS 
MCs are highly heterogeneous in terms of morphology, function and metabolic 
products (Katz et al., 1991; Qu et al., 1995). These cells are implicated in a variety of 
biological responses. They phagocytose, process antigens, produce cytokines and 
release a variety of preformed (e.g., histamine, proteoglycans and proteases) and newly 
formed (e.g., leukotrienes and prostaglandins) physiological mediators (Frangogiannis 
et al., 1998). They carry an array of adhesion molecules, immune response receptors 
and other surface molecules that allow them to react to multiple specific and non-
specific stimuli (Metcalfe et al., 1997). MCs are involved in immediate hypersensitivity 
reactions, host responses to parasites and neoplasms, immunologically non-specific 
inflammatory and fibrotic conditions, angiogenesis, tissue remodelling and wound 
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healing (Gordon et al., 1990; Meininger & Zetter, 1992; Schwartz, 1994; Metcalfe et 
al., 1997). 
MCs are abundant within haemangioma tissues (Mulliken, 1988; Gonzalez-
Cruss et al, 1991; Glowacki et al., 1982; Pasyk et al., 1984). While Gonzalez-Cruss et 
al (1991) and Glowacki et al (1982) found MCs to be abundant in the proliferative 
phase, Takahashi et al (1994) and Tan et al (2000a) showed that they were most 
prominent in the involuting phase, less in the involuted phase and least in the 
proliferating phase. Tan et al (2000a) demonstrated that the proportion of proliferating 
MCs was highest in the proliferative and lowest in the involuted phase.  
All MCs contain the specific glycosylated serine protease, tryptase (MCT) while 
a subgroup of MCs also express neutral protease like chymase (MCTC) (Schwartz, 1994; 
Metcalfe et al., 1997). Tan et al (2000a) showed that although haemangioma biopsies 
contained both MC types, the proportion of MCTC increased from the proliferative 
through the involuting to the involuted phases (Tan et al., 2000a). This correlation of 
MCTC with ongoing involution, paralleled that of progressive deposition of the ECM, 
indicated by increasing fibrosis and fatty deposition (Ruger et al., 1994; Tan et al., 
2000a). In addition, Hasan et al (2000b) found that although MC numbers increased 
four-fold following steroid treatment, the predominance of the histamine phenotype was 
unaltered. 
 
1.3.2.1. ANGIOGENIC ROLES FOR MAST CELLS IN HAEMANGIOMA 
The promotion of neovascularisation by MCs products, such as FGF-2 has been 
known for some time (Norrby et al., 1990; Norrby et al., 1994). MC accumulation has 
been correlated with normal and pathological angiogenesis (Meininger & Zetter, 1992). 
It has been suggested that MC products can act directly on ECs to stimulate their 
migration and/or proliferation or may act by degrading connective tissue matrix to 
provide space for neovascular sprouts (Meininger & Zetter, 1992).  Qu et al (1995) 
identified positive staining for FGF-2 within MCs of the proliferative phase but not in 
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the later phases of haemangioma and suggested that MCs may contribute to the growing 
haemangioma by releasing this polypeptide (Qu et al., 1995) 
An anti-angiogenic role for MCs in haemangioma has also been suggested. Tan 
et al (2004) postulated that although MCs were implicated with the development of 
haemangioma, MC secretion of angiogenic inhibitors such as IFN, IFN, IFN, and 
TGF- may be involved in the regression of these lesions. However, they proposed that 
the involvement of MCs in the life cycle of haemangioma was complex and involved 
stimulators of angiogenesis in the proliferative phase but inhibitors in later phases. 
 
1.3.2.2. ROLE OF MAST CELLS IN APOPTOSIS 
Apolipoprotein J (ApoJ) is implicated in a variety of biological processes 
including membrane remodelling and apoptosis (Wong et al., 1994). Hasan et al (2000a) 
showed ApoJ staining within the MCs of haemangioma by tryptase and alcian blue-
safranin (Csaba) double staining. They showed that expression of ApoJ in MCs was 
localised to the cytoplasmic granules which were also detected in the adjacent EC and 
capillary lumens. During the proliferative phase, only a small proportion of MCs were 
positive for ApoJ, while the proportion of ApoJ positive MCs increased with the 
involution of haemangioma. Due to the localisation of the ApoJ protein in MCs 
granules, these authors proposed that this protein may be synthesised and/or released by 
MCs. They also found ApoJ positive granules in the ECs and capillary lumens. 
Therefore, these authors suggested that MC secretion of ApoJ, an apoptotic modulator, 
may be involved in haemangioma involution.  
 
1.3.3 OTHER CELLULAR COMPONENTS 
1.3.3.1 MACROPHAGES AND MONOCYTES 
 All adult haematopoietic cells originate in the bone marrow and are derived 
from pluripotent haematopoietic stem cells (Buckland, 2002). Two major lineages then 
diverge in the bone marrow into the lymphoid and myeloid lineages. The common 
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lymphoid progenitor differentiates into B and T cells and the common myeloid 
progenitor differentiates to form the cells of the granulocyte/macrophage and the 
megakaryocyte/erythroid lineages including monocytes and macrphages (Akashi et al., 
2000). Monocytes then exit the peripheral circulation, enter tissues and differentiate into 
several cell types with varying functions. Macrophages, the major tissue-resident 
phagocytic cells of the immune system, are derived from monocytes (Rutherford et al., 
1993; Sunderkotter et al., 1994). 
Tissue macrophages are important mediators of physiological and pathological 
angiogenesis (Folkman & Klagsbrun, 1987; Isik et al., 1996; Dipietro
 
& Polverini, 
1993a; Dipietro & Polverini, 1993b; Leibovich et al., 1987; Leibovich & Wiseman, 
1988; Thakral et al., 1979; Hunt et al., 1984; Polverini & Leibovich, 1984; Koch et al., 
1986; Leung et al., 1989). They are important in the induction of new blood vessel 
growth during wound repair, inflammation and tumour growth (Sunderkotter et al., 
1994; Leibovich et al., 1987). They produce soluble mediators such as FGF-2, TGF- 
and -, PDGF and VEGF (Dipietro & Polverini, 1993b). Once activated, macrophages 
can also modulate the ECM composition and induce EC migration and proliferation 
(Sunderkotter et al., 1994; Porras-Reyes et al., 1991; Sunderkotter et al., 1994). 
Tan (2001) suggested an angiogenic role for macrophages in haemangioma. 
This was supported by results that showed increased macrophage infiltration during the 
proliferative phase but reduced numbers in the involuting and involuted phases. 
Monocyte infiltration in haemangioma is suggested to be due to release of cell-
derived chemotactic factors (Isik et al., 1996).  One candidate glycoprotein is the 
monocyte chemoattractant protein-1 (MCP-1) that is specific for monocytes and 
macrophages in vitro (Sunderkotter et al., 1994; Yoshimura et al, 1989; Rollins et al., 
1990). ECs, SMCs, fibroblasts and macrophages can produce MCP-1 (Isik et al., 1996; 
Koch et al., 1992). Isik et al (1996) showed increased expression of MCP-1 mRNA by 
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ECs, SMCs and macrophages in the proliferative phase of haemangioma. They also 
showed that nine out of ten involuting lesions did not express mRNA for this molecule.  
Ritter et al (2006) identified that haematopoietic cells of the myeloid lineage 
constituted a significant proportion of the cells in hemangiomas of the proliferative 
phase and suggested that these cells may be involved in promoting haemangioma 
possibly through expression of cytokines in response to hypoxia/ischemia.  
These authors also observed that haemangioma ECs co-expressed a number of 
myeloid markers, demonstrating yet another unique feature of these cells. From these 
findings, Jia et al (2007) hypothesised that monocytes may be the precursors of 
haemangioma ECs.  
 
1.3.3.2. PERICYTES 
Interactions between ECs and pericytes are known to be important in the 
maintenance of vascular integrity (Furchgott & Zawadski, 1980). Pericytes control EC 
proliferation (Nehls & Drenckhahn, 1991; Orlidge & D’Amore, 1987) and serve as 
guiding structures, aiding the outgrowth of ECs (Nehls et al., 1992). Pericytes also 
regulate capillary blood flow via a contractile mechanism (Paweletz & Knierim, 1989; 
Tilton et al., 1979a; Tilton et al., 1979b). Although pathological neovascularisation is 
associated with pericyte loss (Kuwabara & Cogan, 1963), failure of pericyte 
development during the angiogenic process results in the regression of the newly 
formed blood vessels (Lindahl et al., 1997; Hirschi et al., 1999).  
Plump mitotically active pericytes line the microvessels of proliferating 
haemangioma (Takahashi et al., 1994; Mulliken, 1988; Tan, 2001).  Takahashi et al 
(1994) localised smooth muscle actin (SMA) to the cytoplasm of pericytes in all phases 
of haemangioma. They found that SMA expression was significantly higher in the 
involuting phase than in the proliferative and involuted phases. From their studies, 
Takahashi et al (1994) proposed an inhibitory role of pericytes in haemangioma.  
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1.3.3.3. PROTEASES  
Takahashi et al (1994) showed increased expression of type IV collagenase 
during the proliferative phase of haemangioma. The expression of urokinase was also 
significantly higher during the proliferative and involuting phases than the involuted 
phase. High molecular weight (>150 kDa) metallomatrix proteases (MMPs) have been 
detected in the urine of patients with proliferating haemangioma (Marler et al., 2000). 
These investigators suggested that proteolysis categorised by MMPs and type IV 
collagenase was required to provide space for the proliferating cells in haemangioma 
(Takahashi et al., 1994; Marler et al., 2000) and that the differentiating cells signalled 
an influx of MCs along with the autocrine induction of tissue inhibitor of 
metalloproteinase-1 (TIMP-1) expression. Furthermore, Takahashi et al (1994) showed 
that TIMP-1, while not detected during the proliferative phase, was readily detected in 
the pericyte cytoplasm of microvessels during the involuting phase. 
TIMP-1 is well recognised for its role as an inhibitor of endothelial invasion into 
the yolk sac membrane and as a negative regulator of angiogenesis, by inhibiting 
angiogenic proteases, such as type IV collagenase (Takahashi et al., 1996; Mignatti et 
al., 1989; Takigawa et al., 1990). Therefore, Takahashi et al (1994) suggested that 
TIMP-1 expression along with the presence of MC secreted angiogenic inhibitors, such 
as IFNs and TGFs, (Friesel et al., 1987; Gordon et al., 1990; Antonelli-Orildge et al., 
1989) can result in the down-regulation of haemangiogenesis.  
 
1.4. CYTOKINES AND GROWTH FACTORS IN 
HAEMANGIOMA 
1.4.1. VASCULAR ENDOTHELIAL GROWTH FACTOR  
VEGF is an important angiogenic cytokine that induces EC proliferation and 
differentiation (Risau W., 1995; Brown LF et al., 1996). Sources of VEGF include 
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tumour cells, ECs and MCs. These cells rapidly release VEGF, apparently from a 
preformed pool (Boesiger et al., 1998). Elevated serum levels of VEGF have been 
detected in patients with proliferating haemangioma compared with those with 
involuted lesions (Zhang et al., 2005). Although in situ hybridisation and DNA 
microarray analysis showed low levels of VEGF mRNA in haemangioma (Ritter et al., 
2001; Yu et al., 2001), immunohistochemical studies confirmed the presence of VEGF 
protein within the cytoplasm of ECs and pericytes during the proliferative phase 
(Takahashi et al., 1994; Tan, 2000a). Furthermore, Hasan et al (2000b) found that VEGF 
transcript levels were not altered in steroid-induced involuting haemangioma in vivo 
and suggested that steroids act by modulating other angiogenic factors. 
 
1.4.2. VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS  
VEGF interacts with cells mainly through two RTKs, VEGFR-1 and VEGFR-2. 
VEGFR-1 signalling is essential for vascular remodelling during the early stages of 
embryogenesis (Fong et al., 1995; Carmeliet et al., 1996b). VEGFR-2 is expressed 
primarily on ECs and plays a pivotal role in angiogenesis, by inducing EC 
differentiation and vasculogenesis in both normal and tumour tissue (Millauer et al., 
1996; Quin et al., 1993). VEGFR-2 signalling also regulates proliferation and survival 
of ECs (Zachary & Gliki, 2001). While Brown et al (1996) showed high levels of 
VEGFR-1 and VEGFR-2 mRNA in proliferating haemangioma but not in involuting 
haemangioma, Yu et al (2001) showed that HaemDECs expressed increased mRNA 
levels for these receptors when in culture. 
 
1.4.3. TIE RECEPTORS AND THEIR ANGIOPOIETIN LIGANDS  
High expression of TIE-1, TIE-2 and Ang-2 but low expression of Ang-1 has 
been identified in HaemDECs (Yu et al., 2001). They showed that TIE-2 mRNA and 
protein was up-regulated in response to Ang-1 in HaemDECs which also correlated 
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with increased survival of these cells. The authors confirmed increased TIE-2 
expression in proliferating haemangioma by in situ hybridisation.   
Yu et al (2001) also showed that Ang-2 mRNA was down-regulated in response 
to serum in HaemDECs, but not in normal ECs. They suggested that the regulation of 
the Ang/TIE system was altered in haemangioma. In addition, a mutation in the TIE-2 
gene has been detected in haemangioma (Wang et al., 2004).  
 
1.4.4 FIBROBLAST GROWTH FACTOR-2  
The production and metabolism of FGF-2 is considered to be involved in the 
pathogenesis of haemangioma (Takahashi et al., 1994; Bielenberg et al., 1999; Tan, 
2001). Studies have shown increased expression of FGF-2 mRNA and protein in the 
proliferative phase of haemangioma (Takahashi et al., 1994; Chang et al., 1997). In 
addition, Tan (2001) identified positive staining for FGF-2 in MCs of both the 
proliferating and involuting phases. It has been suggested that FGF-2 may be 
synthesised by MCs and/or by other cells and stored in MCs (Tan, 2001).  In addition, 
Hasan et al (2000) showed that the high urinary levels of FGF-2 noted in individuals 
with proliferating haemangioma (Dosquet et al., 1998) was unaltered following 
successful steroid treatment as were the levels of FGF-2 mRNA transcripts within the 
lesion.  
 
1.4.5 INSULIN GROWTH FACTOR-2  
Another recently identified potential regulator of haemangioma growth is IGF-2. 
DNA microarray studies showed high expression of IGF-2 mRNA in proliferative 
lesions but low levels in involuting lesions. IGF-2 may be a reasonable putative 
regulator of haemangioma proliferation. As it is a known mitogen, IGF-2 can suppress 
apoptosis and regulate angiogenesis (Volpert et al., 1996). Ritter et al (2002) showed 
that IGF-2 protein expression was localised to the tumour vessels and that the addition 
of recombinant IGF-2 protein stimulated vascular sprouting from explanted 
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haemangioma tissue. They also found that that IGF-2 expression was more correlated 
with the proliferative phase of haemangioma than VEGF. These authors suggested that 
high IGF-2 levels could increase expression of VEGF, thereby resulting in an 
increasingly favourable local environment for EC proliferation.   
These results support a placental origin of haemangioma since IGF-2 is highly 
expressed and is important during embryonic development (Grupen et al., 1997; 
Demeestere et al., 2004). Furthermore, as IGFs induce IFN expression (Tu et al., 
1999), Ritter et al (2001) suggested that sustained levels of IGFs could result in a shift 
in the balance of regulators in favour of involution.  
 
1.4.6 OTHER FACTORS 
1.4.6.1 PLATELET DERIVED GROWTH FACTOR, TRANSFORMING GROWTH 
FACTOR- AND INTERLEUKIN-6 
Hasan et al (2000b) identified decreased transcription of PDGF, TGF-1, TGF-
2 and IL-6 mRNA following successful steroid therapy for haemangioma. Therefore, 
these authors suggested that the angiostatic effects of steroids were in part due to the 
down-regulation of these factors.  
 
1.5. EXTRACELLULAR MARKERS 
The attachment of cells to the ECM is crucial for tissue integrity. Cells attach 
either directly to components of the collagen-rich interstitial matrix or to the BM, a 
more distinct sheath of the ECM that surrounds many kinds of tissue (Gumbiner BM, 
1996). Mulliken (1988) found that multilaminated BMs which is a hallmark of a 
haemangioma in the proliferative phase, persisted through to the involuted phase. 
Jang et al (1998) showed that in addition to growth factors, the ECM 
composition of a growing haemangioma was different to those undergoing spontaneous 
involution (see section 1.5.4, page 35). 
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1.5.1 INTERSTITIAL MARKERS 
Tan et al (2000a) showed that the interstitial collagen types I, III and V (Col-I, -
III, -V) were present in the multilaminated BM, in the perivascular and in the stromal 
regions of haemangioma in all phases. They also found that collagen deposition 
increased in the stromal area with progression of haemangioma. These authors 
suggested that this pattern of collagen deposition was concomitant with the decreasing 
cellular content but increasing fibrotic nature of the later phases (Tan et al., 2000a). 
 
1.5.2 BASAL LAMINA MARKERS 
1.5.2.1 COLLAGEN TYPE IV 
Tan et al (2000a) showed that collagen type IV protein was present throughout 
the multilaminated BM in all three phases of haemanigoma. In contrast, Ritter et al 
(2002) identified increased expression of collagen type IV mRNA and protein during 
the proliferative phase which decreased in the involuting phase. These authors 
suggested that the reduced levels of collagen type IV in the involuting and involuted 
phases are an effect, rather than a cause of involution (Ritter et al., 2002).  
 
1.5.2.2 LAMININS 
11 different heterotrimeric assembly forms of laminin are known, each 
consisting of a unique combination of α, β
 
and
 
γ chains (Aumailley & Smith, 1998; Tan, 
2001; Tan et al., 2000a).  
 Tan et al (2000a) showed the presence of α1, β2 and γ1 chains but the absence of 
the α2, β1 and γ2 in the BM of microvessels in all three phases. From these findings 
together with the presence of the basement membrane-specific, heparan-sulphate 
proteoglycan perlecan (Noonan & Hassell, 1993) and the three-chain partially helical 
molecule collagen type IV (Sado et al., 1998) in all phases of haemangioma, the authors 
concluded that the BM of haemangioma contained the same major constituents as 
normal vascular BMs. 
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1.5.3 COLLAGEN TYPE VIII  
Collagen type VIII (Col-VIII) has been detected in the ECM of haemangioma in 
all phases as well as within the MCs (Tan et al., 2000a). Its intracellular localisation to 
MCs only in the early proliferative phase led to the hypothesis that Col-VIII may be 
synthesised by MCs during this phase but secreted into the pericellular and stromal 
region during involution (Tan et al., 2000a). Furthermore, Tan et al (2004) showed that 
the addition of Col-VIII antibodies to haemangioma cultures resulted in the disruption 
of newly developed capillary-like vessels. These results provide evidence for a 
functional role of Col-VIII in haemangioma. 
 
1.5.4 VITRONECTIN 
Plasma-borne molecules include fibronectin and vitronectin. Jang et al (1998) 
found that only vitronectin showed a marked difference in the deposition pattern in 
haemangioma. They found that haemangioma in the proliferative phase had extensive 
deposition of vitronectin in the subendothelial space, while those in the involuting phase 
did not. Furthermore, the vessels located in the adjacent normal dermis lacked 
vitronectin deposition. Therefore, these authors suggested that vitronectin deposition 
may serve as a marker for an actively proliferating lesion. 
 
1.6. CELL ADHESION MOLECULES  
1.6.1. INTEGRINS   
High expression of the cell adhesion molecules, the v3 and 5 integrins, 
have been reported in proliferating haemangioma with decreased abundance in the 
involuting and involuted phases (Ritter et al., 2002; Nguyen et al., 2004). Nguyen et al 
(2004) found that involuting lesions strongly expressed another integrin, 4. They 
showed that while untreated proliferating lesions lacked 4 expression, proliferative 
lesions treated with IFN re-expressed 4. This re-expression clinically corresponded to 
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the involution of haemangioma. Therefore, Nguyen et al (2004) suggested that both 
integrin molecules were involved in transducing mitogenic signals from ECM to the cell 
interior, which would either stimulate or inhibit proliferation of haemangioma. 
 
1.7. THE INVOLUTION OF HAEMANGIOMA  
The most curious biological characteristic of haemangioma is its spontaneous 
involution. Apoptosis is considered an important regulatory event in the involution of 
haemangioma (Razon et al., 1998; Iwata et al., 1996; Mancini & Smoller, 1996). In 
haemangioma, apoptosis begins prior to one year of age, increases five-fold during the 
involuting phase, and reaches a maximum at two years (Razon et al., 1998). Iwata et al 
(1996) showed co-expression of the apoptosis-related antigen, LeY (also considered a 
tumour associated antigen) with the endothelial markers vWF, CD31 and CD34 and 
confirmed that at least some of the apoptotic cells in haemangioma are ECs. 
 
1.7.1. APOPTOTIC PROTEINS IDENTIFIED IN HAEMANGIOMA 
1.7.1.1. THE BCL-2 FAMILY PROTEINS  
 Bcl-2 and Bax protein expression have been implicated in the pathogenesis of 
haemangioma. Wang et al (2003) showed that Bax expression was higher in 
haemangioma compared to other vascular malformations and normal skin (p < 0.01) 
and that Bcl-2 was negative in all phases. However, other investigators have reported 
Bcl-2 expression in the proliferative phase and Bax in the involuting phase (Nakamura, 
2000; Cheng et al., 1999; Zhang et al, 2003; Dyduch et al, 2004). 
Mancini & Smoller (1996) showed decreased Bcl-2 expression with age of the 
tumour. They found that the decrease in proliferation and Bcl-2 expression was detected 
much later in lesions, which exhibited a higher degree of vascularisation. Therefore, 
they suggested that such lesions would undergo longer periods of growth before 
entering the involuting phase. 
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1.7.1.2. APOLIPOPROTEIN J  
ApoJ is a secreted glycoprotein for which many functions have been proposed 
(Jenne et al., 1992) including apoptosis (Wong et al., 1993). It is consistently detected 
in apoptotic cell death paradigms such as the de novo regression of the prostate and 
other hormone-dependent tissues and tumours (Tenniswood et al., 1992; Wong et al., 
1993; French et al, 1993; Wong et al, 1994) and in the involuting mammary gland (Lee 
et al., 1996).  
Hasan et al (2000a) found increased expression of ApoJ mRNA in involuting 
and involuted haemangioma while expression was undetected in proliferative lesions. 
Immunohistochemical analysis demonstrated increased positive granular staining for 
ApoJ localised to the MCs and the flattened endothelium of the involuting phase. 
However, the surrounding fibrofatty tissue was devoid of ApoJ. However, Tan, (2001) 
found that increased ApoJ expression was not associated with steroid-induced 
involution of haemangioma. 
 
1.7.1.3. MITOCHONDRIAL CYTOCHROME B  
Mitochondrial genes are associated with cell senescence and are proposed to 
play an important role in apoptosis (Zamzami et al., 1997). Hasan et al (2001) were the 
first to report increased expression of mitochondrial cytochrome b (mt Cyt b) in 
spontaneous and steroid-induced involution of haemangioma. They also found that 
expression was low or completely absent in proliferative and involuted samples.  
 
1.8. VASCULAR MORPHOGENESIS AND 
MAINTENANCE 
 
1.8.1. THE MAMMALIAN VASCULAR SYSTEM 
The mammalian vascular system is composed of interconnected channels that 
distribute oxygenated blood via arteries and capillaries (Sadler, 1985). These vessels 
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consist of three basic layers, viz., intima, media and adventitia (Figure 1.10) (Schoen & 
Cotran, 1999). The intima is the innermost layer consisting of a single layer of ECs and 
a thin underlying layer of connective tissue called the internal elastic lamina. The media 
is mainly composed of SMCs. Arteries contain abundant elastic matrix to accommodate 
arterial pressure but veins have only a thin media with thinner SMC layers. Capillaries 
lack media but are lined with scattered pericytes. The adventitia is the outermost layer 
composed of mainly connective tissue through which the vessels contact the 
surrounding matrix (Tan, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: The basic structure of the blood vessel walls. Intima, media and adventitia 
are the three basic layers of the vessel wall of arteries, capillaries, veins and lymphatic 
vessels. Intima consists of a single layer of ECs and a thin underlying layer of 
connective tissue composed of elastic and collagen fibres. The media in the arteries and 
veins contain multiple layers of SMCs and elastic matrix. Capillaries lack media and are 
invested by scattered pericytes. The adventitia is mostly composed of connective tissue 
by which the vessels make contact with the ECM (Image reproduced from Sheir et al., 
2004). 
 
 
1.8.2. DEVELOPMENT OF THE MAMMALIAN VASCULAR SYSTEM 
Early in embryonic development, vascular channels are formed by the 
differentiation of mesodermal cells into haemangioblasts (Folkman & D’Amore, 1996; 
Risau, 1995; Sadler, 1985). This de novo differentiation leads to the formation of blood 
islands, which are small aggregations or clumps of haematopoeitic cells. While the cells 
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at the borders, differentiate into angioblasts and EC precursors that would eventually 
line the lumen, the cells in the center differentiate into blood cells (Risau, 1997). These 
islands fuse together to form the primitive vascular channels, i.e., the primary capillary 
plexus. This process is called vasculogenesis (Risau, 1988).  
The plexus continues to undergo remodelling which involves the generation of 
more small and large vessels and also regression of some vessels. Some pruning steps 
take place such as lumen formation, peri-endothelial support cell recruitment and 
sprouting (Nakamura, 1988). These processes are collectively known as angiogenesis 
(Risau, 1988). This angiogenic processes ultimately lead to the formation of 
differentiated blood vessels in the early embryo (Risau, 1988).  These processes are also 
involved with the angiogenic response in the adult (Tan, 2001).  
The mesenchymal cells (MeCs) differentiate into SMCs (Nakamura, 1988; 
Kirby & Waldo, 1995). These cells migrate toward the evolving endothelial tubes and 
differentiate further into mural SMCs in veins and arteries, and into pericytes in the 
capillaries (Tan, 2001). 
 
 
 
 
 
 
 
 
 
 
Figure 1.11.: Vasculogenesis and angiogenesis. Schematic overview of vasculogenesis 
and angiogenesis, showing coalescence of endothelial-cell precursors (angioblasts and 
haemangioblasts) and differentiation into ECs (A), which form the primitive 
vasculogenic networks (vasculogenesis) (B). Remodelling of these networks occurs 
through angiogenesis (C), which involves sprouting resulting in the formation of 
microvessels. (Image redrawn from Hendrix et al., 2003). 
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1.8.2.1 VASCULOGENESIS AND ANGIOGENESIS 
 Vasculogenesis is the process by which new blood vessels are formed by the 
differentiation and migration of endothelial progenitor cells to form interconnecting 
capillaries. Endothelial and haematopoietic cells share a common progenitor, the 
haemangioblast (Figures 1.12 and 1.13). These cells form aggregates in the developing 
yolk sac (also called the blood islands) and ablation of the transcription factor SCL 
present in these cells leads to failure in haematopoiesis and EC development (Robb et 
al., 1995; Robb et al., 1996; Sinclair et al., 1999). Angiogenesis is the generation of 
new blood vessels from pre-existing blood vessels. The signals that regulate the 
migration and organisation of cells into tubes during vasculogenesis and angiogenesis 
are complex and few of the factors involved in these processes have been identified 
(Figures 1.12 and 1.13).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Roles of the vascular endothelial growth factor (VEGF)/VEGFRs) and the 
angiopoietin/TIE-2 systems in embryonic vascular development. (A) VEGF, VEGFR-1 
and VEGFR-2, are critically involved in the formation of the primitive vascular system 
from differentiating mesodermal progenitors (vasculogenesis). (B) During the 
subsequent processes of angiogenesis and remodelling, VEGF and the VEGF receptors 
cooperate with the Ang-1/TIE-2 system. (C) The latter is also involved in the 
maturation of the developing vasculature, by mediating interactions between ECs and 
perivascular support cells. (Image redrawn from Breier, 2000). 
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Gene targeting experiments have provided insights into the functions of VEGF 
and VEGFRs during embryonic vascular development. VEGF is critically involved in 
early stage vascular development. Formation of blood vessels was found to be severely 
impaired in mice that lack VEGF, resulting in embryonic death around day 10 
(Carmeliet et al., 1996; Ferrara et al., 1996). Other early stage processes of vascular 
development such as vasculogenesis, large vessel formation, capillary sprouting and the 
remodelling of the yolk sac vasculature are affected in VEGF knockout embryos.  The 
severe haploid insufficient phenotype indicates that VEGF acts in a strictly does-
dependent manner to maintain angioblast differentiation and survival during early stage 
development. However, the vasculature becomes increasingly independent from VEGF 
after birth (Gerber et al., 1999). Inactivation of VEGFR-2 also causes embryonic 
lethality around mid-gestation but the phenotypes of such mice are distinct from those 
lacking VEGF, thus indicating that both these factors exert different functions (Breier, 
2000). Mice lacking functional VEGFR-2 show complete failure of vasculogenesis, EC 
differentiation and haematopoiesis (Shalaby et al., 1995), consistent with its expression 
in the putative common precursor of endothelial and haematopoietic cells, the 
haemangioblast (Kataoka et al., 1997). VEGFR-1 deficient mouse embryos have 
abnormally enlarged blood vessels (Fong et al., 1995). Fong et al (1999) found that 
VEGFR-1 and VEGFR-2 appears to exert opposite activities, in that VEGF-2 signalling 
was required for the emergence of mature ECs, while VEGFR-1 negatively regulated 
the commitment of angioblasts during vasculogenesis. VEGFR-3 was however 
identified as non important for vasculogenesis but plays a role in the remodelling of the 
vasculature and in the formation of lymphatic vessels (Veikkola et al., 1999).  
 The angiopoietins, Ang-1 and Ang-2, also play a substantial role in angiogenesis 
(Hanahan, 1997). Ang-1, a chemotactic factor for ECs, supports and promotes vessel 
development (Figures 1.12, 1.13 and 1.14). Ang-1 is secreted from cells in the vicinity 
of developing blood vessels, and is considered as the agonistic TIE-2 ligand because 
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Ang-1 and TIE-2 knockout mice show a very similar phenotype. The targeted 
inactivation of Ang-1 or TIE-2 resulted in defective vascular development and 
subsequent embryonic death (Sato et al., 1995; Suri et al., 1996). In contrast to mice 
deficient for VEGF or the VEGFRs, vasculogenesis proceeds normally in Ang-1 and 
TIE-2 deficient mouse embryos, indicating that this signalling system functions 
downstream of the VEGF/VEGFR system. The most prominent defects in Ang-1 or 
TIE-2 deficient mouse embryos are the absence of heart trabeculae, the failure of 
remodelling of the yolk sac vasculature and the absence of capillary sprouts in the 
neural tube. The heart trabeculation phenotype indicates that Ang-1 and TIE-2 are 
involved in the recruitment of perivascular cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Growth factors and their receptors implicated in different stages of 
vasculogenesis and angiogenesis. Key: Ang-1 and -2 refer to angiopoietin-1 and -2 and 
TIE-2 to the angiopoietin receptor; FGF-2 is fibroblast growth factor-2 and FGFR is its 
receptor; VEGF is vascular endothelial growth factor and VEGFR-1 and VEGFR-2 its 
receptors. (Image redrawn from Charnock-Jones et al., 2004)  
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them. Consequently, Ang-1 may also help preserve EC quiescence. Moreover, Ang-1 
also stimulates the formation of EC sprouts in vitro, and it acts synergistically with 
VEGF in this assay (Koblizek et al., 1998). Therefore, it is likely that Ang-1 and VEGF 
co-opperate to stimulate capillary sprouting in the developing organism. Based on the 
failure of blood vessels to interact properly with the underlying matrix or 
periendothelial supporting cells in Ang-1 deficient mouse embryos, it has been 
proposed that Ang-1 activity stabilizes blood vessels (Davis et al., 1999) (Figure 1.14). 
Ang-2 on the other hand, although analogous to Ang-1, it completely inhibits 
Ang-1 induced kinase activation of TIE-2 receptor on ECs (Witzenbichler et al., 1998). 
Inhibition of TIE-2 kinase activity does not block EC proliferation and angiogenesis, 
but rather facilitates it (Hanahan, 1997).  Focal expression of Ang-2 evidently blocks 
the Ang-1/TIE-2 signal, resulting in a loosening of this tight vascular structure and 
thereby exposing the ECs to activating signals from angiogenesis inducers, including 
VEGF. If VEGF (or another angiogenesis inducer) is present, the ECs become activated 
to migrate and proliferate, producing new capillary sprouts and in turn tubes. 
Furthermore, Ang-2 is uniformly expressed at high levels during vascular regression. 
This uniform presence of Ang-1 allows a shift in the local balance of Ang-1/Ang-2 back 
in favour of Ang-1, to effect maturation and stabilization of the newly formed vessels. 
Thus, there appears to be a collaboration between VEGF, Ang-2, and Ang-1 to elicit 
angiogenesis with vascular regression being associated with very high-level expression 
of Ang-2 in the absence of the activating (survival) signal from VEGF. This results in 
preventing the Ang-1 signal leading to catastrophic detachment from matrix and support 
cells, most likely with consequent apoptosis (Hanahan, 1997) (Figure 1.14) 
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Figure 1.14. A model for the regulation of the vascular endothelium by VEGF, Ang-1 and Ang-2. All three ligands bind to their respective receptors and 
elicit distinct downstream cellular responses. VEGF binding to VEGFR-2 sends a classical proliferation signal. When first activated in embryogenesis, this 
interaction induces the birth and proliferation of ECs. In contrast, VEGF binding to VEGFR-1 elicits endothelial cell-cell interactions and capillary tube 
formation. Ang-1 binding to TIE-2 receptor recruits and maintains the association of peri-endothelial support cells (pericytes, smooth muscle cells, 
myocardiocytes), thus solidifying and stabilising a newly formed blood vessel. Ang-2 binds and blocks kinase activation in ECs. The Ang-2 negative signal 
causes vessel structures to loosen, reducing EC contact with matrix and disassociating peri-endothelial support cells. This loosening appears to render the 
ECs more accessible and responsive toward the angiogenic inducer VEGF (and other inducers). Ang-2 is expressed at uniformly high levels in vascular 
regression (e.g., in nonproductive ovarian follicles); the lack of VEGF co-expression suggests that loosening of cell-matrix interactions in the absence of a 
growth or survival signal elicits EC death, likely by apoptosis. Other factors may also play into these distinctive states (Image redrawn from Hanahan, 
1997) 
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1.8.3. THE ANGIOGENIC CASCADE 
The angiogenic process of vascular sprouting involves a cascade of events that 
include: (1) vasodilation and an increase in vascular permeability; (2) activation of 
proteases leading to degradation of the BM; (3) increase in EC proliferation; (4) 
migration of the ECs (probably towards a angiogenic stimulus); (5) assembly of ECs to 
form a tube with a lumen; (6) Recruitment of pericytes and MeCs to the outside of the 
capillary to form a stable vessel and finally (7) vessel maturation which involves 
inhibitory signals and signals required for the reconstitution and formation of the BM 
(Figure 1.15) (Tomanek et al., 2000; Hirschi et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Schematic representation of the angiogenic process. EC activation 
subsequent to exposure of an angiogenic stimulus is followed by BM degredation and 
the extension of the cytoplasmic processes in the direction of the stimulus (A). This is 
followed by EC migration into the surrounding matrix and formation of capillary 
sprouts. EC proliferation occurs just behind the migrating front and lumen formation 
begins in the proximal region of the sprout (B). Sprout maturation occurs with 
recruitment of MeCs to form peri-endothelial cells, reconstitution and formation of new 
BM which coincides with the cessation of cell migration and proliferation (C). 
(Courtesy of Dr Swee. T. Tan.) 
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1.8.4. ANGIOGENIC FACTORS IN BLOOD VESSEL DEVELOPMENT 
Central to vasculogenesis and angiogenesis are the ECs. These cells migrate, 
proliferate and assemble into tubes with tight cell-cell connections to contain blood. 
MeCs are recruited then differentiate into the peri-endothelial support cells (pericytes 
for capillaries, SMCs for larger vessels and myocardiocytes in the heart), which provide 
maintenance and modulatory function to the vessels (Hanahan, 1997; Tomanek & 
Schatteman, 2000). The establishment and remodelling of blood vessels is controlled by 
paracrine and autocrine signals that mainly involve the binding of protein ligands to 
their respective RTKs expressed by vascular ECs (Folkman & Shima, 2000; Hanahan, 
1997; Hanahan and Folkman, 1996) (Figure 1.16).  
The generation of angioblasts from the mesoderm and the formations of ECs 
from these mesodermal cells during vasculogenesis or from pre-existing capillaries 
during angiogenesis (Folkman et al., 1997; Tomanek & Schatteman, 2000) requires the 
action of the FGF family and in particular FGF-2 (Folkman & D’Amore, 1996; Flamme 
& Risau, 1992) (Figure 1.16). 
VEGF is also an important regulator of both vasculogenesis and angiogenesis. 
Although both VEGFR-1 and VEGFR-2 are expressed on angioblasts and the ECs that 
arise from them, only VEGF binding to VEGFR-2 leads to EC proliferation (Shalaby et 
al., 1995) (Figure 1.16). In contrast VEGF binding to VEGFR-1 is required for 
endothelial cell-cell interactions and capillary tube formation (Hanahan, 1997). 
Although disruption of the VEGFR-1 signal permits differentiation of ECs, it results in 
the formation of thin-walled vessels with a larger than normal diameter. Therefore, 
VEGFR-1 is said to be important with the later stags of vasculogenesis (Fong et al., 
1995). 
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Figure 1.16: The role of cytokines and cell-cell interactions in blood vessel formation 
(vasculogenesis and angiogenesis) is a culmination of a number of processes involving 
a variety of molecules and extensive interactions between a number of cell types (see 
text for details) (Reproduced with permission from Tan, 2001) 
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Ang-1 produced by MeCs is the chemotactic factor for ECs and also supports 
and promotes vessel development. Ang-1 binding to TIE-2 activates a signal from the 
ECs, which recruits undifferentiated MeCs to the forming vessel (Folkman et al., 1997; 
Hanahan, 1997). Its signal is also required to maintain EC association with the 
differentiated peri-endothelial support cells, thereby stabilising the newly formed blood 
vessel (Hanahan, 1997) (Figure 1.16). Ang-2 on the other hand, is known as a natural 
antagonist of Ang-1. Ang-2 over expression blocks the stabilising signal of Ang-1 
because Ang-1 can no longer induce TIE-2 receptor activation on ECs (Witzenbichler et 
al., 1998). However, inhibition of TIE-2 kinase activity does not block EC proliferation 
and angiogenesis, instead facilitates it (Hanahan, 1997). This happens because the Ang-
2 negative signal causes vessel structures to become loosened by the reduction of EC 
contact with the matrix and dissociation of peri-endothelial support cells. This loosening 
appears to render the ECs more accessible and responsive to VEGF (and other inducers) 
(Hanahan, 1997). It has also been suggested that high Ang-2 expression, loosening of 
cell-matrix interactions together with the absence of growth factors such as VEGF 
results in EC death most likely by apoptosis (Hanahan, 1997). Other modulators, some 
of which have been described in section 1.4 (page 30) also play into these distinctive 
states of angiogenesis (Plank & Sleeman, 2003).   
Once the primitive vessel tubes are formed, they are remodelled to form the 
mature vessel bed. This remodelling involves the formation of the medial layer 
consisting of SMCs in large vessels and pericytes in the microvasculature, deposition of 
the BM and induction of tissue specific specialisation (Tan, 2001). Upon contact of EC 
with MeCs, the EC-derived TGF- is activated from its latent state (Hirschi et al., 1999; 
Folkman & D’Amore, 1996). The active TGF- leads to the up-regulation of myosin 
and SMA which causes the MeCs to assume the morphology of pericytes or SMCs 
(Folkman & D’Amore, 1996). Failure of pericyte formation has been shown to cause 
regression of the naked nascent endothelial tubes (Folkman & D’Amore, 1996). EC-
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MeC contact also suppresses cell proliferation and stabilises the mature vasculature 
(Tan, 2001) (Figure 1.16). 
In addition to inducing differentiation of MeCs into pericytes or SMCs, the 
activated form of TGF- also inhibits EC proliferation and stimulates matrix deposition 
(Hirschi et al., 1999).  Thus, a lack of local TGF- production could permit increased 
proliferation of ECs.  Furthermore, as TGF- alters integrin expression, the poor 
vascular integrity in the TIE-2/Ang-null mice could be explained by the lack of EC-
SMC contacts and lack of TGF- (Folkman & D’Amore, 1996). 
 
 
1.9 ROLE OF STAT PROTEIN IN TUMOURIGNESIS 
1.9.1 STAT PROTEINS 
STAT proteins comprise a family of transcription factors that consists of seven 
different members: STAT-1, -2, -3, -4, -5A, -5B, and -6 (Darnell, 1997). Abundantly 
produced in many cell types, they are activated by over 40 ligands (Calo et al., 2003). 
These include a series of extracellular signalling proteins such as cytokine, growth 
factors, and hormones that bind to specific cell-surface receptors (Horvath, 2000). 
Aberrant activation of STAT signalling can lead to the deregulation of crucial signalling 
pathways. In this way, STATs take part in tumourigenenic cell transformation 
(Bowman et al., 2000). 
Cytokines that activate STATs include, type I cytokines (interleukins, 
neutrophic factors, and hormones) and type II cytokines (IFNs). Growth factors also 
activate STAT proteins via their receptors. These include epidermal growth factor 
(EGF), hepatocyte growth factor (HGF), PDGF and VEGF (Korpelainen et al., 1999; 
Bartoli et al., 2000). 
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1.9.2 MECHANISMS OF STAT ACTIVATION 
  STAT proteins become activated by tyrosine phosphorylation of critical tyrosine 
residues. These residues are Tyr 701 for STAT-1, Tyr 690 for STAT-2, Tyr 705 for 
STAT-3, Tyr 693 for STAT-4, Tyr 694 for STAT-5 and Tyr 641 for STAT-6 (Becker et 
al., 1998). The best-studied pathway for STAT activation is through the Janus kinases 
(JAKs). JAKs are constitutively associated with cytokine receptors. Ligand binding 
leads to dimerisation of the receptor and activation of the JAKs. These kinases once 
activated can trans-phosphorylate the critical tyrosine residues within the 
intracytoplasmic portion of the receptor chains to provide docking sites for the STAT 
proteins (Briscole et al., 1996). STATs then make contact with the receptor through 
their SH2 domain. On binding, the JAKs subsequently tyrosine phosphorylate the 
‘docked’ STAT at conserved tyrosine residues (Figure 1.17). Upon tyrosine 
phosphorylation, the STAT proteins dissociate from the receptor subunit and form 
dimers by virtue of reciprocal-SH2 phosphotyrosine interactions i.e., the SH2 domain of 
one STAT molecule binds with the SH2 domain of a second STAT molecule containing 
the phosphotyrosine (Chatterjee-Kishore et al., 2000; Darnell, 1997).  
STATs can form homodimers (most commonly) as well as heterodimers 
(Bromberg, 2001). Dimeric STATs are further phosphorylated, this time on serine, 
which makes it an active transcription factor.  STAT dimers then translocate to the 
nucleus, bind to specific DNA-binding elements and activate gene transcription. 
Therefore, while tyrosine phosphorylation activates the STAT proteins, nuclear 
translocation and DNA binding is essential for it to effect gene regulation (Yahata et al., 
2003). Since STAT proteins lack a nuclear localisation signal, chaperone proteins have 
been suggested to assist nuclear translocation of STATs (Johnson et al., 1998). 
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1.9.3 PHYSIOLOGICAL ROLE OF STATS 
STATs play important roles in programming gene expression in biological 
events as diverse as embryonic development, organogenesis, regulation of cell growth 
and apoptosis (Horvath, 2000). Evidence for this comes from cell culture experiments, 
animal experiments and clinical observations on human cancer cells (Bromberg, 2001). 
While in normal cells ligand-dependent activation of STATs is a transient process, 
lasting for several minutes to several hours, many cancerous cell lines and tumors 
exhibit persistently tyrosine phosphorylated and thus constitutively activated STAT 
proteins. Furthermore, deregulated STAT protein signalling contributes to tumour 
development by bringing about the loss of immune surveillance (Bromberg, 2002).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17: Schematic representation of STAT activation via JAK activation. STAT-3 
and STAT-1 activation is induced via signalling though IL-6 and IFN receptors. See 
text for details (Reproduced from Kerr et al., 2003). 
 
 
 52 
  STAT-3 activation is involved in early embryogenesis (Akira, 2000, Takeda et 
al., 1997), in migration of skin epidermic cells and in skin remodelling during wound 
healing (Sano et al., 1999). It is required for the inactivation of the macrophages and the 
inhibition of inflammatory cytokines in the T-helper cell response (Takeda et al., 1999). 
STAT-3 activation is also required to maintain the pluripotent state of proliferating 
embryonic stem cells and for macrophage differentiation (Hirano et al., 2000). 
 
 
1.9.4 STAT-3 IN HUMAN ONCOGENESIS AND REGULATION OF 
APOPTOSIS 
Persistent activation of STAT-3 plays an important role in preventing apoptosis 
in many large tumours and cell lines including lymphomas, leukemias, mycoses 
fungoides (Nielson et al., 1999), multiple myeloma, brain (Bonni et al., 1997; Ihara et 
al., 1997), prostate, breast, lung, and head and neck cancers (Bromberg et al., 2001). 
Studies have shown that the suppression of apoptosis by STAT-3 was due to its ability 
to induce expression of apoptosis suppressor proteins such as Bcl-2 and Bcl-xl (Catlett-
Falcone et al., 1999; Buettner et al., 2002).  
Various studies have shown that STAT-3 activation was required and sufficient 
to mediate cellular transformation (Bromberg et al., 1998a; Turkson et al., 1998; 
Bromberg et al., 1999; Ram et al., 2000). A possible connection between STAT-3 and 
tumourigenesis is its association with c-Jun, the first discovered nuclear proto-oncogene 
(Bromberg, 2001).  
Recently, Chan et al (2004) demonstrated that STAT-3-deficient mice were 
resistant to skin tumour development and suggested that STAT-3 was required for 
epithelial carcinogenesis by maintaining the survival of DNA-damaged stem cells and 
mediating the proliferation necessary for the clonal expansion of these cells during 
tumour promotion (Chan et al., 2004). In addition, Zong et al (2000) found that 
endogenous IGF stimulation resulted in increased STAT-3 activation. Studies have also 
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shown that the stable dimerisation of STAT-3, caused by engineered mutations, was 
sufficient to transform NIH 3T3 cells (Bromberg et al., 1999). All these findings have 
accentuated the importance of STAT-3 activation in   inducing cell proliferation 
(Bromberg et al., 1999). 
 
 
1.9.5 STAT-1 IN GROWTH RESTRAINT, PROMOTER OF 
APOPTOSIS AND TUMOUR SUPPRESSION 
STAT-1 is increasingly being established as a tumour suppressor since its 
activation is associated with growth arrest (Durbin et al., 1996). Kaplan et al (1998) 
showed that STAT-1 deficient mice were more susceptible to tumour development and 
that the STAT-1-/- genotype coupled with the removal of the tumour suppressor gene, 
p53, greatly increased spontaneous tumour formation (Kaplan et al., 1998). 
STAT-1 is now recognised as the principal target of IFNs (Schindler et al., 
1992; Darnell et al., 1994; Stark et al., 1998). Studies have shown that IFN or IFN 
treatment does not inhibit the proliferation of STAT-1 deficient fibroblasts and that 
STAT-1 deficient ostoesarcoma-derived cells do not undergo apoptosis in response to 
IFN or the tumour necrosis factor (TNF) (Su et al., 1997; Sahni et al., 1999; Migone, 
1995). In addition, the defective growth of tumour cells in response to IFN has been 
attributed to STAT-1 activation (Chin et al., 1997; Kumar et al., 1997). 
The involvement of STAT-1 in growth arrest and apoptosis in many cell types, 
seems to be due to its capacity to induce expression of pro-apoptotic mediators such as 
caspases and TRAIL (Choi et al., 2003; Chin et al, 1997; Kumar et al., 1997) while 
decreasing the expression of anti-apoptotic modulators such as Bcl-2 and Bcl-xl 
(Stephanou et al., 2000).  
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1.10 AIM OF THIS PROJECT 
 The overall aim of this thesis is to study the cellular development of 
haemangioma and the signalling pathways that are involved in the proliferation and 
involution of haemangioma. The identification of novel treatment agents that may be 
associated with fewer side effects was also investigated. Studying the cellular processes 
involved in the biology of haemangioma will provide a better understanding of the 
formation of microvessels. This is of importance for both haemangioma growth, and 
also for angiogenesis associated with other proliferating tumours, as inhibiting the 
formation of new blood vessels is an important therapeutic target for reducing tumour 
growth.   
 
1.10.1 OBJECTIVES 
The specific objectives of this study were (1) to identify changes in expression 
of key transcription factors and RTKs involved in cellular proliferation and apoptosis 
during the natural progression of a haemangioma; (2) to study the expression patterns of 
TRAIL and its receptors in proliferating, involuting and involuted haemangioma and to 
elucidate the role of TRAIL receptor signalling in modulating haemangioma 
progression; (3) the utilisation of the newly developed in vitro model to evaluate the use 
of TRAIL as a potential treatment option for haemangioma; (4) the purification, culture 
and characterisation of haemangioma-derived cells  in vitro; and (5) the identification of 
novel genes or cell types which may be important modulators of haemangioma 
development. 
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CHAPTER 2: METHODS 
 
2.1 GENERAL METHODS 
2.1.1 QUANTITATIVE REAL TIME PCR 
2.1.1.1 AN INTRODUCTION TO QUANTITATIVE REAL TIME PCR 
Quantitative real-time polymerase chain reaction (qRT-PCR) assay was used in 
this study to quantify changes in mRNA expression. The basic principles, advantages, 
limitations and the special kinetics of qRT-PCR have been well adequately covered in 
numerous reviewed articles (Bustin, 2000; Giulietti et al., 2001; Yin et al., 2001; 
Rose’Meyer et al., 2003).  However, a brief introduction to qRT-PCR, the detection 
method used in this study and the limitations are described below.  
qRT-PCR is now widely used to measure differences in mRNA expression due 
to its outstanding accuracy, broad dynamic range and sensitivity. It is also fast, highly 
reproducible and requires minimal amount of RNA (Freeman et al., 1999; Heid et al., 
1996). qRT-PCR analysis allows direct quantification of specific PCR products during 
the exponential phase (i.e., at linearity) of the reaction, also taking into account the 
special amplification kinetics of each target.  
For this study, the SYBR green dye was used as the reporter dye. This dye 
fluoresces on binding to double stranded DNA. Therefore, there is an increase in 
fluorescence of dye with the accumulation of PCR product which is reported after every 
cycle. Quantification is achieved by determining the cycle at which the fluorescence 
increases above an arbitrary threshold. This threshold can be manually changed for each 
experiment if necessary. The PCR cycle at which the fluorescence exceeds the chosen 
threshold, due to the linear amplification of the specific product is reported as the Ct 
value (Yin et al., 2001). For most genes, an end point or plateau is reached in less than 
40 cycles (depending on transcript abundance), whereby no further amplification can 
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take place due to competitive PCR effects. Ct values refer to the relative mRNA 
transcript levels for a particular candidate gene, whereby the Ctx value for the reference 
or housekeeping gene is subtracted from the candidate gene Cty in relation to the total 
mRNA concentration and is given by the equation Ct = Cty − Ctx. This means, a single 
Ct difference (Ct = 1) represents a two-fold difference in the amount of specific target 
(Livak & Schmittgen, 2001). Therefore, Ct values decrease linearly with increasing 
input target quantity and this can be used as a quantitative measurement of the input 
target (Giulietti et al, 2001). 
The limitation of SYBR Green I real time detection is that it does not 
differentiate between specific target and non-specific product. To overcome this 
limitation, DNA melt curves were analysed at the end of all qRT-PCR amplifications 
performed in this study. These are graphs obtained by plotting fluorescence as a 
function of temperature as the thermal cycler heats through the dissociation temperature 
of the product. The shape and position of this curve are functions of the GC/AT ratio, 
length and sequence and can be used to differentiate amplified products separated by 
less than 2˚C in melting temperature. Analysis of melting curves can therefore 
distinguish desired from undesired products and also extend the dynamic range of 
template quantification (Ririe et al., 1997) (see Appendix 1, Figure 1.2, page 270) 
Relative quantification was the method chosen to quantify changes in mRNA 
levels in this study.  Because this method quantifies the expression of the target gene 
with respect to a stably expressed reference gene (housekeeper gene), selection of an 
appropriate house keeping gene becomes important. House keeping genes are necessary 
for cell survival. The mRNA synthesis of these genes is considered to be stable between 
tissues and under different experimental treatments. However, numerous studies have 
shown that this is not always the case (Zhang & Snyder et al, 1992; Bhatia et al., 1994; 
Bereta and Bereta 1995; Chang et al., 1998; Thellin et al., 1999; Zhong & Simons, 
1999; Schmittgen & Zakrajsek, 2000; Selvey et al., 2001). In addition, the copy number 
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of the house keeping gene and the target gene should be similar so that measurements 
can be made on the same linear scale (Roche LC technical note 15/2002). 
Quantification using a true reference gene allows for the normalisation of 
differences in the amount of amplifiable RNA or cDNA in individual samples generated 
by (i) different amounts of starting material, (ii) the quality of the starting material, (iii) 
enzymatic efficiency; and (iv) differences in RNA preparation and cDNA synthesis. 
This is because the reference gene is exposed to the same preparation steps as the gene 
of interest.  When a single house keeping gene is used as a reference, differences in 
gene expression ratios may reflect regulation of the house keeping gene rather than the 
gene under investigation. Therefore, relating gene expression to several housekeepers in 
parallel has been suggested (Schmid et al., 2003).  
Some commonly used housekeeping genes include cyclophilin A (CycA) 
(Bjarnason et al., 1998), glyceraldehyde 3 phosphate dehydrogenase (GAPDH) 
(Petersen et al., 1990), hypoxanthine phosphoribosyltransferase (HPRT) (Foss et al., 
1998) and 18SrRNA (Finnegan et al., 1993). These genes were validated for use in this 
study (see Appendix 1, section 1.1.2.2, page 272).  
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2.1.1.2 RNA ISOLATION AND QUANTITATION 
RNA from snap-frozen haemangioma tissue biopsies (1-2 mg of frozen tissue) 
and cell cultures (approximately 1x105 viable cells) was isolated by a modified protocol 
using a combination of TRIzol reagent (Invitrogen, Auckland, New Zealand) and the 
High pure RNA tissue Kit (Roche diagnostics, New Zealand, Ltd).  
 
2.1.1.2.1 RNA extraction from snap frozen tissue biopsies. 
Frozen haemangioma tissue was ground to a powder in liquid nitrogen and added to 
750 µl of Trizol. Samples were left in TRIzol overnight at 4˚C. 350 µl of choloroform 
was then added, mixed for 15 sec and left at room temperature for 10 min. The tubes 
were centrifuged at 4˚C for 15 min at 13,000 X g and the aqueous phases (approx 500 
µl) containing the RNA were transferred into clean eppendorf tubes to which an equal 
volume of 70% ethanol was added. The entire mixture was then applied to the upper 
reservoir  of an assembled High Pure filter and collection tube, and spun in a benchtop 
centrifuge at room temperature for 15 sec at 8,000 X g. The flowthrough was discarded 
and the filter and collection tube re-assembled. Any contaminating DNA was removed 
by adding 90 µl of DNAse I incubation buffer (1 M Nacl, 20 mM Tris-HCL, 10 mM 
MnCl2 pH 7.0) with 10 µl of DNAse I onto the glass filter fleeces of the upper reservoir 
of each filter tube, and incubating for 15 min at 15-25˚C. Next, 500 µl of wash buffer I 
(5 M guanidine hydrochloride, 20 mM Tris-HCL, ethanol, pH 6.6) was added to the 
upper reservoir and spun for 15 sec at 8,000 X g. The flowthrough was discarded and 
500 µl of wash buffer II (20mM NaCl, 2mM Tris-HCL, ethanol, pH 7.5) was added, 
and spun for 15 sec at 8,000 X g. After discarding the flow-through, a final wash step 
using 300 µl of wash buffer II was carried out and the filter tubes were inserted into 
sterile 1.5 ml eppendorf tubes. 50 µl of elution buffer (nuclease-free, sterile, double 
distilled water) was applied to the upper reservoir of the filter tubes and incubated at 
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room temperature for 10 min. RNA was eluted by centrifugation for 1 min at 13,000 X 
g. RNA was stored at -80˚C. 
 
2.1.1.2.2. RNA extraction from cell cultures 
To extract RNA from cell cultures, the culture media was removed from the dish 
and 1ml of TRIzol was pipetted directly into the culture dishes containing 
approximately 1x105 cells. The culture dish was swirled vigorously and RNA was 
purified from the TRIzol reagent as described in section 2.1.1.2.1 (page 58). 
 
2.1.1.3 RNA QUANTIFICATION 
The quantity and purity of each RNA extraction was determined using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, DE).  The 
absorbance was measured at 260 nm from 2 µl of samples. RNA concentration was 
determined using the extinction coefficient for RNA of 40 µg/ml and calculated using 
the following formula. 
Concentration (ng/µl) = A260 x dilution x 40 
The ratio of the absorbance at 260/280 nm was used to determine the purity of 
the RNA. Pure RNA has a ratio between 1.9-2.1. Early in the study the quality of the 
RNA samples were also determined by electrophoresis on agarose gels and by 
visualisation of the integrity of the 18S and 28SrRNA bands. 
 
2.1.2 cDNA SYNTHESIS 
cDNA was synthesised using a Superscript III cDNA synthesis kit (Invitrogen).  
cDNA was synthesised using either random hexamers or Oligo(dT)20 as primers. Each 
reaction contained approximately 400 ng of RNA, 500 µM dGTP, dCTP, dATP, dTTP 
and 2.5 µM Oligo(dT)20 or 250 ng of random hexamer primers. The RNA and primer 
mix was first denatured for 5 min at 65˚C followed by incubation on ice for 1 min. A 
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reaction mixture containing 1X First-Strand buffer (50 mM Tris-HCL, pH 8.3, 75 mM 
KCL, 3 mM MgCl2), 5 mM DTT, 200 U SuperScript III and 40 U RNaseOUT, was then 
added to each tube to a final volume of 20 µl and incubated for 1 hour (hr) at 50˚C. 
cDNA was stored at -20˚C until required.  
Random hexamers primed cDNA templates were used in the housekeeping gene 
validation experiments where 18SrRNA was used as the internal reference gene and 
Oligo(dT)20 was used for all subsequent amplifications.  
 
2.1.3 PRIMER DESIGN AND RECONSTITUTION 
PCR primers for this study were designed using the Oligo 6 software (Version 
6.02, Molecular Biology Insights Inc., MN). Gene sequence information was obtained 
using nucleotide databases (www.ncbi.nlm.gov) and primer sequences were assessed 
for specificity using non-reduntant basic local alignment search tools 
(www.ncbi.nlm.nih.gov/BLAST). Where possible, primers were designed to be intron 
spanning to differentiate between amplification from contaminating DNA and true 
cDNA amplified PCR product. A number of parameters were taken into account when 
the primer pairs were designed: 
• The amplicon size ranged between 80-250 bp  
• All primers were designed to have a GC content of 50-60%.  
• All primer pairs had high melting temperatures (Tm of approximately 68˚C) with 
the difference in Tm being not more than 2˚C apart. 
• Primers with stable 3’ ends, stable hairpins with 5’ overhangs, duplexes with 3’ 
overlaps and mismatches at the 3’ end were avoided as best as possible.  
All the primers were synthesised by Invitrogen. Primers were reconstituted in 10 
mM Tris, pH 8.0, 0.1 mM EDTA to a final concentration of 250 µM. A working 
concentration stock was then prepared for each primer pair containing 10 µM of 
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forward and reverse primer in a single tube, diluted in distilled water (dH2O). Primer 
sequences and product sizes are given in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Primer sequences and cDNA amplicon size (in bp) used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene  Primers: sense (+) 
         Anti-sense (-) 
Product size
 
STAT-3  
 
(+) 5’-GCAGAAAGATACGACTGAGG- 3’;  
(-) 5’-GCAGATCACCCACATTCACT- 3’; 
 
180 bp 
STAT-1 (+) 5’-GGC AAA GAG TGA TCA GAA ACA A- 3’  
(-) 5’-GTT CAG TGA CAT TCA GCA ACT CT- 3’ 
118 bp 
VEGFR-2 (+) 5’ -ATTCCATGTCTCGGGTCCATT- 3’ 
(-) 5’ -CTTGCTGTCCCAGGAAATTCT- 3’ 
107 bp 
CycA (+) 5’ -GGGGAGAAAGGATTTGGCTA- 3’ 
(-) 5’ -ACATGCTTGCCATCCACCC- 3’ 
259 bp 
18SrRNA (+) 5’ -CTT AGA GGG ACA AGT GGC G- 3’ 
(-) 5’ -ACG CTG AGC CAG TCA GTG TA- 3’ 
110 bp 
GAPDH (+) 5’ -TAAAGGGCATCCTGGGCTACACT- 3’;  
(-) 5’ -TTACTCCTTGGAGGCCATGTAGG- 3’ 
200 bp 
HPRT (+) 5’ -CCC CAC GAA GTG TTG GAT ATA A- 3’ 
(-) 5’ -GTC AAG GGC ATA TCC TAC AAC A- 3’ 
82 bp 
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Table 1: Primer sequences and cDNA amplicon size (in bp) used in this study (contd). 
Gene  Primers: sense (+) 
         Anti-sense (-) 
Product size Reference 
 
CD29 
 
(+)5’-TCCAACCTGATCCTGTGTC-3’ 
(-)5’-TCGTTGTTCCCATTCACTG-3’ 
 
88 bp 
 
Gambero et al., 2006 
 
CD133 (+)5’-GCATTGGCATCTTCTATGGTT-3’ 
(-)5’-CGCCTTGTCCTTGGTAGTGT-3’ 
170 bp Liu et al., 2006 
CD44 (+)5’-AGAAGGTGTGGGCAGAAGAA-3’ 
(-)5’-AAATGCACCATTTCCTGAGA-3’ 
116 bp Liu et al., 2006 
CD90 (+)5’-CGCTCTCCTGCTAACAGTCTT-3’ 
(-)5’-CAGGCTGAACTCGTACTGGA-3’ 
143 bp Liu et al., 2006 
PPAR (+)5’-CACAAGAACAGATCCAGTGGTTGCAG-3’ 
(-)5’-AATAATAAGGTGGAGATGCAGGCTCC-3’ 
101 bp Redonnet et al., 2002 
 
Osteonectin (+)5’-AGA AGC TGC GGG TGA AGA A-3’ 
(-)5’-TGC CAG TGT ACA GGG AAG ATG-3’ 
127 bp Yi-xiong et al., 2006  
 
VEGFR-1 (+)5’ -TAC AAA GAA ATA GGG CTT CTG ACC-3’ 
(-)5’-ATG GCC TCT AAG TAA TTT GAC TGG-3’ 
144 bp Hong et al., 2006 
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Table 1: Primer sequences and cDNA amplicon size (in bp) used in this study (contd). 
 
 
Gene  Primers: sense (+) 
         Anti-sense (-) 
 
 
Product size 
 
TRAIL 
 
(+) 5’ -GAG AAC CTC TGA GGA AAC CATT- 3’ 
(-) 5’ -TTT CAT GGA TGA CCA GTT CAC C- 3’ 
 
256 bp 
DR4 (+) 5’ -TGT ACG CCC TGG AGT GAC AT- 3’ 
(-) 5’ -CAC CAA CAG CAA CGG AAC AA- 3’ 
115 bp 
DR5 (+) 5’ -CAA CGC TTC CAA CAA TGA- 3’ 
(-) 5’- ACG TGC CTT CTT TAC ACT GA- 3’ 
  119 bp 
DcR1 (+) 5’ -CCT GCA CCA TGA CCA GAG A- 3’ 
(-) 5’ -TGG CAC CAA ATT CTT CAA CA- 3’ 
168 bp 
DcR2 (+) 5’ - GCG GAG GAG ACA GTG ACC A- 3’ 
(-) 5’ - CCA GGA ACT CGT GAAGGA CA- 3’ 
227 bp 
 OPG (+) 5’ -GTC TTT GGT CTC CTG CTA- 3’ 
(-) 5’ -ACA CTC TCT GCG TTT ACT TT- 3’ 
151 bp 
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Table 1: Primer sequences and cDNA amplicon size (in bp) used in this study (contd). 
 
 
 
Gene  Primers: sense (+) 
         Anti-sense (-) 
 
 
Product size 
 
CD31 
 
(+) 5’ -CAG TGT CCC CAG AAG CAA AT- 3’ 
(-) 5’ -CTC CGA TGA TAA CCA CTG CAA- 3’  
 
88 bp 
GLUT-1 (+) 5’ -CAG CCT GTG TAT GCC ACC ATT- 3’ 
(-) 5’ -TAG CGC GAT GGT CAT GAG TAT- 3’  
155 bp 
CD45 (+) 5’ -TGT CTT TGA ACT GAG ACA TTC CA- 3’ 
(-) 5’ -TGC TCC ACA CTC CAG TTT GTA T- 3’ 
83 bp 
Collagen-I (+) 5’ -CACTGGGTTCGGAGGAGAGT- 3’ 
(-) 5’ -CGGCACAAGGGATTGACAC- 3’ 
84 bp 
Collagen-II (+) 5’ -ATGGAGACTGGCGAGACTTG- 3’ 
(-) 5’ -TGGACAGCAGGCGTAGGA- 3’ 
199 bp 
Collagen-III (+) 5' -GCGGATAGAGATGTCTGGAA- 3' 
(-) 5' -GAGGCTGTGGGCAAAC- 3' 
157 bp 
Collagen-VIII (+) 5' -CTCCTCAGATGCCACCAC- 3' 
(-) 5' -TTCTTTGCCTTTCTTGGGTA- 3' 
209 bp 
Laminin-V (+) 5’ -AGGGCAACCAGATGAGCA- 3’ 
(-) 5’ -AGGAAGACAGCCGAGGAGAT- 3’ 
211 bp 
IGF-2 (+) 5' -CCGTGCTTCCGGACAACTTC- 3' 
(-) 5' -TGGACTGCTTCCAGGTGTCA- 3' 
72 bp 
VEGF (+) 5' -TGA GGA GTC CAA CAT CAC CAT- 3’ 
(-) 5' -TGT GCT GTA GGA AGC TCA TCT- 3’ 
88 bp 
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2.1.4 THE QUANTITATIVE REAL-TIME PCR ASSAY 
  qRT-PCR analysis was performed using the Platinum SYBR Green qPCR 
supermix UDG (Invitrogen) appropriately diluted to a final reaction volume of 20 µl. 
Each reaction contained SYBR Green I, 1.5 U/ml Taq DNA polymerase, 20 mM Tris-
HCL (pH 8.4), 50 mM KCL, 3mM MgCl2, 200 µΜ dGTP, dCTP, dATP and dTTP, 1 
U/ml UDG, 0.1 µM gene-specific primers with 1 µl of template (reverse transcribed 
cDNA or purified PCR product) and 10 nM fluorescein (Invitrogen). All reactions were 
performed in duplicate. Controls included a no template (water) control and 
amplification from an equivalent amount of RNA that had not been reverse transcribed. 
Amplification was achieved with an initial denaturation at 95°C for 30 sec, followed by 
35 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 20 sec and 
extensions at 72°C for 20 sec. Data was collected from both the annealing and extension 
steps. A melt-curve analysis was performed at the end of every amplification via a 
temperature gradient from 65 to 95°C in 0.5°C increment steps measuring fluorescence 
at each temperature for a period of 30 sec. The melt-curve analysis was performed to 
confirm the absence of spurious amplification products and primer dimers. Agarose gel 
electrophoresis was also performed on selected amplifications from each run to confirm 
that products of the expected size were amplified.  Amplification products and the Ct 
values were detected using an iQ qPCR system and associated software (Bio-Rad 
Laboratories Pty Ltd, Auckland, New Zealand). The cycle numbers were calculated 
from areas of exponential amplification of the traces. The amount of mRNA expression 
was determined relative to a chosen internal house keeping gene included with each run. 
In some cases, the relative fold change in expression was also calculated using the 
formula. 
Fold change in expression = 2 –Ct 
 
 
 66 
2.1.5 HAEMANGIOMA SPECIMENS  
All haemangioma specimens were obtained according to a protocol approved by 
the Wellington Ethics Committee. Part of each specimen was snap-frozen in liquid 
nitrogen for subsequent mRNA and protein analysis while the remainder was fixed in 
paraformaldehyde prior to wax embedding for immunohistochemistry. The 
haemangioma biopsies were categorised clinically into proliferating, involuting and 
involuted phases and the assignments confirmed by histological analysis as previously 
described (Tana et al., 2000). 
 
2.1.6 CELL CULTURE  
 
2.1.6.1 CULTURE FACILITY SET-UP 
All plasticware (except pipette tips and eppendorfs) and scalpels were obtained 
sterile from the manufacturers. The pipette tips, eppendorfs, and glass bottles, were 
sterilized by autoclaving at 120ºC for 20 min before use. Spatulas and microforceps 
were wiped with 70% ethanol to prevent contamination. All handling of the tissues and 
transfer of all liquids were conducted under asceptic conditions in a sterile Email Air 
Handling Class II Biological safety cabinet (AES Environmental Pty LTD, Auburn 
Australia). Latex gloves were used at all times to prevent contamination. 
Several different cell lines were used in the present project. Cell cultures were 
grown in a Heracell incubator (Kendro Laboratory Prodects GmbH, Hanau, Germany) 
at 37ºC in humidified air with 5% CO2; herein referred to as the cell culture incubator. 
All cell line stocks were stored at -80ºC using 1 ml cryotubes (Greiner Bio-one, 
Frickenhausen, Germany) at 1x106 cells/ml in 10% DMSO (dimethyl sulfoxide)  and 
90% heat-inactivated foetal calf serum (FCS) (Gibco-BRL, Invitrogen).  
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2.1.6.2 CELL LINES USED IN THIS STUDY 
 
2.1.6.2.1 HeLa cells 
HeLa cells are an immortalized adherent cervical cancer cell line isolated from 
Henrietta Lacks, who died from her cancer in 1951 (Master, 2002). HeLa cells were 
grown in Roswell Park Memorial Institute 1640 with Glutamine (RPMI 1640 + 
Glutamine, Gibco-BRL) medium supplemented with 10% FCS and 2% Penstrep (100 
µg/ml streptomycin sulfate and 100 µg/ml penicillin G, Gibco-BRL), herein referred to 
as cell culture medium. Cells were maintained in either 25cm2 or 75cm2 sterile cell 
culture flasks (Greiner Bio-One) and were passaged by splitting the cells 1:10 twice 
weekly. 
2.1.6.2.2 3T3 fibroblasts  
The mouse fibroblast cell line, 3T3 fibroblasts, were obtained from Mr An Tan, 
Malaghan Institute of Research, Wellington, New Zealand. This is an immortalized cell 
line originally established from primary mouse embryonic fibroblast cells by two 
scientists called George Todaro and Howard Green in 1962 (Todaro & Green, 1963). 
3T3 cells were grown in cell culture medium and maintained in a similar way as 
decribed for HeLa cells.  3T3 cells were passaged by splitting the cells 1:5 twice 
weekly.  
 
2.1.6.2.3 Human vascular endothelial cells  
Human vascular endothelial cells (HUVECs) were a kind gift from Dr Sarah 
Gunningham, Christchurch School of Medicine and Health Sciences, Otago University. 
HUVECs were grown in RPMI 1640 + glutamine, 10% FCS, 2% Penstrep and 30 µg/ml 
endothelial cell growth supplement (ECGS, Sigma-Aldrich, New Zealand). Cells were 
passaged 1:3 when the cells reached 80% confluencey. 
 68 
2.1.6.2.4 Haemangiendothelioma cells  
The mouse derived haemangiendothelioma cell line (EOMA) was purchased 
from the American Type Culture Collection (ATCC). Cells were obtained frozen and 
thawed as described in section 2.1.6.3. EOMA cells were grown in cell culture medium 
and passaged by splitting the cells 1:5 twice weekly. 
 
2.1.6.3. STANDARD CELL CULTURE TECHNIQUES  
When required, cells frozen at -80 ºC were thawed in a water bath at 37ºC. Cells 
were then transferred to 15 ml centrifuge tubes (Greiner Bio-one) containing 10 ml of 
pre-warmed cell culture medium and centrifuged at 300 X g (1000 rpm) for 5 min at 
room temperature. Following removal of the supernatant, the cell pellet was 
resuspended in fresh cell culture medium and transferred to culture flasks for expansion.    
To passage cells, the medium was removed and the cells were rinsed with sterile 
phosphate buffered saline (PBS) (Appendix 4, section 4.2.1). To dissociate the cells, an 
appropriate volume of pre-warmed trypsin-ethylenediaminetetraacetic acid (EDTA) 
(Invitrogen) (Final concentration of 0.05%-0.02%, respectively) was added, enough to 
cover the surface of the dish and the flasks were returned to the incubator for 2 - 5 min, 
or until the cells had detached. Media containing 5% FCS was then added at three times 
the volume of trypsin and cells were collected and transferred to 15 ml polypropylene 
centrifuge tubes. Cells were centrifuged at 300 X g (1000 rpm) for 5 min at room 
temperature. The supernatant was discarded, the cell pellet resuspended in fresh cell 
culture medium, and an appropriate volume of the cell suspension was transferred into 
new culture dishes.  
When required the percentage of viable cells were counted after trypsinisation 
by the trypan blue dye exclusion using a haemocytometer. The pellet obtained after 
centrifugation following trypsinisation was resuspended in 500-1000 µl of fresh cell 
culture medium.  A 10 µl sample of the suspended cells was diluted in 10 µl of 0.02% 
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trypan blue (Invitrogen) in PBS and 10 µl of this mixture was loaded into the groove of 
the haemocytometer.  Only the cells which excluded the trypan blue dye were counted 
and the percentage of viable cells determined.  
 
2.1.7 IMMUNOHISTOCHEMISTRY  
 
 
2.1.7.1 PREPARATION OF SLIDES  
For immunohistochemistry (IHC), slides were first cleaned with 70% ethanol, 
dried and submerged in a freshly prepared 2% solution of 3-amino-
propyltriethoxysilane (APES, Sigma) prepared in acetone for 1 min. Slides were then 
transferred to a large tank of water to wash off any remaining APES and dried overnight 
in an oven at 37˚C. The poly-cationic nature of APES allows interaction with the 
anionic sites of tissue sections resulting in strong adhesion, thus preventing loss of 
sections during the staining procedures (Howard & Bethell, 2001). 
 
2.1.7.2 PARAFFIN EMBEDDED TISSUE SECTIONS  
Although paraformaldehyde (PFA) fixation provides good tissue preservation and 
high resolution for light microscopy, it crosslinks proteins so strongly that antigenic 
sites become obscured thereby inhibiting or distorting immunoreaction. Unmasking of 
hidden antigenic epitopes was carried out using non-enzymatic methods as described in 
the following sections. 5 µm sections of formalin fixed paraffin embedded tissues were 
cut using a Reichert-Jung Biocut microtome (Leica Instruments, Nussloch, Germany), 
stretched in a 48˚C water bath, transferred onto APES-coated glass slides and dried at 
room temperature overnight. Prior to immunostaining, paraffin embedded haemangioma 
biopsies were de-paraffinised in xylene (2 changes, 5 min each), re-hydrated  through a 
graded ethanol (100%, 95%, 85% and 70%) series followed by a final rinse in dH2O for 
5 min.  
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2.1.7.3 CELL CULTURE PREPERATIONS  
Cultured cells were plated onto 13 mm diameter coverslips (BDH, Palmerson 
North, New Zealand) which were cleaned and stored in a sealed container in 70% 
ethanol until needed.  Prior to plating, the coverslips were flame-sterilised, and four 
coverslips were placed in each 35 mm diameter cell culture dish (Greiner Bio-one). The 
dishes containing the coverslips were then placed under UV light for 15 minutes.  
After trypsinisation, approximately 1000-5000 cells were plated onto each 
coverslips in a total volume of 20 µl and allowed to attach for 15 minutes. The 
appropriate culture medium was then added to the dish and the cells were left overnight 
in the incubator.  
 
2.1.8 STAINING PROCEDURES 
 
2.1.8.1 HISTOCHEMISTRY 
For histochemical analysis, tissue sections were stained with Mayer’s 
haematoxylin and eosin (H&E) (Luna, 1992). Slides were deparaffined in xylene (2 
changes, 5 min each), rehydrated through a graded ethanol series and rinsed in dH2O. 
The slides were submerged in haematoxylin for 2 min and washed in running tap water 
for 5 min before counterstaining with eosin for 1 min. They were then dehydrated in 
95% alcohol and absolute alcohol (2 changes for 5 min), cleared in xylene (2 changes 
for 3 min each) and mounted in D.P.X (BDH Chemicals Ltd, Poole, United Kingdom). 
 
2.1.8.2 FLOURESCENT IMMUNOHISTOCHEMISTRY  
 Sensitive detection systems were employed to facilitate the immunolocalisation 
of some proteins. Sources and dilutions for the primary and secondary antibodies used 
in this study are given in Tables 2 and 3, respectively. Antibodies used in this study 
were raised in either, a mouse, a rabbit or a goat but are know to specifically recognise 
the human antigen.  
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Table 2: Primary antibodies used in this study, their dilutions and sources. 
 
Marker 
 
Species  
 
Antibody 
dilution 
 
Technique 
employed 
 
Source of primary antibody 
STAT-1 Mouse 1:50 
1:100 
1:1000 
IHC-P 
IHC-C 
WB 
Cell Signalling, MA 
STAT-3 Rabbit 
Mouse 
Mouse 
1:30 
1:100 
1:1000 
IHC-P,IHC-C 
IHC-C 
WB 
Cell Signalling 
STAT-5 Mouse 1:100 IHC-C Invitrogen 
VEGFR-2 Rabbit 1:30 
1:1000 
IHC-P,IHC-C 
WB 
Cell Signalling 
CycA 
 
Rabbit 1:100 
1:1000 
IHC-P 
WB 
BIOMOL Research Laboratories 
Inc, PV 
GAPDH Mouse 1:1000 WB Abcam Limited, Cambridge, UK 
DR4 Mouse 1:100 
1:1000 
IHC-P,IHC-C 
WB 
Imgenex, SD 
DR5 Mouse 1:200 IHC-P,IHC-C Imgenex 
DcR1 Rabbit 1:100 IHC-P,IHC-C Imgenex 
DcR2 Rabbit 1:200 
1:1000 
IHC-P,IHC-C 
WB 
Imgenex 
OPG Mouse 5 µg/ml 
 
IHC-P,IHC-C 
WB 
R&D systems, MN 
vWF Rabbit 1:200 IHC-P,IHC-C Dako Corp, Glostrup, Denmark  
GLUT-1 Rabbit 1:100 IHC-P,IHC-C Dako Corp 
VEGFR-1 Goat 5 µg/ml 
0.2 µg/ml  
IHC-C 
WB 
R&D systems 
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Table 2: Primary antibodies used in this study, their dilutions and sources (contd). Key: 
IHC-C-Immunohistochemistry on cultured cells, IHC- Immunohisotchemistry on 
paraffin embedded tissue sections, FACS-Flow cytometry cell sorting, WB-Western 
blotting. 
 
 
 
 
Marker 
 
Primary 
antibody 
 
Antibody 
dilution 
 
Technique 
employed 
 
Source of primary antibody 
p-STAT-3 
(Tyr 705) 
Rabbit 
Mouse 
1:50 
1:1000 
IHC-P, IHC-C 
WB 
Cell Signalling 
p-STAT-1 
(Tyr 701) 
Goat 5 µg/ml IHC-C Santa Cruz Biotechnology, CA 
p-STAT-5 
(Tyr 695) 
Rabbit 1:50 IHC-C Cell Signalling 
Vimentin Mouse 
mAb 
1:100 IHC-C Dako Corp 
-SMA Mouse 
mAb 
1:100 IHC-C Dako Corp  
VEGF Mouse 5 µg/ml WB R&D systems 
PCNA Mouse 1:50 IHC-P Chemicon International, CA 
CD34 Mouse 1:50 IHC-C Dako Corp 
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Table 3: Secondary antibodies used in this study, their dilutions and sources. Key: IHC-
C-Immunocytochemistry, IHC- Immunohisotchemistry, FACS-Flow cytometry cell 
sorting, WB-Western blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
Secondary antibody 
 
Antibody dilution 
 
Source of antibody 
Biotinylated sheep anti-goat IgG 1:50-IHC-C Sigma 
Sheep anti-goat Streptavidin 
AlexaFluor 555 conjugated IgG 
1:250-IHC-C 
1:2500-FACS 
Invitrogen 
Sheep anti-rabbit Cy3 conjugated 
IgG 
1:250-IHC-P, IHC-C Sigma 
Sheep anti-mouse AlexaFluor 488 
conjugated IgG 
1:250-IHC-P, IHC-C Invitrogen 
Sheep anti-goat AlexaFluor 488 
conjugated IgG 
1:1000-WB Invitrogen 
Biotinylated goat anti-rabbit IgG 1:200-IHC-P Sigma 
Sheep anti-rabbit digoxigenin 
(DIG) conjugated IgG 
1 µg/ml-IHC-P, IHC-C Chemicon  
Sheep anti-mouse DIG 
conjugated IgG 
1:25- IHC-P, IHC-C Roche Diagnostics 
Sheep anti-mouse Fluorescein 
(FITC) conjugated IgG 
1:100- IHC-P, IHC-C 
1:1000- WB 
Sigma 
Sheep anti-DIG Rhodamine 
conjugated IgG 
0.5-µg/ml-IHC-P, IHC-C Roche Diagnostics 
Biotinylated horse anti-mouse 
IgG 
1:200-IHC-P Vector Laboratories 
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2.1.8.2.1 Paraffin embedded tissue sections 
Following deparaffinisation and rehydration, slides were rinsed in dH2O and then 
in tris buffered saline (TBS, pH 7.5, Appendix 4) containing 0.1% Tween-20 (BDH 
Chemicals) (TBST, Appendix 4) for 5 min each. To unmask cross-linked antigenic 
epitopes, the tissue sections were immersed in coplin jars containing boiling 10 mM 
sodium citrate (pH 6.0) for 10 min, except for VEGFR-2 staining for which a 1 mM 
EDTA (pH 8.0) solution was used. The coplin jars were placed in a pressure cooker 
containing boiling water and the lid of the cooker was loosely placed on top to contain 
the heat. The coplin jars were removed from the cooker and left to cool to room 
temperature for 40 min on the bench. The slides were then rinsed in TBST (2 changes, 5 
min each). Autofluorescence from the tissue sections was quenched by washing the 
slides in three changes of freshly prepared 0.5% (w/v) sodium borohydride (NaBH4) 
solution in TBS for 15 min each.  Slides were then washed in TBST for 5 min and 
blocked with either 5% bovine serum albumin (BSA) or 5% goat serum prepared in 
TBST for 60 min at room temperature. This was followed by incubation with primary 
antibodies diluted in TBST containing either 1% BSA or 1% goat serum at 4°C 
overnight. Controls included the omission of the primary antibodies. The next day, 
sections were washed in TBST (3 changes, 5 min each) before incubation with the 
secondary antibodies diluted in TBST containing 1% BSA or 1% goat serum for 2 hours 
at room temperature. Slides were washed in TBST (3 changes, 5 min each) and the cell 
nuclei were counterstained with 4’,6-diamino-2-phenylindole (DAPI; Boerhinger 
Mannheim Biochemicals, IN) and mounted in Antifade (Vectorshield, Burlingame, CA) 
or ProLong ® Gold Antifade (Invitrogen) (see section 2.1.8.3, page 75). 
 
2.1.8.2.2 Cultured cells 
Coverslips with the attached cells were removed from the culture medium and 
washed in TBS before being fixed. Cells were fixed in an ice cold solution of methanol 
 75 
and acetone (1:1, v/v) for 10 min at -20°C except where indicated. Fixed cells were 
washed in TBST (2 changes, 5 min each). Boiling 10 mM sodium citrate, pH 6.0 or 1 
mM EDTA, pH 8.0 (for VEGFR-2 staining) solution was poured over the coverslips 
and allowed to cool on the bench top for at least 30 min. Coverslips were washed in 
TBST (3 changes, 5 min each) and non-specific binding sites were blocked for 60 min 
at room temperature in TBST containing 5% BSA. Coverslips were then incubated in 
the respective primary antibodies diluted in TBST containing 1% BSA overnight at 
4°C. The next day, the coverslips were rinsed in TBST and incubated in the respective 
secondary antibodies diluted in TBST containing 1% BSA for at least 1 hr at room 
temperature in a humidified chamber.  Coverslips were washed in TBST (3 changes, 5 
min each) and the cell nuclei were counterstained with DAPI or propidium iodide (PI) 
(Sigma) (see section 2.1.8.3) and mounted in Antifade onto clean micorscope slides. In 
some cases, a post fixation wash in 4% PFA for 2 min was included after antibody 
incubation and prior to mounting in Antifade.  
 
2.1.8.3 COUNTER STAINING OF THE NUCLEUS 
DAPI was used to label the nucleus in fluorescently labelled samples. DAPI 
stock (100 µg/ml prepared in PBS, and stored in the dark at -20ºC) was diluted 
immediately before use in TBST to a final concentration of 20 µg/ml. Tissue sections 
and cell culture samples were counterstained in DAPI for 10 min after fluorescent 
labelling, washed and mounted in Antifade. 
 For some experiments, the nuclei were stained with PI (10 g/ml). PI stock was 
prepared in PBS to a final concentration of 2 mg/ml and stored in the dark at 4ºC until 
required.  
 
2.1.8.4 COLORIMETRIC VISUALISATION WITH DAB  
Diaminobenzidine (DAB) colorimetric visualisation of immunostaining was 
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used to detect STAT-1 expression in haemangioma. STAT3, STAT-1 and CycA 
immunoreactive MCs were detected using DAB staining in conjunction with Csaba 
(alcian blue-safranin solution) staining. Five specimens each of proliferating, involuting 
and involuted haemangiomas were processed as for fluorescent immunohistochemistry, 
except the treatment with NaBH4 was replaced with a 30 min incubation in 3% 
hydrogen peroxide (H2O2) prepared in methanol and slides were blocked with TBST 
containing 5% horse serum for 60 min at room temperature. Slides were incubated with 
either mouse anti-STAT-1, mouse anti-STAT-3 or rabbit anti-CycA primary antibodies 
followed by detection with a sensitive 3-step biotin-streptavidin/immunoperoxidase 
technique. Bound primary antibodies were detected by incubating the sections with 
either biotinylated anti-mouse or anti-rabbit antibodies for 1 hr at room temperature and 
then washed in TBST (3 changes, 5 min each). The Vecta stain Elite ABC reagent 
containing peroxidase-conjugated streptavidin (Vector Labs, CA) was then added to the 
section and incubated for 30 min at room temperature. All incubations were carried out 
in a humidified chamber. The sections were washed in TBST (3 changes, 5 min each) 
and immunoreactivity was detected by incubation with 0.05% 3’3’-diaminobenzidine 
tetrahydrochloride (Sigma), 0.01% H202 in 50 mM Tris HCL, pH 7.5 from 5-20 min. 
Stained sections were  immersed in Csaba stain (see Appendix 4, section 4.2.10, page 
299) for 15 min to identify MCs (Tan et al., 2000). The sections were then rinsed 
thoroughly in tap water, dehydrated in tertiary butyl alcohol, cleared in xylol (BDH 
Chemicals) and mounted in D.P.X. 
 
2.1.8.5 NEGATIVE CONTROLS 
All immunostaining experiments included control sections which were 
processed in the same way as the test sections but excluded incubation with the primary 
antibody.  For the DAB stained sections, the control slides were incubated with the 
DAB substrate for the same length of time as the test slides.  
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2.1.8.6 IMAGE ANALYSIS 
Immunostained slides were viewed using an Olympus AX70 photomicroscope 
(Olympus Opticals Co., Hamburg, Germany) equipped with appropriate narrow band 
fluorescence filters. Images were captured using an Olympus DP70 CCD camera. Some 
slides were visualised using a Leica TCS 4D confocal laser-scanning microscope fitted 
with a krypton/argon laser (Leica Lasertechnik, Heidelberg, Germany). For presentation 
purposes, images were background corrected and overlaid to produce dual colour 
images using Adobe Photoshop versions CS2 software.  
 
2.1.9 WESTERN BLOTTING 
 
2.1.9.1 SAMPLE PREPARATION FOR WESTERN BLOTS 
 
2.1.9.1.1 Tissue lysate  
 Snap frozen tissue biopsies were weighed and crushed to a powder in liquid 
nitrogen and transferred to a sterile 1.5 ml eppendorf containing freshly prepared lysis 
buffer (50 mM Tris-Hcl pH 6.8 containing 5 mM EDTA, 2.5 mM NaF, 2 mM NaO3V, 2 
mM PMSF and 2% SDS) at 100 mg/ml. Activation of Na3VO4 is required before use 
(see Appendix 4, section 4.2.2, page 297). Tissue was further homogenised with a 
plastic pestle (Sigma) and boiled in a dry heat block for 10 min at 100ºC.  Lysates were 
then spun in a microcentrifuge at 14,000 rpm for 15 min at 4ºC. Supernatants were 
transferred to fresh eppendorf tubes and stored at -20 ºC until required for protein 
analysis.  
2.1.9.1.2 Cell lysate 
 To prepare cell lysates for Western blotting, the cell culture media was first 
removed. The cells were rinsed with PBS and covered with 0.2 ml of freshly prepared 
lysis buffer. The cells were then mechanically detached from the cell culture dish using 
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a rubber cell scrapper and spun in a microcentrifuge at 14,000 rpm for 15 min at 4ºC. 
From this point the cell lysates were processed in the same way as the tissue lysates.  
 HeLa cell lysates were also prepared for Western blots. The cells were grown to 
95% confluence in cell culture media in 100 cm2 tissue culture dishes. The media was 
then replaced with fresh cell culture media containing IFNα-2b (Schering-Plough Ltd, 
New South Wales, Australia) at 10,000 U/ml and returned to the incubator for 10 min. 
Cells were then lysed and lysates were prepared for Western blotting as described 
above.  
 
2.1.9.2 PROTEIN DETERMINATION 
 Protein concentrations in tissue and cell culture lysates were determined using 
the bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology, Inc., WA). Serial 
dilutions of the BSA standard were prepared in lysis buffer ranging from 2 mg/ml to 15 
µg/ml and 25 µl of each diluted BSA standard was added in duplicate into a 96-well 
plate.  25 µl of each lysate was also analysed in duplicate along with 25 µl of lysis 
buffer alone without protein. The BCA working reagent was made up as per 
manufacturer’s instructions, as 50 parts solution A to 1 part solution B and 200 µl was 
pipetted into each well. The solutions in the wells were mixed and the plate incubated 
for 30 min at 37ºC. Colour development was measured in a VersaMAX multiwell plate 
spectrophotometer (Molecular Devices, CA). The absorbance was measured at a 
wavelength of 562 nm, blanked against lysis buffer alone containing no protein. Results 
were analysed with the Softmax Pro software programme (Molecular Devices) and the 
protein concentrations determined using a linear fit for the protein standards by plotting 
absorbance against concentration in µg/ml. 
 
2.1.9.3 GEL ELECTROPHORESIS 
 All reagents for protein electrophoresis were purchased from Invitrogen except 
where indicated. Samples were prepared for electrophoresis according to 
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manufacturer’s instructions. Briefly, 5 µl NuPage® LDS sample buffer (4X), 2 µl 
NuPage® reducing agent (10X) with the appropriate volume of lysate was made up to 
20 µl with deionised water. Samples were heated for 10 min at 70ºC in a heat block, 
centrifuged and loaded into each lane of  precast 4-12% gradient MES NuPAGETM Bis-
Tris gels alongside 7 µl of Sea Blue® Plus-2 pre-stained standard for size 
determination.  The gel was run in 1XNuPage MES running buffer in a XCell 
SureLockTM Mini-Cell electrophoresis unit for 1 hr at 120 volts. 
 
2.1.9.4 WESTERN BLOT TRANSFER 
 Following electrophoresis, the gel was soaked in Western blot transfer buffer 
(Appendix 4, section 4.2.6, page 298) for 10 min. An immobilon low fluorescence 
PVDF (polyvinylidine difluoride)  membrane (0.2 µm pore size, Millipore Corporation, 
MA) was pre-soaked in methanol for 2 min, then 1 min in dH2O and 5 min in transfer 
buffer before being placed onto the gel for transfer. The materials for the transfer were 
stacked in transfer buffer in a Western transfer apparatus (Appendix 4, section 4.2.23, 
page 301), avoiding air bubbles between the layers. The tank was filled with freshly 
prepared, ice cold transfer buffer, and the black side of the assembled cassette was 
placed nearest to the black electrode Transfer was carried at 4ºC in a mini-
TRANSBLOT Cell transfer tank (BioRad Laboratories) for 6 hours at 100 volts onto 
the PVDF membrane.  
 
2.1.9.5 IMMUNOSTAINING OF WESTERN TRANSFERRED PROTEINS 
 After protein transfer, the gels were stained with Comassie Blue and destained 
(see Appendix 4, section 4.2.5, page 298). Transfer efficiency was determined by eye 
on examining the level of protein that remained in the gel post transfer. 95-99% transfer 
efficiency of was assumed when all of the highest molecular weight markers of the 
protein ladder was successfully transferred onto the membrane. Following protein 
transfer, the membranes were rinsed in dH2O and blocked, protein side up, in TBST 
 80 
containing 5% non-fat milk for 1 hr at room temperature. All membrane incubations 
were performed on a rocker platform at room temperature unless otherwise specified. 
The blocking agent was removed and the membranes were washed in TBST (3 changes, 
5 min each) followed by incubation with the respective primary antibodies.  All primary 
antibodies were diluted 1:1000 in TBST containing 5% non-fat milk and incubated 
overnight at 4ºC. The next day, the PVDF membranes were rinsed in TBST (3 changes, 
5 min each) before incubation with secondary antibodies. Primary antibody binding was 
detected using either anti-mouse or anti-goat AlexaFluor 488 conjugated antibodies or 
with anti-rabbit Cy3 conjugated secondary antibodies. All secondary antibodies were 
diluted 1:1000 in TBST and incubated for 1 hr at room temperature. Following 
secondary antibody incubation, the membranes were rinsed in TBST (3 changes, 5 min 
each). Membranes were then scanned using a Fujifilm FLA-5100 imaging system (Fuji 
Photo Film Co Ltd., Tokyo, Japan).  
 
2.1.9.6 ANALYSIS OF WESTERN TRANSFERRED PROTEINS 
Image analysis and densitometry was performed using Image J software 
(National Institute of Health, MD). To obtain the band densities, the total area under the 
histogram for each band measurement was first calculated to obtain a band value. The 
same calculation was made on an equivalent area on the blot containing no band and 
was used as the background value. The background value was then subtracted from the 
band value to obtain a final band density measurement. This value was used for 
statistical analysis.  
 
2.1.10 GENERAL MOLECULAR BIOLOGY TECHNIQUES 
See Appendix 4, section 4.1 (page 294). 
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2.2 METHODS FOR CHAPTERS 3 AND 6 
 
2.2.1 PRELIMINARY EXPERIMENTS  
 
 Methods pertaining to all preliminary experiments can be found in Appendix 1, 
section 1.1.1 (page 267). 
 
2.2.2 GENE EXPRESSION CHANGES IN HAEMANGIOMA 
 
 
2.2.2.1 QUANTITATIVE REAL TIME PCR 
 RNA was extracted from each of eight randomly selected proliferating, 
involuting and involuted haemangioma specimens. Oligo(dT)20 primed cDNA was 
synthesised and qRT-PCR was performed for STAT-3, STAT-1, VEGFR-2, CycA and 
GAPDH according to sections 2.1.2 and 2.1.4 (pages 59 and 65). mRNA expression 
levels were determined relative to the internal reference gene GAPDH using the 
formula:  
    Ct = Ct(TEST GENE) − Ct(GAPDH)  
 
 
The relative fold change in mRNA expression was calculated using the formula: 
                                      Fold change in expression = 2 –Ct  
(Wang et al., 2006; Miracle et al., 2006; Ortiga-Carvalho et al., 2005) 
 
The data is expressed as the relative fold change in mRNA levels ± s.e.m.   
 
 
2.2.2.2 WESTERN BLOTTING 
 Western blotting was performed as described in section 2.1.9 (page 77). Total 
protein was extracted and quantified from five proliferating, four involuting and five 
involuted haemangiomas biopsies and quantified using the BCA protein assay kit 
(section 2.1.9.2, page 78) and 50 µg of total protein was separated on a 4-12% MES 
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NuPage gradient gel. Lysate (50 µg) from HeLa cells treated with IFN-2b was 
included as a positive control. Following electrophoresis and transfer, membranes were 
blocked and incubated with primary antibodies against STAT-3, p-STAT-3 (Tyr 705), 
STAT-1, VEGFR-1, CycA and GAPDH at 4ºC overnight followed by incubation with 
AlexaFluor 488 conjugated anti-mouse or anti-goat secondary antibodies. CycA 
immunoreactivity was detected by incubating the membranes with Cy3 conjugated anti-
rabbit antibodies. Membranes were then washed and scanned on a fluorescent scanner.  
 
2.2.2.3 FLOURESCENT IMMUNOHISTOCHEMISTRY 
Sources and dilutions of the primary and secondary antibodies are given in 
Chapter 2, Tables 2 and 3, respectively and the general protocol used for 
immunostaining in section 2.1.8.2.1 (page 74). To facilitate the immunolocalisation of 
some proteins however, a 3-step detection system was employed as described in the text 
below.  
Paraffin embedded haemangioma tissue sections (five from each phase) were 
immunostained with primary antibodies against VEGFR-2, STAT-3, p-STAT-3 (Tyr 
705), CycA and GLUT-1. Staining for PCNA was undertaken in conjunction with that 
for STAT-3 and p-STAT-3 (Tyr 705) by incubating both primary antibodies together. 
Immunoreactivity for VEGFR-2, STAT-3 and p-STAT-3 (Tyr 705) was detected using 
an anti-rabbit DIG conjugate followed by an anti-DIG-Rhodamine conjugate for 
visualisation. Bound PCNA antibodies were detected using an anti-mouse FITC 
conjugate. Bound CycA and GLUT-1 antibodies were detected using an anti-rabbit Cy3 
conjugate. 
 
2.2.2.4 COLORIMETRIC VISUALISATION WITH DAB  
DAB staining was used to detect STAT-1 expression in haemangioma. 
Following immunolabelling, the STAT-1 stained tissue sections were counterstained 
with the Csaba stain as described in section 2.1.8.4 (page 75). To identify MC 
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expression of STAT-3 and CycA, DAB staining in conjunction with Csaba staining was 
performed as described in section 2.1.8.4 (page 75). 
2.2.2.5 CELL COUNTING  
2.2.2.5.1 STAT-3 and PCNA expression in haemangioma
 A minimum of 600 cells were counted from a typical ‘proliferative’ area 
(densely packed blood vessels with small lumens lined by plump ECs), an ‘involuting’ 
area (larger vessel lumens with flattened endothelia) and an ‘involuted’ area of each 
immunolabelled tissue section.  Cells that stained positive for STAT-3, PCNA and 
STAT-3+PCNA were tabulated and the data plotted as the number of positively stained 
cells/unit area.  
 
2.2.2.5.2 STAT-3 and CycA expression by MCs in haemangioma 
At least 200 MCs were counted from proliferating and involuting specimens 
(four samples per phase). The data for STAT-3 and CycA staining within MCs is 
plotted as total number of MCs that were positive and negative for STAT-3 and 
CycA/unit area. The average number of positively stained MCs in each phase was 
evaluated statistically.  
 
2.2.2.5.3 p-STAT-3 (Tyr 705) and PCNA expression in haemangioma 
 Five proliferative and three involuting specimens were counted as described in 
section 2.2.2.5.1. All cells that stained for p-STAT-3 (Tyr 705), PCNA and those that 
stained for both p-STAT-3 (Tyr 705) and PCNA were tabulated and the data from 
individual samples were plotted as histograms. ‘Proliferative’ areas from proliferating 
specimens and ‘involuting’ areas from involuting specimens were analysed from each 
section.  
 
 
 
 
 
 84 
2.2.2.6 STATISTICS  
All statistical analysis for qRT-PCR data was performed using the R package (R 
Development Core Team., 2005). The linear mixed effects method of analysis was used 
to allow for repeated measures on subjects (Pinheiro & Bates, 2000) and for each 
transcript, a sequential bonferroni adjustment was made for multiple testing. Data is 
represented as relative fold changes in mRNA expression ± standard error of the mean 
(s.e.m).  SPSS software (version 12.0) was used to calculate the Spearman rank 
correlation coefficients between STAT-3 and VEGFR-2, STAT-3 and STAT-1 and 
between STAT-1 and VEGFR-2 mRNA expression. The MC data sets were analysed 
with the Binary Logistic Regression test using SPSS. The non-parametric Kruskal-
Wallis one-way ANOVA by ranks test was applied to the band densities obtained from 
the immunoblotting data sets. The multiple comparisons test was then applied to 
determine where significant changes occurred. For all the statistical tests, significant 
changes were accepted at p < 0.05. 
 
 
 
 
 
 
 
 
 
 85 
2.3 METHODS FOR CHAPTER 4 
 
 
2.3.1 TISSUE CULTURE MEDIUM  
MCDB 131 powder medium (Sigma) containing trace elements and L-glutamine 
was reconstituted with 1.18 g/L sodium bicarbonate (Sigma) to a final volume of 1 litre 
with dH2O. To this, 2% Penstrep and 2.5 µg/ml Amphotericin B (Sigma) were added. 
The mixture was agitated vigorously to ensure complete solubilisation of the additives 
and the solution was filter sterilized through a 0.2 µM filter (Greiner Bio-One). The 
medium was either used immediately or stored at 4ºC for up to eight weeks. 
 
2.3.2 HAEMANGIOMA TISSUE SPECIMENS AND SAMPLE 
PREPARATION 
 
Six proliferating and two involuting haemangioma biopsies were obtained 
according to protocols approved by the Wellington Ethics Committee. The specimens 
were kept moist and cleansed of all blood clots with PBS. Pieces of fresh operative 
haemangioma tissue were cut at room temperature into 1-mm explants and submerged 
in disinfecting media which was made up of MCDB 131 medium containing 1.18 g/L 
sodium bicarbonate, 10% Penstrep (500 µg/ml streptomycin sulfate, 500 µg/ml 
penicillin G), 25 µg/ml Amphotericin B and 2 mM L-glutamine (Gibco-BRL). 
Disinfection was carried out on a rocking platform for at least 2 hours at room 
temperature.  
 
2.3.3 GEL PREPARATION AND IN VITRO TISSUE CULTURE 
25 ml of the tissue culture medium prepared as described in section 2.3.2 was 
transferred to a 50 ml centrifuge tube (Greiner Bio-One) containing 75 mg of sheep 
fibrinogen I (Sigma) to a final concentration of 3 mg/ml. The tube was mixed gently for 
2 min and 6 ml was transferred aseptically into 15 ml conical tubes, to which 0.5 U/ml 
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of human thrombin (Serva Electrophoresis GmbH, Heidelberg, Germany) was added. 
The tube was then mixed by inverting and 400 µl of the mixture was added into each 
well of a 24-well tissue culture plate (Greiner Bio-One). The plates were left in the hood 
for 20 min at room temperature to allow gel formation after which a piece of the 
haemangioma tissue specimen was placed on the centre of each gel. The tissue pieces 
were allowed to attach to gel surfaces for 20 min in the laminar hood. A second aliquot 
of fibrinogen-thrombin-medium mixture was then added so that the tissue fragment was 
sandwiched between two layers of fibrin gel (total volume 0.8 ml). Following gel 
formation, 1.5 ml of supplemented MCDB 131 medium was added to each well. The 
plates were incubated at 37ºC in 3% CO2/97% air in a humidified environment using a 
Heracell incubator (Kendo Laboratory Products). 
This model was used to test the effect of AG490 on capillary-like outgrowth. 
From a stock solution of 1 mM AG490 (Sigma) dissolved in 100% DMSO (Sigma, 
Appendix 4 section 4.2.12, page 299), AG490 was diluted into both gel sandwiches and 
also into the liquid medium overlaying the cultures at the concentrations indicated. In 
addition, control cultures were treated with the same volume of DMSO as that used for 
the highest concentration of AG490. At least six cultures were used for each treatment 
type.
 
2.3.4 MODIFICATION OF THE IN VITRO TISSUE CULTURE MODEL 
This model was used for the purification of the outgrowing cells from 
haemangioma explants. Following disinfection, the haemangioma explants were 
cultured as described above in section 2.3.3, except for a few modifications. These are, 
(i) 10% FCS (Gibco-BRL) was added to the tissue culture medium before use, (ii) 350 
µl of the fibrinogen-MCDB 131-thrombin mixture was placed in each well of 24-well 
culture plate and the tissue explants were placed into the gel before the gel formed. 
Therefore, only one layer of gel was used for each explant. After gel formation, 500 µl 
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of the supplemented MCDB 131 containing 10% FCS was added to cover the gel in 
each well and the cultures were allowed to grow at 37°C under a 3% CO2/97% air 
humidified environment. The culture medium was replaced every 3-4 days until the 
explant was used for dissociation. 
This model was used to test the effect of VEGF and AG490 on haemangioma 
capillary-like outgrowth. Following three days of culture, only those explants which 
exhibited capillary-like outgrowth were selected. Culture media was removed and 
replaced with 500 µl of serum free MCDB 131 media containing 2% Penstrep. 
Following 24 hours of serum starvation, culture medium was removed once more and 
replaced with fresh serum free media containing either 50 ng/ml of VEGF (Sigma) 
and/or 50 µM of AG490. Cultures were maintained for a period of six days with the 
drug. Images of each explant were photographed before and after drug treatment for 
analysis.   
 
2.3.5 QUANTITATION OF OUTGROWTH FROM TISSUE PIECES  
Capillary-like outgrowth was recorded during the culture period by capturing 
images with an Olympus IX51 inverted microscope (upgraded to IX71) fitted with 
phase contrast objectives and a color view 1 camera (Tokyo, Japan). For most tissue 
pieces, the region of outgrowth from the original tissue piece exceeded the field view at 
X4 magnification. Therefore, a set of overlapping images were taken for each explant 
and Adobe Photoshop CS2 was used to generate a single image to include the entire 
region of outgrowth for analysis. Neovascular area was calculated by applying a grid 
(150 pixels/150 pixels) to each image and counting the boxes containing three or more 
vessels. The capillary-like outgrowth is expressed as a ratio of the area occupied by the 
neovessels to the area of haemangioma tissue from which they emanated (Hasan et al., 
2003; Hasan et al., 2000).  
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2.3.6 ISOLATION AND CULTURE OF HAEMANGIOMA TISSUE-
DERIVED CELLS 
Within 10-15 days of culture, significant growth of cells from the tissue explants 
was observed. To purify these outgrowths from the haemangioma tissue explants, the 
culture medium was first removed. Sterilized (autoclaved and cleaned with 70% 
ethanol) forceps were used to remove the original tissue piece from the gel. Removing 
the tissue piece did not disturb the outgrowths which remained in the gel. The gel 
containing the outgrowths were then scraped off the well and digested in serum free 
RPMI media containing 1 mg/ml elastase (Worthington Biochemicals Corp, NJ) at 37ºC 
for 2-5 min or until the gel was completely dissolved. The RPMI medium-elastase 
mixture was filter sterilized through a 0.2 µM filter and warmed to 37ºC before being 
used.  On an average, the gels from three wells of a 24-well plate were digested in 2 ml 
of dissociation media. Once dissolved, enzyme activity was quenched by the addition of 
3-4 ml of cell culture media (10% FCS, 2% penstrep in RPMI 1640 media) and the 
tubes were centrifuged at room temperature for 5 min at 300 X g (1000 rpm). The 
supernatant was then discarded and the cell pellet resuspended in 500 µl of fresh cell 
culture medium. The percentage of viable cells was determined by trypan blue dye 
exclusion and seeded at a density of 1x104 viable cells/cm2 in tissue culture flasks. Cells 
were incubated at 37ºC in 97% humidity with 95% air and 5% CO2 along with the other 
cell lines. The day after dissociation, the cell culture media was replaced with fresh 
media to remove non-attached, dead cells and cell debris. Following this, cultures were 
fed every 3-4 days and passaged 1:3 weekly or as required.  
In addition, using previously described methods with a few modifications, the 
isolation of ECs from human haemangioma biopsies was also attempted (see section 
2.3.16, page 99). This was to be used as a patient matched comparative cell line. 
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2.3.7 CHARACTERISATION OF HAEMANGIOMA CAPILLARY-
LIKE OUTGROWTHS  
 
2.3.7.1 MORPHOLOGICAL ANALYSIS 
 
2.3.7.1.1 Change in cell morphology 
To detect changes in morphology with passage number, the haemangioma 
explant-derived cells (HaemDCs) were photographed at each passage using an Olympus 
IX51 inverted microscope (upgraded to IX71) fitted with phase contrast objectives and 
a color view 1 camera (Tokyo, Japan). 
2.3.7.1.2 In vitro angiogenesis  
To test capillary-like formation in vitro approximately 3000 HaemDCs were 
resuspended in 300 µl of cell culture media containing (3 mg/ml fibrinogen and 5 U/ml 
thrombin) and plated into 24-well culture dishes. The gel matrix was then overlayed 
with 500 µl of cell culture media and maintained in 95% air, 5% CO2 at 37 ºC. 
HUVECs were also plated in parallel for comparison in cell culture media 
supplemented with 30 µg/ml ECGS. 
2.3.7.1.3 Proliferation of HaemDCs 
HaemDCs were plated at a density of 1x104 cells per well into 24-well plates in 
cell culture medium. Cell numbers were counted using a haemocytometer at days 0, 2, 
4, 6 and 9 and cell viability was assessed by the ability of the cells to exclude the trypan 
blue dye. 
 
2.3.8 QUANTITATIVE REAL-TIME PCR 
 
2.3.8.1 HaemDCs mRNA CHARACTERISATION 
RNA was isolated from approximately 1x105 HaemDCs and qRT-PCR was 
performed as described in the General Methods (sections 2.1.1.2.2, 2.1.2 and 2.1.4, 
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pages 59 and 65). For mRNA characterisation experiments, qRT-PCR was performed 
for CD29, CD44, CD90, CD133, CD31, VEGFR-1, VEGFR-2, CD45, GLUT-1, 
Collagen-I, Collagen-II, Collagen-III, Collagen-VIII, Laminin-V, IGF-2 and VEGF. 
Primer sequences are listed in Table 1 (page 62). Changes in gene expression are 
reported relative to a GAPDH as Ct. Based on cell morphology and mRNA 
expression profiles, the HaemDCs were characterised as haemangioma-derived 
mesenchymal cells (HaemDMCs) 
 
2.3.8.2 HaemDMCs DIFFERENTIATION EXPERIMENTS 
Following adipocytic and osteocytic differentiation, mRNA was extracted from 
differentiated and undifferentiated cells and qRT-PCR was performed for PPAR and 
osteonectin using GAPDH as the internal reference gene. Changes in gene expression 
between treatment groups are reported  as Ct values ± s.e.m. 
 
2.3.9 IMMUNOFLUORESCENT CHARACTERISATION OF 
HaemDMCs 
 
 Immunofluorescent staining of HaemDMCs, HUVECs and 3T3 fibroblasts was 
performed as described in section 2.1.8.2.2 (page 74). Fixed cells were incubated with 
primary antibodies overnight at 4ºC against either -SMA, vimentin, vWF, GLUT-1, 
CD34, OPG, VEGFR-1 or VEGFR-2. Immunoreactivity was detected using either an 
anti-mouse AlexaFluor 488 conjugate or an anti-rabbit Cy3 conjugate. To detect bound 
VEGFR-2 antibodies, coverslips were incubated with an anti-rabbit DIG conjugate 
followed by an anti-DIG-Rhodamine conjugate. VEGFR-1 immunoreactivity was 
detected using an anti-goat biotin conjugate followed by incubation with an AlexaFluor 
555 streptavidin conjugate.  All antibodies were diluted in TBST containing 1% BSA in 
a humidified chamber. For the EC specific markers, CD34, vWF, VEGFR-1 and 
VEGFR-2, HUVECs and 3T3 fibroblasts were stained in parallel as positive and 
negative controls, respectively. For all other markers, negative controls were included in 
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each staining procedure and consisted of HaemDMCs cultured on coverslips and 
processed in the same way as the test with the omission of the primary antibody.  
Immunofluorescent detection of OPG was performed on confluent HaemDMCs 
cultured for at least eight days as described above. Dual staining was performed on 
HUVECs for vWF and OPG by incubating both primary antibodies together in TBST 
containing 1% BSA overnight at 4°C. OPG and vWF immunoreactivity was detected 
using anti-mouse AlexaFluor 488 and anti-rabbit Cy3 conjugated antibodies, 
respectively. 
 
2.3.10 DIFFERENTIATION OF HaemDMCs 
HaemDMCs at passage 3 were plated at 2x104 cells/cm2 onto 13-mm diameter 
coverslips in 35-mm culture dishes and cultured in cell culture medium. At 90% - 95% 
confluence, cells were differentiated into adipocytes or osteocytes in specific induction 
media. Differentiation media was replaced every 2-3 days.   
 
2.3.10.1 OSTEOGENIC DIFFERENTIATION 
Osteogenic differentiation was induced by culturing HaemDMCs for a minimum 
of 14 days in osteogenic medium containing 10% FCS, 2% Penstrep, 100 nM 
Dexamethasone (Mayne Pharma Ltd, Victoria, Australia), 0.2 mM Ascorbic acid 
(Sigma) and 10 mM -glycerophosphate (Sigma) in RPMI 1640 + glutamine media. 
Alizarin Red (BDH Laboratories chemicals group, Poole, UK) was used to detect 
calcium deposition indicative of osteogenesis on both uninduced and induced cells 
(Tropel et al., 2004; Lee et al., 2004; Sutherland et al., 2005).   
 
2.3.10.2 ADIPOGENIC DIFFERENTIATION 
Adipogenic differentiation was induced by culturing HaemDMCs in adipogenic 
medium containing 10% FCS, 2% Penstrep, 100 nM Dexamethasone, 0.2 mM Ascorbic 
acid, 10 mM -glycerophosphate, 5 µg/ml insulin (Sigma) and 60 µM indomethecin 
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(Sigma) in RPMI 1640 + glutamine media. Cells were cultured in adipogenic medium 
for a minimum of 21 days and stained with Oil-Red O (Sigma) to detect lipid laiden 
adipocytes (Tropel et al., 2004; Lee et al., 2004; Sutherland et al., 2005).  
 
2.3.10.3 ENDOTHELIAL CELL DIFFERENTIATION 
 To induce EC differentiation, confluent HaemDMCs were cultured in RPMI 
medium containing 2% Penstrep and either 2% FCS or 10% FCS along with 50 ng/ml 
of VEGF (Oswald et al., 2004). After 14 days of induction, cells were immunostained 
for EC specific markers, vWF, CD34 and VEGFR-2 as described in section 2.3.9 (page 
90). 
 
2.3.11 CELL CULTURE HISTOCHEMISTRY 
 
2.3.11.1 ALIZARIN RED STAINING 
 Following osteocytic differentiation, cells were fixed with 4% PFA for 5 min 
and washed thoroughly in tap water. Cells were stained with Alizarin Red solution (pH 
4.2, see Appendix 4, section 4.2.14, page 299) for 5 min. After removal of excess dye, 
the coverslips were dipped in acetone (20 dips) followed by a mixture of acetone-xylene 
(1:1) solution and finally in xylene alone. Coverslips were then mounted in D.P.X 
mounting medium.  
 
2.3.11.2 OIL RED STAINING 
 Following adipocytic induction, cells were fixed in 4% PFA for 5 min and then 
thoroughly rinsed in tap water. Following a 5 min wash in 60% isopropanol, the cells 
were stained in a working solution of Oil Red O (see Appendix 4, section 4.2.15, page 
300) for 15 min. Excess stain was then washed off by rinsing in 60% isopropanol. Cell 
nuclei were then lightly stained using Harris’s haematoxylin and rinsed in dH2O before 
being mounted in glycerine jelly (see Appendix 4, section 4.2.16, page 300).  
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 As HaemDMCs differentiated into adipocytes and osteocytes (see Chapter 4), 
the cells are here in referred to as haemangioma-derived mesenchymal stem cells 
(HaemDMSCs).   
 
2.3.12 EFFECTS OF VEGF AND AG490 ON HaemDMSCs 
 
2.3.12.1 VEGF CELL PROLIFERATION ASSAY 
The effect of VEGF on proliferation of HaemDMSCs and HUVECs was 
determined using the colorimetric EZ4U cell proliferation assay, according to 
manufacturer’s instructions (Biomedica, Vienna, Austria). Briefly, 5000 cells in 50 µl 
of RPMI media containing 0.1% FCS (for HaemDMSCs) or 2% FCS (for HUVECs) 
were seeded into 96-well plates and allowed to attach overnight. The next day, the cells 
were treated with 50 µl of fresh media containing various concentrations of VEGF for 
the times indicated. Fresh media (50 µl) containing VEGF was added to the 
HaemDMSCs cultures every 48 hours to maintain the VEGF concentration. At the end 
of the culture period, substrate was dissolved in 2.5 ml of activator and pre-warmed to 
37°C. 20 µl of this solution was added to each well and the cells were incubated at 37°C 
for 2 hours. Colour development was measured in a VersaMAX multiwell plate 
spectrophotometer. The absorbance was measured at wavelengths of 492 and 620 nm 
and blanked against wells containing medium but no cells. Results were analysed with 
the Softmax Pro software programme. Data is plotted as the mean absorbance value 
obtained from three wells per treatment group ±  s.e.m.  
 
2.3.12.2 EFFECT OF AG490 ON HaemDMSCS PROLIFERATION BY BrdU 
LABELLING 
5x105 HaemDMSCs were plated onto 35 mm culture dishes in RPMI media 
containing 5% FCS and 2% Penstrep and allowed to adhere for 6 hours. Media was then 
replaced with fresh media containing 100 µm or 50 µm of AG490 diluted into the 
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media from a stock solution (see Appendix 4, section 4.2.12, page 299) and cells were 
returned to the incubator for 17 hours (an overnight incubation). Cells were given two 
pulses of BrdU (5-bromo-2-deoxyuridine, 20 nmol, Sigma) to achieve a final 
concentration of 10 µM. BrdUwas added at 3 hours intervals for the last 7 hours of a 24 
hr incubation period with AG490. Cells were then trypsinized, pelleted and resuspended 
in 1 ml of TBS. Following a second centrifugation step, cells were resuspended in 300 
µl of TBS. Cells were then fixed in 70% ethanol by slowly adding 700 µl of ice cold 
ethanol (100%) to the tube containing the cells while the tube was being vortexed. This 
was to avoid clumping of the cells on adding the fixative. Cells were fixed overnight at 
4ºC. Fixed cells were washed in cold TBS and digested in 0.5% Triton-X in 2 M HCL 
for 30 min at room temperature. Washed cells were treated with 0.1 M Na2B4O7 (pH 
8.5) to neutralise the samples and incubated with a biotin conjugated anti-BrdU 
antibody (1:100, Invitrogen) overnight at 4ºC. The next day, cells were washed in TBS 
and incubated an AlexaFluor 555 streptavidin conjugate for 2 hours at room 
temperature. All antibodies were diluted in TBST containing 1% BSA. At least 1x104 
cells were analysed for fluorescence per experimental condition on a FACScan (Becton 
Dickinson & Co, MA). To determine antibody specificity, BrdU unpulsed 
HaemDMSCs (1x104 cells) were also incubated with the anti-BrdU antibodies and 
treated in the same way as the experimental samples. The fraction of cells in S phase 
was determined from the number of cells that had incorporated BrdU using the 
CellQuest software (Becton Dickinson & Co).  
 
2.3.12.3 EFFECT OF AG490 ON IN VITRO CAPILLARY-LIKE FORMATION AND 
QUANTITATION 
 To test the effect of AG490 on capillary-like formation by HaemDMSCs in 
vitro, 3x105 cells/ml were resuspended in RPMI culture medium containing 5% FCS, 
2% Penstrep and 3 mg/ml fibrinogen along with either DMSO alone (control cultures) 
or AG490 at various concentrations. Immediately after adding 0.5 U/ml of thrombin to 
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the cell-media mixture, 300 µl containing approximately 1x105 cells were plated into 
each well of a 24-well culture dish. Culture plates were maintained in the laminar flow 
hood until gel formation occurred after which the gel was overlayed with 500 µl of 
RPMI media containing either vehicle alone (DMSO) or AG490 at the required doses. 
Cultures were maintained at 37ºC in 5% CO2/97% air for 12 days. During the culture 
period, half the media was replaced with fresh media containing the drugs at 72 hr 
intervals.  
 Capillary-like formation was quantified using the Image J software (National 
Institute of Health, MD). A counting frame (1000 µm/1000 µm) was applied to each 
image and the measure tool was used to calculate total capillary-like length. Cell nuclei 
present in each counting frame were counted using the cell counter tool.  
 
2.3.13 WESTERN BLOTTING 
 
2.3.13.1 EFFECT OF VEGF, AG490 AND IFN-2b ON p-STAT-3 PROTEIN 
EXPRESSION 
 1x106 HaemDMSCs were plated onto 100 cm2 culture dishes in cell culture 
medium and left to attach overnight. Culture media was then replaced with fresh media 
containing either 50 ng/ml of VEGF, 50 µm AG490 or 10,000 U /ml of IFN-2b and 
the dishes were returned to the incubator for the times indicated. For the combination 
treatment of AG490 and VEGF, the cells were pre-treated with AG490 for one hr prior 
to adding VEGF for an additional 45 min. Following drug treatments, cells were lysed 
and subjected to Western blotting as described in section 2.1.9 (page 77). 50 µg of total 
protein from HaemDMSCs lysates and HeLa cell lysate (IFN-2b treated for 10 min) 
was separated by electrophoresis and transferred onto PVDF membranes. The 
membranes were then blocked and incubated with mouse anti-p-STAT-3 (Tyr 705) and 
mouse anti-GAPDH primary antibodies. Anti-mouse AlexaFluor 488 conjugated 
secondary antibodies were used for detection. Following fluorescence scanning, the 
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membranes were stripped for 30 min (see Appendix 4, section 4.2.7 for the stripping 
buffer recipe, page 298) at room temperature and re-scanned to ensure signal from the 
p-STAT-3 protein bands were lost. Membranes were then probed with mouse anti-
STAT-3 and goat anti-VEGFR-1 primary antibodies followed by incubation with anti-
mouse and anti-goat AlexaFluor 488 conjugated secondary antibodies and scanned. 
Image analysis and densitometry was performed using the Image J software.  
 
2.3.13.2 DETECTION OF VEGF IN THE CONDITIONED MEDIA OF HaemDMSCs 
To detect if VEGF is secreted into the conditioned media by HaemDMSCs, 
1x106 HaemDMSCs were plated onto 100 cm2 culture dishes. On day 3, culture media 
was replaced with 10 ml of fresh serum free RPMI culture media containing 2% 
Penstrep. 24 hours later, the media was discarded and replaced with fresh serum free 
media. The cells were cultured for 96 hours after which the conditioned medium was 
collected in fresh tubes and the cells were overlayed with fresh cell culture medium 
containing 10% FCS and 2% Penstrep. HaemDMSCs were cultured for an additional 3 
days and lysed as described in section 2.1.9.1.2 (page 77). Conditioned medium was 
collected and centrifuged to remove cell debris or particulate matter. The supernatant 
was then transferred to a pre-rinsed centricon-20 (Millipore Pty Ltd, Australia) and 
concentrated by centrifugation 4000 x g for 15 min to 200 µl (final volume). 
Concentrated medium was then precipitated using the ProteoExtract protein 
precipitation kit (Chemicon) as per manufacturer’s instructions. Briefly, four volumes 
(800 µl) of precipitant was added to 200 µl of concentrated HaemDMSCs conditioned 
media and precipitated overnight at -20°C. The next day, precipitated protein was 
collected by centrifugation at 14,000 rpm for 10 min. The pellet was washed, 
resuspended in 50 µl of lysis buffer and quantitated as described in section 2.1.9.2 (page 
78). Approximately 40 µg of total protein from HaemDMSCs conditioned media, 100 
µg of haemangioma tissue, 100 µg of HaemDMSCs lysate was added to protein gel 
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loading buffer (10 X stock) (Appendix 4, section 4.2.20, page 301) in 1.5 ml 
microcentrifuge tubes to obtain a final concentration of at least 1X loading buffer along 
with 2.5 mM -mercaptoethanol. Samples were boiled for 10 min at 100°C on a heated 
dry block and subjected to electrophoresis on 1.5 mm thick, 10% SDS polyacrylamide 
gels using a 4% stacking gel (Appendix 4, sections 4.2.18 and 4.2.19, pages 300 and 
301) in a Miniprotean cell (BioRad Laboratories) along with 10 µl of Magic Mark 
prestained molecular weight markers (Invitrogen). An additional gel containing 
HaemDMSCs and haemangioma tissue lysate, (100 µg each) was run for the negative 
control. Gels were run for 120 min at 100 V in SDS running buffer (see Appendix 4, 
section 4.2.21, page 301). 
 Following gel electrophoresis and immunotransfer, the membranes were 
incubated with anti-mouse VEGF and anti-mouse GAPDH antibodies followed by anti-
mouse AlexaFluor 488 conjugated secondary antibodies. The negative control 
membranes were incubated with secondary antibodies only. Antibody detection was 
analysed by scanning the membranes on a fluorescent scanner.  
 
2.3.14 IMMUNOCYTOCHEMISTRY 
 
2.3.14.1 EFFECT OF VEGF, IFN-2b AND ADIPOCYTIC DIFFERENTIATION 
CONDITIONS ON STAT PROTEIN EXPRESSION  
1x105 HaemDMSCs were plated onto sterile 13 mm diameter coverslips in cell 
culture medium and allowed to attach overnight. Culture media was removed and 
replaced with fresh media containing either 50 ng/ml VEGF, 10,000 U/ml IFN-2b or 
adipocytic differentiation media and the dishes were returned to the incubator for the 
times indicated. Culture media was then removed and the dishes were rinsed in PBS. 
Cells were fixed in 4% PFA for 5 min at 4°C. After washing in PBS (2 changes, 5 min), 
cells were permeabilised in 10% acetic acid prepared in 100 % methanol for 10 min at -
20°C (Ma et al., 2005). Cells were then washed in PBS and subjected to antigen 
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retrieval with 10 mM sodium citrate (pH 6) and blocking as described in section 
2.1.8.2.2 (page 74). Coverslips were incubated with rabbit anti-p-STAT-3 (Tyr 705), 
rabbit anti-p-STAT-5 (Tyr 694), goat anti-p-STAT-1(Tyr 701), mouse anti-STAT-3 or 
mouse anti-STAT-5 primary antibodies. p-STAT-3 and p-STAT-5 expression was 
detected using an anti-rabbit-DIG conjugate followed by either an anti-DIG FITC 
conjugate or an anti-DIG rhodamine conjugate, while p-STAT-1 expression was 
detected using an anti-goat biotin conjugate and an AlexaFluor 488 strepavidin 
conjugate. STAT-3 and STAT-5 immunoreactivity was detected using an anti-mouse 
AlexaFluor 488 conjugate. Cell nuclei were stained using either PI (10 µg/ml) or DAPI 
(20 µg/ml) as described in section 2.1.8.3 (page 75) and the coverslips were mounted in 
Prolong Gold Antifade reagent (Invitrogen) on pre-cleaned glass slides. 
Image analysis of p-STAT-5 (Tyr 694) nuclear translocation was performed 
using Image J software. At least 20 cells from each treatment group were identified and 
their nuclear boundaries traced. The intensity of p-STAT-5 (Tyr 694) immunoreactivity 
within these defined areas was measured and used as an index of STAT translocation 
(Ma et al., 2005). 
 
2.3.15 IMMUNOHISTOCHEMISTRY 
Fluorescent immunohistochemical staining was performed on paraffin 
embedded haemangioma tissue sections (six from the proliferative phase and five from 
the involuting and involuted phases) as described in section 2.1.8.2.1 (page 74). Antigen 
retrieval was performed by immersing the slides in boiling 10 mM sodium citrate (pH 
6.0) for 10 min. Sections were incubated with rabbit anti-vWF, mouse anti-PCNA and 
mouse anti-OPG primary antibodies. Bound primary antibodies were detected with anti-
rabbit Cy3 and anti-mouse AlexFluor 488 conjugated secondary antibodies.  
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2.3.16 ISOLATION OF ENDOTHELIAL CELLS AND ENDOTHELIAL 
PROGENITOR CELLS FROM PROLIFERATING HAEMANGIOMAS 
  
Approximately 1 g of proliferating haemangioma tissue was cut into 1 mm2 and 
disinfected for at least 4 hours as described in section 2.3.2 (page 85).  Tissue pieces 
were then pelleted by centrifugation for 5 min at 300 X g and resuspended in serum free 
RPMI medium. Following a second centrifugation step, the tissue was resuspended and 
digested in serum free RPMI media containing 0.5 mg/ml Collagenase P (Roche) and 
2% Penstrep for 30 min in a water bath maintained at 37°C. The digested tissue was 
then passed through a 45 µm cell strainer (Greiner Bio-one) and the collagenase activity 
was quenched by adding FCS to 10% of the total volume. The undigested tissue was 
transferred to a fresh 50 ml falcon tube using the digestion medium, gently 
homogenised in a glass homogeniser and then allowed to digest for an additional 30 
min. The cells were strained and the collagenase activity quenched as above. The single 
cell suspension was washed in FACS buffer (Appendix 4, section 4.2.13, page 299) and 
counted using a haemocytometer. The ECs were isolated with CD31 coated magnetic 
dynal beads (Invitrogen) using approximately five beads per cell. The required volume 
of coated beads was added to the cells and the final volume was made up to 300 µl with 
FACS buffer and transferred to a FACS tube. The cell bead mixture was then incubated 
at 4°C on a tube rotator for 1 hr. The FACS tube was placed into a magnetic particle 
concentrator (MPC) and the beads were allowed to collect to the magnet. The remaining 
FACS buffer containing the unbound fraction was removed. The tube was then removed 
from the MPC and the beads were resuspended in fresh cell culture media and plated 
onto 1% gelatine coated culture dishes (see Appendix 4, section 4.2.11, page 299). 
 The bead purification step was omitted in later experiments due to low yield. 
From then on the entire single cell suspension obtained after digestion was directly 
plated onto 1% gelatine coated dishes and cultured in RPMI media containing 20% 
FCS, 2% Penstrep and 15 µg/ml ECGS (Sigma; Appendix 4, section 4.2.17, page 300).  
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2.3.17 STATISTICS  
To test for an effect of VEGF and AG490 on capillary-like outgrowth a 2-way 
ANOVA was used.  To test for an effect of various concentrations of AG490 on 
capillary-like outgrowth and for the effect of VEGF on HUVEC and HaemDMSCs 
proliferation, a 1-way ANOVA was used. All ANOVA tests were followed by 
Bonferroni’s post hoc test to determine where significant differences between 
experimental groups occured. For these experiments, the statistical tests were performed 
on the data from replicate wells set up with biopsies from a single patient. Therefore, 
since all the samples tested came from a single patient and were performed on the same 
day, a normal distribution can be assumed. This allows the use of the parametric method 
of statistical testing. 
Statistical analysis on p-STAT-5 nuclear translocation was performed using the 
non-parametric Mann-Whitney U test. For all other data sets, the Kruskil-Wallis by 
ranks test was performed followed by multiple comparisons to determine where 
significant effects occurred. For these data, although the cell line used was consistent, 
normal distribution cannot be assumed as the experiments were performed on different 
days. Therefore, non-parametric statistical tests by ranks were applied. For all statistical 
tests, differences with p values of < 0.05 were considered significant.    
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2.4 METHODS FOR CHAPTER 5 
2.4.1 QUANTITATIVE REAL TIME PCR 
RNA was extracted from frozen haemangioma tissue and from HaemDMSCs as 
described previously in the section 2.1.1.2 (page 58). Oligo (dT)20 primed cDNA was 
synthesised and qRT-PCR was performed for TRAIL, DR4, DR5, DcR1, DcR2 and 
OPG according to sections 2.1.1.2.1, 2.1.2 and 2.1.4 (pages 58, 59 and 65). Primer 
sequences are listed in Table 1 (page 63). Changes in TRAIL and TRAIL-Rs mRNA 
expression between phases are expressed relative to that for GAPDH as Ct values. 
Changes in gene expression between haemangioma tissue samples and HaemDMSCs 
are expressed as Ct values ± s.e.m. 
 
2.4.2 FLOURESCENT IMMUNOHISTOCHEMISTRY 
Four proliferative paraffin embedded haemangioma biopsies were 
immunostained as described in section 2.1.8.2.1 (page 74). All slides except those 
which were stained for DR5 were subjected to heat induced antigen retrieval by boiling 
in 10 mM sodium citrate (pH 6.0) for 10 min. No antigen retrieval was required for 
DR5 detection. All slides were blocked in TBST containing 5% BSA for 60 min which 
was followed by incubation with primary antibodies overnight at 4ºC against either 
mouse anti-DR4, mouse anti-DR5, rabbit anti-DcR1, rabbit anti-DcR2 or mouse anti-
OPG. The next day, the slides were washed and incubated with secondary antibodies as 
follows, (i) for DR4 detection, slides were incubated with an anti-mouse DIG conjugate 
followed by an anti-DIG Rhodamine conjugate, (ii) for DR5 and OPG detection, slides 
were incubated with an anti-mouse AlexaFluor 488 conjugate and (iii) for DcR1 and 
DcR2 detection, slides were incubated with an anti-rabbit DIG conjugate followed by 
an anti-DIG FITC conjugate (see Tables 2 and 3 for antibody dilutions, pages 71 and 
73).  
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Immunofluorescent staining of HaemDMSCs was performed as described in 
section 2.1.8.2.2 (page 74). Fixed cells were incubated with primary and secondary 
antibodies antibodies as described above except for DR4 detection. Following 
incubation with anti-DR4 antibodies, coverslips were washed and incubated with an 
anti-mouse AlexaFluor 488 conjugate.  
 All slides and coverslips were counterstained with either DAPI or PI (see 
section 2.1.8.3, page 75). Negative controls were included in each staining experiment 
in which the primary antibody was omitted. 
 
2.4.3 EFFECT OF INTERFERON AND TRAIL ON HAEMANGIOMA 
CAPILLARY-LIKE OUTGROWTH  
 Proliferative haemangioma biopsies were cultured as described in section 2.3.3 
(page 85). For drug treatments, TRAIL (250 ng/ml, BIOMOL) and IFN-2b (4600 U/ml 
and 23000 U/ml; Schering-Plough Pty Ltd, Wellington, New Zealand) was dissolved in 
the fibrinogen-thrombin-medium mixture and in the supplemented medium. A 
minimum of six wells were used for each treatment type and 18 wells were used as the 
untreated control cultures. Microvessel outgrowth was analysed on day 9 in culture as a 
ratio of the area occupied by the neovessels to the area of haemangioma tissue (section 
2.3.5, page 87) from which they emanated (Hasan et al., 2003; Hasan et al., 2000) and 
is expressed as % Control ± s.e.m. 
 
2.4.4 EFFECT OF IFN-2b AND TRAIL ON HaemDMSCs  
The effect of IFN-2b and TRAIL on HaemDMSCs was determined using the 
colorimetric EZ4U cell proliferation assay, according to the manufacturer’s instructions 
(Biomedica). Briefly, 5000 cells were seeded in 50 µl of RPMI media containing 0.1% 
FCS into each well of a 96-well plate and allowed to attach overnight. The next day, the 
cells were treated with 50 µl of fresh media containing either TRAIL (250 ng/ml) 
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and/or IFN-2b (4600 U/ml and 23000 U/ml). Fresh media (50 µl) containing the drugs 
were added to each well after 48 hours. Following 96 hours of incubation with the 
drugs, the EZ4U substrate was dissolved in 2.5 ml of activator and prewarmed to 37°C. 
20 µl of this solution was added to each well and the cells were incubated at 37°C for 2 
hours. Absorbance was read at 492 and 620 nm. The experiment was performed with 
HaemDMSC isolates from three separate patients and the results are expressed as % 
Control ± s.e.m. 
 
2.4.5 WESTERN BLOTTING 
 
2.4.5.1 DR4 AND DcR2 DETECTION 
 Protein was extracted from snap frozen haemangioma biopsies of the same 
patients that were used for the in vitro explant model, as described in section 2.1.9.1.1 
(page 77). Protein from HaemDMSCs was extracted using the same protocol with the 
following exceptions. 100 cm2 tissue culture dishes containing HaemDMSCs at 90% 
confluence were used from each patient. Culture media was removed and the cells were 
rinsed once with PBS. 50 µl lysis buffer was added to each plate and the cells were 
mechanically scrapped off the dish using a rubber cell scrapper. Cell lysate was 
transferred to a new eppendorf tube. From here on, cell lysates were treated in the same 
way as tissue lysates.  50 µg of total protein from cell and tissue lysate was subjected to 
Western blotting as described in section 2.1.9 (page 77). Immunoblots were incubated 
with either mouse anti-DR4 or rabbit anti-DcR2 along with mouse anti-GAPDH 
primary antibodies followed by incubation with anti-mouse and/or anti-rabbit 
AlexaFluor 488 conjugated secondary antibodies. Antibody binding was detected as 
described in section 2.1.9.5 (page 79). The negative control membranes were treated in 
the same way as the test with the omission of primary antibody incubation.  
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2.4.5.2 OPG DETECTION 
 To detect OPG protein, HaemDMSC conditioned media and cell lysates were 
prepared as described in section 2.3.13.2 (page 96). Following gel electrophoresis and 
immunotransfer, the membranes were incubated with anti-mouse OPG and anti-mouse 
GAPDH antibodies followed by anti-mouse AlexaFluor 488 conjugated secondary 
antibodies. The negative control membranes were incubated with secondary antibodies 
only. Antibody detection was analysed by scanning the membranes on a fluorescent 
scanner. 
 
2.4.6. STATISTICS 
To test for significant changes in TRAIL and TRAIL receptor mRNA 
expression between phases, the R package (R Development Core Team., 2005) was 
used. The linear mixed effects method of analysis was used to allow for repeated 
measures on subjects (Pinheiro & Bates, 2000) and for each transcript, a sequential 
Bonferroni adjustment was made for multiple testing. To test for changes in mRNA 
expression between HaemDMSCs and haemangioma tissue biopsies, the non-
parametric Friedmann’s test for paired samples was applied to the Ct values 
obtained for each gene. To test for an effect of TRAIL and IFN-2b on capillary-like 
outgrowth and on HaemDMSCs proliferation, a 2-way ANOVA was used.  As multiple 
ANOVA tests were performed for each treatment, sequential bonferroni adjustments 
were applied to the resultant p values. Pairwise comparisons were performed between 
each treatment group using the Bonferroni’s post hoc test. The Mann Whitney U test 
was applied to the band densities obtained from the immunoblotting data sets. 
Differences with p
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CHAPTER 3:  ROLE OF STAT PROTEINS 
AND VEGFR-2 IN HAEMANGIOMA   
 
3.1 INTRODUCTION 
Given the high frequency of deregulated STAT-3 and STAT-1 signalling in 
tumors  (see section 1.9, page 49) and the elevated levels of VEGF found in 
proliferating haemangiomas (Takahashi, et al., 1994; Tan et al., 2000a), a model for the 
involvement of these genes in haemangioma was proposed (Figure 3.1). This model 
suggests that increased expression of VEGFR-2, STAT-3 and the activated form of 
STAT-3, p-STAT-3 (Tyr 705) is associated with the proliferative phase whereas the 
involuting phase involves apoptosis induced by increased STAT-1 signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Proposed model for the role of STAT-3, p-STAT-3 (Tyr 705), STAT-1 and 
VEGFR-2 in haemangioma. 
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3.2 AIMS  
The aim of this study was to test the model proposed in section 3.1 (Figure 3.1).  
This study investigated whether increased VEGFR-2, STAT-3 and p-STAT-3 (Tyr 705) 
expression was present during the proliferative phase of haemangioma and if increased 
STAT-1 expression was present during involution. qRT-PCR was used to determine 
changes in mRNA expression of STAT-3, STAT-1 and VEGFR-2 in proliferating, 
involuting and involuted haemangioma specimens. To correlate changes of mRNA with 
protein abundance, Western blotting and IHC procedures were used to examine protein 
expression, distribution and state of phosphorylation. 
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3.3 RESULTS 
3.3.1 PRELIMINARY EXPERIMENTS  
 Preliminary experiments were conducted to assess the amplification kinetics 
of the qRT-PCR amplification assays used in this study. All amplifications were linear 
over a 10,000-fold range and only primer sets with greater than 96% efficiency were 
used. Preliminary experiments determined that GAPDH was the most suitable internal 
reference gene to use in qRT-PCR of those tested (18SrRNA, HPRT and CycA), as its 
expression did not vary significantly between the phases of haemangioma when 
normalised to total RNA content (Appendix 1, section 1.1.2.2, page 272). The mean Ct 
value for GAPDH was 20 (s.e.m. = 1.0) using 25 ng of input RNA. 
 In addition, specificity of the various antibodies used in this study was validated 
by immunohistochemical and Western blotting studies on cell lines and tissue sections 
known to express those proteins (see Appendix 1, section 1.1.2.3, page 275).   
 
3.3.2 GENE EXPRESSION CHANGES IN HAEMANGIOMA 
3.3.2.1 CHANGE IN mRNA EXPRESSION  
The relative change in mRNA expression for STAT-3, STAT-1 and VEGFR-2 
was determined for five proliferating, eight involuting and seven involuted 
haemangioma samples. Proliferating haemangioma specimens expressed more STAT-3 
mRNA than involuting and involuted specimens, with a significant difference detected 
between proliferating and involuted lesions (p < 0.05; Figure 3.2). Expression of 
VEGFR-2 mRNA was significantly greater in proliferating haemangioma compared 
with both involuting and involuted lesions (p < 0.05 and p < 0.01, respectively; Figure 
3.3). No statistically significant difference in STAT-1 mRNA expression was detected 
between proliferating and involuting lesions, however, significantly lower levels were 
detected in involuted lesions compared to both, proliferative and involuting lesions (p < 
0.05, Figure 3.4)  
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Figure 3.2: Changes in STAT-3 mRNA expression. The mRNA levels for STAT-3 were 
determined for five proliferating, eight involuting and seven involuted specimens 
relative to GAPDH. Proliferating haemangioma specimens expressed significantly 
higher levels of STAT-3 mRNA than involuted specimens (* p < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Changes in VEGFR-2 mRNA expression. VEGFR-2 mRNA levels were 
determined in the same samples as in Figure 3.2. Proliferating haemangioma specimens 
expressed highest levels of VEGFR-2 mRNA which decreased in the involuting and 
involuted specimens (* p < 0.05, ** p < 0.01).  
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Figure 3.4: Changes in STAT-1 mRNA expression. mRNA levels for STAT-1 were 
determined in five proliferating, eight involuting and seven involuted specimens relative 
to GAPDH. Proliferating and involuting samples expressed more STAT-1 mRNA 
compared to involuted samples (* p < 0.05).  
 
 
 
 
 
In addition, mRNA expression of VEGFR-2 and STAT-3 varied proportionately 
across all the three phases (r = 0.820; p < 0.001; Figure 3.5). Graphs showing the 
correlation between STAT-3 with STAT-1 mRNA (r = 0.692; p < 0.001) and VEGFR-2 
with STAT-1 mRNA (r = 0.75; p < 0.001) are given in Appendix 1, Figure 1.9, page 
280.  The raw ∆Ct values obtained for STAT-3, VEGFR-2 and STAT-1 mRNA from 
proliferating, involuting and involuted haemangioma biopsies are given in Table 4, page 
111. 
As the method used in this study reports gene expression changes relative to the 
internal reference gene (GAPDH) using the same amount of input mRNA, it 
circumvents the possibility of identifying false changes in gene expression. 
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Figure 3.5: Correlation between STAT-3 and VEGFR-2 mRNA expression in 
proliferating, involuting and involuted haemangiomas. The mRNA levels for STAT-3 
and VEGFR-2 were determined from haemangioma biopsies from the different clinical 
phases using qRT-PCR. The threshold value (Ct) was determined for each gene and 
then expressed as a difference (Ct) between that for the target gene and that for 
internal house-keeping gene, GAPDH. Low Ct values reflect greater mRNA 
expression. Proliferating haemangiomas () had greatest STAT-3 and VEGFR-2 
expression compared with involuting (+) and involuted () lesions. VEGFR-2 and 
STAT-3 mRNA expression were correlated (Spearman rho r = 0.893; p < 0.001). 
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Table 4: ∆Ct values for STAT-3, VEGFR-2 and STAT-1 obtained from proliferating, 
involuting and involuted haemangioma biopsies.  
 
 
 
 
Phase 
 
∆ STAT-3 
 
∆ VEGFR-2 
 
∆ STAT-1 
 
Patient-1 
 
Proliferating 
 
1.1 
 
3.3 
 
5.2 
Patient-2 Proliferating 2.1 3.8 4.9 
Patient-3 Proliferating 1.5 3.6 4.7 
Patient-4 Proliferating -2.3 3.1 3.6 
Patient-5 Proliferating 1.45 -1.1 -1 
Patient-6 Involuting 0.8 4.2 -0.8 
Patient-7 Involuting 1.85 6.3 2 
Patient-8 Involuting 4.2 12.8 4.9 
Patient-9 Involuting 0.65 3.7 1.8 
Patient-10 Involuting 3 6.2 5.5 
Patient-11 Involuting 2.95 8.9 4.5 
Patient-12 Involuting 2.2 8.5 3.4 
Patient-13 Involuting -0.1 2.8 0.7 
Patient-14 Involuted 4.4 14.4 7.2 
Patient-15 Involuted 4.4 13.3 7.9 
Patient-16 Involuted 5.1 10.7 6.4 
Patient-17 Involuted 4.4 10.1 8.6 
Patient-18 Involuted 4.6 11.25 7.1 
Patient-19 Involuted 2.6 7.6 3.8 
Patient-20 Involuted 4.2 10.7 6.1 
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3.3.2.2 DIFFERENCES IN PROTEIN EXPRESSION BY WESTERN BLOTTING OF 
HAEMANGIOMA SPECIMENS 
Antibody specificity was confirmed by using HeLa cells as a positive control. 
Immunoreactive bands detected on all immunoblots were at the expected molecular 
weights. In addition, negative controls in which the primary antibody was omitted, 
showed minimal staining. Therefore, all immunoreactivity observed in this study was 
presumed to be due to specific labelling of the primary antibodies. All band density 
analyses were made on the same gel. 
 
3.3.2.2.1 STAT-3 AND p-STAT-3 (TYR 705) 
To determine whether changes in STAT-3 mRNA expression correlated with 
changes in its protein abundance, the same samples used for mRNA analysis were 
analysed by Western blotting. Lysates prepared from four proliferating, three involuting 
and three involuted haemangioma biopsies were analysed for STAT-3 protein 
expression. As discussed in Chapter 1, p-STAT-3 (Tyr 705) is the activated form of 
STAT-3. Levels of p-STAT-3 (Tyr 705) were studied in five proliferating, three 
involuting and five involuted haemangioma biopsies. All samples showed STAT-3 and 
p-STAT-3 (Tyr 705) immunoreactive bands at 92 kDa as expected (Wu et al., 2003). 
No statistically significant difference in STAT-3 protein abundance was found between 
proliferating, involuting and involuted specimens (Figure 3.6-A and -B).  
Immunoblotting for p-STAT-3 (Tyr 705) showed that the amount of p-STAT-3 
(Tyr 705) was greatest in proliferating haemangioma and decreased in involuting and 
involuted lesions, however, this difference in expression was not statistically significant 
(p = 0.23) as very little p-STAT-3 (Tyr 705) was detected (approximately 5% of that of 
IFN-2b stimulated HeLa cells) (Figure 3.6-C and -D).  
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Figure 3.6: Western blotting for STAT-3 and p-STAT-3 (Tyr 705). 50 µg of total 
protein from proliferating, involuting and involuted haemangioma lesions were 
subjected to immunoblotting as described in section 2.2.2.2. Membranes were incubated 
with either mouse anti-STAT-3 or mouse anti-p-STAT-3 (Tyr 705) along with mouse 
anti-GAPDH antibodies. With equal protein loaded from each sample (A), no 
statistically significant change in total STAT-3 protein expression was found between 
phases as determined by densitometry analysis (B). Although abundance of p-STAT-3 
(Tyr 705) decreased with phase (C), this decrease failed to reach statistical significance. 
In addition, p-STAT-3 (Tyr 705) expression levels were significantly lower within 
haemangioma biopsies compared to IFN-2b stimulated HeLa cells (D).  
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3.3.2.2.2 STAT-1  
STAT-1 protein expression was studied in five proliferating, three involuting 
and four involuted haemangioma biopsies. Immunoreactive bands were detected at 
approximately 90 kDa as expected (Lemmink et al., 2001). Although there appeared to 
be a decrease in relative STAT-1 protein expression with ongoing involution (Figure 
3.7-A), this change did not achieve significance (data not shown).  
 
3.3.2.2.3 VEGFR-1   
Five proliferating, three involuting and four involuted haemangioma biopsies 
were examined for VEGFR-1 protein expression. Immunoreactivity was detected at 180 
kDa as expected (Takahashi & Shibuya, 1997). No significant change in VEGFR-1 
expression was detected between the lesions (Figure 3.7-B and -C). 
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Figure 3.7: Western blotting for STAT-1 and VEGFR-1 expression in proliferating, 
involuting and involuted haemangioma lesions. 50 µg of total protein from 
proliferating, involuting and involuted haemangioma lesions were subjected to 
immunoblotting as described in section 2.2.2.2. The membranes were blocked and 
probed with mouse anti-STAT-1 or goat anti-VEGFR-1 antibodies along with mouse 
anti-GAPDH antibodies. (A) STAT-1 expression within the haemangioma lesions was 
found to be significantly lower compared to IFN-2b stimulated HeLa cells (A). No 
statistically significant difference in STAT-1 (A) and VEGFR-1 (B) protein expression 
was found between proliferating, involuting and involuted specimens (C).
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3.3.2.3 IMMUNOHISTOCHEMICAL ANALYSIS 
3.3.2.3.1 STAT-3 EXPRESSION 
Immunohistochemical staining of haemangioma specimens (five samples per 
phase) showed that STAT-3 was readily detectable in all three phases of haemangioma 
(Figure 3.8). Proliferating lesions showed highest STAT-3 expression in the plump ECs 
lining the densely packed blood vessels of the proliferative phase (Figure 3.8-A and -
D). Some of these cells were found to be actively proliferating as they co-expressed 
PCNA (Figure 3.8-A and -D, yellow arrows). Panels-B and -E show STAT-3 staining in 
the flattened endothelium lining the large dilated vessels and in the pericellular regions 
of the involuting phase. There were also fewer PCNA-positive cells present during the 
involuting phase (Figure 3.8-B and -E, yellow arrows). Minimal STAT-3 expression 
was detected in involuted lesions which were devoid of any proliferating PCNA-
positive cells. The same pattern of staining was observed when a different STAT-3 
antibody was used. 
The decrease in STAT-3 expression seen between phases in Figure 3.8 appears 
to be due to a decrease in cell number as apposed to a decrease in STAT-3 staining 
intensity per cell.  
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Figure 3.8: Immunohistochemical localisation of STAT-3 and PCNA in paraffin 
embedded haemangioma biopsies. Proliferating (A&D), involuting (B&E) and 
involuted (C&F) haemangioma sections were stained with rabbit anti-STAT-3 and 
mouse anti-PCNA antibodies as described in section 2.2.2.3. Bound STAT-3 antibodies 
were detected using an anti-rabbit DIG conjugate and an anti-DIG-Rhodamine 
conjugate. Bound PCNA antibodies were detected using an anti-mouse FITC conjugate. 
Cell nuclei were counterstained with DAPI (blue). Panels D, E & F are enlargements of 
the areas outlined in A, B & C, respectively. Proliferating lesions (A&D) contained the 
greatest number of PCNA stained nuclei (light blue staining, yellow arrows) and 
showed the greatest STAT-3 expression (red staining). Involuting (B&E) and involuted 
lesions (C&F) contained fewer PCNA positive cell nuclei, and showed less staining for 
STAT-3 protein. Red blood cells in the lumen of the blood vessels appear green, due to 
autofluorescence. Scale bars: 50 µm. 
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3.3.2.3.2. VEGFR-2 
Greatest VEGFR-2 immunoreactivity was detected in proliferating lesions, less 
in the involuting, and the least in the involuted specimens (Figure 3.9). Within the 
proliferative lesions, VEGFR-2 staining was restricted to the cells lining the blood 
vessels (Figure 3.9-A, white arrows). These cells have been characterised as plump ECs 
with “immature” morphology, that is, large nuclei and scant cytoplasm, lining small 
nascent vessels but also in the interstitial regions (Yu et al., 2004). Serial sections 
stained with anti-vWF antibody showed a similar staining pattern for vWF (Figure 3.9-
D) and VEGFR-2 (Figure 3.9-B). These results indicated that most of the VEGFR-2 
positive cells also expressed vWF. However, not all vessels in the involuting 
haemangiomas expressed VEGFR-2 (Figure 3.9-B, yellow arrows) with almost 
negligible staining in the involuted lesions (Figure 3.9-C). Although the IHC technique 
is not considered to be quantitative, different staining intensities for VEGFR-2 were 
observed within a single field of view. Figure 3.9-B shows that within an involuting 
lesion, the small vessels continue to express high levels for VEGFR-2 (white arrows) 
while the larger, more established or ‘mature’ vessels show decreased immunoreactivity 
for VEGFR-2 (yellow arrows). 
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Figure 3.9: Immunohistochemical localisation of VEGFR-2 in haemangioma. 
Proliferating (A), involuting (B&D) and involuted (C) haemangioma biopsies were 
stained with rabbit anti-VEGFR-2 antibodies (A-C) or rabbit anti-vWF antibodies (D) 
as described in section 2.2.2.3. Bound VEGFR-2 antibodies were detected using an anti-
rabbit DIG conjugate and an anti-DIG-Rhodamine conjugate (A-C). vWF 
immunoreactivity was detected using an anti-rabbit Cy3 conjugate (D). Red blood cells 
in the lumen of the blood vessels appear red, due to autofluorescence. Cell nuclei were 
counterstained with DAPI (blue). VEGFR-2 expression (red staining) was found to be 
the greatest in the proliferating lesions (A, white arrows) and less in involuting lesions 
(B, white arrows) with immunoreactivity localized to the cells surrounding the vessel 
lumens (white arrows). Note some large vessels in the involuting do not stain for 
VEGFR-2 (B; yellow arrows) whereas other smaller vessels in the vicinity still express 
VEGFR-2 (B; white arrows). There was negligible VEGFR-2 expression in involuted 
lesions (C). Immuonoreactivity for vWF (red) was also localised to the cells 
surrounding the blood vessel lumens (D) indicating that VEGFR-2 expression may be 
predominantly expressed by the ECs in haemangioma. Scale bars: 50 µm. 
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3.3.2.3.3 STAT-1 
The anti-STAT-1 antibody used in this study did not yield a detectable signal on 
immunofluorescently labelled tissue sections. Therefore, STAT-1 immunoreactivity 
was visualised using a peroxidase conjugated secondary antibody in combination with 
DAB as the enzyme substrate.  
STAT-1 immunoreactivity was present in the plump ECs lining the vessels as 
well as in the interstitium of the proliferative phase (Figure 3.10-A) and decreased in 
the involuting phase (Figure 3.10-B). The difference in STAT-1 expression between the 
proliferative and involuting phase may be merely a consequence of decreased cellular 
content in the involuting lesions as compared with proliferating lesions. Involuted 
lesions (Figure 3.10-C) showed almost negligible STAT-1 immunoreactivity, which 
was similar in staining intensity to the negative control (Figure 3.10-D). Some MCs in 
the proliferative and involuting phases also expressed STAT-1 (Figure 3.10- A and –B, 
black arrows).  
STAT-1 protein abundance was also analysed by Western blotting (see section 
3.3.2.2.2, Figure 3.7-A, page 115). From a total of 12 samples, only one proliferative 
lesion exhibited a strong immunopositive band for STAT-1. Week bands were detected 
from two other proliferating lesions and one involuting lesion. The IHC and Western 
blotting results therefore suggest that haemangioma express low levels of STAT-1. 
 
 
3.3.2.3.4 GLUT-1  
 GLUT-1 has been identified as an immunohistochemical marker expressed in all 
three phases of haemangioma but not in other vascular malformations (North et al., 
2000).  Some of the haemangioma biopsies used in this study were stained with rabbit 
anti-GLUT-1 antibodies. An example of GLUT-1 immunoreactivity on haemangioma 
samples is shown in Figure 3.11. 
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Figure 3.10: Immunohistochemical localisation of STAT-1 in haemangioma. 
Proliferating (A), involuting (B) and involuted (C) haemangioma tissue sections were 
stained with anti-STAT-1 antibodies and counterstained with Csaba to identify MCs 
(light blue) as described in section 2.2.2.4. Most STAT-1 immunoreactivity (brown 
staining) was detected in the ECs surrounding the blood vessels of the proliferative 
phase (A) and the involuting phase (B). Some STAT-1 expression was also detected in 
the MCs (light blue staining, black arrows). Weak STAT-1 expression was present in 
the involuted phase with only a few positively stained flattened endothelia (C). An 
involuting haemangioma section used as the negative control showed no non-specific 
staining of the STAT-1 antibody (D). Note the increase in MC numbers in the 
involuting phase (B&D). Immunoreactivity was detected with DAB and visualised 
using bright field microscopy. Scale bars: 50 µm. 
 
Figure 3.11: Intense GLUT-1 immuoreactivity in a proliferating haemangioma. Sections 
were stained with rabbit anti-GLUT-1 antibodies as described in section 2.2.2.3. Bound 
GLUT-1 antibodies were detected with an anti-rabbit Cy3 conjugate (red). (A) GLUT-1 
immunoreactivity (red staining) was detected on the cells that surround the blood 
vessels. Panel B shows the overlayed image of the DAPI stained cell nuclei (blue) and 
the GLUT-1 positive vessels (red). Scale bars: 50 µm. 
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3.3.2.3.5 MAST CELLS EXPRESS STAT-3  
Csaba staining was used to identify MCs (Rüger et al., 1994) and showed that 
there was a three-fold increase in MC numbers in involuting haemangiomas compared 
with proliferating haemangiomas, and that the MCs were predominantly of biogenic 
amine phenotype throughout the development of haemangioma (Figures 3.12). These 
findings are consistent with those previously reported (Tan et al., 2000a, Tan, 2001).  
This study showed that MCs in both the proliferative and involuting phases 
expressed STAT-3 protein. Of 200 MCs counted, those that stained positive for STAT-3 
(STAT-3 + MCs) and negative (STAT-3 – MCs) were identified in the proliferative and 
involuting phases. Although the total number of MCs was higher in the involuting phase 
than the proliferative phase, the proportion of STAT-3 expressing MCs was highest 
during proliferative phase and decreased in the involuting phase (Figure 3.12-C and 
Table 5). This change was found to be statistically significant with p < 0.05. 
 
 
 
Table 5: The total number and percentage of STAT-3 positive MCs in proliferating and 
involuting haemangioma. Values are mean ± s.e.m; n indicates the average number of 
fields counted at a magnification of X40.  
 
 
 
 
Developmental Phase 
 
Number of STAT-3 + MCs 
 
% STAT-3 + MCs 
 
Proliferative 
 
195.33 ± 6.6 (n = 30),  
 
90.5 
 
Involuting 
 
164. 5 ± 5.5 ( n = 10),  
 
76.1 
 
Proliferative vs Involuting 
 
p < 0.05 
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Figure 3.12: Mast cells present in proliferating and involuting haemangiomas express 
STAT-3. STAT-3 immunoreactivity was detected by DAB staining (brown) and 
counterstained with Csaba to identify the MCs (light blue). Double labelling of a 
proliferating (A) and an involuting (B) haemangioma with STAT-3 antibodies and 
Csaba stain demonstrated the presence of STAT-3 protein within MCs (black arrows).  
(C) The black columns show STAT-3 positive MCs and the white columns show 
STAT-3 negative MCs.  Fewer MCs were present in proliferating lesions per unit area 
compared to involuting lesions which contained a three-fold increase in the number of 
MCs per unit area. However, 90% of MCs in proliferating lesions expressed STAT-3 
while only 76% of MCs expressed STAT-3 in the involuting phase. This change 
reached statistical significance with * p < 0.05. Scale bars: 50 µm. 
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3.3.2.4 STAT-3 AND p-STAT-3 (TYR 705) IMMUNOLOCALISATION 
Confocal microscopy was used to examine the intracellular localisation of 
STAT-3 and p-STAT-3 (Tyr 705) within proliferating haemangioma biopsies. Tissue 
sections were double labelled with PCNA and STAT-3 or p-STAT-3 (Tyr 705). STAT-
3 expression was detected in the cytoplasm of both proliferating and non-proliferating 
cells (Figure 3.13, red staining). While immunoreactivity for p-STAT-3 (Tyr 705) was 
localised to the nucleus across all haemangioma tissue sections examined, p-STAT-3 
(Tyr 705) staining was detected in both proliferating (PCNA positive) (Figure 3.14) and 
non-proliferating cells (PCNA negative) (data not shown). Figure 3.14 shows a region 
on a proliferating haemangioma tissue section where p-STAT-3 (Tyr 705) expression 
was detected within the nuclear compartment of PCNA positive cells.  
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Figure 3.13: Confocal serial optical sections 
through a STAT-3 and PCNA dual labelled 
haemangioma section. (A-E) Bound STAT-3 
antibodies were detected using an anti-rabbit DIG 
conjugate and anti-DIG-Rhodamine conjugate 
(red). Bound PCNA antibody was detected using an 
anti-mouse FITC conjugate (green). Note the 
localisation of STAT-3 to the cytoplasm clearly 
distinct from the PCNA positive nuclei. Panel B 
shows STAT-3 immunoreactivity on PCNA 
negative cells (white arrows) and Panel D shows 
STAT-3 immunoreactivity on PCNA positive cells 
(yellow arrows).  
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Figure 3.14: Confocal images through a p-STAT-3 (Tyr 705) and PCNA dual-labelled proliferating haemangioma section. (A) Bound p-STAT-3 (Tyr 705) 
antibodies were detected using an anti-rabbit DIG conjugate and an anti-DIG-Rhodamine conjugate (red). (B) Bound PCNA antibodies were detected using 
an anti-mouse FITC conjugate (green). Cell nuclei were counterstained with DAPI (blue). Panels A ands B show p-STAT-3 (Tyr 705) (white arrow heads, 
red) and PCNA (white arrow heads, green) staining within the cell nuclei, respectively. Panel C is the overlay of A and B showing co-localisation of p-
STAT-3 and PCNA to the nucleus (yellow). Although in this image, p-STAT-3 (Tyr 705) appears to co-localise with PCNA, this was not always case in 
other regions of the same section and on other haemangioma tissue sections. Scale bars: 20 µm. 
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3.3.2.5 STAT-3 PROTEIN EXPRESSION CORELLATES WITH PROLIFERATION 
To investigate if STAT-3 expression correlates with proliferation, 
immunohistochemical staining for STAT-3 was performed in conjunction with PCNA
on haemangioma tissue sections (three from each phase). PCNA is a nuclear antigen 
expressed maximally in the S phase of the cell cycle (Kurki et al., 1986). In order to use 
IHC to make a quantitative measurement of protein abundance, different areas on the 
same slide were analysed. This eliminates variables relating to tissue or slide processing 
and preparation. Although the haemangioma biopsies used in this study were clinically 
assigned to proliferative, involuting or involuted phases, there existed regions within a 
single tissue section that exhibited the characteristics of each phase. Therefore, this 
provided an opportunity to adopt IHC staining to quantitatively measure the correlation 
of STAT-3 expression with proliferation. As described in section 2.2.2.5.1. (page 83), a 
‘proliferative’ area (densely packed blood vessels with small lumens lined by plump 
ECs), an ‘involuting’ area (larger vessel lumens with flattened endothelium) and an 
‘involuted’ area within the same tissue section was chosen using the DAPI channel. At 
least 600 cells were counted from each ‘area’ and the number of STAT-3-positive, 
PCNA-positive and those cells that expressed both STAT-3 and PCNA were tabulated 
and expressed as the number of positively stained cells per unit area (Figures 3.15 and 
3.16). The results from additional lesions analysed are shown in Figures 1.10 and 1.11 
in Appendix 1 (pages 281 and 282). The cells counted represent all positively stained 
cells across the lesions and not only the ECs. Results showed that STAT-3 and PCNA 
protein expression concurred with the mRNA study in that the proliferative areas of 
proliferating haemangiomas had more PCNA stained nuclei and the highest number of 
STAT-3 positive cells compared with the involuting and involuted areas on the same 
section. However, not all PCNA-positive cells expressed STAT-3 and vice versa.   
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Figure 3.15: STAT-3 expression in different areas of proliferating haemangioma. (A)
Results shown here are representative of three different lesions analysed. Black columns 
show STAT-3-positive cells, white columns show PCNA-positive cells and grey 
columns show the number of cells that stain positive for STAT-3 and PCNA 
(STAT3+PCNA). ‘Proliferating’ areas within a proliferating lesion contained the most 
number of STAT-3-positive cells which decreased in the ‘involuting’ and ‘involuted’ 
areas. No significant differences in the number of proliferating cells (PCNA-positive) 
between the ‘proliferating’ and ‘involuting’ areas suggests that the lesion on the whole 
is highly proliferative.  ‘Involuted’ areas contained few STAT-3 and PCNA-positive 
cells. (B) Percentage of cells that stained positive for STAT-3, PCNA and those that 
expressed both STAT-3 and PCNA (STAT3+PCNA).  
 
 
 
 
 
 Proliferative area Involuting area Involuted area 
STAT-3 68% 55.5% 25.7% 
PCNA 15% 25% 11.3% 
STAT3+PCNA 7% 10% 4.5% 
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Figure 3.16: STAT-3 expression in different areas of involuting haemangioma. (A)
Results shown here are representative of three different lesions analysed. Black columns 
show STAT-3-positive cells, white columns show PCNA-positive cells and grey 
columns show the number of cells that stain positive for STAT-3 and PCNA. 
‘Proliferating’ areas within an involuting lesion contained the most number of STAT-3-
positive cells which decreased in the ‘involuting’ and ‘involuted’ areas. There were also 
fewer PCNA-positive cells in the ‘involuting’ area as compared to the ‘proliferative’ 
area. The ‘involuted’ areas were devoid of any PCNA expression. ‘Involuted’ areas 
contained very few STAT-3-positive cells. (B) Percentage of cells that stained positive 
for STAT-3, PCNA and those that expressed both STAT-3 and PCNA 
(STAT3+PCNA). 
 Proliferative area Involuting area Involuted area 
STAT-3 90% 47.3% 26.7% 
PCNA 13% 4.5% 2.4% 
STAT3+PCNA 12% 3.6% 1.9% 
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3.3.2.6 p-STAT-3 (TYR 705) EXPRESSION DOES NOT CORRELATE WITH 
PROLIFERATION 
This study found that p-STAT-3 (Tyr 705) immunoreactivity was not evenly 
distributed across haemangioma tissue sections but was found in distinct but random 
regions. To investigate if p-STAT-3 (Tyr 705) expression correlates with proliferation, 
immunohistochemical staining for p-STAT-3 (Tyr 705) was performed in conjunction 
with PCNA on five proliferating and three involuting haemangioma tissue samples. 
Positively stained cells in three fields of view were counted as described in section 
2.2.2.5.3 (page 83). The counted cells in Figure 3.17 include all p-STAT-3 (Tyr 705) 
and PCNA-positive cells and were not limited only to the ECs in the lesions. 
Proliferating lesions contained the highest number of PCNA-positive cells as compared 
to involuting lesions (Figure 3.17). However, there was no obvious correlation between 
PCNA expression and p-STAT-3 (Tyr 705) expression. Figure 3.17 shows that 
proliferating lesions contained more p-STAT-3 (Tyr 705) expressing cells than 
involuting lesions and that the decrease in p-STAT-3 (Tyr 705) did not correlate with 
PCNA expression. In addition, the staining pattern of p-STAT-3 (Tyr 705) did not 
correlate with either age or treatment regime of the patient. Therefore, these results 
indicate a role for p-STAT-3 (Tyr 705) in signalling pathways other than proliferation 
in haemangioma.  
 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: p-STAT-3 (Tyr 705) expression does not correlate with proliferation. p-
STAT-3 (Tyr 705) and PCNA-positive cells were examined in proliferating and 
involuting haemangiomas as described in section 2.2.2.5.3. (A) Black columns show p-
STAT-3 (Tyr 705)-positive cells and white columns show PCNA-positive cells. 
Proliferative lesions contained the highest number of PCNA-positive cells which 
decreased in the involuting phase. Although proliferating lesions contained more p-
STAT-3 (Tyr 705)-positive cells, its expression did not correlate with PCNA expression 
in that p-STAT-3 (Tyr 705) was not expressed by the same cells that expressed PCNA. 
(B) Number of positively stained cells for p-STAT-3 (Tyr 705) and PCNA and the 
percentage of cells that expressed both p-STAT-3 (Tyr 705) and PCNA (p-STAT-3 (Tyr 
705 + PCNA) within three fields of view (600 µm2). 
Age p-STAT-3 
(Tyr 705) 
PCNA % p-STAT-3 (Tyr 705) 
+ PCNA 
 
4 months 
 
143 
 
164 
 
33 
5 months 74 139 4.4 
5 months 191 129 4.2 
6 months 45 100 1.4 
11 months 234 102 3.7 
1yr and 1 month 27 55 2.5 
1yr and 3 months 18 44 3.3 
4 yrs and 9 months 56 34 14 
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3.4 DISCUSSION  
The proliferative phase of haemangioma is characterised by excessive 
angiogenesis (Mulliken et al., 1995). In section 3.1, a model was proposed in which 
increased VEGFR-2, STAT-3 and p-STAT-3 (Tyr 705) expression was hypothesised to 
be associated with haemangioma proliferation and increased STAT-1 expression with 
haemangioma involution. The following sections will discuss and relate the results of 
this study to the model described in section 3.1. 
 
3.4.1 IS VEGFR-2, STAT-3, p-STAT-3 (Tyr 705) SIGNALLING 
INVOLVED IN HAEMANGIOMA PROLIFERATION? 
Given that the growth of many tumours is dependent on VEGF/VEGR-2 
signalling (Kim et al., 1993; Chen et al., 2004; Strawn et al., 1996, Drevs et al., 2000) 
and that VEGFR-2 expression is found to be three to five-fold higher in ECs of tumour 
vasculature compared with normal vasculature (Plate et al., 1994), this study sought to 
determine if expression of VEGFR-2 differed between the different phases of 
haemangioma.  
Consistent with previous reports, this study found that proliferating 
haemangioma lesions expressed highest levels of VEGFR-2 mRNA which decreased in 
involuting and involuted lesions. IHC staining showed that VEGFR-2 protein concurred 
with mRNA levels, i.e., the plump ECs lining small nascent vessels in the proliferative 
phase strongly expressed VEGFR-2. While all the vessels stained positive in 
proliferating lesions, the number and intensity of VEGFR-2 positive blood vessels 
decreased in the involuting lesions, with the involuted lesions being completely devoid 
of any VEGFR-2 immunoreactivity.  These results confirm that increased VEGFR-2 
expression may be crucial for haemangioma proliferation. This pattern of VEGFR-2 
expression is also consistent with the increasing evidence of its importance in tumour 
vascularisation, growth, and metastasis (Millauer et al., 1994; Bernatchez et al., 1999).  
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VEGFR-2 activates STAT proteins (Bartoli et al., 2000; Bartoli et al., 2003). In 
particular, STAT-3 has been shown to be activated by EC receptors such as Ang-2 and 
VEGFR-2 (Korpelaine et al., 1999; Bartoli et al., 2000; Niculescu et al., 1999; Bartoli 
et al., 2003; Schaefer et al., 2002). While numerous studies have found STAT-3 
activation in a variety of human tumours including breast, prostate, head and neck and 
ovarian cancer (Garcia et al., 2001; Grandis et al., 2000; Dhir et al., 2002; Song & 
Grandis, 2000), other investigators have reported that STAT-3 activation was required 
and sufficient to mediate cellular transformation (Bromberg et al., 1998; Turkson et al., 
1998; Bromberg et al., 1999; Ram et al., 2000). In addition, Chen et al (2004) showed 
that a strong a correlation existed between VEGF, VEGFR-2, STAT-3 and p-STAT-3 
expression in ovarian epithelial carcinoma. A role for STAT-3 has also been identified 
in vasculogenesis as well as angiogenesis. Osugi et al (2002) showed that cardiac-
specific activation of STAT-3 promoted vascular formation in the heart while Funamoto 
et al (2000) found that STAT-3 signalling could control vessel growth during cardiac 
remodelling. In addition, Valdembri et al (2002) found that STAT-3 activation induced 
vessel sprouting from chicken aorta rings.  Chen et al (2007) have also recently 
reviewed the role of STAT-3 in angiogenesis.  
This study found that proliferating haemangioma expressed highest levels of 
STAT-3 mRNA with decreased abundance in involuting and involuted lesions. In 
addition, a strong correlation between VEGFR-2 and STAT-3 mRNA expression was 
identified. This suggests that VEGFR-2 signalling may be important in driving EC 
proliferation through STAT-3 activation, although direct evidence of this relationship 
was not investigated at this stage of the study.  A more functional role for STAT-3 is 
discussed in section 4.3.4 (page 163). Increased transcription of STAT-3 and VEGFR-2 
mRNA is also indicative of the rapid turnover occurring in the proliferative phase. 
Double staining IHC results showed that ‘proliferating’ areas of haemangioma tissue 
sections taken from lesions in the proliferative and involuting phase contained the 
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highest number of STAT-3 cells and also the highest proportion of proliferating nuclei 
(PCNA-positive) as compared to the involuting and involuted areas. IHC results also 
showed that some of these proliferating cells (PCNA-positive) also expressed STAT-3. 
These findings support the role of STAT-3 in haemangioma proliferation. 
In addition, 90% of MCs present in the proliferative phase expressed STAT-3, 
and although the number of MCs increased approximately three-fold in involuting 
lesions, only 70% of the MCs in the involuting phase expressed STAT-3. The 
promotion of neovascularisation by MC products such as FGF-2 has been known for 
some time (Norrby, 1994; Norrby et al., 1990). The positive staining for STAT-3 in 
MCs in both proliferative and involuting lesions suggests that STAT-3 may be 
synthesised and stored by MCs. A similar role for MCs in the synthesis and/or storage 
of other angiogenic proteins has been previously described (Tan, 2001; Tan et al., 
2000a, Tan et al., 2004). 
Although IHC showed that the number of STAT-3 expressing cells was highest 
in the proliferative phase and that fewer STAT-3 expressing cells were present in 
involuting and involuted lesions, Western blotting showed that abundance of STAT-3 
protein per cell remained unaltered between the proliferating, involuting and involuted 
lesions. This discrepancy may be due to the basic biology of these lesions. Through-out 
this study, involuting and involuted lesions contained more fibro-fatty deposits and 
lysates from these lesions contained less total protein per mg of tissue as compared to 
proliferating lesions. Therefore, larger volumes of protein lysate from the involuting 
and involuted lesions were loaded on the gels during Western blotting to maintain equal 
protein loading. These results mean that although the number of STAT-3 expressing 
cells is highest in the proliferative phase compared to the involuting and involuted 
phases, total STAT-3 protein abundance per cell does not change with the phases. 
Interestingly, Yang et al (2005) showed that unphosphorylated STAT-3 can also drive 
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gene expression of proteins such as MET and MRAS, both of which are present at high 
levels in many cancers.  
Phosphorylation of STAT-3 at tyrosine-705 is generally considered to be a 
prerequisite for STAT-3 activation in tumours (Shi et al., 2002). This tyrosine residue is 
constitutively phosphorylated during viral-induced angiogenesis and transformation in 
Kaposi’s sarcoma (Burger et al., 2005). Of particular importance to this study is the fact 
that this residue is phosphorylated by VEGF signalling. Bartoli et al (2000) showed that 
STAT-3 (Tyr 705) phosphorylation occurred within 60-90 min of VEGF stimulation in 
bovine ECs. In addition, Johnson et al (1998) showed that STAT protein nuclear 
translocation was required for their transcriptional ability. 
Consistent with the conventional model of p-STAT-3 (Tyr 705) activation in 
oncogenesis, this study identified that proliferative haemangioma contained more p-
STAT-3 (Tyr 705) protein than involuting and involuted lesions. Interestingly, although 
p-STAT-3 (Tyr 705) immunoreactivity was nuclear in all phases, its expression was not 
restricted to proliferating (PCNA positive) cells. Although unexpected, these results can 
be explained by the involvement of p-STAT-3 (Tyr 705) in cellular processes other than 
proliferation, such as differentiation and apoptosis (Deng et al., 2000; Zhao et al., 
2002). Although expression of p-STAT-3 (Tyr 705) expression was initially thought to 
be associated with the proliferation of haemangioma, the results from this study indicate 
a role for p-STAT-3 (Tyr 705) in the involution of haemangioma. This hypothesis is 
discussed further in other sections of this thesis (see section 4.3.6, page 179).  
VEGFR-1 protein expression was also investigated in haemangioma biopsies in 
proliferating, involuting and involuted haemangioma biopsies. This receptor was 
studied because it was found to be expressed by HaemDMSCs (section 4.3.3.4, page 
153). VEGFR-1 expression in haemangioma is discussed in Chapter 4.  
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3.4.2 IS STAT-1 INVOLVED IN HAEMANGIOMA INVOLUTION?
 STAT-1 is considered a tumour suppressor as it inhibits growth and acts as a 
pro-apoptotic factor (Calo et al., 2003). STAT-1 activation is required for the anti-
proliferative effects of IFN as well as the apoptotic effect of TNF (Bromberg et al., 
1996; Kumar et al., 1997). The loss of STAT-1 signalling enhances oncogenesis 
(Kaplan et al., 1998).  
Due to the involvement of STAT-1 in growth arrest and apoptosis in many cell 
types (Chin et al, 1996; Chin et al, 1997; Kumar et al., 1997), a role for STAT-1 
signalling in the involution of haemangioma was proposed (Figure 3.1). STAT-1 
mRNA and protein expression patterns were investigated in this study. qRT-PCR results 
showed that proliferating and involuting haemangiomas expressed more STAT-1 
mRNA than involuted lesions. This decrease in mRNA levels correlated with a decrease 
in STAT-1 protein expression. IHC showed that proliferating lesions contained more 
STAT-1 protein primarily localised to the cells lining the blood vessels and also in some 
of the interstitial cells. Although IHC detected STAT-1 protein in proliferating and 
involuting haemangioma, Western blotting showed that the overall expression of 
STAT-1 was low. These results suggest that even though STAT-1 is classically 
considered to be a tumour suppressor (Kaplan et al., 1998) and a regulator of apoptosis 
(Chin et al., 1997; Kumar et al., 1997), it may not be an important factor in regulating 
the biology of haemangioma. 
 
3.4.3 LIMITATIONS OF THIS STUDY  
 
The major limitation of this study is that the samples available consisted of only 
formalin-fixed paraffin embedded haemangioma tissue sections and fresh snap frozen 
tissue biopsies. These biopsies were taken from different individuals at different 
developmental ages. In addition, although each lesion was clinically categorised as 
being proliferative, involuting or involuted, it is known that any individual 
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haemangioma lesion can exhibit characteristics typical of all three phases (Tan, 2001). 
Although each of the biopsies predominantly represented one phase of haemangioma 
(i.e., either proliferating, involuting or involuted) it is possible that the tissue sample 
contained regions from the other phases as well. This becomes important during qRT-
PCR and Western blotting studies when gene expression analyses are done on snap 
frozen tissue samples. With IHC, however, it is possible to visually identify and 
discriminate between the different phases.  
A second limitation of this study is that the results obtained in this chapter by 
qRT-PCR, IHC and Western blotting techniques identify correlations in gene 
expression. Ideally, experiments need to be performed on an appropriate cell line 
derived from haemangioma in order to provide functional evidence for the importance 
of VEGF and STAT signalling in these lesions.  
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CHAPTER 4: ROLE OF STEM CELLS IN 
HAEMANGIOMA 
 
4.1 INTRODUCTION 
 
The precise causes for haemangioma remain unknown, however, considerable 
progress has been made towards understanding the cellular and molecular events that 
govern its life cycle. The early proliferating tumour is characterised by excessive 
angiogenesis (Takahashi et al., 1994; Kraling et al., 1996; Bielenberg et al., 1999). 
Several angiogenic factors such as VEGF, FGF-2, PDGF, TGFs and IL-6 (Folkman & 
Klagsbrun, 1987; Folkman, 1997) are now known to be important regulators of 
haemangioma development (Hasan et al., 2000b; Takahashi et al., 1994; Chang et al., 
1999). In addition to increased expression of receptors crucial in angiogenesis, genetic 
alterations and somatic mutations in VEGFRs have been reported (Walter et al., 2002; 
Blei et al., 1998; Walter et al., 1999; Nguyen et al., 2004; Yu et al., 2001; Ritter et al., 
2002). Recently, the presence of endothelial progenitor cells (EPCs), mesenchymal stem 
cells (MSCs) and clonal expansion of ECs with aberrant properties have been identified 
in proliferating haemangioma (Yu et al., 2004a; Yu et al., 2006; Yu et al., 2001, Li et 
al., 2003, Khan et al., 2006; Boye et al., 2001; Walter et al., 2002). 
Primary cultures derived from haemangioma are useful models for in vitro 
studies because it allows the addition of factors to the medium or components of the 
medium to be changed and their effects evaluated. However, as a single haemangioma 
lesion consists of a highly heterogeneous population of cells, the purification and 
establishment of a primary cell line is not straightforward and may often contain 
contamination with other cell types. Other disadvantages of using a cell culture model 
include the formation of abnormal cell architecture and changes in gene expression 
(Kivell, 2003). 
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A scientific approach to the study of the pathogenesis of haemangioma has been 
hampered by the absence of a suitable model for haemangioma. Previous experimental 
models include the induction of ‘haemangioma’ in mice by transgenic ECs (Dubois-
Stringfellow et al., 1994), ECs that have been transformed by the polyoma middle T 
oncogene (Sage, 1992; Williams et al., 1989) or ECs obtained from murine (Meininger 
et al., 1995) and human haemangioma (Boye et al., 2001). ECs have also been 
successfully cultured from human haemangioma on plasma clots (Mulliken et al., 
1982). The limiting factor of these models is the absence of other cellular elements and 
ECM characteristics of human haemangioma as well as the necessity of plasma (Tan, 
2001). Therefore, these models are not ideal for investigating the effect of modulating 
molecules.  
In 2000, Tan et al (2000b) developed a novel human in vitro model for 
haemangioma, which overcomes some of the deficiencies associated with the above 
systems. In this model, freshly obtained haemangioma biopsies are embedded between 
two fibrin gel layers and cultured in serum free conditions. Within days, a complex 
network of capillary-like outgrowth emanates from the tissue fragment. In addition, the 
serum free condition of this model allows for agents such as growth factors, drugs or 
antibodies to be added to the cultures so that their effect on capillary-like outgrowth can 
be studied. However, one limitation of this model is that cell-specific signal 
transduction pathways, in response to drugs or other factors added to the medium, 
cannot be easily investigated.  
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4.2 AIMS  
The capillary-like outgrowth emanating from the haemangioma biopsy in the 
explant model has previously been characterised as ECs (Tan et al., 2000b; Ritter et al., 
2000). As these cells exhibit an aggressive proliferative and migratory characteristic, it 
is hypothesised that these cells are involved in driving the proliferation and involution 
of haemangioma. The aim of this study was to purify, characterise and establish primary 
cultures of these cells in order to further elucidate the mechanisms regulating the 
programmed biological behaviour of haemangioma. A functional role for the 
importance of VEGF and STAT signalling in haemangioma was also investigated using 
the in vitro explant model and the purified cultures.  
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4.3 RESULTS 
4.3.1 MORPHOLOGICAL OBSERVATIONS OF THE IN VITRO 
HAEMANGIOMA CULTURE  
Proliferative haemangioma tissue fragments were cultured using a previously 
described method (Tan et al., 2000b). 90-95% of the explants gave rise to a complex 
array of microvessels emanating from its perimeter within 3-4 days. Early on in this 
study, involuting and involuted haemangiomas were also cultured. However, 
outgrowths from these cultures had fewer sprouts, which were not seen until after 10-12 
days in culture. This difference in growth rates between proliferative, involuting and 
involuted haemangiomas has been reported previously (Tan et al., 2000b). The 
capillary-like outgrowth is shown in Figure 4.1. Additional images can be found in 
Appendix 2, Figure 2.1, page 284. 
Several other observations were made from these explanted cultures. The 
capillary-like structures were often noted to emanate from the tissue perimeter and 
follow a circular path surrounding the original tissue piece (Figure 4.2-A and Appendix 
2, Figure 2.2, page 285). This ring like formation was sometimes seen even before any 
sprouting had occurred (Figure 4.2-B). Removal of the original tissue piece was 
followed by the disruption and the eventual disintegration of the newly formed 
outgrowths (Figure 4.2-C). 95% of the cultures gave rise to the cell type shown in 
Figure 4.1 and Figure 4.2-A. However, in 4-5% of the cultures, a different cell type was 
seen to grow out, sometimes along with another cell type (Figure 4.2-D and Appendix 
2, Figure 2.3, page 285). This cell type was also seen to rapidly proliferate and form a 
sheet-like layer within the fibrin gel (Figure 4.2-E). Morphologically, these cells look 
similar to ECs, however, confirmation of this requires immunohistochemical analysis, 
which was not performed during this study.  In addition, occasionally both cell types 
grew out from some explants (Figure 4.2-F). 
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Figure 4.1: Haemangioma explant model. Phase contrast microscopy of the explant 
cultures at high magnification showing the individual cell structures growing out from 
the haemangioma tissue explant. Scale bars: (A) 500 µm, (B) 200 µm.  
A 
B 
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Figure 4.2: Morphological characteristics of the haemangioma explant model. Proliferating haemangioma biopsies were cultured as 
described in section 2.3.3. (A) Capillary-like like structures that emanated from the explanted tissue followed a circular pattern of growth 
surrounding the original tissue. Photograph was taken on day 14 in culture. (B) A ring like clearing was sometimes observed around the 
explant even before any capillary-like growth. Photograph was taken on day 2 in culture. (C) Capillary-like structures did not survive 
when the original haemangioma tissue piece was removed. Photograph was taken on day 2 after the tissue piece was removed. (D) 4-5% of 
cultured proliferating haemangioma explants gave rise to another cell type emanating from its surface. These cells exhibited the 
morphology similar to ECs. Photograph was taken on day 16 in culture. (E) When present, the second cell type continued to grow forming 
a sheet like layer in the gel matrix. (F) Some explants gave rise to two cells types with different morphologies emanating from the tissue 
surface. Photograph was taken on day 7 of culture. Scale bars: (A,B,C&E) -1000 µm, (D&F) – 200 µm, respectively. 
 145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 146 
4.3.2 MODIFICATION OF THE IN VITRO EXPLANT MODEL 
 In addition to culturing haemangioma explants as described by Tan et al (2000b), 
a modification of this system was also used in this study. Preliminary experiments 
showed that this system (see section 2.3.4, page 86) yielded capillary-like sprouts within 
the same time frame as the sandwich model. The main difference between the two 
systems is that the modified system consisted of the haemangioma tissue piece 
embedded into a single gel layer which was then covered with liquid medium. This 
modified system offered several advantages.  
In testing for the effects of various agents on capillary-like outgrowth, this 
model, (i) allowed easy access of the agent to the explanted haemangioma biopsy; (ii) 
was more economical as it required less culture media and agents to be added; and (iii) 
was less time consuming and tedious. This system was also more suited for the 
purification of the capillary-like outgrowths as lower volumes of the fibrin gel used was 
easily digested with elastase.  
 
4.3.3 PURIFICATION AND CHARACTERISATION OF THE 
CAPILLARY-LIKE OUTGROWTHS  
4.3.3.1 CELL CULTURE CONDITIONS 
Haemangioma explant-derived primary cells (HaemDCs) were isolated from 
explanted cultures of six proliferating and two involuting haemangioma biopsies (see 
section 2.3.6, page 88 for details on the isolation procedure). The adherent cells were 
culture-expanded in RPMI 1640 + L-glutamine medium supplemented with 10% FCS 
and 2% antibiotics. 
 Although previous studies have shown that primary cell cultures often require 
special growth conditions such as the use of high serum concentrations (20%) and 
additional supplements including ECGS and FGF-2, these factors were not required for 
the survival and proliferation of HaemDCs. Preliminary experiments showed that 
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although there was no indication of apoptosis or necrosis when the cells were 
maintained in medium containing 1-2% FCS, the rate of proliferation was slow. Cells 
cultured in medium containing 0-0.1% FCS survived for approximately 6-8 days after 
which the cells showed signs of senescence and eventually death (data not shown).  
Coating the cell culture dish with a protein substrate to aid cell attachment is 
also a common practice for primary cell culture. Preliminary experiments determined 
that although the haemangioma-derived cell cultures attached well to all the substrates 
tested in this study including 10 µg/cm2 Fibronectin (Sigma), 1% Gelatine 
(commercially available from the super-market), Collagen (Sigma) and Poly-D-lysine 
(kindly provided by Dr Bronwyn Kiwell, Victoria University of Wellington), their use 
was found to be unnecessary and was therefore discontinued.  
 
4.3.3.2 MORPHOLOGY AND GROWTH CHARACTERISTICS 
Phase contrast microscopy of HaemDCs demonstrated a homogeneous 
population of fibroblast-like, spindle-shaped cells at passage 1 (Figure 4.3-B), which 
formed colonies when grown at low density. In later passages (> passage 5), the cells 
began to display a broadened, flat morphology (Figure 4.3-C), which is typical of MSCs 
(Tropel et al., 2004). With the appearance of the flattened star-shape morphology, the 
cultures grew exponentially, requiring weekly passages. They could be expanded for 
more than 15 doublings without any more changes in morphology and cryopreservation 
did not affect their growth or morphology (data not shown).  
The HaemDCs also exhibited angiogenesis-like characteristics in vitro. When 
plated back into a fibrinogen-media gel matrix, the cells formed capillary-like structures 
(Figure 4.3-D), which continued to develop with time and resulted in substantial 
formation of capillary-like structures by day 20 in culture (Figure 4.3-E). HUVECs, 
which are normal ECs, did not form these capillary-like structures even after 20 days in 
culture (Figure 4.3-F). 
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Figure 4.3: Morphological characterisation of HaemDCs. (A) Phase contrast microscopy of a proliferating haemangioma explant in 
culture with capillary-like outgrowths emanating from the original tissue piece. (B) Cells purified from the solubilised gel matrix and 
cultured in vitro exhibited fibroblast-like spindle shape morphology at passage 1. (C) At passage 5, cells appeared flat and broadened. (D) 
The purified cells formed capillary-like like structures when cultured in a 3-dimensional medium based gel matrix which continued to 
develop with time (image shown is after 15 days in culture) (E). (F) HUVECs did not form capillary-like structures when plated into the 
medium-based gel matrix. Scale bars: (A) 500 µm, (B-F) 250 µm. 
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To examine the population doubling time of these primary cultures, cell isolates 
from two proliferative and one involuting haemangioma were plated at the same density 
and grown under identical conditions. The cultures derived from the proliferative 
lesions were assayed at passage 5 while the cultures from the involuting lesions were at 
passage 2. Cell numbers were determined on days 0, 2, 4, 6 and 9 and doubling time 
was found to be approximately 4 days (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Population doubling time of HaemDCs.  Cell isolates derived from two 
proliferative haemangioma lesions (pink and blue line) and one involuting lesion 
(yellow line) were plated into 24-well tissue culture plates at a density of 1x104 
cells/well. Cell numbers were counted at days 0, 2, 4, 6 and 9 and plotted as number of 
cells x104. The results are presented as the mean ± s.e.m of triplicate determinations.  
 
 
4.3.3.3 mRNA CHARACTERISATION  
To determine whether the HaemDCs isolated from cultured explants were 
mesenchymal, as suggested by their morphology and growth characteristics, qRT-PCR 
for lineage-specific transcripts was undertaken. Analysis of mRNA transcripts was 
assessed by analysing the threshold cycle (Ct) obtained for each gene by qRT-PCR from 
HaemDCs isolated from four proliferating haemangiomas and one involuting 
haemangioma relative to the house-keeping gene, GAPDH. HUVECs and 3T3 
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fibroblasts were also analysed in parallel for comparison. Table 6 shows that the 
HaemDCs expressed transcripts for the mesenchymal markers, CD29, CD44 and CD90, 
but did not express transcripts for the EC markers, CD31 and VEGFR-2, or the 
haematopoietic antigen, CD45. Low level expression of transcripts for VEGFR-1 was 
detected in the HaemDCs tested. The HaemDCs also expressed mRNA for GLUT-1 
which is the marker used to differentiate haemangiomas from other vascular 
malformations (North et al., 2000). Although HUVECs expressed transcripts for CD29 
and CD44, CD90 mRNA was not detected. In addition, while HUVECs expressed 
transcripts for the EC markers VEGFR-2 and CD31, 3T3 fibroblasts did not express any 
of the above markers with the exception of CD44. These results indicate that the 
HaemDCs isolated from haemangioma explants express a distinct profile of mRNA 
transcripts for a range of MSC markers that is different from both normal ECs and 
fibroblasts.  
In addition, qRT-PCR showed that HaemDCs isolates from four different 
patients expressed transcripts for VEGF , Collagen-I, -II, -III and VIII but not Laminin-
V. Low levels of IGF-2 mRNA were also detected. In contrast, 3T3 fibroblasts did not 
express mRNA for any of these genes. An example of the typical mRNA expression 
profile obtained for these markers in HaemDCs and their corresponding biopsies of 
origin is given in Appendix 2, Figure 2.4, page 286. The raw Ct values (relative to 
GAPDH) for all cell lines analysed for these markers can be found in Appendix 2, Table 
2.1, page 287. 
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Phase 
 
HaemDCs 
 
Passage 
 
GLUT-1 
 
CD133 
 
CD29 
 
CD44 
 
CD90 
 
VEGFR-1 
 
VEGFR-2 
 
CD31 
 
CD45 
 
Prolif 
 
Patient A 
 
3 
 
ND 
 
- 
 
2.9 
 
4.4 
 
5.2 
 
10.1 
 
- 
 
- 
 
- 
Prolif Patient A 9 ND - 2.9 3.7 4.6 9.8 - - - 
Prolif Patient B 3 ND - 1.9 3 2.8 ND - - - 
Prolif Patient C 3 7 - 1 2.5 2.2 10.2 - - - 
Prolif Patient D 3 5.5 - 1.2 3.7 2.6 ND - - - 
Ig Patient F 3 7.9 - 2.2 3.2 2.4 9.9 - - - 
 HUVECS 12 9.7 - 2.3 3.2 - 9.8 9.6 2.2 - 
 3T3 Fibroblasts  - - - 4.1 - - - - - 
Haematopoietic 
antigen 
MSC markers EC markers Stem cell 
marker 
Table 6: mRNA characterisation of HaemDCs.   mRNA expression for GLUT-1, the stem cell marker, CD133, the MSC markers, CD29, CD44 and 
CD90, the EC markers, CD31, VEGFR-1 and VEGFR-2 and the  haematopoietic antigen, CD45 was analysed in HaemDCs isolated from four 
proliferating haemangioma lesions (Patient A-D), one involuting haemangioma lesion (Patient F), HUVECs and 3T3 fibroblasts.  RNA was extracted 
from 1x105 cells, reverse transcribed into cDNA and analysed by qRT-PCR as described in section 2.3.8.1. Expression of transcripts was determined 
relative to GAPDH (Ct). The table gives the Ct values obtained for each gene. HaemDCs expressed mRNA for a number of markers characteristic 
of MSCs including CD29, CD44 CD90 but did not express mRNA for the EC markers, CD31, VEGFR-1 and VEGFR-2 or the hematopoietic marker, 
CD45. HaemDCs and HUVECs expressed mRNA for the the haemangioma antigen, GLUT-1. None of the cell lines expressed mRNA for the stem cell 
marker, CD133. Key: ‘-’ shows no amplification and therefore absence of mRNA transcript; ND indicates not determined. 
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4.3.3.4 IMMUNOHISTOCHEMICAL CHARACTERISATION 
Immunofluorescent labelling of lineage-specific markers revealed that all cells 
stained for vimentin (Figure 4.5-A) and GLUT-1 (Figure 4.5-B) while only some cells 
were positive for -SMA (Figure 4.5-C). In addition, the HaemDCs did not express any 
of the commonly used EC markers, vWF, CD34 or VEGFR-2 (Figure 4.6 and Figure 
4.7). As positive and negative controls in the same experiment, immunostaining for 
vWF, CD34 and VEGFR-2 was carried out on HUVECs and 3T3 fibroblasts, 
respectively. Immunoreactivity for VEGFR-1 was detected on HaemDCs and HUVECs 
but not on 3T3 fibroblasts (Figure 4.7). VEGFR-1 expression by HaemDCs was 
confirmed by Western blotting (Figure 4.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Immunohistochemical localisation of vimentin, -SMA and GLUT-1 on 
HaemDCs. HaemDCs were fixed and immunostained for vimentin, -SMA and GLUT-
1 as described in section 2.3.9. Vimentin and -SMA expression was detected using 
anti-mouse AlexaFluor 488 conjugated antibodies (green staining) and GLUT-1 
expression was detected with an anti-rabbit Cy3 conjuate (red staining). Cell nuclei 
were counterstained with DAPI (blue). All HaemDCs expressed the MSC marker, 
vimentin (A) and the haemangioma marker, GLUT-1 (C) while only some cells showed 
immunoreactivity for another MSC marker, -SMA (B). Scale bars: (A-B) 100 µm, (C) 
50 µm. 
A B 
C 
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Figure 4.6: Immunohistochemical localisation of vWF and CD34 on HUVECs, HaemDCs and 3T3 fibroblasts. HUVECs (A&D), HaemDCs (B&E) and 3T3 
fibroblasts (C&F) were fixed and labelled with rabbit anti-vWF (A-C) and mouse anti-CD34 (D-F) antibodies as described in section 2.3.9. Bound 
antibodies were detected using either an anti-rabbit Cy3 (red) or an anti-mouse AlexaFluor 488 conjugate (green). Cell nuclei were counterstained with 
DAPI (blue).  HUVECs were used as a positive control and expressed both vWF (A) and CD34 (D) while no immunoreactivity was detected for vWF and 
CD34 on the HaemDCs (B&E, respectively) and the cell line used as a negative control, the 3T3 fibroblasts (C&F, respectively). Scale bars: 50 µm.  
 155 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Immunohistochemical localisation of VEGFR-2 and VEGFR-1 on HUVECs, HaemDCs and 3T3 fibroblasts. HUVECs (A&D), HaemDCs 
(B&E) and 3T3 fibroblasts (C&F) were fixed and labelled with rabbit anti-VEGFR-2 (A-C) and goat anti-VEGFR-1 antibodies (D-F). Bound antibodies 
were detected using either an anti-rabbit DIG conjugate followed by an anti-DIG-Rhodamine (red) conjugate or an anti-goat biotin conjugate followed by an 
AlexaFluor 555 streptavidin conjugate (red). Cell nuclei were counterstained with DAPI (blue).  HUVECs used as a positive control, expressed both 
VEGFR-2 (A) and VEGFR-1 (D).  HaemDCs and 3T3 fibroblasts did not express VEGFR-2 (B&C, respectively). Positive staining for VEGFR-1 was 
detected on HaemDCs (E) but was absent on the negative control cell line, 3T3 fibroblasts (F). Scale bars: (A-C) 50 µm, (D-F) 20 µm.
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Taken together, the qRT-PCR and IHC data supports the assertion that the 
primary cultures obtained from the capillary-like outgrowths from haemangioma 
explants are of mesenchymal origin and are now referred to as haemangioma-derived 
mesenchymal cells (HaemDMCs) 
Although the HaemDMCs were found to express VEGF and collagen mRNA, 
protein expression was absent. Western blotting (Figure 4.8) and immunofluorescence 
staining (data not shown) of HaemDMCs showed that the cells neither expressed nor 
secreted VEGF. 50 ng and 25 ng of purified recombinant VEGF165 along with total 
protein from HaemDMCs conditioned media (40 µg), HaemDMCs (100 µg) and 
proliferative haemangioma tissue (100 µg) lysates were subjected to Western blotting 
under reducing conditions. The resulting immunoblot was probed with an anti-VEGF 
antibody that recognises three isoforms of VEGF-A, VEGF121, VEGF165 and VEGF189. 
Immunoreactive bands corresponding to a molecular weight of 23 kDa were detected 
only with the purified VEGF protein (Figure 4.8). 
In addition, picrosirius red staining of HaemDMCs showed no collagen fibres 
either in the cells themselves or in their ECM (data not shown). An involuting 
haemangioma section was used as a positive control and showed expression of collagen 
fibers (Figure 4.9). Staining of collagen fibres with picrosirius red allows the 
visualisation of individual collagen fibres on the basis of double refraction of light 
against a black background, when epipolarisation microscopy is used (Junqueira et al., 
1979). 
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Figure 4.8: Western blotting for VEGF-A. Total protein extracted from the conditioned 
media of HaemDMCs, from HaemDMCs and from proliferating haemangioma tissue 
was subjected to Western blotting as described in section 2.3.13.2. Lane: 1) 50 ng of 
purified VEGF165; 2) 25 ng of purified VEGF165; 3) 40 µg of total protein from the 
medium of HaemDMCs conditioned over a 96 hour period; 4) 100 µg of total protein 
from HaemDMCs and 5) 100 µg of total protein from a proliferative haemangioma 
tissue sample. Following electrophoresis and transfer onto a PVDF membrane, the 
membrane was blocked and probed with an antibody that recognises the VEGF121, 
VEGF165 and VEGF189 isoforms of VEGF-A. Specific immunoreactivity was detected at 
23 kDa from the purified VEGF protein but was absent on the other samples (black 
arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Picrosirius red stained section of an involuting haemangioma tissue section. 
Under a polarised light source, the haemangioma tissue section stained with picrosirius 
red showed the presence of collagen fibers. In the image above, thick fibers appear red 
or yellow while thin fibers appear green. Scale bar: 500 µm. 
1 2 3 
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4.3.3.5 MULTILINEAGE DIFFERENTIATION POTENTIAL OF HaemDMCs  
To determine the multilineage capacity of HaemDMCs cutured cells were 
differentiated toward the adipogenic and osteogenic lineages using lineage-specific 
induction factors. To induce adipogenesis, cells were cultured in medium containing 
Dexamethasone, ascorbic acid, -glycerophosphate, insulin and indomethecin. 
Differentiation into adipocytes was detected within 15 days of induction and continued 
to accumalate over time (Figure 4.10-D). A significant fraction of the cells contained 
multiple, intracellular lipid-filled droplets that accumulated Oil-Red O (Figure 4.10-E). 
No lipid droplets were observed in undifferentiated HaemDMCs (Figure 4.10-A). 
Adipocytic differentiation potential of HaemDMCs was maintained even after 10 
passages, indicating their phenotypic stability and their ability to undergo self-renewal 
in vitro. 
Differentiation into osteoblasts was induced in vitro by treating cells with 
ascorbic acid, -glycerophosphate and Dexamethasone. To confirm osteogenic 
differentiation, calcification of the ECM was assessed using Alizarin Red stain. While 
no calcification was observed in undifferentiated cells (Figure 4.10-A) the HaemDMCs 
readily differentiated into osteocytes. Figures 4.10-B and -C show mineralization of the 
ECM produced by cultured HaemDMCs that was revealed by Alizarin Red staining. 
Consistent with previous findings, differentiation required the cells to be plated at high 
confluencey (greater than 2 X 104 cells/cm2) (Tropel et al., 2004).  
HaemDMCs isolated from proliferating and involuting haemangioma biopsies 
showed similar osteogenic differentiation potential (Figure 4.10-B and -C, respectively). 
However, HaemDMCs isolated from proliferating haemangiomas readily differentiated 
into adipocytes by day 15 (Figure 4.10-E) while HaemDMCs derived from involuting 
lesions took approximately 60 days to produce any lipid vacuoles (Figure 4.10-F).  
In contrast, HaemDMCs isolated in this study did not differentiate into ECs or 
express EC-like markers when cultured in the presence of VEGF (data not shown).   
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Confirmation of differentiation into adipocytes and osteoblasts was investigated 
by qRT-PCR analysis of transcripts for the peroxisome proliferator-activated receptor 
(PPAR-), a key regulatory gene of adipogenesis (Camp et al., 2002), and osteonectin, a 
gene expressed by osteoblasts (Jundt et al., 1987). Table 7 shows the expression levels 
of these genes in mesenchymal cell isolates from five proliferating and one involuting 
haemangioma. Gene expression was determined relative to GAPDH (Ct) in 
undifferentiated versus differentiated cells (Ct).  Expression of PPAR- increased 
as expected (approximately 16-fold) while that for osteonectin did not alter 
significantly. Differentiation experiments were replicated with HaemDMCs isolates 
from five different proliferative biopsies and two involuting biopsies. These data are 
consistent with the HaemDMCs being haemangioma-derived mesenchymal stem cells 
(HaemDMSCs), which are here after referred to as such. An example of the typical 
change in mRNA expression for osteonectin and PPAR, before and after induction, 
from one experiment is shown in Figure 4.11.  
 
   
Table 7: PPAR- and osteonectin mRNA expression. HaemDMCs isolated from five 
proliferating (Patient A-E) and one involuting haemangioma (Patient F) were 
differentiated into adipocytes and osteoblasts. qRT-PCR was performed to identify 
changes in PPAR- and osteonectin mRNA expression in undifferentiated cells versus 
differentiated cells (Ct) 
 
Phase 
 
HaemDMCs 
 
Passage 
 
Ct PPAR- 
 
Ct Osteonectin 
 
Prolif 
 
Patient A 
 
3 
 
4.7 
 
3.4 
Prolif Patient B 3 4.3 -1.5 
Prolif Patient C 3 5.5 1.7 
Prolif Patient D 3 4.9 -0.2 
Prolif Patient E 3 2.9 -1 
Ig Patient F 3 3.3  
-0.4 
 
 
Mean (± 
 
s.e.m.) 
 
 
4 ± 0.4 
 
0.3 ± 0.8 
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Figure 4.10: Differentiation potential of HaemDMCs. HaemDMCs purified from a proliferating (B,D&E) and an involuting haemangioma 
(C&F) were plated onto glass coverslips at 2x104 cells/cm2 and cultured in osteocytic or adipocytic differentiation media as described in section 
2.3.9. HaemDMSCs purified from proliferating (B) and involuting (C) lesions differentiated into osteocytes after 14 days of induction as 
depicted by Alizarin Red staining. HaemDMCs also differentiated into lipid laiden adipocytes. Phase contrast image of adipocyte formation in 
culture by HaemDMCs (D). Cytoplasmic lipid vacuoles were identified by staining with Oil Red O (E&F). HaemDMCs from proliferative 
lesions (E) more readily differentiated into adipocytes than HaemDMCs from involuting lesions (F). Panel E shows increased adipocyte 
formation by HaemDMCs from a proliferative lesion after only 21 days of induction while Panel F shows adipocyte formation by HaemDMCs 
from an involuting lesion after 50 days in induction media. Undifferentiated HaemDMCs islolated from a proliferating haemangioma showed no 
staining with Alizarin Red and Oil Red O (A). Scale bars: 50 µm.  
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Figure 4.11: Validation of adipocytic and osteocytic differentiation of HaemDMSCs. 
Differentiation into adipocytes and osteocytes was validated by qRT-PCR performed 
for PPAR and osteonectin, respectively. Changes in mRNA expression are expressed 
relative to that for GAPDH (the internal reference gene) as Ct values. Black columns 
indicate PPAR expression and white columns indicate osteonectin expression. An 
increase in mRNA expression was observed for both genes in differentiated 
HaemDMSCs compared to undifferentiated cells. A lower Ct indicates higher gene 
expression while a higher Ct indicates low expression. 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Western blot verification of VEGFR-1 and STAT-3 expression by 
HaemDMSCs. Western blotting was performed as per section 2.3.13.1. Each lane 
contains 50 µg of total protein from HaemDMSCs. Following electrophoresis and 
transfer onto a PVDF membrane, the membrane was blocked with goat anti-VEGFR-1, 
mouse anti-STAT-3 and mouse anti-GAPDH antibodies followed by incubation with 
anti-goat and anti-mouse AlexaFluor 488 conjugated secondary antibodies. The 
resulting blot confirmed expression of VEGFR-1 and STAT-3 by HaemDMSCs as 
signal was observed at the appropriate sizes of 180 kDa and 92 kDa, respectively. 
GAPDH was included as the loading control.
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4.3.4 ROLE OF VEGF AND STAT SIGNALLING IN VITRO
 
4.3.4.1 EFFECT OF VEGF AND AG490 ON CAPILLARY-LIKE OUTGROWTH  
The importance of VEGF and STAT signalling on ‘microvessel’ outgrowth was 
investigated using the explant model developed by Tan et al (2000b) and also using the 
modified culture system developed in this study (section 2.3.4, page 86). Explants 
treated with 50 ng/ml of VEGF exhibited a higher degree of capillary-like outgrowth 
after six days in culture compared to controls (p < 0.01). This dramatic sprouting was 
mitigated by the addition of 50 µM of AG490, an inhibitor of STAT protein 
phosphorylation (Huang et al., 2006; Andl et al., 2004), in the culture medium (Figure 
4.13-A). Among the sprouting explants, the VEGF treated group was observed to be 
more advanced in terms of number and length of sprouts. In addition, cultures treated 
with AG490 and VEGF showed significantly less capillary-like growth than untreated 
cultures (p < 0.01) (Figure 4.13-A). This suggests that the inhibitory effect of AG490 
can overcome the stimulatory effect of VEGF on capillary-like outgrowths. Figure 4.13-
A shows the average capillary-like outgrowth of explanted haemangioma tissue 
obtained from two separate patients. Duplicate wells containing an explanted tissue 
piece were used for each treatment.  
  Explants were also cultured with various concentrations of AG490 diluted into 
the gel matrix and in the overlying medium for a period of ten days. Addition of 10 µM 
and 50 µM AG490 at the beginning of the culture inhibited sprouting with significance 
achieved at p < 0.05 and p < 0.001, respectively (Figure 4.13-B). Results shown in 
Figure 4.13-B are representative of two separate experiments conducted with 
haemangioma biopsies obtained from two individual patients. Triplicate wells were 
used for each treatment with at least six wells used as control cultures.   
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Figure 4.13: Effect of AG490 and VEGF on capillary-like outgrowth from proliferating 
haemangioma explants. Proliferating haemangioma explants were cultured as outlined 
in sections 2.3.3 and 2.3.4. In all experiments, DMSO was added to the untreated 
control cultures at the same volume as that used for the highest concentration of AG490.  
(A) Significant increase in capillary-like outgrowth was observed with the addition of 
VEGF (50 ng/ml) to the cultures above that of the controls. This stimulatory effect of 
VEGF was mitigated by including AG490 (50 µM). In addition, including AG490 along 
with VEGF decreased capillary-like growth compared with untreated cultures. 
Capillary-like outgrowth was quantified 6 days post treatment. (B) Pieces of 
proliferating haemangioma biopsies were cultured in the presence of AG490 at various 
concentrations and capillary-like growth was assayed after 9 days in culture. Capillary-
like outgrowth was significantly inhibited by 50 µM and 10 µM AG490. * represents 
significance at p < 0.05, ** at p < 0.01 and *** at p < 0.001. 
 
A 
B 
**
**
0.5 
0 
1 
2 
3 
2.5 
1.5 
3.5 
Control VEGF VEGF+AG490 
0
2
4
6
8
10
12
Control 50 µM 
AG490  
10 µM 
AG490 
1 µM 
AG490 
0.1 µM 
AG490 
Ca
pi
lla
ry
-
lik
e 
o
u
tg
ro
w
th
 
Ca
pi
lla
ry
-
lik
e 
o
u
tg
ro
w
th
 
*** 
*
 165 
4.3.4.2 EFFECT OF VEGF AND AG490 ON HaemDMSCs.  
To investigate if VEGF signalling through STAT proteins is involved in the 
proliferation of HaemDMSCs, cells were incubated with VEGF at various 
concentrations known to stimulate proliferation of ECs and the extent of proliferation 
was measured using the EZ4U assay.  Although VEGF induced proliferation of 
HUVECs (Figure 4.14-A), it did not stimulate the proliferation of HaemDMSCs even at 
low serum concentrations (Figure 4.14-B).  
 166 
 
Figure 4.14: VEGF stimulates proliferation of HUVECs but not HaemDMSCs.
HUVECs (A) and HaemDMSCs (B) were treated with the indicated concentrations of 
VEGF and the extent of cell proliferation was measured using the EZ4U assay as 
described in section 2.3.12.1. The increase in cell number was measured by the increase 
in the absorbance values of HUVEC cultures treated with various concentrations of 
VEGF for 72 hours (A). VEGF did not stimulate proliferation of HaemDMSCs 
proliferation as assayed from the absorbance readings (B). Data shown in (B) is 
representative of two separate experiments performed with HaemDMSCs isolates from 
two haemangioma patients set up in triplicate. HUVECs were cultured in RPMI 
medium containing 2% FCS for 72hrs and HaemDMSCs in 0.1% FCS for 6 days. ** p 
< 0.01. 
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In addition, treatment with VEGF neither induced p-STAT-3 phosphorylation 
(Figures 4.15) nor caused its nuclear translocation (Figure 4.16). Figure 4.15 shows that 
in comparison with IFN treated HeLa cells, unstimulated HaemDMSCs express very 
low levels of p-STAT-3 (Tyr 705) and that VEGF treatment does not significantly alter 
p-STAT-3 (Tyr 705) expression levels. Identical results were obtained when the 
experiment was performed on two separate occasions with HaemDMSCs isolates from 
two different haemangioma biopsies (from two patients).  
In addition, no significant change in p-STAT-3 (Tyr 705) expression was noted 
when HaemDMSCs were treated with AG490 (50 µM) for 24 hours (Figure 4.15). 
Immunoblotting for total STAT-3 and GAPDH protein confirmed equal protein 
loadings.  
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Figure 4.15: VEGF does not induce p-STAT-3 (Tyr 705) expression in HaemDMSCs.
HaemDMSCs isolated from a proliferating haemangioma were treated with either 
VEGF (50 ng/ml), AG490 (50 µM) alone or both for the indicated time periods and 
subjected to Western blotting as described in section 2.3.13.1. HeLa cells stimulated 
with IFN-2b (10,000 U/ml) for 10 min were included as a positive control. 
Immunoblots were probed with mouse anti-p-STAT-3 (Tyr 705) and mouse anti-
GAPDH antibodies. (A) Western blot analysis showed that p-STAT-3 (Tyr 705) 
expression was not induced after VEGF stimulation in whole cell lysates. Membranes 
were then stripped and re-probed with an anti-STAT-3 antibody. The levels of STAT-3 
and GAPDH expression were determined as a control for equivalent protein loading.  
(B) Graphical representation of p-STAT-3 (Tyr 705) expression by densitometry. In 
comparison with IFN treated HeLa cells, unstimulated HaemDMSCs expressed very 
low levels of p-STAT-3. The slight decrease in p-STAT-3 (Tyr 705) expression 
identified with VEGF treatment was not considered significant due to the low 
abundance of p-STAT-3 (Tyr 705) expression in the unstimulated cells to begin with. 
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Localisation of p-STAT-3 (Tyr 705) in response to VEGF treatment was 
determined by confocal microscopy. No change in p-STAT-3 (Tyr 705) expression or 
localisation was detected with VEGF treatment (Figure 4.16-A). Expression pattern of 
p-STAT-1 (Tyr 701) and p-STAT-5 (Tyr 694) was also investigated in HaemDMSCs 
with and without VEGF treatment. Immunoreactivity for p-STAT-1 was observed to be 
cytoplasmic in both unstimulated and VEGF stimulated HaemDMSCs (Figure 4.16-A). 
Although immunoreactivity for p-STAT-5 was undetectable in resting HaemDMSCs, 
there was an increase in p-STAT-5 (Tyr 694) immunoreactivity within the nuclear 
compartment following a 30 min incubation with VEGF (Figure 4.16-A). p-STAT-5 
(Tyr 694) immunoreactivity detected within the nuclei of HaemDMSCs after VEGF 
treatment was significantly greater than that detected in the unstimulated cells (p < 
0.001) (Figure 4.16-B).  
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Figure 4.16: Immunolocalisation of p-STAT-3 (Tyr 705), p-STAT-1 (Tyr 701) and p-
STAT-5 (Tyr 694) in response to VEGF. Panel A: Confocal microscopy was used to 
detect immunoreactivity for p-STAT proteins (green) in unstimulated HaemDMSCs (A-
C) and HaemDMSCs stimulated with VEGF (50 ng/ml) for 30 min (D-F). Cells were 
fixed and stained as described in section 2.3.14.1. Cell nuclei were counterstained with 
PI (red). In untreated cells, immunoreactivity for p-STAT-3 (Tyr 705) (A) and p-STAT-
1 (Tyr 701) (B) was mainly cytoplasmic while staining for p-STAT-5 (Tyr 694) (C) was 
almost negligible. After 30 min of VEGF stimulation an increase in p-STAT-5 (Tyr 
694) immunoreactivity was detected which was found to be predominantly within the 
nuclear compartment (yellow) (F). Overlapping of the green (p-STATs) and the red 
(nucleus) colors (yellow) indicates the presence of p-STAT proteins within the nuclei of 
HaemDMSCs. No significant change in p-STAT-3 (D) or p-STAT-1 (E) expression or 
localisation was detected. Panel B: Graphical representation of the increase in p-STAT-
5 (Tyr 694) expression detected within the nuclei of HaemDMSCs following VEGF 
treatment as determined by densitometry analysis, *** p < 0.001. Scale bars: 50 µm 
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To test if STAT signalling is involved in HaemDMSCs proliferation, cells were 
treated with AG490 in the presence of the thymidine analogue, BrdU. Studies have 
shown that as BrdU is readily incorporated into the DNA of replicating cells and that 
quantifying BrdU incorporation can be a used as a measure of cell proliferation 
(Porstmann et al., 1985).  
Interestingly, after 24 hours of treatment with AG490, the number of BrdU 
positive cells significantly decreased indicating a delay in the accumulation of cells in S 
phase (Figure 4.17-A). A slight increase in the number of cells in G1 phase of the cell 
cycle, with minimal effects on G2/M phase of the cell cycle was also observed (data not 
shown). Results shown in Figure 4.17-A are representative of at least five individual 
experiments.  
In addition, the effect of AG490 on vessel formation was investigated using the 
in vitro assay described in section 2.3.12.3 (page 94). A dose dependent decrease in 
vessel formation was observed when this assay was performed with medium containing 
both 5% (Figure 4.17-B) and 1% FCS (data not shown). The cultures in 5% FCS were 
assayed after a period of 14 days while those in 1% FCS were analysed after 21 days.  
In addition to measuring vessel formation, cell nuclei were also counted for each 
treatment group using counting frames of 1000 cm2 (see section 2.3.12.3, page 94).  A 
dose dependent decrease in cell number was observed with AG490 treatment (Figure 
4.17-C). Figure 4.17-B and -C show the results from of two individual experiments.   
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Figure 4.17: The effect of AG490 on HaemDMSCs. (A) AG490 inhibited proliferation 
of HaemDMSCs by stalling cell cycle progression. HaemDMSCs were treated with 100 
µM or 50 µM AG490 for 24 hrs in culture media containing 5% FCS. Cells were pulsed 
with BrdU for the last seven hours of treatment with AG490 and fixed in ethanol. 
Following incubation with an anti-BrdU antibody, antibody binding was analysed by 
flow cytometry. A minimum of 1x106 cells were analysed per experimental condition 
and the fraction of cells in S phase were determined by BrdU incorporation. Results 
obtained are representative of five individual experiments. (B) AG490 inhibited vessel 
formation of HaemDMSCs. 1x105 HaemDMSCs were plated into each well of a 24-well 
culture dish containing either vehicle alone (DMSO), 100 µM AG490 or 50 µM AG490 
dissolved in the culture media. After 12 days in culture, vessel formation was assessed 
as described in section 2.3.12.3. A significant decrease in vessel formation was detected 
with AG490 at both 100 µM and 50 µM. (C) AG490 inhibited proliferation of 
HaemDMSCs. The total cell nuclei within the same area as that used for assessing 
vessel formation was counted. Results showed that the number of cell nuclei also 
decreased with an increase in AG490 concentration. All values are expressed as the 
mean ± s.e.m. Results shown in (B) and (C) are representative of two individual 
experiments set up in duplicate. Control cultures were set up in quadruplicates. * p < 
0.05, ** p < 0.01.  
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4.3.5 OSTEOPROTEGERIN EXPRESSION IN HAEMANGIOMA.  
Osteoprotegerin (OPG) is involved in osteoclast differentiation and activation 
(Simonet et al., 1997; Tsuda et al., 1997; Fuller et al., 1998). See section 5.3.5 (page 
227) for more details on why OPG expression was investigated in HaemDMSCs.  qRT-
PCR revealed that HaemDMSCs expressed high levels of OPG mRNA (Figure 5.4-A 
and Appendix 3, Figure 3.5). Immunohistochemical staining revealed that 
HaemDMSCs expressed large amounts of OPG protein in the ECM but not within the 
cells (Figure 4.18-D). Consistent with previous reports, OPG co-localised with vWF in 
HUVECs (Figure 4.18-C) (Zannettino et al., 2005). However, HUVECs expressed less 
OPG protein (Figure 4.18-B) than HaemDMSCs (Figure 4.18-B). Since HaemDMSCS 
expressed high levels of OPG protein, it was hypothesised that OPG might serve as a 
marker for MSCs within haemangioma tissues in vivo.  
Immunohistochemical staining of haemangioma tissue sections showed that 
proliferating lesions contained more OPG positive cells (Figure 4.19-B, green staining) 
than involuting lesions (Figure 4.19-E) while involuted lesions contained no OPG 
staining cells (Figure 4.19-H). Dual immunostaining for vWF and OPG revealed that 
most vessels in the proliferating lesions expressed vWF but in a punctate manner 
(Figure 4.19-A, white arrows) and that these cells strongly expressed OPG (Figure 4.19-
B, white arrows). Late proliferative and early involuting phases contained regions that 
exhibited punctuate vWF (Figure 4.19-D, white arrows) and high OPG staining (Figure 
4.19-E, white arrows). These lesions also contained vessels that strongly expressed 
vWF (Figure 4.19-D, yellow arrows) ,which did not express OPG (Figure 4.19-E, 
yellow arrows). In addition, the vessels in the late involuting and involuted phases that 
strongly expressed vWF (Figure 4.19-G, yellow arrows) did not express OPG (Figure 
4.19-H, yellow arrows). Dual staining for vWF and PCNA indicated that regions with 
punctate, weak vWF staining and high OPG expression also contained more PCNA 
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positive cells than regions with strongly staining vWF and no OPG expression (Figure 
4.20).  
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Figure 4.18: Immunohistochemical localisation of vWF and OPG on HUVECs 
and OPG on HaemDMSCs. IHC was performed on HUVECs (A-C) fixed in a 
mixture of methanol and acetone. Cultures were stained with rabbit anti-vWF 
and mouse anti-OPG antibodies as described in section 2.3.11. HaemDMSCs 
were fixed and stained with mouse anti-OPG antibodies (D). Bound vWF 
primary antibodies were detected using an anti-rabbit Cy3 conjugate (red) and 
bound OPG antibodies were detected with an anti-mouse AlexaFluor 488 
conjugate (green). Panel C is the merged image of Panels A with B.  Cell nuclei 
were counter-stained with DAPI (blue). HUVECs expressed vWF (A, red 
staining) and OPG (B, green staining) which was found to colocalize (C, yellow 
staining). Merging images with red and green staining appears yellow. 
HaemDMSCs expressed high levels of extracellular OPG (D, green staining). 
Scale bars: 100 µm.  
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Figure 4.19: Confocal immunohistochemical localisation of vWF and OPG in 
haemangioma. Proliferating (A-C), involuting (D-F) and involuted (G-I) paraffin 
embedded haemangioma tissue sections were stained with rabbit anti-vWF (A,D&G) 
and mouse anti-OPG (B,E&H) antibodies. Bound vWF and OPG antibodies were 
detected using an anti-rabbit-Cy3 conjugate (red) and an anti-mouse AlexaFluor 488 
conjugate (green), respectively.  Panels C, F and I are the merged images of Panels A 
with B, D with E, and G with H, respectively.  Most cells lining the blood vessels in 
proliferating lesions showed punctate immunoreactivity for vWF (A, white arrows). The 
same cells also showed strong staining for OPG (B, white arrows). Involuting lesions 
contained regions that showed punctate vWF staining (D, white arrows). These regions 
expressed high levels of OPG (E, white arrows). However, these lesions also contained 
vessels that showed intense immunoreactivity for vWF (D, yellow arrows) but were 
negative for OPG (E, yellow arrows). Vessels in involuted lesions that strongly stained 
for vWF (G, yellow arrows) were negative for OPG (H, yellow arrows). Scale bars: 50 
µm.  
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Figure 4.20: Immunohistochemical localization of vWF and PCNA on paraffin 
embedded haemangioma tissue biopsies. Proliferating (A-C), involuting (D-F) and 
involuted (G-I) haemangioma biopsies were stained with rabbit anti-vWF antibodies 
and mouse anti-PCNA antibodies. Bound vWF and PCNA antibodies were detected 
using an anti-rabbit-Cy3 conjugate (red) and an anti-mouse AlexaFluor 488 conjugate 
(green) respectively. (A) Proliferating lesions showed punctate immunoreactivity for 
vWF (white arrows) and contained the highest number of PCNA positive cells (green 
staining). (B) In involuting lesions, the vessels that exhibited punctate staining for vWF 
(white arrows) also contained some PCNA positive cells. But vessels that stained 
strongly for vWF (yellow arrows) did not contain any cells that express PCNA. (C) 
Vessels in involuted lesions that strongly expressed vWF were devoid of PCNA 
positive cells. Scale bars: 50 µm.  
A 
B 
C 
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4.3.6 EFFECT OF INTERFERON AND DIFFERENTIATION MEDIA 
ON STAT PROTEIN EXPRESSION IN HaemDMSCs  
IFN-2b treatment significantly decreased proliferation of HaemDMSCs (see 
section 5.3.4, page 224). In addition, treatment of HaemDMSCs with 10,000 U/ml of 
IFN-2b for 15 min resulted in a dramatic increase in p-STAT-3 (Tyr 705) expression 
(Figure 4.21-A) accompanied by its nuclear translocation (Figure 4.21-B). In addition, 
increased expression and nuclear translocation above that of the untreated controls was 
seen for p-STAT-5 (Tyr 694) and p-STAT-1 (Tyr 701) (Figure 4.21-B) in IFN-2b 
treated cultures. These results lead us to the hypothesis that STAT signalling might be 
involved in haemangioma differentiation.  
To test this hypothesis, STAT-3, STAT-5, p-STAT-3 (Tyr 705) and p-STAT-5 
(Tyr 694) expression and localisation was analysed in HaemDMSCs treated with 
adipocyte induction media for 30 min, 4 hours and 24 hours.  No significant change in 
expression or localisation of p-STAT-3 (Tyr 705) and p-STAT-5 (Tyr 694) was 
observed in treated versus the untreated cells at all time points (Appendix 2, Figure 2.5, 
page 288).  
In addition, the effects of IFN-2b and AG490 were tested on the rate of 
adipogenesis. HaemDMSCs were cultured with differentiation media containing either, 
100 U/ml IFN-2b, 15000 U/ml of IFN-2b, 5 µM AG490 or 20 µM of AG490.  These 
differentiation conditions were maintained for a period of 16 days with media being 
changed every 2-3 days. No significant increase in adipocyte formation was observed 
with either dosage of IFN-2b above that of the control cultures containing 
differentiation media alone. In addition, neither dose of AG490 was able to block lipid-
laiden vacuole formation (data not shown).  
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Figure 4.21: IFN-2b induces an increase in p-STAT protein expression and nuclear 
translocation in HaemDMSCs.  (A) HaemDMSCs were treated with IFN-2b for the 
times indicated. Unstimulated and HaemDMSCs stimulated with 10,000 U/ml of IFN-
2b for 5, 10 and 15 min were lysed and subjected to Western blotting as described in 
section 2.3.13.1. While unstimulated HaemDMSCs expressed low levels of p-STAT-3 
(Tyr 705), a time dependent increase in p-STAT-3 (Tyr 705) expression was detected 
with IFN-2b stimulation. (B) Confocal immunohistochemical localisation of p-STAT 
proteins (green) in HaemDMSCs stimulated with 10,000 U/ml IFN-2b for 15 min (D-
F) in comparison with control unstimulated HaemDMSCs (A-C). Cell nuclei were 
counterstained with PI (red). Unstimulated HaemDMSCs expressed low levels of p-
STAT3 (Tyr 705) (A), p-STAT-5 (Tyr 694) (B) and p-STAT-1 (Tyr 701) (C) (green) 
detected only in the cytoplasm. Following IFN-2b treatment, immunoreactivity for p-
STAT3 (Tyr 705) (D), p-STAT-5 (Tyr 694) (E) and p-STAT-1 (Tyr 701) (F) was 
detected within the nuclei of HaemDMSCs (yellow). Overlapping of the green (p-
STATs) and the red (nucleus) colors (yellow) indicates the presence of p-STAT proteins 
within the nuclei of HaemDMSCs. Some immunoreactivity for p-STAT-5 and p-STAT-
1 was also detected in the cytoplasm of the IFN-2b stimulated HaemDMSCs (E&F, 
respectively). Scale bars: 50 µm. 
A 
B 
p-STAT-3 (Tyr 705) p-STAT-5 (Tyr 694) p-STAT-1 (Tyr 701) 
U
n
tr
ea
te
d 
IF
N

-
2b
 
IFN-2b 
min 0 5 10 15 
-
++++
92 kDa 
37 kDa 
p-STAT-3 (Tyr 705) 
GAPDH  
H
eL
a 
 181 
4.3.7 ENDOTHELIAL PROGENITOR CELLS IN HAEMANGIOMA 
Using previously described methods with a few modifications, the isolation of 
ECs from human haemangioma biopsies was attempted. This was to be used as a patient 
matched comparative cell line. However, these attempts were futile as cell yield was 
low after the isolation step with CD31 coated beads. These cells did not proliferate well 
and died following the first passage (See Appendix 2, section 2.1, page 289)  
 However, good yield was obtained when the bead isolation was omitted. The 
morphology exhibited by the cells obtained from digested proliferating haemangioma 
tissues was distinct from HaemDMSCs in that these cells had round central bodies with 
some cytpolasmic projections (Figure 4.22). This morphology has been shown to be 
typical of EPCs (Ashara et al., 1997; Kalka et al., 2000). Immunohistochemical staining 
performed on these cells 48 hours after dissociation showed that the cells expressed 
typical EC markers, vWF (Figure 4.23), VEGFR-1 (Figure 4.25-A) and more 
importantly VEGFR-2 (Figure 4.25-B). These results are consistent with an EC 
phenotype. Therefore, these cells are here in referred to as haemangioma-derived EPCs 
(HaemDEPCs).  
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Figure 4.22: EPC-like cells obtained from a proliferating haemangioma. The cells 
obtained from collagenase treated proliferating haemangioma tissue were plated onto 
gelatin coated culture dishes. These cells exhibited EPC-like morphology i.e., they 
contained round central bodies with some cytplasmic projections. Photograph was taken 
on day 2 in culture. Scale bar: 500 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Immunohistochemical localisation of vWF and OPG on HaemDEPCs. On 
day 2 in culture, HaemDEPCs were fixed and stained with rabbit anti-vWF and mouse 
anti-OPG primary antibodies as described in section 2.3.9. Bound anti-vWF antibodies 
were detected with an anti-rabbit Cy3 (red) conjugate and bound anti-OPG antibodies 
were detected with an anti-mouse AlexaFluor 488 (green) conjugate. Cell nuclei were 
counterstained with DAPI (blue). Positive immunoreactivity was detected for vWF (red) 
and OPG (green) on all HaemDEPCs present on the coverslip. Scale bar: 50 µm. 
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Interestingly, on day 5 in culture, HaemDEPCs had changed to a MSC-like 
morphology, i.e., they appeared flat and broadened (Figure 4.24-A).  At this stage, 
immunohistochemical analysis showed that they no longer expressed vWF (Figure 4.24-
B) and VEGFR-2 (Figure 4.25-D). However, the cells continued to express VEGFR-1 
(Figure 4.25-C) and high levels of extracellular OPG (Figure 4.24-B) which again is 
typical of HaemDMSCs as shown earlier (Figure 4.18-C). Furthermore, the MSC nature 
of the spontaneously differentiated cells was confirmed by the ability of the cells to 
form adipocytes  (Figure 4.26).  These results indicate that there is an EPC to MSC 
transdifferentiation process occurring in vitro.  
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Figure 4.24: Change in HaemDEPC morphology and immunophenotype on day 5 in 
culture in vitro. (A) Phase contrast microscopy showing MSC like morphology, i.e., 
cells appeared flat and broadened. These cells were fixed and stained with rabbit anti-
vWF and mouse anti-OPG primary antibodies as described in section 2.3.9. Bound anti-
vWF antibodies were detected with an anti-rabbit Cy3 (red) conjugate and bound anti-
OPG antibodies were detected with an anti-mouse AlexaFluor 488 (green) conjugate. 
Cell nuclei were counterstained with DAPI (blue). At this point in culture, vWF 
expression (red) was lost while high levels of extracellular OPG staining was observed 
(B). Note the OPG staining pattern (green) is similar to that detected on HaemDMSCs 
(Figure 4.18).. Scale bars: (A) 100 µm, (B) 50 µm.  
A 
B 
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Figure 4.25: Immunohistochemical localisation of VEGFR-1 and VEGFR-2 on 
HaemDEPCs. HaemDMSCs were fixed and stained with goat anti-VEGFR-1 and rabbit 
anti-VEGFR-2 antibodies as described in section 2.3.9. Bound VEGFR-1 antibodies 
were detected with an anti-goat biotin conjugate followed by a Strepavidin 555 
conjugtae (red) and bound VEGFR-2 antibodies were detected with an anti-rabbit DIG 
conjugate followed by an anti-DIG FITC conjugate (green). Cell nuclei were 
counterstained with DAPI (blue). HaemDEPCs expressed VEGFR-1 and VEGFR-2 on 
day 2 in culture (A&B, respectively). The cells continued to express VEGFR-1 on day 5 
(C) but lost VEGFR-2 expression by day 5 in culture (D). Scale bars: 20 µm. 
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Figure 4.26: Adipocytic differentiation of the MSCs transdifferentiated from 
HaemDEPCs. The MSCs-like cells shown in Figure 4.24-A differentiated into 
adipocytes when cultured in adipocytic induction media as described in section 2.3.10.2. 
Lipid-laiden vacoules (circular bodies) appeared within two weeks of induction.  
Scale bar: 200 µm. 
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In addition, when a second dish containing HaemDEPCs was cultured in media 
containing 50 ng/ml of VEGF from day 2 after dissociation, some cells continued to 
exhibit the EPC morphology (Figure 4.27-A). These cells expressed both vWF (Figure 
4.27-B) and OPG (Figure 4.27-C). However, not all cells cultured in VEGF were able to 
maintain their EC phenotype as some cells present in the culture dish were 
morphologically and immunohistochemically similar to HaemDMSCs (data not shown). 
These results indicate that the spontaneous differentiation of HaemDEPCs to 
HaemDMSCs could be delayed with addition of VEGF thereby indicating the 
importance of this growth factor in HaemDEPCs survival and proliferation, but VEGF 
alone is not sufficient to retain the endothelial properties of these cells and that other 
growth factors such as FGF-2 and IGF-2 may be required. Furthermore, these results 
were replicated from a proliferating haemangioma biopsy obtained from a second 
patient. 
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Figure 4.27: HaemDEPCs maintain their endothelial phenotype when cultured in 
VEGF. (A) Phase contrast microscopy showing HaemDEPCs maintained in 50 ng/ml of 
VEGF for ten days. The cells appeared morphologically similar to those from day 2 
after dissociation (Figure 4.22). Immunohistochemical staining for vWF (B) and OPG 
(C) on HaemDEPCs maintained in VEGF for ten days. The cells were fixed and stained 
with rabbit anti-vWF and mouse anti-OPG primary antibodies as described in section 
2.3.9. Bound vWF antibodies were detected with an anti-rabbit Cy3 conjugate (red) and 
bound OPG antibodies were detected using an anti-mouse AlexaFluor 488 conjugate 
(green). Cell nuclei were counterstained with DAPI (blue). Cells expressed vWF (B, 
red) and some OPG (C, green). Note OPG expression is very different from that seen on 
HaemDMSCs (Figure 4.18-D).. Scale bars: (A) 500 µm, (B&C) 50 µm. 
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CHAPTER 4.4:  DISCUSSION 
4.4.1 CHARACTERISATION OF HAEMANGIOMA EXPLANT 
OUTGROWTHS 
The lack of an ideal model system for haemangioma has led to empirical and 
unsatisfactory therapies (Mulliken et al., 1995; Tan et al., 2000b). However, an in vitro 
model that mimics, as closely as possible, the features of haemangioma was developed 
(Tan et al., 2000b) based on the models using the rat aortic rings (Nicosia & Ottinetti, 
1990) and human placenta (Brown et al., 1996). In this model, freshly resected 
haemangioma tissue placed into fibrin gels, develop outgrowths or ‘microvessels’ 
within days of culture. Although these outgrowths have been reported to be ECs (Tan et 
al., 2000b), other reports have shown that these outgrowing cells express EC-specific 
markers only in the area immediately adjacent to the explanted tissue (Ritter et al., 
2002). This suggests that the cells may be dedifferentiating and down-regulating these 
proteins as they acquire a migratory phenotype.  
During this study, a method was developed for the purification and culture of 
these haemangioma explant outgrowths in vitro. This study characterised these cells to 
be MSCs rather than ECs. MSCs derived from proliferating and involuting 
haemangiomas exhibited fibroblast-like morphology in early passages and a flat 
broadened morphology in later passages. qRT-PCR showed that the cells expressed 
mRNA transcripts for the MSC markers, CD29, CD44 and CD90 (Pittenger et al., 1999) 
but not CD133 which identifies haemopoetic precursor cells and EPCs (Hilbe W et al., 
2004). The cells did not express mRNA transcripts for CD31, CD45 and VEGFR-2 and 
were not immunohistochemically positive for vWF, VEGFR-2 or CD31, indicating that 
they were not contaminated with cells of haematopoietic or endothelial origin. These 
results and the finding that the cells expressed mRNA and protein for the haemangioma 
marker, GLUT-1, confirmed that the cells were haemangioma-derived MSCs. 
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Furthermore, consistent with previous reports, the HaemDMSCs expressed -SMA and 
vimentin, which have been used to characterise MSCs (Sutherland et al., 2005; Yu et 
al., 2006). 
As no MSC-specific markers currently exist, rigorous identification of MSCs 
requires demonstration of their capability to differentiate along specific mesenchymal 
lineages. Consistent with previous reports of the presence of MSCs in haemangioma 
(Yu et al., 2006), the HaemDMSCs isolated in this study exhibited capacity for self-
renewal and the ability to differentiate into multiple mesenchymal cell lineages, 
adipocytes and osteoblasts, when cultured in specific induction media. The increase in 
osteonectin and PPAR mRNA expression identified post-induction validated the 
differentiation of the HaemDMSCs into adipocytes and osteocytes, respectively. PPAR 
is a key regulatory gene of adipogenesis (Camp et al., 2002) while osteonectin is 
considered a differentiation marker for bone cells, as its expression has been identified 
in osteoblasts, young osteocytes and also in osteoprogenitor cells (Jundt et al., 1987). 
Similar to bone marrow-derived MSCs (Okuyama et al., 2006), the 
HaemDMSCs expressed mRNA and protein for VEGFR-1. However, unlike bone-
marrow derived MSCs (Oswald et al., 2004), HaemDMSCs did not exhibit EC-like 
characteristics when cultured in high concentrations of VEGF. In addition, Yu et al 
(2001) showed that haemangioma-derived ECs did not express mRNA for VEGF.  
However, the HaemDMSCs isolated in this study expressed high levels of VEGF and 
IGF-2 mRNA, as identified by qRT-PCR. Both these factors are potent stimulators of 
angiogenesis known to be up-regulated during the proliferative phase of haemangioma 
in vivo (Takahashi et al., 1994; Ritter et al., 2002). These data suggest that the MSCs 
present in haemangioma may be an important source of angiogenic regulators that 
govern haemangioma progression. This study also found that HaemDMSCs expressed 
mRNA for Collagen -I, -II,-III and -VIII but did not express or secrete collagen protein 
when cultured in vitro. As these collagen fibres are present in all three phases of 
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haemangioma (Tan et al., 2000a), it may be postulated that in the in vivo environment, 
HaemDMSCs may be involved in synthesising some of the ECM proteins in 
haemangioma.  
 
4.4.2 A ROLE FOR VEGF AND STAT SIGNALLING IN 
HAEMANGIOMA IN VITRO 
As discussed in Chapter 3 of this thesis, VEGF and STAT protein signalling 
may be important in haemangioma proliferation. To obtain functional evidence for this, 
VEGF and STAT signalling was studied in both the haemangioma tissue explants and 
HaemDMSCs. To elucidate the importance of STAT protein signalling, a JAK/STAT 
inhibitor, AG490, was added to haemangioma explants and its effect on capillary-like 
outgrowth was studied. The precise role of VEGF detected in proliferative 
haemangioma (Takahashi et al., 1994; Tan et al., 2000a) is unknown. In this study, 
addition of VEGF to haemangioma explants stimulated significant sprouting of 
outgrowths from haemangioma tissues. This effect was mitigated by addition of AG490 
along with VEGF in the cultures. In addition, incubating the explants with various 
concentrations of AG490 resulted in decreased levels of sprouting. These data suggest a 
model of haemangioma progression in which an important element is the relationship 
between VEGF and STAT proteins.   
The role of VEGF and STAT protein signalling was also studied in the purified 
HaemDMSCs cultures. With respect to the VEGFRs, HaemDMSCs expressed only 
VEGFR-1 but not VEGFR-2, while normal ECs (HUVECs) expressed both receptors. 
This study found that while addition of VEGF significantly induced the proliferation of 
HUVECs, it had no effect on HaemDMSCs proliferation. These results were not 
surprising as previous studies have shown that the activation of VEGFR-2 was required 
for EC proliferation and migration, while the activation of VEGFR-1 resulted in EC 
differentiation (Neufeld et al., 1999).   
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The observation that proliferation was substantially inhibited by AG490 
confirms the importance of STAT protein signalling in HaemDMSCs proliferation. 
Furthermore, blocking STAT signalling reduced vessel formation of HaemDMSCs, 
when cultured in a 3-dimensional fibrin matrix in vitro. Similar to the decrease in vessel 
formation, a dose dependent decrease in cell number was observed with AG490 
treatment. These results suggest that the decrease in vessel formation may simply be a 
secondary effect resulting from decreased cellular proliferation in the presence of 
AG490.  
Various studies have shown that AG490 inhibited phosphorylation and 
activation of STAT-1, STAT-3 and STAT-5 (Zhang et al., 2000; Andl et al., 2004; 
Maziere et al., 2001; Hattori et al., 2001; Yamaura et al., 2003; El-Adawi et al., 2002; 
Banes et al., 2003), however, it is now known that AG490 can affect different members 
of the STAT family depending on the cell type. Andl et al (2004) showed that AG490 
abolished the migration of EPCs by decreasing STAT-1 phosphorylation, while other 
investigators showed that it inhibited the proliferation of ovarian, breast, pancreatic and 
renal cell cancer cells by decreasing STAT-3 phosphorylation and STAT-3 DNA 
binding activity (Burke et al., 2001; Horiguchi et al., 2002; Huang et al., 2006). 
Mascareno et al (2001) showed that AG490 decreased Ang-2 mRNA expression in 
ischaemic hearts by inhibiting activation of STAT-5 and STAT-6 and Seki et al (2000) 
showed that AG490 blocked Ang-2 induced STAT-3 phosphorylation and SMC 
proliferation. The results obtained with AG490 in this study reveal the importance of 
STAT protein signalling in HaemDMSCs and in haemangioma. However, further 
investigation is required to identify the member(s) of the STAT family affected by 
AG490 in HaemDMSCs. 
Studies in other cell culture systems showed increased phosphorylation and 
nuclear translocation of STAT-3, STAT-5 and STAT-1 following VEGF treatment (Lu 
et al., 2006; Bartoli et al., 2003; Yahata et al., 2003; Korpelainen et al., 1999). This 
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study showed that HaemDMSCs expressed both STAT-3 and STAT-5 protein. 
Although a small fraction of STAT-3 was phosphorylated at the steady state, VEGF 
treatment failed to alter the levels and nuclear translocation of both p-STAT-3 (Tyr 705) 
and p-STAT-1 (Tyr 701). In contrast, increased expression of p-STAT-5 (Tyr 694) was 
detected within the nuclei of HaemDMSCs following VEGF stimulation.  
It is now known that the outcome of STAT signalling is determined by its 
integration with other activated signal transduction pathways. For example, Korpelainen 
et al (1999) showed that although all three VEGFRs (VEGFR-1, VEGFR-2 and 
VEGFR-3) activated both STAT-3 and STAT-5, only VEGFR-1 signalling induced the 
expression of a cell cycle inhibitor protein, p21 in a STAT-5 dependent manner. They 
found that although VEGFR-2 and VEGFR-3 signalling suppressed p21 expression, 
their activity was overcome by increased STAT-5 activation.  
This study found that VEGF did not induce HaemDMSCs proliferation or have 
an affect on p-STAT-3 (Tyr 705) and p-STAT-1 (Tyr 701) signalling. However, as 
VEGF induced the nuclear expression p-STAT-5 (Tyr 694) and since HaemDMSCs 
expressed VEGFR-1, it is interesting to speculate that VEGF signalling through p-
STAT-5 is required for cellular processes other than proliferation such as cell migration 
or cell adhesion. Furthermore, since STAT-5 signalling is involved in cell 
differentiation (Dai et al., 2007; Hoshino & Fujii, 2007) and adipogenesis (Nanbu-
Wakao et al., 2002), a role for STAT-5 as a mediator of haemangioma involution was 
tested in this study. These results are discussed in section 4.4.5 (page 212).  
 
4.4.3 ROLE OF OSTEOPROTEGERIN IN HAEMANGIOMA 
 This is the first study to report expression of osteoprotegerin (OPG) in 
haemangioma. OPG, a member of the TNF receptor superfamily (Simonet et al., 1997) 
is a secreted glycoprotein that exists as a 60 kDa monomer and a 120 kDa disulfide-
linked dimer. OPG is critical in the control of bone remodelling by inhibiting 
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osteoclastogenesis. It does this by binding the receptor activator of nuclear factor-B 
ligand (RANKL) and thereby preventing the interaction of receptor activator of nuclear 
factor-B (RANK) and RANKL (Lacey et al., 1998; Yasuda et al., 1998). Transgenic 
mice over-expressing OPG have increased bone mass (Simonet et al., 1997) while 
OPG-deficient mice have decreased bone density (Bucay et al., 1998; Mizuno et al., 
1998; Yun et al., 2001). Osteoclasts are responsible for the resorption of bone during 
normal bone metabolism and for the destruction of bone seen in a variety of 
pathologies, such as rheumatoid arthritis (Haynes et al., 2003) 
In addition to bone, OPG mRNA expression is found in a number of tissues, 
including lung, heart, kidney, liver, stomach, intestine, brain, spinal cord and the thyroid 
gland (Simonet WS et al., 1997; Yasuda et al., 1998). This wide tissue distribution of 
OPG suggests its involvement in processes in addition to bone turnover. This notion is 
supported by the findings of Yun et al (2001) who showed that OPG regulated B cell 
maturation and development. Collin-Osdoby et al (2001) showed that OPG was 
involved in the inflammatory functions of ECs. Furthermore, Price et al (2001) showed 
that administration of OPG prevented vascular calcification induced by treatment with 
warfarin and supra-physiological doses of vitamin D in rats. Therefore, these studies 
provide evidence for the protective vascular effects of OPG. In addition, Hofbauer & 
Schoppet (2004) have reviewed the links between OPG and vascular disease.  
Consistent with previous reports that showed OPG mRNA and protein 
expression by cultured MSCs and marrow stromal cells (Le Blanc et al., 2004; Neville-
Webbe et al., 2004), the HaemDMSCs isolated in this study expressed high levels of 
OPG mRNA and secreted abundant levels of OPG protein which appeared to be 
associated with the ECM. This extracellular pattern of OPG expression has also been 
noted in human osteoblast-like cells (Atkins et al., 2002). Because the HaemDMSCs 
expressed high levels of OPG, it was hypothesised that OPG may serve as a potential 
marker for MSCs within the haemangioma tissue in vivo. In addition, as various studies 
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have shown that proliferating haemangioma contain ECs that express vWF, double 
labelling immunohistochemical analysis for vWF and OPG was performed in this study 
with an aim to differentiate between ECs and MSCs within haemangioma lesions of 
various developmental stages. High OPG expression was identified in the cells 
surrounding the blood vessels. These cells also exhibited weak (punctate) staining for 
vWF. These results suggest that these cells are either immature ECs (the punctate 
staining pattern may represent the immature state of the ECs) or perhaps MSCs which 
have the capacity to differentiate into ECs. Alternatively, it may be possible that the 
MSCs express low levels of vWF when present within the tissue but loose vWF 
expression when cultured in vitro. Findings to support this hypothesis include those of 
Nagaya et al (2004) who showed that MSCs expressed vWF and were involved in 
neovascularisation in the infarcted heart.  
In addition, the regions with high OPG expression and punctate vWF staining 
also contained more PCNA-positive cells. This indicated that these regions were rapidly 
proliferating. Importantly, as the lesions progressed towards the involuting phase, OPG 
and PCNA expression decreased concomitant with increased vWF staining. High PCNA 
expression in proliferating lesions with decreased abundance in involuting lesions has 
already been shown in Chapter 3. These results indicate that OPG protein expression 
correlates with proliferation. 
Because of the high levels of extracellular OPG staining identified on 
HaemDMSCs and the high OPG expression detected in haemangioma tissue sections, 
we hypothesise that in haemangioma, OPG acts as a survival factor and affords 
protection against apoptosis in vivo and in vitro. Previous studies have implicated OPG 
as a mediator of cell survival. Malyankar et al (2000) showed that purified OPG 
protected ECs from apoptosis induced by growth factor deprivation. Cross et al (2005) 
showed that OPG stimulated EC growth, as well as the formation of cord-like structures 
on a matrigel substrate to a similar extent as VEGF. In addition, the increased 
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extracellular OPG secretion by HaemDMSCs could also be a stress response associated 
with the in vitro culture of these cells.  
The cells isolated from dissociated tissue also expressed OPG at similar levels to 
HUVECs rather than the high extracellular levels described for HaemDMSCs. Together 
these data suggest that the dissociated tissue contains abundant EPCs rather than the 
HaemDMSCs. This discrepancy can be accounted for by the observation that the 
putative EPCs spontaneously differentiated in culture to form MSCs, and that the 
resulting haemangioma-derived MSCs were able to differentiate into adipocytes and 
osteoblasts as for the HaemDMSCs. It has been previously suggested that adipocytes 
and ECs have a common progenitor (Planat-Benard et al., 2004). This data supports this 
postulate as the EPCs identified in haemangioma were able to form adipocytes. We 
suggest that the EPCs are stem cells that give rise to MSCs which are able to form 
adipocytes and osteoblasts. While these putative endothelial stem cells are pluoripotent 
and are capable of forming self-renewing MSCs, the self-renewing potential of the 
endothelial stem/progenitor cells was not demonstrated in this study. The observation 
that VEGF treatment of HaemDEPCs was able to inhibit the spontaneous differentiation 
to MSCs suggests a role for VEGF in EC maturation in haemangioma. 
 
4.4.4 THE ROLE OF MSCs AND EPCs in HAEMANGIOMA 
To place the results of this study into context, an introduction to MSCs and 
EPCs is described in sections 4.4.4.1 and 4.4.4.2. In addition, several models for 
haemangioma progression were hypothesised from the findings of this study together 
with the previous identification of EPCs and MSCs in haemangioma (Yu et al., 2004a; 
Yu et al., 2006). These models are discussed in section 4.4.4.3.  
 
4.4.4.1 MESENCHYMAL STEM CELLS 
Stem cells are an attractive source of cells for tissue engineering because of their 
unique biological properties. Stem cells have been isolated from a variety of somatic 
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tissues (Korbling, et al., 2003). MSCs represent a subset of these cells residing in the 
bone marrow. Other sources of MSCs included peripheral blood (Pittenger et al., 1999; 
Zvaifler et al., 2000), umbilical cord blood (Kim et al., 2004) and also connective tissue 
sites including the dermis, muscle, adipose, trabecular bone, and synovial membranes 
(Tuan et al., 2003). MSCs are also present in term cord blood (Zvaifler et al., 2000), in 
foetal organs (such as liver, BM, and kidney), the blood of preterm foetuses (Erices et 
al., 2000; Campagnoli et al., 2001; Almeida-Porada et al., 2002) and the placenta 
(Fukuchi et al., 2004). 
MSCs can be expanded in the laboratory and can be induced to differentiate 
along multiple lineages giving rise to cartilage, bone, fat, muscle, ECs and vascular 
tissue in vitro and in vivo (Jiang et al., 2002; Abedin et al., 2004; Phinney, 2002; 
Devine et al., 2003), displaying the important properties of self-renewal and plasticity 
of stem cells. 
One of the most interesting characteristics of MSCs is their ability to home to 
sites of tissue damage or inflammation (Devine et al., 2001). Homing of MSCs have 
been demonstrated in the settings of bone fracture, cerebral ischemia and the infarcted 
heart (Mosca et al., 2000; Devine et al., 2001; Devine et al., 2002; Price et al., 2006).  
Saito et al (2002) demonstrated that when MSCs were administered intravenously, these 
cells engrafted within regions of myocardial infarction and a distinct subpopulation 
participated in angiogenesis. Pittenger & Martin (2004) showed that the “window” of 
MSC homing was limited i.e., if MSC administration was delayed until two weeks after 
infarction, no significant cardiac engraftment was observed and that most of the cells 
had returned to the bone marrow. In addition, Rombouts & Ploemacher (2003) showed 
that the in vitro expansion of MSCs diminished the efficacy of injury-induced homing.  
The possible involvement of MSCs in neovascularisation has been recently 
proposed due to their capacity to contribute to tumour angiogenesis in vivo (Reyes et al., 
2002) and due to their plasticity to differentiate into endothelial-like cells (Reyes et al., 
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2001). Tang et al (2003) showed that neovascularisation induced by MSCs involved 
secretion of paracrine factors by the MSCs themselves. This resulted in vessel sprouting 
and incorporation of MSCs into newly forming blood vessels. In addition, Silva et al 
(2004) found increased vascularity and improved cardiac function with the implantation 
of MSCs into chronically ischaemic myocardium. These authors showed that implanted 
MSCs homed to the site of injury and differentiated into both, ECs and SMCs, which 
formed the vessel walls.  
MSCs have also been shown to differentiate into ECs when cultured in the 
presence of VEGF (Oswald et al., 2004). Wu et al (2005) showed that when MSCs 
were co-cultured with mature ECs, about 25% of the MSCs began to express KDR but 
not vWF. Their morphological appearance was also different from that of the adjacent 
mature ECs. Previous studies have shown that ECs go through different stages of 
differentiation. They initially express VEGFR-2, one of the earliest differentiation 
markers for ECs, which plays an important role in ECs growth and vasculogenesis, 
followed in sequence by TIE-2, TIE-1, VE-cadherin, CD34 and vWF (Vittet et al., 
1996; Yamashita et al., 2000). Wu et al (2005) suggested that MSCs possess the milieu-
dependent differentiation potential along endothelial lineage when co-cultured with 
mature ECs. These authors also found that the VEGFR-2-positive MSCs cells did not 
co-express CD105 or CD166. These results indicate that the cells lose the phenotypic 
characteristics of MSCs as they differentiate toward ECs. In addition, Wu et al (2005) 
showed that the addition of anti-VEGF antibodies inhibited the differentiation of MSCs, 
indicating the important role of VEGF in EC differentiation.  
 
4.4.4.2 ENDOTHELIAL PROGENITOR CELLS 
EPCs were first discovered by Ashara et al (1997) as a population of cells that 
co-expressed EC specific markers such as vWF (Shi et al., 1998) and VEGFR-2 
(Peichev et al., 2000) along with the stem cell marker, CD133 (Fargeas et al., 2003). 
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Since then, EPCs have been found in the bone marrow, blood circulation, foetal liver 
and skeletal muscle (Peichev et al., 2000; Majka et al., 2003).  
EPCs are involved in tissue neovascularisation, post-natal organ generation, 
arteriogenesis and also tumour angiogenesis (Rafii et al., 2002; Rafii & Lyden, 2003; 
Fuchs et al., 2001; Asahara et al., 1997; Al-Khaldi et al., 2003; Kocher et al., 2001 
Orlic et al., 2001; Jackson et al., 2001; Kinnaird et al., 2004; Carmeliet & Luttun, 
2001). Incorporation of EPCs and MSCs into sites of physiological and pathological 
neovascularisation in vivo has also been reported (Asahara et al., 1997; Asahara et al., 
1999; Shi Q et al., 1998). Studies have  also shown that EPCs are highly proliferative. 
These cells form new blood vessels de novo as well as enhance neovascularisation when 
administered systemically (Rafii & Lyden, 2003; Kalka et al 2000).  
Tepper et al (2005) showed that hypoxia initiated a cellular cascade with 
localised migration and proliferation of bone marrow–derived EPCs in vitro and in vivo, 
which resulted in angiogenesis. In animal models of myocardial infarction, the injection 
of ex vivo expanded EPCs significantly improved blood flow and cardiac function 
(Kawamoto et al., 2001; Kocher et al., 2001). Furthermore, Lyden et al (2001) showed 
that impaired recruitment of bone marrow-EPCs blocked tumour angiogenesis and 
growth. Various studies also showed that terminally differentiated mature ECs did not 
improve neovascularisation (Kalka et al., 2000; Kocher et al., 2001; Hur et al., 2004).  
 
4.4.4.3 PROPOSED MODELS FOR HAEMANGIOMA 
4.4.4.3.1 The Original Model 
One of the main findings from this study is that MSCs rapidly grow out from 
explanted haemangioma biopsies. This suggests that MSCs are present at high numbers 
in haemangioma. The initial clinical description of a promontory mark of haemangioma 
as ‘an anemic nevi’ or ‘area of low blood flow’ suggests that tissue hypoxia, a powerful 
stimulus for neovascularisation, may be involved (Al Buainian et al., 2003; Hamlat  et 
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al., 2005). A recent study has also reported that proliferating haemangiomas contain 
large numbers of haematopoietic cells of the myeloid lineage which are known to 
migrate to zones of hypoxia (Ritter et al., 2006). Additionally, Kleinman et al (2007) 
demonstrated that hypoxia-induced factors which are important for post natal 
vasculogenesis are upregulated in children with proliferating haemangiomas. These 
include hypoxia inducible factor-1 (HIF-1), stromal cell-derived factor-1 (SDF-1), 
matrix metalloprotease-9 (MMP-9) and VEGF-A. Kleinman et al (2007) also suggested 
that even though overexpression of these factors can occur in normoxic tissues in 
certain types of cancers (Zhong et al., 1999), the lack of increased HIF-1 expression in 
involuting haemangioma biopsies indicates that physiological mechanisms are active in 
haemangioma and that these lesions are truly hypoxic. There is also data to suggest that 
hypoxia may be the initial stimulus for chorangioma, a tumour of the placenta that is 
histologically similar to haemangioma (Ogino et al., 2003). 
The original model proposes the recruitment of MSCs to the site of the 
haemangioma as a result of hypoxia. The recruited MSCs then express high levels of 
VEGF and other growth factors which act in an autocrine manner to induce MSC 
differentiation into ECs. This is supported by the findings of Annabi et al (2003) who 
showed that in a hypoxic environment MSCs secreted increased levels of VEGF that in 
turn induced MSC migration in an autocrine manner. They also showed increased 
expression of matrix metalloproteinase-1 (MMP-1) during hypoxia and suggested that 
this protein was involved in MSCs-mediated tube formation. However, the 
HaemDMSCs isolated in this study failed to differentiate and exhibit EC characteristics 
when cultured in the presence of 50 ng/ml VEGF along with low serum (2%) and 
normal serum (10%) concentrations. These culture conditions have been previously 
described for MSC differentiation into ECs (Oswald et al., 2004; Wu et al., 2005). 
These results suggest that HaemDMSCs either lose their ability to differentiate into ECs 
when in culture in vitro or that a second progenitor cell type is responsible for the origin 
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of ECs in haemangioma. Based on these findings, a second model involving EPCs was 
hypothesised for haemangioma progression. 
4.4.4.3.2 An Alternative Model 
The ECs in early proliferating haemangioma are described as ‘angioblastic’ and 
are similar to embryonic rather than neonatal vascular ECs based on their morphology 
and protein expression patterns (Malan, 1974; Pack & Miller, 1950; Dosanjh et al., 
2000). These findings suggest that haemangioma contain primitive ECs. Increased 
levels of circulating EPCs have been noted in haemangioma patients (Kleinman et al., 
2003). Furthermore, Yu et al (2004a) isolated EPCs from proliferating haemangioma by 
purifying a population of cells that expressed the EC marker, VEGFR-2 and the stem 
cell marker, CD133. They speculated that these EPCs were responsible for the 
uncontrolled clonal expansion of ECs in haemangioma.  
The cellular pathways of EPC mobolisation and trafficking are becoming clear. 
HIF-1, SDF-1  and VEGF-A are now known to be capable of enhancing the 
mobilisation and recruitment of EPCs to hypoxic tissues during post natal 
vasculogenesis (Ceradini et al., 2004; Rafii et al., 2003; Kalka et al., 2000; Park et al., 
2004; Forsythe et al., 1996). Increased expression of these mediators has been recently 
identified in proliferating haemangiomas (Kleinman et al., 2007). 
In the alternative model for haemangioma (Figure 4.28), both MSCs and EPCs 
are recruited to the site of the haemangioma as a result of hypoxia during the 
proliferative phase. Both cell types express high levels of OPG that prevents them from 
undergoing apoptosis during this phase. The MSCs secrete growth factors such as 
VEGF which first induce EPC proliferation followed by EPC differentiation into mature 
ECs as the lesion progresses towards involution. The presence of EPCs together with 
the possibility that MSCs can then themselves differentiate into vascular smooth muscle 
cells now creates a perfect environment to form functional capillary networks in vivo. 
This phenomenon has been recently shown by Melero-Martin et al (2007). These 
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authors found that implantation of EPCs with SMCs subcutaneously into 
immunodeficient mice resulted in the formation of an extensive blood vessel network 
within one week. Wu et al (2004) showed that EPC-derived ECs had the ability to 
assemble into a microvascular-like network when seeded on three-dimensional glycolic 
scaffolds along with SMCs. 
The alternative model is based on results from other studies that have reported 
the differentiation of EPCs into mature ECs (Gehling et al., 2000; Peichev et al., 2000). 
In addition, studies have also reported the secretion of angiogenic factors such as VEGF 
by MSCs (Hamano et al., 2000; Villars et al., 2000). The VEGF family of polypeptides 
includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PIGF (Korpelainen EI 
& Alitalo K, 1998; Veikkola et al., 2000; Veikkola & Alitalo, 1999). The VEGF-A gene 
can be alternatively spliced resulting in gene products corresponding to amino acids 
121, 165, 189 and 206 main splice forms in humans. VEGF-A is expressed during 
MSC-derived osteoblastogenesis (Furumatsu et al., 2003; Mayer et al., 2005). Mayer et 
al (2005) showed that mRNA for VEGF165, VEGF121 and VEGFR-1 increased during 
osteogenenesis and also under hypoxic conditions. Furthermore, this secreted VEGF 
induced increased EC sprouting. Therefore, these authors suggested that human MSCs 
secreted VEGF-A as an angiogenic factor in a differentiation dependent manner. In 
addition, VEGF has been shown to mobilise EPCs from bone marrow (Asahara et al., 
1997) and also cause EPC maturation to ECs (Ehrbar et al., 2005).  
qRT-PCR results from this study showed that HaemDMSCs expressed VEGF 
and IGF-2 mRNA transcripts to similar levels as that seen in the original haemangioma 
tissue. Both these factors have been identified as modulators of haemangioma in the 
proliferative phase in vivo (Takahashi et al., 1994; Ritter et al., 2000). Since Yu et al 
(2001) found that the isolated ECs from proliferating haemangiomas expressed very low 
levels of VEGF transcript, we hypothesised that the HaemDMSCs may be the source 
for at least some of the angiogenic modulators of haemangioma. However, Western 
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blotting experiments showed that the secreted isoforms of VEGF-A, VEGF121 and 
VEGF165 were not present in the conditioned medium of the cultured HaemDMSCs. In 
addition, Western blotting results showed that neither VEGF121, VEGF165 nor VEGF189 
were detected within HaemDMSCs themselves or in proliferative haemangioma tissue.  
Other studies that reported on the high expression of VEGF protein during the 
proliferative phase (Tan et al., 2000a; Takahashi et al., 1994) did not provide details on 
the member(s) of the VEGF family detected in their studies. Although, all members 
show some degree of sequence homology, the anti-VEGF antibody used in this study 
was specific for the VEGF121, VEGF165 and VEGF189  isoforms of VEGF-A. Therefore, 
these findings suggest that VEGF expression seen in haemangioma may be that of the 
other members of the VEGF family and not the VEGF isoforms of VEGF-A which 
were tested for, in this study.  
Yu et al (2006) first speculated that MSCs were the source of adipocytes that 
appeared during involution of haemangioma. Consistent with this theory, this 
investigation found that MSCs rapidly grew out from explanted haemangioma tissue 
pieces and that these HaemDMSCs maintained their adipocytic and osteocytic 
differentiation properties in vitro (The Alternative Model; Figure 4.28). These findings 
further support the model in which MSCs are likely to be precursors of the adipocytes 
during involution of haemangioma in vivo.  
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Figure 4.28: An Alternative Model For Haemangioma. This model suggests that there are two main cell types, the MSCs and EPCs which are 
involved in the pathogenesis of haemangioma. Both cell types may be recruited to the site of the haemangioma perhaps, in response to 
hypoxia. Both cell types express increased levels of OPG and exhibit punctate immunoreactivity for vWF indicating their immature state. 
High OPG expression prevents apoptosis during the proliferative phase. This model suggests that the MSCs are the main source for a variety 
of angiogenic modulators such as VEGF and IGF-2. These growth factors secreted by MSCs can in turn act on the recruited EPCs to enhance 
their survival, proliferation and also induce EPC maturation to ECs.  This model also proposes that a yet-to-be identified signal is involved in 
inducing MSCs differentiation into the adpiocytes which is seen during involution and that when a proliferating haemangioma explant is 
cultured in vitro, it is the MSCs that rapidly grow out from the tissue piece. These HaemDMSCs maintain their ability to differentiate into 
adipocytes and osteocytes in vitro. The role of IFNs and STAT proteins in haemangioma is discussed further in section 4.4.5. 
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4.4.4.3.3 The Final Model  
Towards the end of this study, tissue from a proliferating haemangioma was 
treated with collagenase to obtain a single cell suspension and the cells were cultured in 
vitro. These cells had a distinct appearance in that they had round central bodies with 
some cytoplasmic projections. This morphology has been shown to be typical of EPCs 
(Asahara et al., 1997; Quirici et al., 2001). After two days in culture, cells obtained 
directly from dissociated proliferative tissue biopsies were also immunophenotypically 
similar to EPCs as they stained for vWF, VEGFR-1 and VEGFR-2 which is consistent 
with previous findings (Ziegler et al., 1999). VEGFR-2 is one of the earliest markers 
expressed on EPCs. In addition, although these cells expressed OPG, the pattern of 
OPG expression was not extracellular as seen in MSCs, but was similar to the OPG-
vWF staining pattern seen on normal ECs or HUVECs.  
Following continued culture, an interesting change in cell morphology to that of 
the flat, broadened shape of MSCs was noted within five days. The cells now lost vWF 
expression and exhibited the MSC-like extracellular pattern of OPG expression. 
Furthermore, these cells differentiated into adipocytes under appropriate conditions 
which confirmed their plasticity and mesenchymal characteristics. However, when the 
same cells were cultured in VEGF for eight days, some cells retained their EPC-like 
morphology and continued to express both vWF and OPG, while some others showed 
MSC morphology, did not express vWF and expressed high levels of extracellular OPG.  
From these results, we propose a final model for haemangioma in which the 
HaemDEPCs represent the primary and most important component in a proliferating 
haemangioma (Figure 4.29). In this model, the high levels of VEGF present within the 
lesions during the proliferative phase are involved in EPCs survival, proliferation and/ 
or maturation of ECs. Results from this study also suggest that VEGF alone may not be 
enough to maintain the endothelial phenotype of the HaemDEPCs and that other growth 
factors such FGF-2 or IGF-2 may be required. High levels of both these growth factors 
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have been identified during the proliferative phase and have been found to decrease 
with involution (Tan et al., 2000a; Ritter et al., 2001). Khan et al (2006) also isolated 
HaemDEPCs from proliferative haemangioma biopsies and maintained them in culture 
medium containing various factors including VEGF, FGF-2, IGF-2, hydrocortisone, 
heparin, ascorbic acid, and cAMP. These authors did not provide any information on the 
consequence of removing these factors.   
In this study, all the HaemDEPCs cultured in vitro spontaneously differentiated 
into MSCs in the absence of VEGF.  We established this phenomenon as a 
transdifferentiation process as opposed to a situation in which one cell type outgrows 
another within the same culture dish. This was based on the following reasons. In the 
absence of VEGF, a change in cell morphology was observed to be uniform across the 
entire dish with every single cell exhibiting a flat, broadened shape within five days in 
culture. If two cell types were present and one cell type was outgrowing the other, the 
presence of both cell types would have been seen sometime during the two-five day 
culture period but this was not the case. In contrast, both cell types (EPCs and MSCs) 
were observed in the second situation examined in this study i.e., culturing 
HaemDEPCs in the presence of VEGF. This suggests that VEGF along with other 
factors may be required for HaemDEPCs to maintain their endothelial phenotype.  
In the model shown in Figure 4.29, we hypothesise that involution of 
haemangioma is triggered by a decrease in the levels of VEGF (and other growth 
factors). The consequence of this is that the EPCs no longer survive and proliferate as 
ECs but transdifferentiate into MSCs that further differentiates into the adipocytes seen 
in the involuting and involuted phases of haemangioma. Furthermore, when 
haemangioma biopsies are cultured in vitro, we believe that it is the EPCs that migrate 
out but as they migrate further away from the tissue they are no longer exposed to the 
growth factors present with the original lesion (i.e., VEGF and others). This results in 
their transdifferentiation from EPCs to MSCs. It was these MSCs that were isolated 
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from the in vitro haemangioma model and characterised in this study (see section 4.4.1, 
page 189). These migrating MSCs retain their ability to form both adipocytes and 
osteocytes in vitro. This is consistent with the findings of Ritter et al (2001) who 
identified that the sprouting outgrowths contained ECs only in the area immediately 
adjacent to the explant tissue whereas cells further away from the tissue no longer 
expressed these markers.  The ECs in their study were characterized by their expression 
for CD31 and CD34 as well as for the positive staining for G. simplicifolia isolectin, a 
documented endothelial stain (Faraggiana et al., 1989; Sahagun et al., 1989; Hansen-
Smith et al., 2001).  
This kind of endothelial to mesenchymal transdifferentiation (EMT) occurs in 
response to TGF- signalling in the developing heart (Ramsdell & Markwald, 1997; 
Boyer et al., 1999). Frid et al (2002) found that a small percentage of cells in EC 
preparations from bovine arteries can undergo EMT. Dvorin et al (2003) showed that in 
addition to ECs, EPCs were also capable of transdifferentiating into a mesenchymal 
phenotype, in response to TGF-. Camenisch et al (2002) showed that once EMT took 
place, endothelial functions such as the ability to form tube-like structures and to adhere 
leukocytes in response to inflammatory signals, were lost.  
Finally, Paruchi et al (2006) have shown that clonal ECs isolated from the 
pulmonary valves of a nine month-old infant exhibited EMT in response to TGF-. 
However, they stated that the resulting MeCs failed to differentiate into adipocytes or 
osteocytes. In contrast, the HaemDMSCs isolated in this study, could undergo 
adipocytic differentiation under appropriate conditions. This suggests that these 
trandifferentiated cells are MSCs and exhibit MSC-like properties.  
From these results we hypothesise that the cells obtained by the direct 
dissociation of a proliferating haemangioma biopsy are EPCs as they could differentiate 
from an endothelial phenotype expressing all the ECs markers into MSCs.  
Furthermore, the pattern of EC marker expression seen on the HaemDEPCs was 
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consistent with that detected in vivo by immunohistochemical analysis of haemangioma 
tissue sections.  
The results from this investigation also provide evidence for the role of VEGF in 
maintaining the endothelial characteristics of HaemDEPCs. Results showed that with 
the withdrawal of VEGF, the HaemDEPCs differentiated into HaemDMSCs that further 
differentiated into the adipocytes seen in involuting and involuted haemangioma.  
Chapter 3 (section 3.3.2.2.3, page 114) described the expression of VEGFR-1 in 
all phases of haemangioma whereas VEGFR-2 expression decreased with involution. 
VEGFR-1 expression detected on both EPCs and MSCs isolated in this study indicates 
that its constant expression may be required for the differentiation processes occurring 
throughout the different developmental phases of haemangioma progression, i.e. EPCs 
to mature ECs and EPCs to MSCs to adipocytes. In contrast, VEGFR-2 expression 
detected only on EPCs suggests that activation of this receptor, in response to the high 
levels of VEGF, could be responsible for EPCs surivival and proliferation during the 
proliferative phase (The Final Model, Figure 4.29).  
Finally, although CD133 expression by HaemDEPCs was not directly investigated in 
this study, the ability of these cells to differentiate from one cell type to another meets 
the criteria of a stem cell (Lovell & Mathur, 2004). A point to note here is that CD133 
expression is now known to be quickly down-regulated in culture (Wu et al., 2004). To 
our knowledge there have not been any previous reports of an EPC to MSC 
transdifferentiation process occurring in haemangioma. Therefore, these findings 
represent novel insights into the pathogenesis of haemangioma.  In the final model, we 
hypothesise that the EPC to MSC differentiation process governs haemangioma biology 
(Figure 4.29). 
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Figure 4.29: The Final Model For Haemangioma. In this model, the EPCs represent the primary component of a proliferating haemangioma. 
These cells express OPG which acts as a survival factor. They also show punctuate or weak immunoreactivity when immunostained for vWF. This 
punctuate staining may represent their immature developmental state. During the proliferative phase, high levels of growth factors, such as VEGF 
present in the lesion act on the EPCs to enhance their survival and induce their proliferation. VEGF may also play a role in EPC maturation into 
ECs. These mature ECs exhibit intense immunoreactivity when immunostained for vWF, seen as the lesion progresses towards involution. The 
decreasing concentrations of VEGF and other growth factors in the involuting phase results in the differentiation of the EPCs to MSCs. These 
MSCs can then further differentiate into the increasing numbers of adopicytes seen in the involuting and involuted phases of haemangioma. In 
addition, this model suggests that when proliferative haemangioma explants are cultured in vitro, the EPCs grow out but as they migrate further 
away from the original tissueand are thereby exposed to low VEGF concentrations, the cells transdifferentiate into MSCs. These HaemDMSCs 
maintain their ability to differentiate into adipocytes and osteocytes in vitro. Finally, although the findings from this investigation did support the 
notion that IFN-2b can accelerate adipogenesis, it would be interesting to further investigate the role of STAT proteins in haemangioma 
adipogenesis. 
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4.4.5 ROLE OF INTERFERONS AND STAT PROTEINS IN 
HAEMANGIOMA ADIPOGENESIS 
Results from this study also provide evidence for the involvement of STAT 
proteins and IFN signalling in HaemDMSCs (see section 4.3.6, page 179). The 
identification of increased expression of IFN stimulated genes together with the 
increased expression of IFN in the dermis overlying involuting and involuted 
haemangioma (Ritter et al., 2000; Bielenberg et al., 1999) suggests that IFN signalling 
may be important in driving haemangioma involution. As IFN-2b has been used as 
treatment for haemangioma, we hypothesise a model for haemangioma in which 
expression of IFNs in the overlying dermis of involuting and involuted haemangioma 
activates the STAT proteins which then causes and/or accelerates MSC adipogenesis 
(Figures 4.28 and 4.29). Several members of the STAT family play a role in the 
regulation of genes that contribute to the phenotype of the mature adipocyte (Stephens 
et al., 1996; Stephens et al., 1999; Floyd and Stephens, 2003). 
In order to provide functional evidence for the role of IFNs and STAT proteins 
in adipogenesis, adipocytic differentiation of HaemDMSCs was induced in presence of 
IFN-2b (15,000 U/ml) and AG490 (20 µM). As both drugs inhibited HaemDMSCs 
proliferation (see section 4.3.4.2, page 165, for AG490 and Chapter 5, section 5.3.4, 
page 224, for IFN-2b), the doses selected for the differentiation experiments were 
chosen with the rationale being that the drugs should have a biological effect on their 
target proteins without significantly affecting cell proliferation. Failure to detect 
accelerated adipogenesis with IFN-2b may be due to several possibilities, (i) the 
physiological concentrations of IFNs in haemangioma is currently unknown therefore 
the arbitrarily chosen IFN-2b concentration used in the differentiation experiments of 
this study, may not have been high enough to induce adipogenesis above that of the 
control, (ii) this study did not examine the effects of other IFNs such as IFN and IFN 
which also activate STAT proteins (Darnell, 1997; Durbin et al., 1996; Meraz et al., 
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1996). Given that IFN expression has been detected in the dermis overlying involuting 
haemangioma (Bielenberg et al., 1999), it may be useful to test its effect on 
HaemDMSCs adipogenesis in future experiments. In addition, as stated in section 4.4.2. 
(page 191), AG490 affects different STAT proteins depending on the cell type. The 
identification of adipocytes in the presence of AG490 suggests that the particular STAT 
protein members that are involved in HaemDMSC adipogenesis are not inhibited by 
AG490.  
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CHAPTER 5: TRAIL - A POTENTIAL 
TREATMENT FOR HAEMANGIOMA? 
 
5.1 INTRODUCTION 
Although most haemangiomas require no intervention (Margileth et al., 1965), 
treatment is necessary in 10 to 20% of cases during the proliferative phase because of 
their location, size, or behaviour (Takahashi et al., 1994; Mulliken et al., 1995). The 
mainstay treatment for haemangioma during the proliferative phase is pharmacologic 
therapy with glucocorticoids being the first line of treatment (Mulliken et al., 1995). 
However, not all lesions respond to steroids. IFNα is considered the second-line of 
treatment and is indicated for lesions that fail to respond to steroid therapy (Mulliken et 
al., 1995; White et al., 1991; Spiller et al., 1992; Blei et al., 1993; Ohlms et al., 1994), 
with accelerated regression seen in 90% of cases (Mulliken et al., 1995). However, IFN 
treatment is accompanied by serious side-effects (Vial & Descotes, 1994; Barlow et al., 
1998; Dubois et al., 1999). Most children given IFN develop fevers for the first one-
two weeks of therapy (Tan, 2001). Reversible toxicoses such as transient neutropenia, 
anaemia and a five-fold increase in liver transaminases is also seen (Tan, 2001). 
Significant neurotoxicity also occurs with spastic diplegia in 10% of cases (Barlow et 
al., 1998). The neurological sequelae are arrested by cessation of treatment. In some 
cases they resolve completely but in others varying degrees of residual deficit persists 
(Tan, 2001). 
The actual mechanism of action of IFNs in the regression of haemangioma is 
unknown. IFNs are a family of cytokines which are classified into two groups, type I 
(IFN and IFN) and type II (IFN). In addition to their anti-viral effects, IFNs exhibit 
pleiotropic biological activities, including anti-tumor, anti-proliferative and 
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immunomodulatory effects (Morris and Zvetkova 1997; Gresser et al 1997; Stark et al., 
1998) and transcriptionally regulate over 100 genes (Stark et al., 1998). 
IFNs act as apoptosis-inducing cytokines on various cancer cell lines (Chawla-
Sarkar et al., 2003), including multiple myeloma, (Chen et al., 2001), melanoma 
(Chawla-Sarkar et al., 2001), and ovarian carcinoma (Morrison et al., 2002). Greater 
cell growth-inhibitory effects of IFN compared with IFN has been shown consistently 
(Borden et al., 1982; Rosenblum et al., 1990; Johns et al., 1992). IFNs have also been 
shown to up-regulate the expression of different apoptosis-related proteins including 
death receptors and their respective ligands, caspases and several members of the Bcl-2 
family in a variety of cells (Ossina et al., 1997; Spanaus et al., 1998). Transcriptional 
induction of TRAIL has been found to be one of the earliest events following IFN 
administration (Chen et al., 2001; Sato et al., 2001). IFN pre-treatment has been found 
to sensitise human melanoma cells to TRAIL-induced apoptosis (Chawla-Sarkar et al., 
2002; Leaman et al., 2002), which were otherwise resistant to TRAIL treatment alone.  
TRAIL is a member of the TNF superfamily, that induces rapid apoptosis in a 
wide variety of transformed cell lines, but appears to have little or no detectable toxicity 
on normal cells in vitro and in vivo (Walczak et al., 2000; Pitti et al., 1996; Walczak et 
al., 1999). TRAIL binds to four distinct membrane-bound receptors, DR4 (TRAIL-R1), 
DR5 (TRAIL-R2), DcR1 (TRAIL-R3), DcR2 (TRAIL-R4), and a soluble receptor, 
OPG. These receptors are expressed by tumour, transformed and normal cells (Griffith 
et al., 1999; Walczak et al., 1997; Green, 2000; Spierings et al., 2004). TRAIL induces 
apoptosis through the activation of DR4 and DR5, which engage the ‘cell-extrinsic’ 
apoptosis pathway (LeBlanc & Ashkenazi, 2003; Kelly and Ashkenazi, 2004) (Figure 
5.1). TRAIL binding, leads to the formation of the death inducing signalling complex 
(DISC) consisting of the apoptosis ‘initiating’ proteases, caspase-8 and caspase-10, and 
an adaptor molecule, the Fas-associated death domain (FADD). Once recruited, the 
activated caspase-8 and -10 in turn activate ‘effector’ caspases, including caspase-3, -6 
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and -7, which then execute the cell’s apoptotic demise (Sprick et al., 2000; Kischkel et 
al., 2000). In some cancer cell lines, TRAIL-induced caspase-3 activation is further 
augmented through engagement of the cell-intrinsic apoptosis pathway (LeBlanc et al., 
2002; Deng et al., 2002; Ravi and Bedi, 2002) (Figure 5.1). In this case, caspase-8 or 
caspase-10 cleaves and activates the pro-apoptotic Bcl-2 family member Bid, which 
then interacts with two other pro-apoptotic members, Bax and Bak, to induce the release 
of cytochrome c and Smac/Diablo from the mitochondria. Cytochrome c together with 
Apaf-1 activates caspase-9, which contributes to further activation of caspase-3, -6 and -
7. Smac/Diablo binds to inhibitor of apoptosis proteins (IAPs), such as X-chromosome-
linked IAP (XIAP). This prevents the IAPs from physically binding caspase-3, hence 
promoting further caspase-3 activation.  In certain cancer cells, Bax is essential to 
connect the extrinsic and intrinsic pathways. Loss of function mutations have been 
shown to render cells resistant to TRAIL. However, the resistance associated with Bax 
inactivation can be circumvented by pre-exposing the cells to chemotherapy, which up-
regulates levels of DR5 and Bak (Kelley & Ashkenazi, 2004)
Binding of TRAIL to DcR1, DcR2 and OPG does not transduce the death signal 
as they do not contain a functional cytoplasmic death domain and are therefore 
considered as competitive decoys receptors for TRAIL (Griffith et al., 1998; Ashkenazi 
et al., 1999; Degli-Esposti, 1999; Ashkenazi & Dixit, 1998). Interestingly, DcR1 and 
DcR2, as anti-apoptotic genes, are expressed in many normal tissues, but their 
expression are frequently lost in various types of human cancers (Ashkenazi & Dixit, 
1998; Kelley Ashkenazi, 2004). 
In addition to inducing apoptosis in cancer cell lines (Mitsiades et al., 2001; 
Naka et al., 2002), recombinant soluble TRAIL shows remarkable efficacy against 
tumour xenografts of colon carcinoma (LeBlanc et al., 2002; Ashkenazi et al., 1999), 
breast carcinoma (Walczak et al., 1999), multiple myeloma cells (Mitsiades et al., 2001) 
and glioma cells (Fulda et al., 2002; Pollack et al., 2001).  
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Furthermore, the potential for TRAIL to act synergistically with other anti-
cancer therapies is of particular interest. TRAIL has been shown to act synergistically 
when combined with IFN (Shigeno et al., 2003), genotoxic agents including 
doxorubicin, cisplatin or etoposide (Arizono et al., 2003; Bouralexis et al., 2003; Miao 
et al., 2003; Hotta et al., 2003; Jones et al., 2003; Xu et al., 2003), DNA-damaging 
drugs (Morrison et al., 2002; Ashkenazi et al., 1999), radiotherapy (Gong & Almasan 
2000; Chinnaiyan et al., 2000; Ramp et al., 2003), and cyclooxygenase-2 inhibitors 
(Totzke et al., 2003).  
IFNα was found to sensitise cells to TRAIL-induced apoptosis through an up-
regulation of DR4 and DR5 (Oshima et al., 2001; Shigeno et al., 2003). In addition, 
Kumar-Sinha et al (2002) showed that a synergistic apoptotic response was achieved in 
breast cancer cells with the combined treatment of IFNα and TRAIL. In certain tumour 
cell lines, IFN induced TRAIL expression by the tumour cells themselves. This resulted 
in TRAIL-mediated apoptosis by an autocrine or paracrine mechanism (Chen et al., 
2001; Oshima et al., 2001). Therefore, from these studies, Kumar-Sinha et al (2002) 
have suggested that IFNs may ‘prime’ cells for TRAIL induced apoptosis.  
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Figure 5.1: Activation of the cell-extrinsic and cell-intrinsic apoptosis pathways by 
TRAIL (Image re-drawn from Ashkenazi & Kelley, 2004).  TRAIL binding to the death 
receptors (DR4 and DR5) activates the cell-extrinsic pathway and is sufficient to trigger 
apoptosis in some cell types, whereas in other cell types amplification of this pathway 
through the intrinsic pathway is needed to commit the cell to apoptosis. Crosstalk 
between these two pathways involves cleavage of Bid and subsequent activation of Bax 
and Bak. See text for details.
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5.2 AIMS  
As described in section 5.1, various reports of the anti-tumour effects of IFN 
have been documented. In addition, IFN has been shown to be effective as an 
angiogenic inhibitor in a variety of angiogenic diseases (Gutterman, 1994). 
Furthermore, the high expression of IFN in the dermis overlying involuting and 
involuted haemangioma but not in the dermis overlying proliferating lesions, together 
with the efficacy of IFN in the treatment of haemangioma, suggests that this cytokine 
may play an important role in haemangioma involution. Unfortunately, the significant 
side effects associated with high dose IFN therapy especially neurotoxocicity has 
limited its use for haemangioma (Tan, 2001).  In this study, it was hypothesised that if a 
lower dose of IFNα shows improved efficacy in combination with another agent, it may 
be of greater clinical value.  
Therefore, in this study the efficacy of the combined treatment of IFNα-2b with 
TRAIL was investigated. mRNA levels of TRAIL and its receptors were investigated 
using qRT-PCR in proliferating, involuting and involuted haemangioma biopsies. IHC 
analyses of the TRAIL receptors (TRAIL-Rs) on paraffin embedded haemangioma 
tissue sections were performed. Using the in vitro model (described in Chapter 4), the 
effect of TRAIL and IFNα-2b treatment on haemangioma capillary-like growth was 
investigated.  
 
 
 
 
 
 221 
5.3 RESULTS 
5.3.1 mRNA EXPRESSION OF TRAIL AND ITS RECEPTORS 
Relative changes in mRNA expression for TRAIL, DR4, DR5, DcR1, DcR2 and 
OPG was determined in 11 proliferating, 4 involuting and 6 involuted haemangioma 
samples relative to GAPDH as Ct values. The average Ct values obtained for each 
gene per phase are presented in Table 8.  
TRAIL was abundantly expressed in all three phases of haemangioma at similar 
levels. The expression profile for TRAIL receptors was similar for the proliferating and 
involuted samples. DR4 mRNA was the most abundant and was expressed in all three 
phases at greater levels than DR5 (at least 30-fold more). Surprisingly, DR5 expression 
could not be detected in the involuting samples although it was detected in the 
proliferating and involuted specimens (p < 0.05) albeit at low levels. The decoy 
receptors DcR1, DcR2 and OPG were detected at low but comparable levels within all 
three phases. 
 
 
 
Table 8: Expression of TRAIL and TRAIL receptors mRNA in haemangioma. Relative 
expression levels of mRNA for TRAIL and TRAIL receptors in 11 proliferating, 4 
involuting and 6 involuted specimens determined by qRT-PCR using GAPDH as the 
internal house-keeping reference gene. Values are expressed as the average Ct value 
obtained for each gene ± s.e.m. Lesions from all phases expressed high levels of TRAIL 
mRNA and moderate levels of DR4, DcR1, DcR2 and OPG mRNA. Very low levels of 
DR5 mRNA were detected in all samples.   
 
 
 
Phase 
 
TRAIL 
 
DR4 
 
DR5 
 
DcR1 
 
DcR2 
 
OPG 
 
Proliferating 
(n=11) 
 
4.3 ± 0.5 
 
8.1 ± 0.2 
 
14.3 ± 0.7 
 
9.5 ± 0.7 
 
9.5 ± 0.3 
 
10.7 ± 0.5 
Involuting 
(n=4) 
5.2 ± 0.3 9.9 ± 0.3 > 18 13.6 ± 0.3 12.1 ± 0.4 11.7 ± 0.7 
Involuted 
(n=6) 
3.4 ± 1.4 8.3 ± 3.4 13.6 ± 5.6 10.2 ± 4.2 10 ± 4.1 8.8 ± 3.6 
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5.3.2 PROTEIN EXPRESSION OF TRAIL AND ITS RECEPTORS 
 Immunohistochemical staining revealed a positive reaction for all five TRAIL 
receptors in proliferating haemangioma tissue sections. Confocal laser scanning showed 
that proliferating haemangioma lesions expressed low levels of DR4 (Figure 5.2-A, 
white arrows) and DR5 protein (Figure 5.2-B, white arrows), moderate levels of DcR1 
protein (Figure 5.2-C, white arrows), high levels DcR2 (Figure 5.2-D, white arrows) 
and OPG protein (Figure 5.6-A and -B).  While staining for DR4, DR5, DcR1 and 
DcR2 was essentially cytoplasmic in all lesions analysed (Figure 5.2, white arrows), 
immunoreactivity for OPG was detected in the cytoplasm (Figure 5.6, yellow arrows) as 
well as within the nuclear compartment in some cells (Figure 5.6, white arrows). 
Negative controls included immunostaining without primary antibody incubation and 
showed no staining throughout the study. In addition, antibody specificity for DR4 and 
DcR2 was determined by Western botting (Figure 5.7). As expected, immunoreactive 
bands were detected for DR4 and DcR1 at 55 kDa and 32 kDa, respectively (Grataroli et 
al., 2002; Vindrieux et al., 2002). Unfortunately, antibody specificity for the anti-DR5 
and anti-DcR1 antibodies could not be verified, as the antibodies did not perform well 
on Western blots. 
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Figure 5.2: Confocal immunohistochemical localisation of TRAIL receptors in 
haemangioma. Paraffin embedded proliferating haemangioma tissue sections were 
stained with primary antibodies against DR4 (A), DR5 (B), DcR1 (C) and DcR2 (D) as 
described in section 2.4.2. Bound DR4 antibodies were detected using an anti-mouse 
DIG conjugate and an anti-DIG-Rhodamine conjugate (red). Bound DR5 antibodies 
were detected using an anti-mouse AlexaFluor 488 conjugate (green). Bound DcR1 and 
DcR2 antibodies were detected using an anti-rabbit-DIG and an anti-DIG-FITC 
conjugate (green). Cell nuclei were counterstained with either DAPI (blue) or PI (red). 
Positive immunoreactivity was detected for all four TRAIL receptors. Red staining 
indicates DR4 expression (Panel A), while green staining indicates DR5 (Panel B), 
DcR1 (Panel C) and DcR2 (Panel D) expression. White arrows show cytoplasmic 
staining detected for all receptors. Scale bars: 50 µm. 
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5.3.3 EFFECT OF INTERFERON AND TRAIL ON CAPILLARY-LIKE 
GROWTH 
Freshly resected haemangioma tissue has been shown to develop outgrowths or 
‘microvessels’ within days of placing in culture (Tan et al., 2000b). Using this system, 
the effect of exogenously applied TRAIL (250 ng/ml) and a low and high dose of IFN-
2b (4600 U/ml and 23000 U/ml, respectively), singly and in combination was tested on 
proliferating haemangioma tissue explants isolated from five different patients (Figure 
5.3-A). Haemangioma explants when grown in the absence of TRAIL and IFN under 
serum-free culture conditions grew well and gave rise to numerous microvessel-like 
outgrowths by nine days in culture. Figure 5.3-A graphically represents the extent of 
microvessel outgrowth for all five patients relative to the control (C). TRAIL treatment 
(T) alone had negligible effect on microvessel outgrowth in all five patients. Except for 
the tissue explants that were treated with TRAIL (T) alone, all other treatments resulted 
in significant inhibition of microvessel outgrowth compared to untreated control (C) 
cultures (p < 0.01). In addition, while low dose of IFN-2b (IL) inhibited outgrowth (p < 
0.01), IFN-2b (IL) when used in conjunction with TRAIL (T+IL) resulted in a 
synergistic inhibition of microvessel outgrowth (p < 0.001) such that the level of 
inhibition was similar to that seen with high dose IFN-2b treatment (IH) alone. While 
cultures treated with high dose IFN-2b (IH) showed reduced microvessel outgrowth (p 
< 0.001), the combined treatment with TRAIL and high dose IFN-2b (T+IH) reduced 
microvessel outgrowth further but not to a statistically significant extent.  
 
5.3.4 EFFECT OF INTERFERON AND TRAIL ON HaemDMSCs  
The EZ4U assay was used to test the effect of TRAIL (250 ng/ml) and IFN-2b 
(4600 U/ml and 23000 U/ml) on HaemDMSC proliferation. No effect was detected at 
the end of a 48 hour incubation period. HaemDMSCs were also treated with IFN-2b 
and TRAIL for 96 hours in a similar manner as the tissue explants. Figure 5.3-B shows 
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that similar to the tissue explants, treatment with TRAIL alone did not inhibit 
proliferation of HaemDMSCs. While IFN-2b treatment (low dose and high dose) 
significantly inhibited HaemDMSC proliferation compared to untreated cultures (p < 
0.01), the combined treatment of TRAIL with low dose of IFN-2b (T+IL) did not show 
a synergistic effect on HaemDMSC proliferation (Figure 5.3-B) as that seen with the 
cultured tissue explants shown in Figure 5.3-A.  All proliferation assays were performed 
on the purified cells from at least three different patients. Cultures were assayed in 
triplicate for each treatment type.  
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Figure 5.3: Effect of TRAIL and IFN-2b on haemangioma cultures, in vitro. The effect 
of 250 ng/ml TRAIL (T), 4600 U/ml IFN-2b (IL) and 23000 U/ml IFN-2b (IH) was 
tested on haemangioma capillary-like outgrowth (A) and HaemDMSC proliferation (B). 
(A) Capillary-like outgrowth was calculated by the area occupied by the outgrowing 
vessels relative to the area of the tissue from which they emanated and is expressed as 
% Control. Data presented shows the average results obtained following nine days of 
treatment from five different proliferating haemangioma patients ± s.e.m. (B) Extent of 
HameDMSC proliferation following 96 hours of treatment with TRAIL and IFN-2b. 
Proliferation was assessed as a direct measure of absorbance and the results are 
presented as % Control. Data shown in Panel B represent the average results obtained 
from three individual experiments performed with HaemDMSC isolates from three 
proliferating haemangioma patients ± s.e.m. To detect statistically significant changes, a 
2-way ANOVA was applied to all data sets. ** represents significance at p < 0.01. 
%
 
Co
n
tr
o
l 
C IL T+IL IH T+IH T 
%
 
Co
n
tr
o
l 
A 
B 
**
**
**
**
**
**
C IL T+IL IH T+IH T 
 227 
5.3.5 mRNA AND PROTEIN EXPRESSION OF TRAIL AND ITS 
RECEPTORS IN HaemDMSCs 
The difference in response to the combined treatment of TRAIL and IFN-2b on 
the tissue explants compared with the HaemDMSCs was speculated to be due to 
differences in TRAIL receptor expression. Using qRT-PCR, the expression profiles of 
mRNA for TRAIL and TRAIL receptors in HaemDMSCs and the tissue pieces from 
which they were isolated were compared. The difference in mRNA expression between 
the tissue and the cultured cells normalised to expression of GAPDH as Ct values 
(Figure 5.4-A) is graphically represented as the average Ct values for the six 
biopsies analysed (Figure 5.4-B). Small differences in expression of mRNA for DR4, 
DR5 and DcR1 were found but there was a large induction of OPG expression (p < 
0.001) and DcR2 (p < 0.01) decoy receptors in the HaemDMSCs. This increase in 
decoy receptor expression was also matched by a similar decrease in TRAIL expression 
(p < 0.001) by the cultured cells. The raw Ct values are listed in Table 3.1, Appendix 
3, page 292. 
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Figure 5.4: Differences in mRNA levels for TRAIL and TRAIL receptors in 
haemangioma tissue and HaemDMSCs. Relative mRNA levels for TRAIL and TRAIL 
receptors were determined by qRT-PCR from six proliferating haemangioma tissues 
and the corresponding HaemDMSC isolates from each tissue. (A) The table gives the 
average Ct values obtained for each gene from tissue pieces (HaemTissue) and cell 
isolates (HaemDMSCs). (B) Differences in TRAIL and TRAIL receptor expression 
between the HaemDMSC cell lines relative to tissues were determined as Ct 
values. Data presented shows the average Ct values obtained for each gene 
between tissue and cells. A low value indicates higher expression of the gene in the 
tissue while a high value shows higher mRNA expression of that gene by 
HaemDMSCs. Significant differences in gene expression between tissues and cells were 
detected using the Friedmann’s non-parametric test for paired samples, where ** 
represents significance at p < 0.01 and *** at p < 0.001. 
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IHC analysis showed strong positive cytoplasmic immunoreactivity for DR4, 
DR5 and DcR2 on HaemDMSCs (Figure 5.5-A, -B and -D, respectively). Low levels of 
DcR1 were also detected (Figure 5.5-C). As mentioned in Chapter 4, HaemDMSCs 
showed strong extracellular staining for OPG (Figure 5.6-C) which was clearly different 
from cytoplasmic (Figure 5.6-A and -B, yellow arrows) and nuclear staining (Figure 
5.6-A and -B, white arrows) seen within the tissue lesion in vivo. In addition, OPG 
expression by HaemDMSCs was found to increase with time (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Confocal immunohistochemical localisation of TRAIL receptors on 
HaemDMSCs. Cells were fixed and stained with antibodies against DR4 (A), DR5 (B), 
DcR1 (C) and DcR2 (D) as described in section 2.4.2. Bound primary antibodies were 
detected using either an anti mouse AlexaFluor 488 conjugate (green) or a FITC 
conjugated anti-DIG secondary antibody (green). Cell nuclei were counterstained with 
PI (red). Green staining shows high expression for DR4, DR5 and DcR2 but low 
expression of DcR1 in HaemDMSCs. Scale bars: 50 µm. 
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Figure 5.6: Confocal immunohistochemical localisation of OPG in haemangioma. 
Paraffin embedded proliferating haemangioma tissue sections (A&B) and HaemDMSCs 
were stained with a mouse anti-OPG antibody as described in section 2.4.2. 
Immunoreactivity was detected using an anti-mouse AlexFluor 488 conjugate (green). 
Cell nuclei were counterstained with DAPI (blue). In proliferative haemangioma lesions 
(Panels A&B), OPG expression was detected in the cytoplasm (yellow arrows) as well 
as within the nuclear compartment (white arrows). HaemDMSCs showed strong 
extracellular staining for OPG (Panel C, green staining). Scale bars: 50  µm.  
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To determine whether changes in DR4 and DcR2 mRNA expression correlated 
with changes in its protein abundance, the same samples were used for immunoblotting 
as described in section 2.4.5.1 (page 103). The immunoblots shown in Figure 5.7 clearly 
shows that although equal amounts of total protein (100 µg/well) were loaded from each 
sample, HaemDMSCs expressed greater amounts of GAPDH protein compared to 
proliferating haemangioma tissues. No significant difference in total DR4 protein 
expression was detected between the cells and tissues (Figure 5.7-A). Consistent with 
mRNA studies, DcR2 protein expression was significantly higher in HaemDMSCs than 
in the tissues (p < 0.05; Figure 5.7-B and -C). 
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Figure 5.7: DR4 and DcR2 protein expression in haemangioma. DR4 (A) and DcR2 (B) 
protein expression was examined in proliferative haemangioma tissue biopsies and 
HaemDMSCs by Western blotting as described in section 2.4.5.1. Each gel contained 
50 µg of total protein extracted from haemangioma tissues from four patients and five 
HaemDMSCs cell lines. Membranes were incubated with mouse anti-DR4 or rabbit 
anti-DcR2 antibodies followed by AlexaFluor 488 conjugated anti-mouse or anti-rabbit 
secondary antibodies. Immunoreactive bands were detected for DR4 and DcR2 at 55 
kDa and 32 kDa, respectively, corresponding to the expected molecular weight for these 
proteins. Membranes were also probed with mouse anti-GAPDH antibodies. The 
immunoblots showed that HaemDMSCs expressed greater amounts of GAPDH protein 
than tissue biopsies. No change in total DR4 protein expression was found between 
cells and tissues. In contrast, HaemDMSCs expressed greater amounts of DcR2 protein 
than haemangioma biopsies. (C) Densitometry analysis of DcR2 band densities 
confirmed that the increase was significant with p < 0.05 (*). Negative controls were 
included in each experiment in which lysate from haemangioma tissue and 
HaemDMSCs were immunoblotted with secondary antibody only. No non-specific 
immunoreactive bands were detected on the negative control immunoblots therefore 
validating the specificity of the anti-DR4 and anti-DcR2 primary antibodies.  
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 5.3.6 HaemDMSCs SECRETE OPG INTO THE CULTURE MEDIUM 
AND OPG ANTIBODY SPECIFICITY 
 To determine whether HaemDMSCs secrete and release OPG when cultured in 
vitro, Western blot analysis was performed using the MAB8051 anti-OPG antibody 
(R&D Systems) as described in section 2.4.5.2 (page 104). Under reducing conditions, 
the immunoblots showed that the culture media conditioned over a 96 hour period, 
contained detectable levels of the monomeric form of OPG (60 kDa) (Figure 5.8-A, red 
arrow). In addition, a band at approximately 220 kDa was also detected in the 
conditioned media of HaemDMSCs (Figure 5.8-A, black arrow). Both bands were 
detected when the experiment was repeated with conditioned media obtained over a 72 
hour culture period (Appendix 3, Figure 3.1, page 293). In addition, no bands were 
detected when unconditioned media was analysed in the same way as conditioned media 
(Appendix 3, Figure 3.1, page 293). These results suggest that perhaps the 220 kDa 
band represents a novel hyper-glycosylated form of OPG. The dimeric form of OPG has 
been shown to be 120 kDa and was not detected in either experiment.  
 In addition, HaemDMSCs lysate and haemangioma tissue lysate were also run 
on the same gel and subjected to immunoblotting. Bands at both 60 kDa and 220 kDa 
were detected from HaemDMSCs lysate (Figure 5.8-A, red and black arrows, 
respectively). In order to determine the specificity of antibody binding, immunoblotting 
was performed with the omission of the primary antibody and incubation with 
secondary antibodies only. The resulting immunoblot showed no bands at either 60 kDa 
or 220 kDa using HaemDMSCs lysates (Figure 5.8-B). Furthermore, GAPDH 
immunoreactivity was not detected from the conditioned media (Figure 5.8-C, black 
arrow). These results indicate that the OPG protein detected in the media was not the 
result of HaemDMSCs lysing during the experiment  
  Waterman et al (2007) recently showed that the MAB8051 anti-OPG antibody 
recognises a 30 kDa band in addition to OPG in breast cancer tissues and prostate 
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cancer cell lines. Using MALDI-TOF, these authors identified that the 30 kDa band 
corresponded to carbonic anhydrase II (CA II). In this study, only the haemangioma 
tissue lysates showed an immunoreactive band at 30 kDa with this antibody (Figure 5.8, 
green arrow). Since neither the conditioned medium nor the HaemDMSCs lysates 
showed this 30 kDa band, it was confirmed that the immunohistochemical studies 
performed for OPG on HaemDMSCs was not detecting CA in the cultured cells but was 
specific for OPG or at the least, a protein that contains an OPG domain. However, 
caution is required in interpreting results of OPG immunohistochemical analysis in 
paraffin embedded haemangioma tissue sections because of the non-specific binding of 
the MAB8051 anti-OPG antibody on haemangioma tissue lysate. 
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Figure 5.8: OPG protein expression in HaemDMSCs conditioned media, in 
HaemDMSCs and in a proliferative haemangioma tissue biopsy. (A) 40 µg of total 
protein from the medium of HaemDMSCs conditioned over a 96 hour period (M), 100 
µg of total protein from HaemDMSCs (CL) and proliferating haemangioma tissue lysate 
(TL) were analysed by SDS-PAGE and immunoblotted with the mouse anti-OPG 
MAB8051 primary antibody. (B) A negative control immunoblot containing lysate from 
HaemDMSCs (CL) and haemangioma tissue lysate (TL) was probed with secondary 
antibody only. The test sample showed immunoreactive bands at 60 kDa (red arrow) 
and at 220 kDa (black arrow) from the conditioned media and HaemDMSCs. These 
bands were absent in tissue lysate and on the negative control.  In contrast, a band at 30 
kDa was detected from tissue lysate (green arrow) which was absent in the conditioned 
media, the HaemDMSCs lysates and the negative control. (C) The test immunoblot was 
probed with anti-GAPDH antibodies. Absence of an immunoreactive band for GAPDH 
(38 kDa) from conditioned media (M) indicates that the band corresponding to OPG 
protein (60 kDa, red arrow) from the media did not come from lysed cells.  
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5.4 DISCUSSION 
5.4.1 THE EFFECT OF TRAIL AND INTERFERON ON 
HAEMANGIOMA CAPILLARY-LIKE OUTGROWTH 
The cellular and molecular biology of haemangioma and its spontaneous and 
therapy-induced regression is still largely unknown. Understanding the molecular 
pathways that are active in these tumours could lead to the development of more 
effective therapies, as molecules that are involved in proliferation or involution could be 
targeted.  
Recombinant TRAIL protein offers great promise as a cancer therapy as it 
shows the unique property to destroy several types of tumour cells but spares most 
normal cells (Smyth et al., 2003). TRAIL also induces the expression of a cohort of IFN 
stimulated genes (ISGs) including IFN, caspase 7 and STAT-1 which are involved in 
apoptosis. This suggests the existence of molecular cross-talk between the TRAIL death 
receptor and IFN signalling pathways (Kumar-Sinha et al., 2002). Increased expression 
of ISGs has been identified during haemangioma involution.  In addition, apoptosis has 
been shown to increase five-fold in haemangioma undergoing regression (Razon et al., 
1998). It is therefore interesting to postulate that TRAIL receptor signalling may be a 
regulator of haemangioma progression, presumably through the induction of apoptosis 
of the ECs that form the microvasculature characteristic of haemangioma. Given the 
potential use of TRAIL in anti-cancer therapy, this study investigated the effects of 
TRAIL and IFN-2b on haemangioma capillary-like outgrowth when added singly and 
in combination. The expression of TRAIL and TRAIL-Rs in proliferating haemangioma 
biopsies and on HaemDMSCs was also investigated.  
This study showed that although proliferating haemangioma expressed protein 
for the functional receptors for the TRAIL ligand, DR4 and DR5, TRAIL alone did not 
affect rate of capillary-like outgrowth. However, combining TRAIL with a low dose 
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IFN-2b resulted in a synergistic inhibitory effect on capillary-like outgrowth. In 
addition, for some explants, this inhibition was similar to the inhibition caused by high 
dose IFN-2b alone. These results suggest the possibility of substituting high dose 
IFN-2b therapy with the combined treatment of TRAIL with a low dose of IFN-2b, 
thereby possibly reducing the harmful side effects seen clinically with IFN treatment.  
This study also investigated the effect of TRAIL and IFN-2b on HaemDMSCs 
proliferation. Although TRAIL and IFN-2b added singly inhibited HemDMSCs 
proliferation to a certain extent, the synergistic effect of TRAIL with IFN was not 
detected. qRT-PCR and immunohistochemical analysis showed that although the cells 
expressed DR4, DR5 and DcR1, the expression of DcR2 and OPG was greatly up-
regulated in the cultured cells.  
The molecular mechanism by which DcR2 confers resistance to TRAIL-induced 
apoptosis remains unclear (Almasan & Ashkenazi, 2003; Bouralexis et al., 2003;
Davidovich et al., 2004). Various studies have found that DcR2 overexpression 
protected cells from TRAIL-induced apoptosis (Degli-Esposti et al., 1997; Marsters et 
al., 1997). In addition, decreased DcR2 expression caused due to the hypermethylation 
of the DcR2 gene has been identified in a number of tumours and tumour cell lines 
tumours including breast, lung, prostate, bladder, cervical cancer, ovarian, lymphoma, 
leukaemia and multiple myeloma and neuroblastomas (Shivapurkar et al., 2004; Van 
Noesel et al., 2002). Mérino et al (2006) showed that DcR2 impaired TRAIL-DISC 
processing and initiator caspase activation while Meng et al (2000) showed that the 
over-expression of DcR2 delayed p53-induced apoptosis in human colon cancer cells. 
Liu et al (2005) reported that while DcR2 over-expression in human lung cancer cells 
was protective against chemotherapeutic agent–induced apoptosis, silencing of DcR2 
expression enhanced apoptosis. These findings support the possibility that the increased 
expression of DcR2 by HaemDMSCs may be to some extent protecting them from 
apoptosis. 
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During this study, increased extracellular OPG deposition by HaemDMSCs was 
consistently detected by immunohistochemical studies. From these results, we 
hypothesise that HaemDMSCs secrete increased levels of OPG, which then acts as a 
protective shield around the cells preventing apoptosis. We also postulate that increased 
OPG production is a stress response that results from culturing these cells in vitro i.e. 
outside their normal environment. Previous studies have shown that the in vitro culture 
of primary cell lines can result in the formation of abnormal cell architecture and can 
cause significant changes in gene expression (Kivell, 2003). Kanzaki et al (2006) found 
that application of a cyclical tensile strain up-regulated OPG mRNA expression in 
human periodontal ligament cells (hPLDCs). Yamamoto et al (2006) also found that 
hPLDCs exposed to mechanical stress as hydrostatic pressure showed increased OPG 
mRNA expression compared to the untreated cells. In addition to increased OPG 
mRNA expression, Tang et al (2006) showed increased concentrations of OPG protein 
in the conditioned medium of MC3T3-E1 osteoblastic cells subjected to cyclic tensile 
strain. The presence of secreted OPG in the conditioned media of HaemDMSCs and the 
increased expression of OPG by HaemDMSCs are consistent with these findings. 
In contrast, although immunohistochemical studies showed OPG expression 
within the haemangioma lesions (Figure 5.6), Western blotting analysis failed to detect 
an immunoreactive band at the correct size using haemangioma tissue lysates (see 
section 5.3.6, page 233). These data suggest that proliferating haemangioma lesions do 
not express high levels of OPG and this could explain why the combined treatment of 
IFN-2b and TRAIL resulted in the synergistic inhibition of capillary-like growth from 
explanted biopsies. 
To date, the physiological functions of the multiple TRAIL-Rs remain obscure. 
Although various studies have suggested that the ratio of death and decoy receptors are 
critical in the regulation of the apoptotic pathway (Ashkenazi, 2002; Bouralexis et al., 
2003), other investigators have shown that there is no correlation between TRAIL 
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receptor expression and susceptibility to TRAIL-induced apoptosis (Keane et al., 1999; 
Wen et al., 2000; Knight et al., 2001). In addition, several other mechanisms of 
resistance to TRAIL have been proposed in different cell types including cFLIP, a 
caspase-8 and a caspase-10 related molecule that lacks catalytic activity and acts as a 
competitive inhibitor of death receptor-mediated apoptosis (Tschopp et al., 1998; 
Leverkus et al., 2000). XIAP can also bind to caspase-3 and caspase-9 and inhibit their 
activity (LeBlanc & Ashkenazi, 2003; Salvesen, 2002; MacFarlane et al., 2002). 
Furthermore, sensitivity of some cell types to TRAIL is hinged on the balance between 
pro-apoptotic (e.g., BAX and BAK) and anti-apoptotic (e.g. Bcl-2 and Bcl-xl) members 
of the Bcl-2 family (Kelly & Ashkenazi, 2004).  
 There is mounting evidence to suggest that the interaction of OPG with TRAIL 
is biologically important, particularly in in vitro culture systems. OPG has been shown 
to protect serum-starved ECs and fibroblast-like synovial cells from TRAIL-triggered 
cell death (Pritzker et al., 2004; Miyashita et al., 2004). OPG also acts in a paracrine 
and autocrine manner by binding TRAIL to promote the survival of prostate cancer cells 
(Holen et al., 2002), breast cancer cells (Neville-Webbe et al., 2004), multiple myeloma 
cells (Shipman & Croucher, 2003) and ameloblastoma cells (Sandra et al., 2006). 
Although further studies are required to elucidate the ability of OPG to counteract the 
biological activity of TRAIL in vivo, it is clear that the relative concentrations and the 
expression patterns of OPG in the local environment is a key determinant in TRAIL-
mediated cell toxicity. Based on these findings, we hypothesise that the HaemDMSCs 
isolated in this study are resistant to TRAIL mediated apoptosis due to increased protein 
levels of OPG and DcR2.  However, further experiments would be required to confirm 
this. This would include testing the effect of TRAIL on HaemDMSCs transfected with 
short interfering RNA (siRNA) for the OPG and DcR2 genes.  
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5.4.2 OPG ANTIBODY SPECIFICITY 
OPG is secreted as a covalent, disulfide-linked homodimer, which has been 
shown to be the predominant extracellular form (Simonet et al., 1997). While the 
homodimer has a molecular weight of 120 kDa, immunoblotting for OPG under 
reducing conditions shows an immunoreactive band at 60 kDa corresponding to the 
OPG monomer (Hyanes et al., 2003). In addition to the monomerric and dimeric forms 
of OPG, alternative splicing of the OPG gene has been shown to give rise to three 
mRNA isoforms: mature mRNA and two splice variants (Morinaga et al., 1998). The 
splice variant sequences contain a premature stop codon and are predicted to encode 
truncated proteins of 30-40 kDa.  
There have been conflicting reports on the specificity of the MAB 8051 
antibody. This antibody was used in this study to detect OPG protein expression. 
Although Haynes et al (2003) showed that the antibody detected both, the monomeric 
and the dimeric forms of OPG, Waterman et al (2007) advised caution when using this 
antibody. Their studies showed that the antibody, in addition to OPG, also detected a 30 
kDa band on immunoblots that corresponded to CA II.  To determine the specificity of 
the MAB 8051 antibody, Western blotting was performed in this study with 
HaemDMSCs lysates, HaemDMSCs conditioned media and haemangioma tissue 
lysates.  
Consistent with the findings of Waterman et al (2007), an immunoreactive band 
at 30 kDa was detected when haemangioma tissue lysates were subjected to 
immunoblotting. However, this band was not detected using either HaemDMSC lysates 
or the HaemDMSC conditioned medium run on the same gel and therefore subjected to 
the same conditions as the tissue lysates.  In contrast, the HaemDMSCs lysates and 
HaemDMSCs conditioned media showed the presence of an immunoreactive band at 60 
kDa which corresponds to the molecular weight of the native OPG monomer. 
Furthermore this band was absent on haemangioma tissue lysates. However, 
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haemangioma tissue lysates did not show any immunoreactive bands at the appropriate 
size. Therefore, we conclude that the immunohistochemical studies performed during 
this study using the MAB 8051 anti-OPG antibody may be non-specifically cross 
reacting to CA II within the haemangioma tissue sections.  
CA II is a highly conserved enzyme which catalyses the hydration of carbon 
dioxide and the dehydration of bicarbonate. In addition to normal cells (Onji, 1999), 
increased CA II expression is detected in brain tumors (Parkkila et al., 1995), leukemia 
(Leppilampi et al., 2002), the tumour endothelium of melanoma, renal cell carcinoma, 
oesophageal and lung cancers (Yoshiura et al., 2005). CA II is considered an important 
factor for tumour cell growth as rapidly proliferating cells have a requirement for a high 
influx of bicarbonate to support their metabolic processes (Bianchi et al., 2005). 
Increased CA II expression has been reported in acidic and hypoxic conditions 
mimicking a tumour environment (Yoshiura et al., 2005). Furthermore, CA II inhibitors 
can inhibit the growth of cancer cell lines such as prostate and breast cancer cells and 
cell lines (Supuran & Scozzafava, 2000; Mallory et al., 2005). Consistent with the 
function of this enzyme, the high expression of CA II identified within the proliferative 
phase seems logical, as most cells in this phase, being highly proliferative would require 
increased levels of CA II. In contrast, minimal proliferation in the involuting and 
involuted phases corresponds to reduced CA II expression.  
However, it is important to note that the epitope recognised by the MAB 8051 
anti-OPG antibody within haemangioma tissue sections still differentiated between the 
cells that exhibited punctuate vWF immunoreactivity and those that showed strong vWF 
immunoreactivity (see section 4.3.5, page 174). Therefore, this antibody may be useful 
in determining the ‘maturity’ of the ECs within haemangioma.    
Finally, an additional immunoreactive band was detected with both 
HaemDMSCs lysates and HaemDMSCs conditioned medium and had a molecular 
weight of 220 kDa. Two groups have investigated the domains of OPG and their 
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importance to function. These studies have shown that the first four domains of OPG 
(encompassing the TNF receptor-like region) were required for activity in an 
osteoclastogenesis assay while the last intra-chain disulfide bond was critical for OPG 
function (Simonet et al., 1997; Yun et al., 1998). Cundy et al (2002) reported a mutant 
form of OPG that resulted from the loss of an aspartate residue. They showed that this 
mutant form was secreted and was hyperglycosylated. It is known that glycosylation is 
important for correct folding, trafficking, stabilisation and protection from proteases, as 
well as for interaction with other molecules (Dwek, 1998). The primary sequence of 
OPG contains six potential glycosylation sites but the degree of glycosylation at each of 
these sites in vivo has not been investigated previously (Cundy et al., 2002).  
Since the band at 220 kDa was repeatedly detected on the immunoblots from 
two separate experiments performed during this study and was not detected when 
unconditioned media was anaylsed in the same way, we can conclude that this band 
may represent a novel glycosylated form of the OPG protein. However, de-
glycosylation experiments or carbohydrate detection methods would need to be 
performed to confirm this. We hypothesise that the protein at 220 kDa being detected by 
the antibody must at least contain an OPG domain.  
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CHAPTER 6: CYCLOPHILIN A IN 
HAEMANGIOMA 
 
6.1 INTRODUCTION 
 
 CycA, a ubiquitously distributed protein, belongs to the immunophilin family 
(Galat, 1993) and is defined on the basis of its binding to the potent immunosuppressive 
drug cyclosporine A (Fruman et al., 1992; Liu et al., 1991). Intracellular CycA has 
peptidylprolyl cis-trans-isomerase (PPIase) activity, which is crucial for folding and 
isomerisation of many proteins. (Galat, 1993; Kofron  et al., 1991). CycA also acts as a 
potent chemoattractant for monocytes (Sherry et al., 1992), neutrophils (Sherry et al., 
1992; Xu et al., 1992), eosinophils (Xu et al., 1992) and T cells (Allain et al., 2002) in 
vitro. Xu et al (1992) showed that CycA also elicited an inflammatory response 
characterised by a rapid influx of neutrophils when injected in vivo.  
Initially believed to exist solely as an intracellular protein, various studies have 
shown that CycA is secreted by cells in response to inflammatory stimuli (Sherry et al., 
1992; Xu et al., 1992). Jin et al (2000) showed that CycA functioned as a secreted 
oxidative-stress-induced growth factor from rat SMCs and mediated extracellular signal 
regulated kinase (ERK1/2) activation and SMCs growth. They also found that 
recombinant CycA mimicked the effects of secreted CycA. Seko et al (2004) found that 
CycA was secreted by cardiac myocytes in response to hypoxia/reoxygenation and that 
CycA secretion resulted in the activation of the ERK1/2 pathway and increased Bcl-2 
expression. These authors suggested a protective role for CycA against oxidative stress-
induced apoptosis. In addition, Yang et al (2005) showed that CycA induced EC and 
SMC proliferation while Jin et al (2004) showed that it activated ECs in a pro-
inflammatory manner.  
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6.2 AIMS  
In this study, CycA was first investigated as a house keeping gene. However, 
preliminary qRT-PCR results identified that CycA mRNA levels differed between the 
three developmental phases (see Appendix 1, section 1.1.2.2, page 272).  Therefore, 
CycA expression was investigated as a test gene. qRT-PCR was used to measure 
changes in levels of CycA mRNA while Western blotting and IHC techniques were 
used to measure CycA protein abundance in proliferating, involuting and involuted 
haemangioma samples.  
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6.3 RESULTS 
6.3.1 CHANGE IN mRNA EXPRESSION 
The relative change in mRNA expression for CycA was determined for 
proliferating, involuting and involuted haemangioma samples (eight samples per phase) 
by qRT-PCR as described in section 2.2.2.1 (page 81). Expression of CycA mRNA was 
highest in proliferating haemangiomas and decreased in involuting and involuted lesions 
with a significant difference detected between proliferating and involuting lesions (p < 
0.05) (Figure 6.1).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Changes in CycA mRNA expression. mRNA levels for CycA were 
determined for eight proliferating, eight involuting and eight involuted haeamgnioma 
samples relative to GAPDH. Proliferating samples expressed more CycA mRNA than 
involuting and involuted lesions. Significance was achieved between the proliferative 
and involuting phases (* p < 0.05). 
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6.3.2. PROTEIN EXPRESSION  
6.3.2.1 WESTERN BLOTTING 
Some of the samples used for qRT-PCR were examined by Western blotting to 
identify if CycA protein abundance correlated with changes in mRNA expression. 
Figure 6.2 shows immunoreactive bands for CycA protein detected at 18 kDa, as 
expected (Hamilton & Steiner, 1998), from four proliferating, three involuting, three 
involuted haemangioma biopsies and HeLa cells. Immunoblots were also analysed for 
GAPDH to confirm equal amounts of total protein. Although CycA mRNA levels 
varied with phase, no statistically significant difference in CycA protein expression was 
found between the specimens (Figure 6.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Western blotting for CycA in haemangioma. 50 µg of total protein from 
proliferating, involuting and involuted haemangioma lesions were subjected to 
immunoblotting as described in section 2.2.2.2. Membranes were incubated with rabbit 
anti-CycA and mouse anti-GAPDH antibodies. With equal protein loaded from each 
sample (as determined by GAPDH immunoreactivity), no change in total CycA protein 
expression was found between phases.  
Proliferating Involuting Involuted 
GAPDH 
HeLa 
CycA 
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6.3.2.2 IMMUNOHISTOCHEMICAL ANALYSIS 
6.3.2.2.1 CycA EXPRESSION 
Immunohistochemical staining of haemangioma specimens (five samples per 
phase) showed that CycA was detectable in all phases of haemangioma (Figure 6.3, red 
staining). CycA protein was detected in the plump ECs of the proliferative phase 
(Figure 6.3-D, white arrows) and in the flattened ECs of the involuting (Figure 6.3-E, 
white arrows) and involuted phases (Figure 6.3-F, white arrows). In addition, the cells 
in the fibrofatty residuum of the involuting and involuted phases also expressed CycA 
(Figure 6.3-E and -F, respectively, yellow arrows). The decrease in CycA expression 
seen between phases in Figure 6.3 appears to be due to a decrease in cell number as 
opposed to a decrease in CycA staining intensity per cell.  
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Figure 6.3: Immunohistochemical localisation of CycA in haemangioma. Proliferating 
(A&D), involuting (B&E) and involuted (C&F) paraffin embedded haemangioma 
sections were stained with a rabbit anti-CycA antibody. Bound antibodies were detected 
using an anti-rabbit Cy3 conjugate (red). Cell nuclei were counterstained with DAPI 
(blue). Panels D, E & F are the enlargements of the areas outlined in A, B & C, 
respectively. CycA expression (red staining) was detected in the plump ECs of the 
proliferative phase (D, white arrows) and also in the flattened ECs of the involuting and 
involuted phases (E&F, respectively, white arrows). Involuting (E) and involuted (F) 
lesions also contained CycA positive cells in the interstitium (yellow arrows).  
Scale bars: 50 µm. 
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6.3.2.2.2 MAST CELLS EXPRESS CycA 
 To detect if MCs express CycA, DAB colorimetric visualisation of CycA 
immunoreactivity in conjunction with Csaba staining was performed as described in 
section 2.2.2.4 (page 82). Of the 200 MCs counted, those that stained positive for CycA 
(CycA + MCs) were identified in the proliferative and involuting phases. Consistent 
with earlier results (see section 3.3.2.3.5, page 122), a three-fold increase in the number 
of MCs was identified in involuting samples as compared to proliferating samples. 
However, the proportion of MCs expressing CycA did not vary with phase (Table 9, 
Figure 6.4) 
 
 
 
 
Table 9: CycA expression by MCs in haemangioma. CycA positive and negative MCs 
were counted from five samples of the proliferative and involuting phases as described 
in section 2.2.2.5.2. Of a total of 200 MCs counted from each lesion, the values in the 
table gives the number of CycA positive MCs (CycA+Mcs) and the percentage of CycA 
expressing MCs (% CycA+Mcs) . Values are the mean (of five lesions) ± s.e.m; n 
indicates the total number of fields of view counted at a magnification of X40.  
 
 
 
 
 
 
 
Developmental Phase 
 
Number of CycA + MCs  
 
% CycA + MCs 
 
Proliferative 
 
169 ± 2.3 (n = 25), 
 
81 
 
Involuting 
 
177 ± 6.5 (n = 7)  
 
85 
 
Proliferative vs Involuting 
 
p < 0.1 
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Figure 6.4: MCs in proliferating and involuting haemangiomas express CycA. CycA 
immunoreactivity was detected by DAB staining (brown) and counterstained with 
Csaba to identify the MCs (light blue). Double labelling of a proliferating (A) and an 
involuting (B) haemangioma with CycA antibodies and Csaba stain demonstrated the 
presence of CycA protein within MCs (black arrows). In Panel B, the yellow arrows 
show few MCs that do not express CycA. (C) The black columns show CycA positive 
MCs and the white columns show CycA negative MCs.  As identified earlier in this 
study, involuting lesions contained approximately three-fold more MCs per unit area as 
compared to proliferating lesions. However, approximately 80% of MCs present in 
proliferating and involuting lesions expressed CycA. Scale bars: 50 µm. 
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6.4 DISCUSSION 
 This is the first study to examine CycA expression in haemangioma. This study 
found that proliferating lesions expressed highest levels of CycA mRNA with decreased 
abundance in involuting and involuted haemangiomas.  However, Western blotting 
studies showed that total protein levels of CycA did not differ between the phases. IHC 
confirmed this finding. Immunohistochemical staining showed that CycA 
immunoreactivity was detected in lesions from all three phases and that as a 
consequence of a decrease in cell number between phases, more CycA staining was 
present in proliferating lesions as compared to involuting and involuted lesions.   
Although the findings from this study are purely descriptive, due to the presence 
of CycA in all phases of haemangioma together with its known function in protein 
remodelling and refolding as well as in EC proliferation and apoptosis, a model for the 
role of CycA in haemangioma was hypothesised and is depicted in Figure 6.5.   
In this proposed model, a hypoxic event induces high expression and secretion 
of CycA from various cell types within the lesion. Secreted CycA then acts in a 
paracrine manner to induce further EC proliferation during the proliferative phase. With 
the initiation of involution, CycA functions as PPIase and participates in the tissue 
remodelling events that characterises the regression of haemangioma. The presence of 
CycA in MCs is of unclear significance. Perhaps the influx of MCs during the 
involuting phase still expressing CycA is required to maintain CycA protein levels 
within the lesion. A second role for CycA in the involuting phase of haemangioma may 
be in the induction of EC apoptosis. This is supported by the findings of Jin et al (2004) 
who showed that CycA can induce EC apoptosis similar to the proapoptotic effect of 
TNF. However, further investigation is required to determine the precise role(s) of 
CycA in the pathogenesis of haemangioma. 
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Figure 6.5: A role for CycA in haemangioma progression. See text for details. 
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CHAPTER 7: KEY FINDINGS AND FINAL 
CONCLUSIONS 
 
7.1 THE SIGNIFICANCE OF THIS RESEARCH   
Over the past two decades, various studies have identified a number of cellular 
and extracellular markers associated with haemangioma. However, the molecular 
mechanisms that govern haemangioma proliferation and its subsequent involution are 
still largely unknown. This research aimed to enhance the current understanding of the 
molecular basis of haemangioma, as well as the complexity of cell signalling in the 
biology of this tumour. In this study, quantitative and qualitative differences in 
expression were investigated for a set of genes that were chosen because of their 
association with tumour susceptibility and angiogenesis. It was hoped that results of this 
research would identify novel markers that would lead to the development of more 
effective treatments. This study was also conducted in order to develop a working 
model for the biology of haemangioma. The following is a summary of some of the 
novel findings of this study. 
 
7.1.1 KEY FINDINGS 
7.1.1.1 VEGF, VEGFRs AND STAT PROTEINS IN HAEMANGIOMA  
 Using an in vitro model, that mimics as closely as possible the features of 
haemangioma, this study confirmed VEGF to be an important factor governing 
haemangioma proliferation. The addition of exogenous VEGF resulted in significant 
outgrowth of capillary-like structures from haemangioma explants. These results are 
consistent with the known role of VEGF as an angiogenic factor (Ferrara, 2000) as well 
as its high expression during the proliferative phase of haemangioma (Takahashi et al., 
1994; Tan, 2001). In addition, proliferating lesions expressed highest levels of VEGFR-
2 as compared to involuting and involuted lesions. These findings confirm that 
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VEGF/VEGFR-2 signalling is involved in the proliferation of haemangioma. In 
contrast, the presence of VEGFR-1 in all phases of haemangioma suggests that 
VEGFR-1 signalling may be required during the entire life cycle of haemangioma. As 
VEGFR-1 is involved in cellular differentiation (Neufeld et al., 1999), it is postulated 
that VEGFR-1 activation may be involved in transforming the highly cellular content of 
the proliferative phase into the fibro-fatty residuum of the involuting and involuted 
phases.  
 This study identified that STAT protein signalling is required for capillary-like 
outgrowth from explanted haemangioma tissues and for the proliferation of 
haemangioma tissue-derived cells. Of the seven members in the STAT family of 
transcription factors, STAT-3 expression was examined in haemangioma samples due to 
its association with tumour proliferation (Bromberg et al., 1998). Although there were 
high levels of STAT-3 in proliferating lesions, total abundance of STAT-3 per cell did 
not vary with the different phases. This suggests that STAT-3 abundance decreases with 
ongoing involution of haemangioma and that this decrease is concomitant with a 
reduction in cell number in involuting and involuted lesions. In addition, VEGF did not 
activate STAT-3 in cells purified from haemangioma lesions in vitro and activated 
STAT-3 did not correlate with proliferation in vivo. STAT-1 was also investigated due 
to its association with apoptosis. However, all lesions examined in this study showed 
low expression for STAT-1. These findings suggest that although STAT-3 and STAT-1 
signalling may be occurring in haemangioma, these transcription factors are not critical 
regulators of haemangioma. However, preliminary experiments conducted in this study 
showed that STAT-5 activation is associated with VEGF signalling in haemangioma. 
Since STAT-5 is now known to be critical in cell transformation, its activators and 
down-stream targets in haemangioma biology warrants further investigation. 
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7.1.1.2 THE USE OF TRAIL AS TREATMENT FOR HAEMANGIOMA  
 Pharmacological therapy is the mainstay treatment for haemangioma during the 
proliferative phase with steroids being the first line of treatment and IFN, the second 
choice, both of which were discovered serendipitously. These treatments are slow and 
are associated with serious side-effects. Surgery and laser therapy are indicated if 
pharmacological therapy fails. However, all these treatment modalities are empirical 
measures and leave definite sequelae (Tan, 2001). Therefore, one of the aims of this 
investigation was to use the in vitro haemangioma model (Tan et al., 2000b) to help 
elucidate the mechanisms of action of existing therapies, such as IFN, and also identify 
novel agents for the treatment of haemangioma. Findings from this research identified 
TRAIL in combination with a low dose of IFN as a potential treatment for 
proliferating haemangioma. Results showed that the combined effect of TRAIL with a 
low dose of IFN acted synergistically and inhibited capillary-like outgrowth from 
haemangioma explants to a similar extent as the singly added high dose of IFN. Since 
TRAIL is known to be non-toxic to normal cells, this novel finding of its effect against 
haemangioma capillary-like outgrowth deserves further investigation.  
 
7.1.1.3 THE IDENTIFICATION OF STEM CELLS AND THEIR ROLE IN 
HAEMANGIOMA PROGRESSION 
 The proliferative phase of haemangioma is characterised by rapid proliferation 
of ECs with the accumulation of other cellular elements involved in angiogenesis 
including MCs, pericytes and macrophages (Takahashi et al., 1994). However, the most 
curious biological characteristic of haemangioma is the spontaneous regression. 
Although various cell types and cell-specific markers have been identified in 
haemangioma, the mechanisms of origin of the heterogeneous cell population, their 
post-natal presentation and their distinctive pattern of limited growth and involution are 
poorly understood.  
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 In this study, EPCs and MSCs were purified from haemangioma tissues. We 
postulate that abnormal stem cell development and differentiation underlies the 
aethiopathogenesis of haemangioma.  Although EPCs and MSCs have been previously 
reported in haemangioma (Yu et al., 2004a; Yu et al., 2006), this study showed that the 
cellular structures that rapidly emanated from explanted proliferative haemangioma 
biopsies were MSCs as they readily differentiated into osteocytes and adipocytes in 
vitro. However, the cells obtained from the direct dissociation of proliferating lesions 
were characterised as immature EPCs. These EPCs then further differentiated into 
MSCs with continued culture in vitro. This de novo transdifferentiation process in vitro 
may be due to the culture of the EPCs in the absence of growth factors which were 
present in the original lesion. This study also found that the MSCs that differentiated 
from EPCs maintained their plasticity into adipocytes in vitro. Since adipocyte 
deposition is associated with the spontaneous involution of haemangioma, we 
hypothesise that this process of transdifferentiation from EPCs to MSCs and MSCs to 
adipocytes regulates the biology of haemangioma. 
 
7.1.1.4 HOW DO THE FINDINGS FROM THIS STUDY FIT IN WITH THE 
CURRENT KNOWLEDGE OF HAEMANGIOGENESIS? 
The high incidence of haemangioma in the head and neck region together with 
the solitary and segmental post-natal presentation of these lesions led Waner et al 
(2003) to suggest that developmental detriments may be influential in the pathogenesis 
of haemangioma.   
To put the findings of this investigation into context, the developmental origins 
of the face are briefly described.   
The face begins to form during the 4th week of embryological development with 
the formation of the mesenchyme. The head mesenchyme is distinctive in that it is 
derived from neural crest cells rather than mesoderm (Risau & Flamme, 1995). The 
neural crest cells that form the face migrate dorsolaterally from the nueral tube to 
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produce five craniomesenchyme prominences consisting of a single frontonasal 
prominence, paired maxillary and paired mandibular prominences (Mitchell & Sharma, 
2005). These cranial neural crest cells are encoded with specific morphogenetic 
information prior to their migration (Gilbert, 1994). These prominences then 
differentiate into cartilage, bone, cranial neurons, glia and the connective tissues of the 
face including the corneal endothelium and stroma and the dermis and adipose tissue of 
the skin. However, the fate of the neural crest cells depends to a large degree upon 
where the cells migrate and settle and to the local environmental cues (Le Douarin et 
al., 2004).  
Neural crest-derived mesenchyme unlike mesoderm-derived mesenchyme, do 
not possess endogenous angioblasts and must rely on in-migrating angioblasts and 
vascular sprouts for vascularisation (Noden, 1988). Angioblasts are the EC precursors 
that form the primitive vascular channels during embryonic development (Risau et al., 
1988; Risau, 1997). Angioblast migration is particularly prominent in the head region 
implying the presence of increased levels of motility or chemotactic factors (Noden, 
1991). Therefore, Waner et al (2003) proposed that haemangioma preferentially occured 
in regions where neural crest-associated angiogenic mechanisms were elevated.  
The association between segmental haemangioma and PHACES syndrome 
deserves special consideration. Several of the associated anomalies, such as lingual 
thyroid and sternal clefting, have their origin between 6 and 8 weeks of gestational age, 
suggesting a so-called developmental-field defect (Frieden et al., 1996).Furthermore, 
the parotid glands are frequently involved by overlying plaque-like haemangiomas. 
These glands also begin their development at about 6 weeks of intra-uterine life. Waner 
et al (2003) suggested that the precursors of parotid hemangiomas may have reached the 
region during this early time frame, with proliferation held in check until latter in 
gestation or after birth. The authors also suggested that the differential patterns of tissue 
involvement seen in focal and segmental haemangioma may reflect the timing of 
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deposition of haemangioma precursor cells, with earlier events resulting in segmental 
haemangioma and later events resulting in focal haemangioma. These ideas, although 
speculative, suggests that haemangioma is not just a tumour but may be a 
developmental problem associated with abnormal angiogenesis.  
In order to explain the fascinating relationship between haemangioma and the 
placenta, Waner et al (2003) suggested that the regions of growing neuromesenchyma 
represented the ‘fertile ground’ for the implantation and proliferation of embolised 
placental cells or aberrant angioblasts by virtue of their inherent need to attract invading 
vascular precursors.   
In view of these ideas and the findings from our investigation, we propose a 
model for the involvement of neural crest cells in the pathogenesis of haemangioma 
(Figure 7.1). In this model, some migrating neural crest cells possess abnormalities that 
may be caused by mutations (Figure 7.1-A). While normal neural crest-derived 
mesenchyma recruit angioblasts as part of the normal developmental process, the 
presence of abnormal neural crest cells leads to excessive recruitment of these cells 
resulting in the presence of excessive EPCs in the region of the haemangioma (Figure 
7.1-B).  We propose that these EPCs are recruited either from the developing 
vasculature or embolised from the placenta. A placental origin for these EPCs could 
explain the expression of various placental antigens by the ECs in haemangioma.  
We hypothsise that EPC proliferation may be inhibited at this stage by passive 
immunity within the intra-uterine environment afforded by maternal circulation. During 
gestation, the maternal immune response against the foetus occurs in part by secretion 
of immuno-suppressors through the placenta (Jauniaux et al., 1995). Circulating 
maternal angiogenesis inhibitors have also been described during pregnanacy (Klauber 
et al., 1997; Levine et al., 2004). Thus, birth removes the intra-uterine suppression of 
angiogenesis and allows the proliferation of a pre-established lesion. This could explain 
the observed post-natal growth of these lesions. Alternatively, in the immediate post-
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natal period, an unknown factor could stimulate excessive angiogenesis in the region of 
the ‘nascent’ haemangioma. The idea that hypoxia may initiate and maintain 
haemangioma growth is supported by a number of clinical observations, although direct 
experimental data is not yet been available. For example, a blanched area of skin is 
usually noticed before the actual growth of the lesion. This may be an area of local 
ischaemia in the skin, caused by an unknown event that creates a hypoxic environment 
and thus, triggers growth factor expression. Studies have shown increased expression of 
IGF-2 and VEGF in response to hypoxia (Yu et al., 2004b; Levy et al., 1998; Stein et al., 
1998; Tong et al., 2006). This could explain the high levels of these growth factors seen 
during the proliferating phase of haemangioma. Also observed on haemangioma ECs is 
GLUT-1, another hypoxia-inducible molecule (Loike et al., 1992).  
We hypothesise that the high levels of VEGF and IGF-2, in turn, induces 
proliferation of the EPCs and results in the recruitment of support cells including MCs, 
pericytes and macrophages. At this stage the EPCs are protected from apoptosis due to 
OPG expression. All these events ultimately result in increased blood vessel formation 
that characterises the proliferative phase of haemangioma (Figure 7.1-C). Preliminary 
results suggest that STAT-5 is activated in response to VEGF. 
However, in the early stages of the involuting phase, an unknown angiogenic 
inhibitory factor is induced which results in the down-regulation of growth factor levels 
within the lesion. The consequence of low levels of VEGF (and other growth factors) 
results in the differentiation of EPCs into MSCs. These MSCs, in turn, differentiate into 
adipocytes that form the fibro-fatty tissue seen in involuting and involuted lesions 
(Figure 7.1-D). The signal for MSC differentiation into adipocytes in vivo is unclear. 
We propose a role for insulin and Dexamethasone in the adipogenesis of haemangioma, 
as these factors are involved in adipocytic differentiation in vitro.  
The trigger for involution has also been suggested to be due to the ‘loss of 
protection’ of haemangioma cells from immune surveillance mechanisms (Ritter et al., 
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2003; Friedlander et al., 2005). Recent research has suggested that an immune response 
may be involved in the proliferation and involution of haemangioma.  Ritter et al (2003) 
reported the expression of peripheral T cell surface markers, CD3 and CD8, and 
suggested a cytotoxic T cell phenotype in haemangioma. These authors also identified 
high levels of indoleamine 2, 3 dioxygenase (IDO) in proliferating haemangioma which 
decreased during involution. IDO is an enzyme involved in the tryptophan degradation 
Availability of tryptophan is critical to the function of T cells in promoting apoptosis 
(Frumento et al., 2002).  Ritter et al (2003) therefore suggested that the high levels of 
IDO and concomitant low tryptophan concentrations in the proliferative phase delays 
the onset of involution. In retrospect, the trigger for involution could occur as a 
consequence of low IDO levels, high tryptophan concentrations and therefore increased 
T cell cyto-toxicity within the lesion.   
Although a number of aspects in the model shown in Figure 7.1 are speculative, 
the possible link between neural crest cell development and the non-random facial 
presentation of haemangioma is an exciting notion that warrants further investigation.   
 
7.1.1.5 THE OVERALL SIGNIFICANCE OF THIS RESEARCH 
This investigation has resulted in an improved understanding of the cellular and 
molecular mechanisms regulating haemangioma proliferation and involution. The 
identification of an EPC to a MSC differentiation which may be responsible for 
governing the biology of haemangioma progression and the identification of TRAIL as 
potential therapy for haemangioma represent novel findings. From a clinician’s 
perspective, the ultimate aim of haemangioma research is to acquire substantial 
understanding of haemangiogenesis that would allow the development of effective 
treatments for haemangioma. The results presented in this thesis have led to a better 
understanding of the pathogenesis of haemangioma with the potential to develop novel 
treatment strategies for this common tumour of infancy.  
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Figure 7.1: A proposed model for the development of haemangioma based on the 
speculative ideas and findings from this investigation. (see section 7.1.1.4 for details). 
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Figure 7.1: A proposed model for the development of haemangioma based on the 
speculative ideas and findings from this investigation. contd (see section 7.1.1.4 for 
details). 
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Figure 7.1: A proposed model for the development of haemangioma based on the 
speculative ideas and findings from this investigation. (contd) (see section 7.1.1.4 for 
details). 
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APPENDIX 1: CHAPTER 3 
1.1 PRELIMINARY EXPERIMENTS  
 
1.1.1. METHODS 
 
1.1.1.1 QUANTITATIVE REAL TIME PCR 
In order to perform qRT-PCR accurately, a number of preliminary experiments 
were performed. These included (i) optimisation of PCR parameters for each primer set 
to yield PCR products of the predicted sizes without spurious non-specific bands and 
primer dimer, (ii) testing the efficiency of each primer set and (iii) identification of an 
appropriate house keeping gene to use as the internal reference gene. The importance of 
the house keeping gene and a brief introduction to qRT-PCR is discussed in section 
2.1.1.1 (page 55).   
1) Testing the PCR Efficiencies of Each Primer Pair: RNA purified from snap 
frozen normal skin was reverse transcribed into cDNA as described in sections 2.1.1.2.1 
and 2.1.2 (pages 58 and 59). qRT-PCR was carried out as outlined in section 2.1.4 (page 
65). PCR products were then separated by electrophoresis on 2.5% Agarose gels (See 
Appendix 4, section 4.1.4, page 295). PCR products were excised and purified from the 
gels as described in Appendix 4, section 4.1.5 (page 296). 
 Efficiencies for all the primer pairs used in this study were determined from 
diminishing dilutions of the respective purified PCR products. An initial 500-fold 
dilution of the purified PCR product was prepared from which eight-fold serial dilutions 
were prepared. 1 µl of each dilution was then used as template and amplified in 
duplicate by qRT-PCR for each primer set. The threshold Ct was plotted against the 
Log of template concentrations and the slope of the line generated was used to calculate 
the Efficiency (E) according to the equation:  
                     E = 10[–1/slope] - 1 (Rasmussen, 2001). 
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 Efficiencies for all the primer pairs were calculated to be approximately 2 which is the 
theoretical maximum (Rasmussen, 2001).  
 
2) Validation of an Appropriate Internal Reference Gene: Two approaches were 
used to identify an appropriate internal reference gene for this study.  
A) RNA was purified from six proliferating, eight involuting and seven involuted 
haemangioma biopsies and cDNA was synthesised using random hexamers as described 
in section 2.1.2 (page 59). GAPDH, CycA and 18SrRNA were amplified by qRT-PCR 
and the Ct values of GAPDH and CycA mRNA were calculated relative to 18SrRNA 
using the formula :  
Ct = Ct(GAPDH or CycA) − Ct(18SrRNA)  
 
B) cDNA was also synthesised using Oligo(dT)20.  qRT-PCR was performed for 
GAPDH and CycA and the absolute Ct values were calculated when 500 ng of total 
RNA was used in the cDNA synthesis reaction.  
 
1.1.1.2 IMMUNOHISTOCHEMICAL OPTIMISATION 
HeLa cells, HUVECs, EOMA cells and placenta tissue sections were initially 
used to optimise the IHC staining procedures for the various antibodies used in this 
study. Cultured cells were grown onto 13 mm diameter borosilicate glass coverslips and 
cultured in their respective culture medium as described in section 2.1.6.2 (page 67). 
Immunostaining for STAT-3, p-STAT-3 (Tyr 705) and STAT-1 was performed on 
cultured HeLa cells fixed with 4% PFA and immunostaining for VEGFR-2 was done on 
HUVECs and EOMA cells fixed with a mixture of acetone:methanol, as decribed in 
section 2.1.8.2.2 (page 74). Fixed cells were incubated with primary antibodies against 
STAT-3, p-STAT-3 (Tyr 705), STAT-1 and VEGFR-2 followed by incubation with 
either an anti-rabbit DIG conjugate or an anti-mouse DIG conjugate followed by 
incubation with an anti-DIG-Rhodamine conjugate. Coverslips were stained in DAPI 
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(see section 2.1.8.3, page 75) and mounted in Antifade. Control coverslips were 
included in each experiment in which the primary antibody was omitted.  
 Formalin fixed paraffin embedded placenta sections were deparaffinised, 
rehydrated and subjected to a sodium citrate antigen retrieval step as outlined in section 
2.1.8.2.1 (page 74). Sections were then blocked and incubated overnight at 4ºC with 
rabbit anti- GLUT-1 primary antibodies. Bound GLUT-1 antibody was detected with an 
anti-rabbit Cy3 conjugate. Slides were then stained in DAPI and mounted in Antifade.  
 
1.1.1.3 STATISTICS  
The non-parametric Kruskil Wallis by ranks test was used to identify changes in 
CycA and GAPDH mRNA expression with 500 ng of RNA. This was followed by the 
multiple comparisons test to determine where the significant changes occurred. The R 
package was used to determine changes in mRNA expression relative to 18SrRNA. The 
linear mixed effects method of analysis was used to allow for repeated measures on 
subjects and for each transcript, a sequential bonferroni adjustment was made for 
multiple testing. Data is represented as relative fold changes in mRNA expression ± 
s.e.m.  
 
1.1.2 RESULTS 
 1.1.2.1 PCR QUALITY CONTROL 
PCR efficiencies were calculated as described in section 1.1.1.1 (page 267). All 
qRT-PCR assays were linear over a 10,000-fold range with Ct values ranging between 
12.5 and 37 cycles (Figure 1.1). The correlation coefficients were consistently > 0.98 in 
each assay and each PCR amplification displayed an efficiency close to 2 (Figure 1.3). 
Melt-cure analyses were performed after every amplification to ensure the reactions 
were free from contaminating DNA. A typically melt-curve plot is shown in Figure 1.2. 
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Figure 1.1: An example of the cycling numbers obtained during a typical real-time PCR 
amplification of serially diluted PCR template. The Ct values changed proportionally 
according to the serial dilution of the sample. The figure above shows the PCR curves 
obtained when serially diluted STAT-1 PCR product was amplified by qRT-PCR. 
Samples that had Ct values below 30 were considered positive when there was no 
evidence of amplification in the no-template negative controls. A maxiumum of 1 Ct 
difference between duplicates was accepted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The melt-curve obtained at the end of a PCR amplification with serially 
diluted STAT-1 template. As the amplified product have the same length and are of the 
same nucleotide ratio, they have the same melting temperature. This can be observed by 
a series of peaks one on top of each other on the melt-curve. Absence of other peaks 
indicates the absence of spurious non-specific product formation. 
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Figure 1.3: qRT-PCR primer pair efficiencies. The PCR amplification efficiencies using 
primers for STAT-1 (A), STAT-3 (B) and VEGFR-2 (C) were calculated as described 
in section 1.1.1.1. Serially diluted PCR product was amplified by qRT-PCR in 
duplicate. The slope of the line obtained by plotting the Ct value against Log 
[Concentration] was then used to calculate the efficiency of the PCR reaction. 
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1.1.2.2 VALIDATION OF AN APPROPRIATE INTERNAL REFERENCE GENE 
Primer pairs for four commonly used house keeping genes, 18SrRNA, GAPDH, 
CycA and HPRT, were designed for use in this investigation. An ideal reference gene 
would be one that is not differentially regulated across the three phases of haemangioma 
(proliferating, involuting and involuted) and is expressed at relatively similar levels as 
the gene of interest (Roche LC technical note 15/2002; Vandesompele et al., 2002). 
 Preliminary experiments showed that a neat cDNA sample (from normal skin) 
amplifies 18SrRNA at cycle 10 (Ct = 10) whereas the test genes were not amplified 
until cycle 25 or later, representing an approximately 500,000-fold difference in 
abundance. Because the 18SrRNA transcript is far more abundant than all the test 
genes, it was not considered a suitable internal reference gene for this study. The use of 
HPRT as an internal reference was also discounted because of its late amplification in 
haemangioma samples.  
To validate the use of GAPDH and CycA as internal reference genes, two 
different approaches were used. Absolute Ct values were calculated from proliferating, 
involuting and involuted haemangioma biopsies (eight per phase) for both genes when 
500 ng of total RNA was used for the cDNA synthesis reaction. CycA mRNA 
expression changed between phases (Figure 1.4-A), with significant differences 
between the proliferative and involuting phase (p < 0.01) and also between the 
proliferative and involuted phase (p < 0.01). However, no significant change in GAPDH 
mRNA expression between the phases was identified (p < 0.34, Figure 1.4-B).  
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Figure 1.4: Validation of an appropriate internal house-keeping gene (Experiment 1). 
The Ct values obtained when qRT-PCR was performed with 500 ng of starting mRNA 
from each sample, were used to detect differences in CycA (A) and GAPDH (B) mRNA 
expression across phases of haemangioma. (A) Significant changes in CycA mRNA 
levels was detected between the proliferative and involuting phase and between the 
proliferative and involuted phase (** p < 0.01). (B) GAPDH mRNA levels did not vary 
between phases.  
 
 
For the second approach, qRT-PCR was performed for GAPDH and CycA using 
18SrRNA as the internal reference gene. The use of 18SrRNA was accepted in this case 
as it was found to be expressed in the same dynamic range as GAPDH and CycA. The 
Ct values for GAPDH and CycA mRNA were calculated relative to 18SrRNA using 
the formula Ct = Ct (GAPDH or CycA) − Ct (18SrRNA). Relative to 18SrRNA, GAPDH and 
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CycA mRNA levels did not change between phases (p < 0.1229 and p < 0.054, 
respectively) (Figure 1.5).  However, since the p value obtained for CycA expression (p 
< 0 .054) was so close to the chosen threshold for significance, GAPDH was chosen as 
a more suitable reference gene for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5:Validation of an appropriate internal house-keeping gene (Experiment 2). To 
detect changes in CycA (A) and GAPDH (B) mRNA between proliferating, involuting 
and involuted lesions, Ct values for CycA and GAPDH mRNA relative to 18SrRNA 
were analysed. Statistical analysis was performed using the R package as described in 
section 1.1.1.3. Relative to 18SrRNA, no statitstically significant change in CycA or 
GAPDH mRNA expression was identified across the phases. 
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1.1.2.3 IMMUNOHISTOCHEMICAL OPTIMISATION 
Paraffin embedded placenta sections, HeLa cells and EOMA cells were used at 
the start of this study to optimise the IHC staining procedures and to determine antibody 
specificity. Control slides in which the primary antibody was omitted showed no 
staining. Paraffin embedded tissue sections exhibited some background fluorescence, 
thought to be due to the autofluorescence of collagen fibres. A tissue bleaching step was 
therefore introduced into the immunostaining protocol using NaBH4 which effectively 
reduced the problem, allowing specific signal to be detected. 
HeLa cells in culture expressed STAT-3 (Figure 1.6-A). However, STAT-1 and 
p-STAT-3 (Tyr 705) expression was low in these cells (Figure 1.6-C and -E, 
respectively). Treatment with IFN-2b for 10 min induced STAT-1 and p-STAT-3 (Tyr 
705) expression (Figure 1.6-D and -F, respectively). 
 As expected, positive immunoreactivity was detected for VEGFR-2 and GLUT-
1 when IHC staining was performed on EOMA cells and placenta tissue sections 
respectively (Figure 1.7). Previous studies have shown that VEGFR-2 is expressed by 
EOMA cells (Ilan et al., 2003), and GLUT-1 is expressed in placenta (Hahn et al., 
1998). 
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Figure 1.6: Immunohistochemical localisation of STAT-3, p-STAT-3 (Tyr 705) and 
STAT-1 on HeLa cells. Cells were fixed and stained with rabbit anti-STAT-3 (A), 
rabbit anti-p-STAT-3 (Tyr 705) (C&D) or mouse anti-STAT-1 (E&F) antibodies. 
Bound antibodies were detected with either an anti-rabbit DIG conjugate or an anti-
mouse DIG conjugate followed by incubation with an anti-DIG-Rhodamine conjugate 
(red). Cell nuclei were counterstained with DAPI (blue). (A) STAT-3 was expressed by 
unstimulated HeLa cells growing in culture. IFN-2b (10,000 U/ml) stimulation for 10 
min induced both p-STAT-3 (Tyr 705) (D) and STAT-1 (F) expression as compared to 
unstimulated cells (C&E, respectively). No staining was detected when the primary 
antibodies were omitted (B). Scale bars: 500 µm (A&B), 100 µm (C&D), 50 µm (E&F).  
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Figure 1.7: Immunohistochemical localisation of VEGFR-2 on EOMA cells and GLUT-
1 on placenta tissue sections. EOMA cells were fixed and stained with rabbit anti-
VEGFR-2 antibodies. Bound antibodies were detected with an anti-rabbit-DIG 
conjugate followed by an anti-DIG-Rhodamine conjugate (Panel A, red staining). 
Placenta sections were incubated with rabbit anti-GLUT-1 antibodies followed by an 
anti-rabbit Cy3 conjugate (Panel C, red staining) for visualization. Cell nuclei were 
counter stained with DAPI (blue). No staining was detected in the negative controls 
(Panels B&D, respectively). The red staining seen in Panel D are the autofluorescent 
blood cells. Scale bars: 50 µm. 
 
1.1.2.4 WESTERN BLOTTING 
1.1.2.4.1 Lysate preparation, transfer conditions and antibody specificity 
In preliminary experiments, snap frozen normal skin and HeLa cells were used 
to optimise the Western blotting technique. Three lysis buffers were tested, (i) RIPA 
buffer, (ii) 50 mM Tris-HCL, pH 6.8, 5 mM EDTA and 2%SDS, and (iii) RIPA buffer 
lysis buffer containing 2% SDS and additional protease and phosphotase inhibitors. 
This modified RIPA buffer was chosen because it was highly reducing and effectively 
prevented the action of proteases and phosphotases from degrading the proteins within 
the samples. This allowed for long-term storage of the samples at -80ºC for several 
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months. Proliferating haemangioma tissues had a higher concentration of proteins (570 
µg/mg) than involuting and involuted haemangioma tissues (114 µg/mg and 27 µg/mg, 
respectively). 
Skin was crushed to a powder in liquid nitrogen before the addition of the lysis 
buffer in order to maximise protein output as the skin tissue became tough and rubbery 
when solid pieces were put directly into the lysis buffers. 
Complete transfer of proteins onto the PVDF membranes was a problem in this 
study. Therefore, a number of different combinations of the basic Western blotting 
transfer buffer components and transfer conditions were tested to ensure 90-95% of the 
protein bands were transferred onto the membranes. Increasing transfer time and adding 
SDS along with methanol to the transfer buffer resulted in the transfer of 90-95% of the 
protein onto the PVDF membranes. Following transfer, gels were stained with 
Comassie Blue-R (See Appendix 4, section 4.2.5, page 298). In initial experiments, 
prior to the blocking step, the membranes were also stained with Ponceau S to detect the 
presence of the fractionated proteins. The recipe for the Ponceau S stain is given in 
Appendix 4, section 4.2.22 (page 301). 
 
1.1.2.4.2 Antibody quantitation 
In preliminary experiments, lysates prepared from normal infant skin and Hela 
cells, treated and untreated with IFN-2b (10,000 U/ml), for 10 min were used to show 
the staining patterns for STAT-3, p-STAT-3 (Tyr 705), STAT-1, CycA and GAPDH 
antibodies. All antibodies showed immunoreactive bands at the appropriate sizes and 
also stained in a quantitative manner i.e., when increasing amounts of protein lysates 
were run on the NuPage MES gels, there was an increase in band intensity of the correct 
size on the membrane (Figure 1.8). Figure 1.8-B and -C show decreasing band 
intensities with a decrease in protein concentration as identified by densitometry 
analysis using the Image J software. These results indicate that this method of 
quantification can be used to measure protein changes in haemangioma. 
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Figure 1.8: Antibody specificity by Western blotting. Decreasing amounts of total 
protein from HeLa cell lysates showed concomitant decrease in band intensity for 
STAT-3 (A). This decrease was quantifiable using the Image J program. Panel B and C 
show the decrease in STAT-3 (B) and p-STAT-3 (Tyr 705) (C) band densities obtained 
with decreasing amounts of total protein.  
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1.2 GENE EXPRESSION CHANGES IN HAEMANGIOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Correlation between STAT-3, STAT-1 and VEGFR-2 mRNA expression in 
proliferating, involuting and involuted haemangiomas. The mRNA levels for STAT-3, 
STAT-1 and VEGFR-2 were determined in haemangioma biopsies from the different 
clinical phases using qRT-PCR. The threshold value (Ct) was determined for each gene 
and then expressed as a difference (Ct) between that for the target gene and that for 
internal house-keeping gene, GAPDH. Low Ct values reflect greater mRNA 
expression. Proliferating haemangiomas () had greatest STAT-3 and VEGFR-2 
expression compared with involuting (+) and involuted () lesions while involuting 
lesions expressed slightly higher STAT-1 mRNA than proliferating and involuted 
lesions. (A) STAT-3 and STAT-1 mRNA expression were correlated (Spearman rho r = 
0.692; p < 0.001). (B) STAT-1 and VEGFR-2 mRNA expression were correlated 
(Spearman rho r = 0.750; p < 0.001). 
A 
B 
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Figure 1.10: STAT-3 expression correlates with proliferation in proliferating 
haemangioma. Black columns show STAT-3 positive cells, white columns show PCNA 
positive cells and grey columns show number of cells that stain positive for STAT-3 
and PCNA. ‘Proliferating’ areas within proliferating lesions contained the most number 
of STAT-3 positive cells which decreased in the ‘involuting’ and ‘involuted’ areas. 
‘Involuted’ areas contained few STAT-3 and PCNA positive cells. Percentage of cells 
that stained positive for STAT-3, PCNA and those that expressed both STAT-3 and 
PCNA (STAT-3+PCNA) are given in the corresponding table below each graph.  
Lesion 2 Proliferative area Involuting area Involuted area 
STAT-3 25.7% 31.1% 30.4% 
PCNA 17.8% 11.4% 7.7% 
STAT3+PCNA 8.0% 5.2% 3.9% 
Lesion 3 Proliferative area Involuting area Involuted area 
STAT-3 70.4% 31.1% 38.9% 
PCNA 27.3% 13.3% 24.5% 
STAT3+PCNA 12.7% 4.9% 10.6% 
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Figure 1.11: STAT-3 expression correlates with proliferation in involuting 
haemangioma. Black columns show STAT-3 positive cells, white columns show PCNA 
positive cells and grey columns show number of cells that stain positive for STAT-3 
and PCNA. ‘Proliferating’ areas within an involuting lesion contained the most number 
of STAT-3 positive cells which decreased in the ‘involuting’ and ‘involuted’ areas. 
There were also fewer PCNA positive cells in the ‘involuting’ area as compared to the 
‘proliferative’ area. The ‘involuted’ areas were devoid of any PCNA expression. 
‘Involuted’ areas contained very few STAT-3 positive cells. Percentage of cells that 
stained positive for STAT-3, PCNA and those that expressed both STAT-3 and PCNA 
(STAT-3+PCNA) are given in the corresponding table below each graph. 
Lesion 2 Proliferative area Involuting area 
STAT-3 60.7% 62.9% 
PCNA 27.3% 23.5% 
STAT3/PCNA 19.4% 21.1% 
Lesion 3 Proliferative area Involuting area 
STAT-3 49.1% 41.5% 
PCNA 7.4% 11.7% 
STAT3/PCNA 5.1% 9.3% 
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APPENDIX 2: CHAPTER 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2.1: Haemangioma explant model (1).  Tissue taken from a proliferative 
haemangioma was embedded in fibrin gel and cultured as described in sections 2.3.2 and 
2.3.3. Photographs were taken on day 7 in culture. (A) Phase contrast image showing the 
entire tissue piece with capillary-like outgrowths emanating from the tissue perimeter. 
Panel B and C are the enlargements of the areas outlined in Panels A and B, respectively. 
Scale bars: (A) 500 µm, (B) 200 µm and (C) 100 µm.
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Figure 5.3: The haemangioma explant model. Proliferating haemangioma biopsies were 
cultured as described in section 5.3.2 and 5.3.3. (A-F) at 14 days in culture, capillary-like 
like structures grow out and follow a circular growth pattern around the original tissue. 
Scale bars: 500 µm
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Haemangioma explant model (2). Proliferating haemangioma biopsies were 
cultured as described in sections 2.3.2 and 2.3.3. Panels A to F are the phase contrast 
images showing that the capillary-like structures follow a circular pattern of growth around 
the original tissue piece. Photographs were taken on day 14 in culture. Scale bars: 500 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Phase contrast images showing the growth of a different cell type from 
haemangioma explants. 4-5% of cultured proliferating haemangioma explants gave rise to 
another cell type emanating from its surface. These cells exhibited the morphology similar 
to that of ECs. Photographs were taken on day 16 in culture. Scale bars: (A) 1000 µm and 
(B) 500 µm. 
A B 
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Figure 2.4: qRT-PCR results showing mRNA expression patterns for Collagen I, -II, -III, -
VIII, Laminin-V, IGF-2 and VEGF-2 in HaemDMSCs and their original biopsy of origin. 
(A) Black columns show mRNA expression in HaemDMSCs and white columns show 
expression in the tissue piece. HaemDMSCs expressed similar levels of mRNA for 
Collagen I (Col-I), -II, -III and IGF-2 as the original biopsy from which they originated. 
They expressed more mRNA for Col-VIII but lower levels of VEGF mRNA than the tissue. 
mRNA for Lamining V (Lam-V) was not detected in the HaemDMSCs. (B) An ethidium 
bromide stained 1% agarose gel confirming that that the amplified products were of the 
expected size.  
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Table 2.1: mRNA characterisation of HaemDCs. qRT-PCR was used to detect mRNA transcripts for various markers in HaemDCs. The table 
shows the raw Ct values (relative to GAPDH) obtained from HaemDC isolates designated HaemDCs-A, HaemDCs-B, HaemDCs-C and 
HaemDCs-D. The original tissue pieces of HaemDCs-A and HaemDCs-B, HUVECs and 3T3 fibroblasts were also analysed in parallel. Key: ‘-’ 
indicates no amplification showing absence of mRNA transcripts; NA: Not applicable. See section 4.3.3.3 for details. 
 
Phase 
 
Patient 
 
Passage 
 
Collagen-I 
 
Collagen-II 
 
Collagen-III 
 
Collagen-VIII 
 
Laminin-V 
 
VEGF 
 
IGF-2 
 
Prolif 
 
HaemDCs-A 
 
3 
 
1.3 
 
9.8 
 
1.9 
 
2.6 
 
- 
 
7.5 
 
12.8 
Prolif HaemDCs-B 3 6.2 13.3 4 4.4 - 10.1 - 
Prolif HaemDCs-C 3 7 12.8 4.5 8.5 - 7.1 14.4 
Prolif HaemDCs-D 3 6.5 13 5.4 5.7 - - 11.3 
Prolif Tissue-A NA 5.1 12.9 2.9 10.4 12.5 2.6 10 
Prolif Tissue-B NA 3.7 9.9 1.8 - 9.3 2.9 9.6 
 HUVECS 12 - - 12.2 6.6 13.6 10.6 13.1 
 3T3 Fibroblasts  - - - - - - - 
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Figure 2.5: Adipocytic differentiation conditions does not induce the nuclear translocation 
of p-STAT proteins in HaemDMSCs. Immunolocalisation for STAT and p-STAT proteins 
was performed as described in section 2.3.14.1. Panel A: Immunolocalisation of p-STAT-3 
(Tyr 705) (red) and STAT-3 (green) in HaemDMSCs before (A&B, respectively) and after 
stimulation with adipocytic differentiation media for 24 hrs (B&D, respectively). Cell 
nuclei were counterstained with DAPI (blue). Panel B: Immunolocalisation of p-STAT-5 
(Tyr 695) (red) and STAT-5 (green) in HaemDMSCs before (A&B, respectively) and after 
stimulation with adipocytic differentiation media for 24 hrs (B&D, respectively). Scale 
bars: 20 µm. 
A 
B 
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2.1 PURIFICATION OF HAEMANGIOMA DERIVED ENDOTHELIAL 
CELLS  
 
Boye et al (2001) have purified ECs from fresh haemangioma biopsies using Ulex-
lectin coated magnetic beads. In this study, a similar protocol was used except that 
magnetic beads coated with antibodies to the EC specific marker, CD31 was used. 
However, in this study, purification of ECs from fresh haemangioma biopsies using this 
technique was unsuccessful. This may be due to several reasons, (i) low quantities of 
starting material. Boye et al (2001) did not specify the weight or volume of starting 
material that allowed successful isolation of ECs in their lab. (ii) different culture media 
and growth supplements. During this study, the quantity of haemangioma tissue available 
was a limiting factor. Cell recovery was low after the collagenase digestion and magnetic 
bead separation steps performed as described in section 2.3.16 (page 99). Similar to the 
conditions described by Boye et al (2001), this study utilised both fibronectin and gelatin 
coated dishes for cell culture. In addition, most of the additional supplements were added to 
the culture media with the exception of FGF-2. Another difference was that MCDB 131 
minimal medium was used instead of the endothelial basal medium (EBM) medium 
described previously (Boye et al., 2001). Unfortunately, the few cells that survived the 
purification procedure did not survive passed the first passage to allow for 
immunohistochemical characterisation. Figure 2.7 shows the isolated cells in culture 
following bead purification from two haemangioma biopsies. 
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Figure 2.6: CD31+cells isolated from two proliferating haemangioma biopsies. Photographs 
were taken on day 7 in culture. The beads used for purification remained attached to some 
of the cells in culture. Scale bars: (A) 500 µm, (B) 200 µm. 
A 
B 
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APPENDIX 3: CHAPTER 5  
 
 
 
Table 3.1: Differences in mRNA levels for TRAIL and TRAIL receptors in 
haemangioma tissue and HaemDMSCs. qRT-PCR was used to analyse mRNA 
expression levels of TRAIL and TRAIL receptors in proliferating haemangioma 
biopsies and in their respective HaemDMSC isolates. Values in the table are the raw 
Ct values obtained for each gene from the haemangioma tissue pieces (T) and the 
HaemDMSCs isolates (C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 1 
 
Patient 2 
 
Patient 3 
 
Patient 4 
 
Patient 5 
 
Patient 6 
 
T C T C T C T C T C T C 
 
TRAIL 
 
3.9 
 
>16 
 
6.6 
 
>16 
 
5.1 
 
>16 
 
4.9 
 
>16 
 
4.9 
 
15.7 
 
4.9 
 
>16 
DR4 5.9 9.5 11.5 9.4 7.1 11.5 7.6 12.4 7.9 13.5 6.8 11.8 
DR5 8.6 13.5 15.1 14.8 9.8 15.1 10.8 13 21 16.3 10.6 15.8 
DcR1 5.6 9 11.5 9.7 6.3 11.5 8.4 11.2 10.7 12.1 7.9 12.3 
DcR2 8.5 4.9 6.5 5.5 10.9 5.8 8.3 6.4 9.9 4.4 8.3 7.4 
OPG 11.9 1.2 11.6 2.1 10.1 9.9 11.9 4.5 9.7 3.7 9.1 4.7 
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Figure 3.1: OPG protein expression in the media of HaemDMSCs conditioned over a 
72-hour period. Lane 1: 40 µg of total protein from conditioned media, Lane 2: 5 µg of 
total protein from conditioned media Lane 3: contains an equivalent amount of 
concentrated unconditioned cell culture media. Following electrophoresis and transfer 
onto a PVDF membrane, the membrane was blocked with the mouse anti-OPG 
MAB8051 primary antibody. Lane 1 shows the presence of an immunoreactive band at 
60 kDa from the conditioned media of HaemDMSCs (black arrow). In addition, a band 
at 220 kDa was also detected (red arrow) in Lanes 1 and 2. Both bands were not present 
in unconditioned media (Lane 3). 
 
 
1 2 3 
220 kDa 
100 kDa 
80 kDa 
60 kDa 
40 kDa 
30 kDa 
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APPENDIX 4 
 
4.1 GENERAL MOLECULAR BIOLOGY TECHNIQUES 
 
4.1.1 RNA Precipitation 
Where necessary, RNA was precipitated by adding 2.5 times the volume 100% 
ethanol and 1/10 sodium acetate (pH 5.2). This was left at -20˚C for a minimum of 20 
min and centrifuged at 13,000 X g for 15 min at 4˚C. The pellet was air dried in a 
laminar flow hood for 10 min and resuspended in 10-15 µl of nuclease-free, sterile 
dH2O. 
 
4.1.2 PCR Amplification 
During PCR set-up, all reagents were kept on ice. Latex gloves, dedicated 
pipettors and barrier tips were used in a designated PCR product free room to prevent 
contamination by previously amplified material. Reactions were performed using thin-
walled microamp (Invitrogen) PCR tubes in Perkin Elmer GeneAmp PCR system 2700 
(version 2.07 software). All reagents were purchased from Invitrogen. Reactions 
followed the general protocol of using a cocktail mix of buffer, deoxynucleotide 
triphosphates (dNTPs) and dH2O. The use of a cocktail of common reagents ensures 
that reactions contain identical reagent concentrations and delinearing larger volumes 
increase pipetting accuracy.  All PCR reactions were performed alongside a no template 
(water) control and amplification from an equivalent amount of RNA that had not been 
reverse transcribed. The control was necessary to ensure contamination was not present. 
Amplification was verified by agarose gel electrophoresis of 5 µl of PCR product and 
staining with ethidium bromide.  
 
4.1.3 PCR Reaction Using Taq DNA Polymerase 
cDNA synthesised from normal skin was used as template to optimize annealing 
conditions and primer concentrations for all primer sets used in this study.  Optimum 
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reaction conditions were obtained in 20 µl final volume with 1X PCR Buffer (20 mM 
Tris-HCL (pH 8.4), 50 mM KCL), 1.5 mM MgCl2, 200 µM dGTP, dCTP, dATP and 
dTTP, 1 U Taq polymerase (Invitrogen), 1µl cDNA template with varying primer 
concentrations. A range of annealing temperatures was examined for each gene. The 
thermal cycling conditions used for the PCR amplification involved the following steps: 
an initial denaturation at 95˚C for 2 min, followed by 35 cycles of a 3-cycle 
amiplification:denaturation at 95˚C for 15 sec, annealing of primers to the template 
DNA initially carried out at 5˚C below the Tm of the primer with the lowest Tm for 20 
sec and extension at 72˚C for 30 sec. This 35 cycle sequence was then followed by 72˚C 
for 5 min, and the reaction was then held at 4˚C. Tm of a given primer was calculated 
using the formula:  
Tm = [3 x G/C] + [2 x A/T] 
The resulting PCR fragments were visualised by agarose gel electrophoresis as 
outlined in section 4.1.4. For each gene, primer concentration titrated to 0.1 µM with an 
annealing temperature of 60˚C produced a clean PCR fragment of the expected size 
with no visible non-specific products or primer dimers. Therefore, these conditions were 
used for all qRT-PCR amplifications (see section 2.1.4, page 65).  
 
4.1.4 Agarose Gel Electrophoresis 
DNA samples were mixed with 1 µl of 6 x agarose loading buffer (30% glycerol 
(v/v) in dH2O, 0.025% bromophenol blue) and loaded into 1% agarose gels. The 
agarose gels were prepared by dissolving the appropriate amount of low melting point 
agarose (Sigma) in TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0). The 
solution was heated in a microwave to facilitate dissolution of the agarose and then 
cooled by running the flask under cold water. The solution was then supplemented with 
1 µg/ml of ethidium bromide. The molten agarose was transferred into a cassette and a 
plastic comb inserted to form the lanes for loading he DNA samples. After 
polymerisation, the gel was immersed in TAE and the comb carefully removed. A 100 
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bp ladder (Invitrogen) was used as a standard. Electrophoresis was performed at 100 V 
for 45 min, or until the dye front was two-thirds of the way down the gel. Bands were 
observed under UV light and polaroid photographs taken.  
 
4.1.5 Purification of DNA Fragments from Agarose Gels. 
PCR products of the appropriate sizes were cut out of the agarose gel and 
purified using the QIAquick® gel extraction kit (Qiagen, GmbH, Germany). The slice 
was weighed, and 300 µl of QG buffer (pH 7.5) was added for every 100 mg of gel. The 
sample was incubated at 50˚C until the gel slice had dissolved. Isopropanol (100 µl of 
100%) was added per 100 mg of gel slice, and the sample was mixed. The sample was 
then loaded to the upper reservoir of a QIAquick® spin column provided in the kit 
placed in a 2 ml collection tube and centrifuged in a table top centrifuge for 1 min at 
10,000 X g. Flow-through was discarded and 750 µl of PE buffer added. The solution 
was incubated for up to 5 min at room temperature before centrifugation for 1 min at 
10,000 X g. After discarding the flow-through again, the column was centrifuged once 
again to elute the residual flow-through. The column was then placed in a clean 1.5 ml 
microcentrifuge tube, and 50 µl of elution buffer (10 mM Tris-HCL, pH 8.5) was added 
to the centre of the QIAquick® membrane. The sample was left to stand for 5 min to 
increase the DNA yield and then eluted by centrifugation at 13,000 X g for 2 min. 
Purified DNA was stored at -20˚C until required. 
 
4.1.6 Acetone Protein Precipitation 
To each sample, four times the volume of ice cold acetone was added. The tubes 
were vortexed and incubated overnight at -20˚C. The tubes were centrifuged at 13,000 
X g for 10 min at 4˚C and the supernatant was removed without disturbing the pellet. 
The uncapped tubes were airdried for 10-15 min on the bench top. The protein pellets 
were then resuspended in freshly prepared Western blotting lysis buffer.  
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4.2 STOCK SOLUTIONS, BUFFERS AND OTHER RECIPES 
 
4.2.1 Phosphate buffered saline (PBS) 0.15 M pH 7.4 
Reagents     g/L 
NaCl      0.8 g 
KCL      0.2 g 
Na2HPO4     1.15 g 
KHPO4     0.2 g 
 
PBS was made by dissolving the salts in dH2O. The pH was adjusted to 7.4 using 
concentrated HCL or NaOH 
 
4.2.2 Tris buffered saline (TBS)  
Reagents     g/L 
Tris      2.42 g 
NaCL      8 g 
 
TBS was made by dissolving the salts in dH2O. The pH was adjusted to 7.6 using 
concentrated HCL  
 
4.2.3 Tris Buffered Saline-Tween-20  
TBST was prepared by adding 1ml Tween-20 to 1 L of TBS buffer.  
 
4.2.4 RIPA Buffer (100 ml) 
790 mg Tris base and 900 mg NaCl was dissolved in 75 ml dH2O and the pH 
adjusted to 7.4. 10 ml of NP-40 and 2.5 ml of 10% Na-Deoxycholate was added and the 
solution was stirred until it turned colourless. 1 ml of 100 mM EDTA was added and the 
final volume adjusted to 100 ml with dH2O. The solution was aliquoted and stored at -
20°C. Final concentration: 50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% Na-
Deoxycholate, 150 mM NaCl, 1 mM EDTA.  
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4.2.5 For Coomassie R-250 staining 
Comassie staining solution : 0.2 g Coomassie R-250, 10 ml  acetic acid, 100 ml 
methanol was dissolved in 90 ml dH2O.  
Destaining Solution: 10% acetic acid, 40% methanol and 50% dH2O. 
 
4.2.6 Western blot transfer buffer  
Reagents      g/L 
Tris     3.03 g 
Glycine    14.4 g 
SDS     0.38 g 
Methanol    150 ml 
The reagents were combined and the volume made upto 1 L with dH2O. 
 
4.2.7 Stripping Buffer 
2 g SDS, 750 µl -mercaptoethanol and 10 ml Tris-HCL (0.5 M, pH 6.8) was 
dissolved in 90 ml dH2O. Final concentration: 100 mM -mercaptoethanol, 2% SDS, 
62.5 mM Tris-HCL pH 6.8. 
 
4.2.8 4% Paraformaldehyde  
4 g of PFA was added to 100 ml PBS. A few drops of NaOH were added 
followed by gentle heat treatment in a microwave. Once dissolved the pH was adjusted 
to 7.1 using concentrated HCL.   
 
4.2.9 10 mM Sodium Citrate (pH 6.0) 
This solution was made up fresh for each use. 0.3 g of tri-sodium citrate was 
dissolved in 100 ml of dH2O. The pH was adjusted to 6.0 using a 1M HCL solution. 
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4.2.10 Csaba Stain 
Briefly, the alcian-blue-safranin solution (Csaba stain) was prepared by adding 
900 mg alcian blue, 45 mg of safranin, 1.2 g of ferric ammonium sulphate to 250 ml of 
0.2 M sodium acetate buffer, pH 7.42. 
 
4.2.11 Coating culture dishes with 1% gelatin 
1 g of commercially available gelatin was dissolved in 100 ml of PBS by gentle 
heating in a microwave. Once dissolved this solution was autoclaved and filter sterilised 
through a 0.2 µM filter. For coating culture dishes, enough 1% gelatin was added to 
cover the entire surface and the dish was left for at least 20 min in the incubator. 
Immediately before use, the gelatin was removed and the culture dishes were rinsed 
once with sterile PBS.  
 
4.2.12 AG490 Stock Solution 
 
AG490 powder was dissolved in 100% DMSO to a final concentration of 340 
mM.  A stock solution of 1mM was prepared by diluting 15 µl of AG490 (340 mM) into 
5 ml cell culture media. This solution was passed through a 0.2 µM filter, aliquoted and 
stored at -20ºC.  
 
4.2.13 FACS buffer   
 100 ml PBS was combined with 100 mg sodium azide.  
 
 
4.2.14 Alizarin Red Staining Solution 
2 g of Alizarin red solution was dissolved in 100 ml of dH2O. The pH was 
adjusted to 4.1-4.3 with 10 % ammonium hydroxide. This solution was stored at room 
temperature.   
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4.2.15   (A) Oil Red O stock stain 
0.5 g of Oil red O (sigma) was dissolved in 100 ml of isopropanol and was 
stored at room temperature. 
  (B) Oil Red O working solution  
Oil red stock stain was dissolved in dH2O at a ratio of 3:2 and allowed to stand 
for a minimum of 10 min. The solution was then passed through a 75 µM cell strainer 
and used immediately.  
 
4.2.16 Glycerin Jelly Mounting Medium 
1 g of Gelatin was dissolved in 6 ml of dH2O to which 7 ml of glycerol was then 
added. The mounting medium was stored at 4ºC 
 
4.2.17 Endothelial Cell Growth Supplement - For 3 mg/ml Stock Solution  
15 mg of ECGS powder was resuspended in 5 ml pre-warmed PBS. To ensure 
dissolution, the vial was left at 37ºC for 15 min and mixed at 5 min intervals. The 
solution was then filter sterilized through a 0.2 µM filter, aliquoted and stored at -20ºC 
until required. ECGS was used in cell culture media at a final concentration of 15 µg/ml 
unless otherwise stated.  
 
4.2.18 10% SDS Polyacrylamide Gels 
             (2 gels-1.5 mm thick) 
Reagents     g/L 
Acrylamide/bis (30% stock)   6.66 ml 
1.5 M Tris pH 8.8    5 ml 
dH2O      8 ml 
10% SDS in dH2O    200 µl 
TEMED     10 µl 
10% ammonium persulphate   100 µl 
 
The solutions were added in order shown. TEMED and 10% ammonium 
persulphate were added last to initiate polymerisation. The gel solution was added to the 
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casting apparatus and overlayed with isopropanol. The gel was left to polymerise for 30 
min. The isopropanol was removed and the stacking gel was then made and cast on top 
of the separating gel.  
 
4.2.19 4% Stacking Gel 
(2 gels 1.5 mm thick) 
Reagents     g/L 
Acrylamide/bis (30% stock)   1.33 ml 
0.5 M Tris pH 6.8    2.5 ml 
dH2O      6.1 ml 
10% SDS in dH2O    100 µl 
TEMED     10 µl 
10% ammonium persulphate    50 µl 
 
4.2.20 Protein Gel Loading Buffer (10X) 
To make 20 ml loading buffer, 11.3 ml Glycerol, 2.3 g SDS and 10 mg 
bromophenol blue was dissolved in 8.76 ml of Tris-Hcl (0.5 M, pH 6.8). Buffer was 
stored in aliquots at -20°C.  
 
4.2.21 1X SDS Page Running Buffer (For 1 Litre) 
 3.03 g Tris base, 14.4 g Glycine, 1g SDS was dissolved in 1L of dH2O.   
 
4.2.22 Ponceau S Stain 
Ponceau S Staining Solution was made up with 0.1% (w/v) Ponceau S 5% (v/v) 
acetic acid dissolved in dH2O.   
 
4.2.23 Western Blotting Apparatus 
 
 
 
 
 
 
 
Bottom 
Top 
Grey Side of Cassette 
Fibre pad 
3 MM Filter Paper 
Electrophoresed Gel 
PVDF Membrane 
3 MM Filter Paper 
Fibre pad 
Clear Side of Cassette 
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4.2.24 Sodium Orthovanadate 
    A 200 mM solution of sodium orthovanadate was prepared in dH2O and the pH was 
adjusted to 10.0 using either 1M NaOH or 1M HCl. The yellow solution was boiled in a 
microwave until it turned colourless after which it was allowed to cool to room 
temperature. The pH was adjusted to 10.0 and the solution was boiled. These steps were 
repeated until the solution remained colourless and the pH stabilised at pH 10.0. 
Activated sodium orthovanadate was stored in 20 µl aliquots at -20°C until required.   
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